

Please type a plus sign (+) inside this box ☐

+

65/101/06

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		Application Number	09/904,485
		Filing Date	July 13, 2001
		First Named Inventor	Avi ASHKENAZI
		Group/Art Unit	1647
		Examiner Name	Christine J. Saoud
Total Number of Pages in This Submission	144	Attorney Docket Number	39780-1618.P2C7
<b>ENCLOSURES (check all that apply)</b>			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> After Final Rejection <input type="checkbox"/> Version With Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 <input type="checkbox"/> Copy of Notice	<input type="checkbox"/> Copy of an Assignment <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> <b>Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)</b> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> <b>ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW):</b> <input checked="" type="checkbox"/> <b>Items 1-7 listed under Evidence Appendix of Appeal Brief; and Stamped Return Postcard</b>	Remarks  <b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39780-1618P2C7.</b>
<b>SIGNATURE OF APPLICANT, ATTORNEY OR AGENT</b>			
Firm or Individual name	HELLER EHRMAN LLP 275 Middlefield Road, Menlo Park, California 94025		
Signature	B. D. GREENE (Reg. No. 46,740) Telephone: (650) 324-7000 Facsimile: (650) 324-0638		
Date	APRIL 28, 2006	Customer Number:	35489

<b>CERTIFICATE OF EXPRESS MAILING</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: <b>MAIL STOP APPEAL BRIEF -PATENTS</b> , Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: <b>APRIL 28, 2006</b>			
Express Mail Label <b>EV 765 973 150 US</b>			
Typed or printed name	L. ACOSTA		
Signature		Date	APRIL 28, 2006

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ) Examiner: Saoud, Christine J.  
)  
Avi ASHKENAZI, *et al.* ) Art Unit: 1647  
)  
Application Serial No. 09/904,485 ) Confirmation No: 8938  
)  
Filed: July 13, 2001 ) Attorney's Docket No. 39780-1618 P2C7  
)  
For: **SECRETED AND** ) **Customer No. 35489**  
     **TRANSMEMBRANE** )  
     **POLYPEPTIDES AND NUCLEIC** )  
     **ACIDS ENCODING SAME** )

---

EXPRESS MAIL LABEL NO.: EV 765 973 150 US  
DATE MAILED: APRIL 28, 2006

**ON APPEAL TO THE BOARD OF PATENT APPEALS AND INTERFERENCES**  
**APPELLANTS' AMENDED BRIEF IN RESPONSE TO NOTICE OF NON-**  
**COMPLIANT APPEAL BRIEF**

**MAIL STOP APPEAL BRIEF - PATENTS**

Commissioner for Patents -  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

On October 1, 2004, the Examiner made a final rejection to pending Claims 39-46 and 49-51. A Notice of Appeal was filed on January 5, 2005, and an Appeal Brief was filed on August 5, 2005. An Examiner's Answer was mailed on November 10, 2005, and Appellants' Reply Brief was filed on January 10, 2006.

A Notification of Non-Compliant Appeal Brief was mailed March 28, 2006, which stated that the brief was defective because it lacked a "Related Proceedings" Appendix. The following amended appeal brief has been corrected to include the "Related Proceedings" Appendix (Section 10).

The following constitutes the amended version of Appellants' Brief on Appeal.

## **1. REAL PARTY IN INTEREST**

The real party in interest is Genentech, Inc., South San Francisco, California, by an assignment of the patent application U.S. Serial No. 09/665,350 recorded July 9, 2001, at Reel 011964 and Frame 0181.

## **2. RELATED APPEALS AND INTERFERENCES**

The claims pending in the current application are directed to a polypeptide referred to herein as "PRO217". There exist two related patent applications, (1) U.S. Serial No. 09/906,742, filed July 16, 2001 (containing claims directed to polynucleotides encoding PRO217 polypeptides), and (2) U.S. Serial No. 09/904,011, filed July 11, 2001 (containing claims directed to antibodies that bind PRO217 polypeptides). Both applications are also under final rejection from the same Examiner and based upon the same outstanding rejection, and appeal of these final rejections is being pursued independently and concurrently herewith.

## **3. STATUS OF CLAIMS**

Claims 39-46 and 49-51 are in this application.

Claims 1-38 and 47-48 are canceled.

Claims 39-46 and 49-51 stand rejected and Appellants appeal the rejection of these claims.

A copy of the rejected claims involved in the present Appeal is provided as Appendix A.

## **4. STATUS OF AMENDMENTS**

The claims involved in the appeal have been amended by an amendment filed concurrently with this appeal brief. The claims listed in the Appendix incorporate this amendment.

## **5. SUMMARY OF CLAIMED SUBJECT MATTER**

The invention claimed in the present application is related to an isolated polypeptide comprising the amino acid sequence of the polypeptide of SEQ ID NO:4; the amino acid sequence of the polypeptide-of SEQ ID NO:4, lacking its associated signal peptide; or the amino

acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256 (Claims 44-46 and 49). The invention is further directed to polypeptides having at least 80%, 85%, 90%, 95%, or 99% amino acid sequence identity to the amino acid sequence of the polypeptide of SEQ ID NO:4; the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256, wherein the polypeptide is capable of stimulating proliferation of T-lymphocytes (Claims 39-43). The invention is further directed to a chimeric polypeptide comprising one of the above polypeptides fused to a heterologous polypeptide (Claim 50), and to a chimeric polypeptide wherein the heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin (Claim 51).

The full-length PRO217 polypeptide having the amino acid sequence of SEQ ID NO:4 is described in the specification at, for example, page 35, lines 3-15, page 99, lines 17-29, in Figure 4 and in SEQ ID NO:4. The cDNA nucleic acid encoding PRO217 is described in the specification at, for example, Example 2, in Figure 3 and in SEQ ID NO:3. Page 58, lines 33-36 of the specification provides the description for Figures 3 and 4. PRO polypeptide variants having at least about 80% amino acid sequence identity with a full length PRO polypeptide sequence or a PRO polypeptide sequence lacking the signal peptide are described in the specification at, for example, page 57, lines 2-14, while PRO polypeptide variants having at least about 80% sequence identity to an amino acid sequence encoded by any of the disclosed human cDNAs deposited with the ATCC are described in the specification at, for example, page 57, lines 15-27. The preparation of chimeric PRO polypeptides, including those wherein the heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin, is set forth in the specification at page 116, lines 12-35. Examples 53-56 describe the expression of PRO polypeptides in various host cells, including *E. coli*, mammalian cells, yeast and Baculovirus-infected insect cells. PRO217 is described as a polypeptide having homology to epidermal growth factor (EGF)-like proteins (page 2, line 8, to page 3, line 38, and page 99, lines 17-29).

Example 74 shows that PRO217 tested positive in the mixed lymphocyte reaction (MLR) assay, demonstrating that PRO217 is active as a stimulator of the proliferation of stimulated T-lymphocytes, and therefore would have utility in the treatment of conditions where the



enhancement of an immune response would be beneficial. In addition, Example 69 shows the ability of PRO217 to induce endothelial cell apoptosis, using HUVECs as a model system, while Example 77 shows that PRO217 tested positive in the skin vascular permeability assay.

**6. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL**

- I. Whether the data generated in the MLR assay (Example 74) satisfies the utility requirement of 35 U.S.C. § 101 such that claims 39-46 and 49-51 should be accorded the priority of U.S. provisional application Serial No. 60/100,858 filed on September 17, 1998.
- II. Whether Claims 39-43 and 50-51 satisfy the enablement requirement of 35 U.S.C. § 112, first paragraph.
- III. Whether Claims 39-43 are patentable under 35 U.S.C. §102 over Hsieh *et al.* (Nature 398:431-436 (1999)) and Brewer *et al.* (WO 98/54963, published December 10, 1998).
- IV. Whether Claims 44-46 and 49 are patentable under 35 U.S.C. §102 or alternatively under 35 U.S.C. §103 over Hsieh *et al.* (Nature 398:431-436 (1999)) and Brewer *et al.* (WO 98/54963, published December 10, 1998).

## 7. ARGUMENT

### Summary of the Arguments:

#### Issue I: Utility

Although the Examiner has granted utility for the claimed PRO217 polypeptide based upon its activity of inhibiting VEGF stimulated proliferation of adrenal cortical capillary endothelial cells, Appellants submit that data derived from the mixed leukocyte reaction (MLR) assay, first disclosed in U. S. Application Serial No. 60/100,858 filed September 17, 1998, is also sufficient to establish a patentable utility for the claimed PRO217 polypeptide. Appellants rely upon this utility in order to provide an effective filing date of September 17, 1998.

The MLR is a well-established assay for evaluating test compounds for their ability to stimulate T-lymphocyte proliferation *in vitro*. The MLR assay has been used to identify immunomodulatory compounds, such as tepoxalin or tautomycetin, which have been shown to have real world utility in the suppression of graft rejection. The specification explains that compounds which stimulate proliferation of lymphocytes in this assay, such as PRO217, "are useful therapeutically where enhancement of an immune response is beneficial." Stimulators of T-cell proliferation find utility in fighting viral infections, including retroviral infections, such as HIV infection or Epstein-Barr infection, as well as in the treatment of cancers such as melanoma.

Appellants have also submitted, with their Preliminary Amendment filed July 12, 2004, the Declaration of Dr. Sherman Fong. Dr. Fong provides examples of important clinical applications for immune stimulants which have been shown to stimulate T-cell proliferation in the MLR assay, such as the chemokine IL-12, used in the treatment of melanoma. Dr. Fong concludes that "a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity at least 180% of the control, as specified in the present application, is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant."

The Examiner has asserted that "the results of the MLC (a.k.a. MLR) assay do not support a specific and substantial utility for the claimed invention because the assay is not predictive of immune response in general, and one of ordinary skill in the art would not expect a stimulatory effect in the MLC assay to correlate to a general stimulatory effect on the immune system, absent evidence to the contrary." (Page 6 of the Office Action mailed October 1, 2004).

In support of the assertion that "the MLR assay, which is art recognized for determining histocompatibility, does not appear to be predictive of general immune response *in vivo*," the Examiner has cited references by Kahan *et al.*, Picotti *et al.* and Campo *et al.*

Appellants submit that the Examiner applied an improper legal standard when making this rejection. The applicant does not have to prove that a correlation exists between a particular activity and an asserted therapeutic use of a compound as a matter of statistical certainty. The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration. Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner has made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant.

The Examiner has provided a detailed discussion of alleged inadequacies in the MLR protocol disclosed in the instant specification, including the supposed absence of essential controls. Appellants submit that the Examiner has misinterpreted the focus of the assay disclosed in the specification. The purpose of the assay is not to test the properties of the stimulator cells, as in a typical MLR assay, but to test the ability of a protein, such as PRO217, to enhance the expected response of the T cells, thus demonstrating general immunostimulant activity.

Appellants further submit that the Examiner has not shown that a lack of correlation between results of the MLR assay *in vitro* and immunomodulatory activity *in vivo* is typical. In fact, Picotti *et al.* and Campo *et al.* support Appellants' position that the *in vitro* MLR assay can and has been successfully used to identify compounds having immunomodulatory activity *in vivo*.

The Examiner takes issue with Dr. Fong's statement that "[t]he MLR assay of the present application is designed to measure the ability of a test substance to 'drive' the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously," asserting that this statement is not supported in the specification as filed. Appellants submit that one of skill in the art would have

understood at the time of filing that (i) molecules which enhanced the proliferation of stimulated T-cells would increase the ability of dendritic cells to convert antigens to immunogens, and (ii) such stimulatory molecules would allow antigens that were not usually immunogenic, such as known melanoma or viral antigens, to become immunogenic. This conclusion would have been apparent to the skilled artisan based solely upon knowledge about dendritic cells and their role in antigen presentation that was widely known in the art at the time of filing.

Accordingly, Appellants submit that the MLR assay suffices to provide patentable utility for the subject matter of the instant claims. The claims are therefore entitled to the September 17, 1998, priority date of U.S. Provisional Application No. 60/100,858 in which the results of this assay were first disclosed.

## **Issue II: Enablement**

Claims 39-43 and 50-51 stand rejected under 35 U.S.C. §112, first paragraph, because the specification allegedly "does not reasonably provide enablement for a polypeptide not identical to at least the mature form of SEQ ID NO:4 which is capable of stimulating proliferation of T-lymphocytes." (Page 8 of the Office Action mailed October 1, 2004). The Examiner has asserted that "the basis for this limitation is found in Example 74, which has been shown not to support utility for the claimed invention, and therefore, is likewise, not enabled." (Page 7 of the Office Action mailed July 15, 2003).

Appellants submit that, as discussed above, the MLR assay demonstrates utility for the PRO217 polypeptide for the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable, including viral infections such as HIV and Epstein-Barr, and cancers such as melanoma. Based on such a utility, one of skill in the art would know exactly how to use the claimed polypeptides for the treatment of viral infections and cancer, without any undue experimentation.

Appellants note that the claimed variants, in addition to having at least 80% amino acid sequence identity to SEQ ID NO:4, also have the functional limitation that "the polypeptide is capable of stimulating proliferation of T-lymphocytes." Thus the claimed variants all share the disclosed utility of the PRO217 polypeptide as an immunostimulant. The specification provides ample guidance to allow the skilled artisan to identify those polypeptide variants which meet the limitations of the claims, including a detailed protocol for the MLR assay. The specification also

provides detailed guidance as to how to identify and make polypeptides having at least 80% amino acid sequence identity to PRO217 (SEQ ID.NO:4). Accordingly, one of ordinary skill in the art would understand how to make and use the recited polypeptide variants without any undue experimentation.

**Issue III: Anticipation by Hsieh *et al.* and/or Brewer *et al.*, WO 98/54963**

Claims 39-43 stand rejected under 35 U.S.C. §102(a) as being anticipated by Hsieh *et al.* (Nature 398:431-436, published April 1, 1999). Claims 39-43 further stand rejected under 35 U.S.C. §102(b) as being anticipated by Brewer *et al.* (WO 98/54963, published December 10, 1998).

The instant application claims priority to U.S. Provisional Application Serial No. 60/100,858, filed on September 17, 1998, over six months before the publication date of Hsieh *et al.* and over two months before the publication date of Brewer *et al.* U.S. Provisional Application Serial No. 60/100,858 first disclosed that the PRO217 polypeptide tested positive in the MLR assay.

The instant application has not been granted the earlier priority date on the grounds that "a review of the instant application and this assay do not lead to a conclusion of utility based on this assay, and therefore, priority to the provisional application is not afforded." (Page 3 of the Office Action mailed October 1, 2004).

Appellants respectfully submit that as discussed above under Issues I and II, the presently claimed invention is supported by a specific, substantial and credible utility and, therefore, the present specification teaches one of ordinary skill in the art "how to use" the claimed invention without undue experimentation. Accordingly, the instant application is entitled to the effective filing date of September 17, 1998, and thus neither Hsieh *et al.* nor Brewer *et al.* is prior art.

**Issue IV: Anticipation or Obviousness over Hsieh *et al.* and/or Brewer *et al.*, WO 98/54963**

Claims 44-46 and 49 stand rejected under 35 U.S.C. §102(a) as being anticipated by, or, in the alternative, under 35 U.S.C. §103(a) as obvious over Hsieh *et al.* Claims 44-45 and 49 further stand rejected under 35 U.S.C. §102(b) as being anticipated by, or, in the alternative, under 35 U.S.C. §103(a) as obvious over Brewer *et al.*

As discussed above, the instant application is entitled to priority to U.S. Provisional Application Serial No. 60/100,858, and to the effective filing date of September 17, 1998. Thus neither Hsieh *et al.* nor Brewer *et al.* is prior art.

These arguments are all discussed in further detail below under the appropriate headings.

**ISSUE I: The Data Generated in the MLR Assay Satisfies the Utility Requirement of 35 U.S.C. § 101 for Claims 39-46 and 49-51**

Appellants have asserted that U.S. Application No. 60/100,858, filed September 17, 1998, discloses stimulatory activity in the mixed leukocyte reaction (MLR) assay, and that the data generated in the MLR assay (shown in Example 74 of the instant specification) establish patentable utility for the claimed PRO217 polypeptides. The Examiner has asserted that although "the claimed invention has met the utility requirement based on its activity of inhibiting VEGF stimulated proliferation of adrenal cortical capillary endothelial cells ... the invention lacks utility based on the assertion that the claimed invention could be used therapeutically to enhance the immune response in an individual." (Page 3 of the Office Action mailed October 1, 2004).

Appellants submit, for the reasons set forth below, that the MLR assay disclosed in Example 74 of the specification provides at least one credible, substantial and specific asserted utility for the claimed PRO217 polypeptides.

**A. The Legal Standard for Utility**

According to 35 U.S.C. § 101:

Whoever invents or discovers any new and *useful* process, machine, manufacture, or composition of matter, or any new and *useful* improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. (Emphasis added.)

In interpreting the utility requirement, in *Brenner v. Manson*<sup>1</sup> the Supreme Court held that the *quid pro quo* contemplated by the U.S. Constitution between the public interest and the interest of the inventors required that a patent applicant disclose a "substantial utility" for his or her invention, i.e. a utility "where specific benefit exists in currently available form."<sup>2</sup> The Court

---

<sup>1</sup> *Brenner v. Manson*, 383 U.S. 519, 148 U.S.P.Q. (BNA) 689 (1966).

concluded that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion. A patent system must be related to the world of commerce rather than the realm of philosophy."<sup>3</sup>

Later, in *Nelson v. Bowler*<sup>4</sup> the C.C.P.A. acknowledged that tests evidencing pharmacological activity of a compound may establish practical utility, even though they may not establish a specific therapeutic use. The court held that "since it is crucial to provide researchers with an incentive to disclose pharmaceutical activities in as many compounds as possible, we conclude adequate proof of any such activity constitutes a showing of practical utility."<sup>5</sup>

In *Cross v. Iizuka*<sup>6</sup> the C.A.F.C. reaffirmed *Nelson*, and added that *in vitro* results might be sufficient to support practical utility, explaining that "*in vitro* testing, in general, is relatively less complex, less time consuming, and less expensive than *in vivo* testing. Moreover, *in vitro* results with the particular pharmacological activity are generally predictive of *in vivo* test results, i.e. there is a reasonable correlation there between."<sup>7</sup> The court perceived "No insurmountable difficulty" in finding that, under appropriate circumstances, "*in vitro* testing, may establish a practical utility."<sup>8</sup>

Furthermore, M.P.E.P. 2107.03 (III) states that:

"If reasonably correlated to the particular therapeutic or pharmacological utility, data generated using *in vitro* assays, or from testing in an animal model or a combination thereof almost invariably will be sufficient to establish therapeutic or pharmacological utility for a compound, composition or process."

Thus, the legal standard accepts that *in vitro* or animal model data is acceptable utility as long as the data is "reasonably correlated" to the pharmacological utility described.

---

<sup>2</sup> *Id.* at 534, 148 U.S.P.Q. (BNA) at 695.

<sup>3</sup> *Id.* at 536, 148 U.S.P.Q. (BNA) at 696.

<sup>4</sup> *Nelson v. Bowler*, 626 F.2d 853, 206 U.S.P.Q. (BNA) 881 (C.C.P.A. 1980).

<sup>5</sup> *Id.* at 856, 206 U.S.P.Q. (BNA) at 883.

<sup>6</sup> *Cross v. Iizuka*, 753 F.2d 1047, 224 U.S.P.Q. (BNA) 739 (Fed. Cir. 1985).

<sup>7</sup> *Id.* at 1050, 224 U.S.P.Q. (BNA) at 747.

<sup>8</sup> *Id.*

The case law has also clearly established that applicants' statements of utility are usually sufficient, unless such statement of utility is unbelievable on its face.<sup>9</sup> The PTO has the initial burden to prove that applicants' claims of usefulness are not believable on their face.<sup>10</sup> In general, an Applicant's assertion of utility creates a presumption of utility that will be sufficient to satisfy the utility requirement of 35 U.S.C. §101, "unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope."<sup>11, 12</sup>

Compliance with 35 U.S.C. §101 is a question of fact.<sup>13</sup> The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration.<sup>14</sup> Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant. The issue will then be decided on the totality of evidence.

The well established case law is clearly reflected in the Utility Examination Guidelines ("Utility Guidelines")<sup>15</sup>, which acknowledge that an invention complies with the utility requirement of 35 U.S.C. §101, if it has at least one asserted "specific, substantial, and credible utility" or a "well-established utility." Under the Utility Guidelines, a utility is "specific" when it is particular to the subject matter claimed. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic without also identifying the conditions that are to be diagnosed.

---

<sup>9</sup> *In re Gazave*, 379 F.2d 973, 154 U.S.P.Q. (BNA) 92 (C.C.P.A. 1967).

<sup>10</sup> *Ibid.*

<sup>11</sup> *In re Langer*, 503 F.2d 1380,1391, 183 U.S.P.Q. (BNA) 288, 297 (C.C.P.A. 1974).

<sup>12</sup> See also *In re Jolles*, 628 F.2d 1322, 206 U.S.P.Q. 885 (C.C.P.A. 1980); *In re Irons*, 340 F.2d 974, 144 U.S.P.Q. 351 (1965); *In re Sichert*, 566 F.2d 1154, 1159, 196 U.S.P.Q. 209, 212-13 (C.C.P.A. 1977).

<sup>13</sup> *Raytheon v. Roper*, 724 F.2d 951, 956, 220 U.S.P.Q. (BNA) 592, 596 (Fed. Cir. 1983) cert. denied, 469 US 835 (1984).

<sup>14</sup> *In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d (BNA) 1443, 1444 (Fed. Cir. 1992).

<sup>15</sup> 66 Fed. Reg. 1092 (2001).



In explaining the “substantial utility” standard, M.P.E.P. §2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, any reasonable use that an applicant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient, at least with regard to defining a ‘substantial’ utility.”<sup>16</sup> Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement,<sup>17</sup> gives the following instruction to patent examiners: “If the applicant has asserted that the claimed invention is useful for any particular practical purpose . . . and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility.”

**B. The Data and Documentary Evidence Supporting a Patentable Utility**

Appellants submit that the mixed lymphocyte reaction (MLR) assay described in Example 74 is sufficient to establish patentable utility under 35 U.S.C. §101 for the PRO217 polypeptide. The positive result for PRO217 in the MLR assay, described in Example 74, at pages 208-209 of the specification, demonstrates that PRO217 is active as a stimulator of the proliferation of stimulated T-lymphocytes.

The MLR is a well-established assay for evaluating test compounds, such as the PRO217 polypeptide, for their ability to stimulate T-lymphocyte proliferation *in vitro*, and consequently, for assessing the immune response of an individual. The MLR assay is well-described in standard textbooks, including, for example, *Current Protocols in Immunology*, unit 3.12; edited by J E Coligan, A M Kruisbeek, D H Marglies, E M Shevach, W Strober, National Institutes of Health, Published by John Wiley & Sons, Inc., which is referenced in Example 74, and the entire content of which is expressly incorporated by reference into the disclosure of the present application (see page 208, lines 33-35). In brief, in this method, an immune response results upon mixing T-cells from antigenically distinct individuals under cell culture conditions. An MLR reaction can be monitored quantitatively by, for example, following the incorporation of

---

<sup>16</sup> M.P.E.P. §2107.01.

<sup>17</sup> M.P.E.P. §2107 II (B)(1).

tritiated thymidine during DNA synthesis, or by observing blast formation, or by other methods well known in the art.

According to the specification, positive increases over control in this assay are considered to be positive results, with increases of greater than or equal to 180% being preferred. However, any value greater than control indicates a stimulatory effect for the test protein. PRO217 (SEQ ID NO: 4) tested positive in this assay, using the described criteria. Example 74 further explains that compounds which stimulate proliferation of lymphocytes in this assay "are useful therapeutically where enhancement of an immune response is beneficial." Accordingly, PRO217 has utility in the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable.

In support of this assertion, Appellants submit that the MLR assay has been extensively used and is the best *in vitro* model for screening immunosuppressive agents for use in the prevention of graft-versus-host disease and graft rejection. It is well known that the transplantation of tissues or organs between individuals with MHC incompatibilities quickly activates the recipient's immune system which then attempts to destroy the transplanted tissue or organ. Transplantation across minor histocompatibility loci generally induces a more indolent response. Physicians analyze the major and minor histocompatibility differences to predict the success of the graft and to adjust the aggressiveness of immunosuppressive therapy.

Inhibitors of the MLR find utility in suppressing unwanted immune response, and thus suppress unwanted graft rejection. For example, the ability of tepoxalin, an immunomodulatory compound, to suppress graft-versus-host reaction, has been demonstrated using the MLR assay (Fung-Leung *et al.*, *Transplantation* 60:362-8 (1995); submitted with the Response filed September 8, 2003). Other immunosuppressants have also been routinely identified using the MLR assay. For example, the immunosuppressive efficacy of SNF4435 and D, produced by a strain of *Streptomyces spectabilis*, has been tested using the MLR assay. As recently as 2002, the immunosuppressive effect of tautomycin (TMC) was assessed with mixed lymphocyte reactions, and confirmed *in vivo* using TMC-treated rats that received a heterotopic cardiac allograft (Shim *et al.*, *Proc. Natl. Acad. Sci USA* 99(16):10617-10622 (2002); made of record in the Response filed September 8, 2003). Based upon the MLR data, the authors were able to

conclude with confidence that "TMC has the capacity to inhibit the intracellular signaling pathway leading to T cell activation and proliferation." (See page 10621, second column).

Thus, the art as a whole clearly establishes that the mixed lymphocyte reaction (MLR) is a widely used *in vitro* assay for identifying immunomodulatory compounds.

In further support of utility based upon the MLR assay, Appellants have submitted (with their Preliminary Amendment filed July 12, 2004) the Declaration of Sherman Fong, Ph.D. Dr. Fong is an inventor of the above-identified patent application, and an experienced scientist familiar with the MLR assay, which was used by him and others under his supervision, to test the immune stimulatory or immune inhibitory activity of novel polypeptides discovered in Genentech's Secreted Protein Discovery Initiative project, including PRO217.

The Fong Declaration explains how the MLR reaction was performed in the instant application using peripheral blood mononuclear cells (PBMCs), which contain responder T-cells, and allogenic, pre-treated (irradiated) PBMCs, which predominantly contained dendritic cells. Dr. Fong proceeds to explain (paragraph 7 of the Declaration) that dendritic cells are potent antigen-presenting cells that are able to "prime native T cells *in vivo*." Once activated by dendritic cells, the T-cells are capable of interacting with other antigen-presenting cells (B cells and macrophages) to produce additional immune responses from these cells.

As Dr. Fong states, the MLR assay of the present application is designed to measure the ability of a test substance to "drive" the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously. (Paragraph 8 of the Fong Declaration.)

As Dr. Fong emphasizes, immunostimulants are important and highly desirable in the treatment of cancer and in enhancing the effectiveness of previously identified treatments for cancer. Supportive evidence also comes from teachings in the art such as Steinman *et al.* (submitted as Exhibit B with the Preliminary Amendment filed July 12, 2004) who state that **"...medicine needs therapies that enhance immunity or resistance to infections and tumors"** (page 1, column 1, line 7; emphasis added).

In paragraph 9 of his Declaration, Dr. Fong provides examples of important clinical applications for immune stimulants which have been shown to stimulate T-cell proliferation in the MLR assay. As Dr. Fong explains,

"IL-12 is a known immune stimulant, which has been shown to stimulate T-cell proliferation in the MLR assay. IL-12 was first identified in just such an MLR [Gubler et al. PNAS 88, 4143 (1991) (Exhibit C)]. In a recent cancer vaccine trial, researchers from the University of Chicago and Genetics Institute (Cambridge, MA) have demonstrated the efficacy of the approach, relying on the immune stimulatory activity of IL-12, for the treatment of melanoma. [Peterson et al. Journal of Clinical Oncology 21 (12), 2342-48 (2003) (Exhibit D)] They extracted circulating white blood cells carrying one or more markers of melanoma cells, isolated the antigen, and returned them to the patients. Normally patients would not have an immune response to his or her own human antigens. The patients were then treated with different doses of IL-12, an immune stimulant capable of inducing the proliferation of T cells that have been co-stimulated by dendritic cells. Due to the immune stimulatory effect of IL-12, the treatment provided superior results in comparison to earlier work, where patients' own dendritic cells were prepared from peripheral blood mononuclear cells (PBMCs), treated with antigens, then cultured *in vitro* and returned to the patient to stimulate anti-cancer response. [Turner et al. J. Exp. Med. 190 (11), 1669-78 (1999) (Exhibit E)]."

Dr. Fong concludes that (paragraph 10):

It is my considered scientific opinion that a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity at least 180% of the control, as specified in the present application, is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant."

Accordingly, the positive results obtained in this assay clearly establish the immunostimulant utility for the polypeptides claimed in the present application, and the specification, in turn, enables one skilled in the art to use the compounds for the asserted purpose.

The Examiner has asserted that "the specification fails to provide any data or evidence of the results of the assay, therefore, one of ordinary skill in the art cannot evaluate the conclusion." (Page 5 of the Office Action mailed October 1, 2004). Appellants respectfully submit that the specification clearly discloses that PRO217 tested positive in the MLR assay. The Fong Declaration reinforces the teachings of the specification that a PRO polypeptide with an activity

in the MLR assay of at least 180% of the control is expected to have the type of activity exhibited by IL-12, and would therefore find practical utility as an immune stimulant.

Appellants respectfully submit that the Examiner seems to be applying a heightened utility standard in this instance, which is legally incorrect. The Examiner appears to ignore the teachings within an expert's declaration without any basis, or without presenting any evidence to the contrary. Appellants respectfully draw the Board's attention to the Utility Examination Guidelines (Part IIB, 66 Fed. Reg. 1098 (2001)) which state that:

"Office personnel must accept an opinion from a qualified expert that is based upon relevant facts whose accuracy is not being questioned; it is improper to disregard the opinion solely because of a disagreement over the significance or meaning of the facts offered".

Thus, barring evidence to the contrary, Appellants maintain that the positive result for PRO217 in the MLR assay is significant, and forms the basis for the utility claimed herein.

The Examiner has further asserted that "the ability of a protein to stimulate lymphocyte proliferation in this assay does not support a specific and substantial utility for the claimed invention. The ability to stimulate or inhibit lymphocyte proliferation in the MLR assay is an artificial *in vitro* system and does not provide for what specific conditions or for which specific diseases the claimed invention would predictably function. The assertion that the claimed invention could be useful for the treatment of conditions where the enhancement of the immune response would be beneficial ... is not specific since there are many such conditions, and it is not predictable of which conditions the claimed invention may function, if any." (Page 3 of the Office Action mailed July 15, 2003).

Appellants submit that the teachings of the specification are properly evaluated through the eyes of one skilled in the pertinent art at the effective filing date of the present application. In 1998 it was well known in the art, as it is today, that T-cells are highly important in the body's natural defense mechanisms for fighting infections. For example, viral infections, such as HIV infection, are well known to result in reduced T cell count. Indeed, the count of T-cell lymphocytes is a generally accepted measure of the extent and seriousness of HIV infection and resultant AIDS. Accordingly, stimulators of T-cell proliferation find utility in fighting viral infections, including retroviral infections, such as HIV infection or Epstein-Barr infection.

It was also well known at the time of filing that T cells can recognize tumor antigens and

kill tumors. See, for example, Thurner *et al.*, J. Exp. Med. 190:1669-1678 (1999) (submitted as Exhibit E with the Preliminary Amendment filed July 12, 2004), which describes experimental procedures designed to treat melanoma by boosting the immune response. Accordingly, immunostimulant molecules such as PRO217 also have utility in the treatment of cancers such as melanoma.

As discussed above, the legal standard is that *in vitro* results are acceptable to demonstrate utility. Further, the data derived from the MLR assay is "reasonably correlated" to the asserted pharmacological utility, because one of ordinary skill in the art would understand, based upon the discussion above, that molecules showing immunostimulant activity as measured in the MLR assay would be useful in the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable, including viral infections such as HIV and Epstein-Barr, and cancers such as melanoma. Accordingly, a valid case for utility has been made and would be considered credible by a person of ordinary skill in the art.

**C. A prima facie case of lack of utility has not been established**

The Examiner has asserted that the data derived from the MLR assay is not correlated to pharmacological utility, because the MLR assay is allegedly not predictive of the general immune response. In particular, the Examiner has asserted that "the results of the MLC (a.k.a. MLR) assay do not support a specific and substantial utility for the claimed invention because the assay is not predictive of immune response in general, and one of ordinary skill in the art would not expect a stimulatory effect in the MLC assay to correlate to a general stimulatory effect on the immune system, absent evidence to the contrary." (Page 6 of the Office Action mailed October 1, 2004). In support of this assertion, the Examiner has cited the immunology texts "Basic and Clinical Immunology" and "Manual of Clinical Laboratory Immunology," as well as references by Kahan *et al.*, Picotti *et al.* and Campo *et al.*

Appellants submit that the Examiner has misinterpreted the focus of the assay disclosed in the specification. The purpose of the assay is not to test the properties of the stimulator cells, as in a typical MLR assay, but to test the ability of a protein, such as PRO217, to enhance the expected response of the T cells, thus demonstrating general immunostimulant activity. Appellants further submit that the Examiner has not correctly characterized the teachings of Kahan *et al.*, Picotti *et al.* and Campo *et al.* These references, in combination with those cited by

Appellants, demonstrate the art as a whole recognizes that the mixed lymphocyte reaction (MLR) is in fact a widely used *in vitro* assay for identifying immunomodulatory compounds.

1. *The MLR assay is used to demonstrate general immunostimulant activity of the test protein PRO217*

In support of the rejection, the Examiner goes into considerable detail explaining the mechanism of the MLR, also known as the mixed lymphocyte culture (MLC) assay. The Examiner's primary point is that the MLR assay allegedly has not been shown to be predictive for general immune responses *in vivo* because it is a special case of antigen stimulation in which T lymphocytes respond to foreign histocompatibility antigens on unrelated lymphocytes or monocytes. According to the Examiner, this "reaction is not predictive of general responses of the immune system because, *in vivo*, activation of a lymphocyte is controlled not only by antigen binding but also by interactions with other cells."

Appellants respectfully point out that the MLR assay also depends upon the interactions of T lymphocytes with other cells, in particular, with the stimulator cells used in the described MLR protocol. As explained in the textbook "Basic and Clinical Immunology," cited by the Examiner, T cells cooperate with antigen presenting cells (page 31, col. 2) *in vivo*. The most potent antigen presenting cells are dendritic cells, which are the predominant cell type found in the irradiated stimulator cell population, as explained in the Fong Declaration (see paragraphs 5-6). Thus the MLR assay does measure the interaction of T-lymphocytes with other cells, and therefore is a valid predictive model system in this respect.

The Examiner has further asserted that "[t]he ability of the claimed invention to stimulate proliferation in the MLC assay may not be a general stimulus to lymphocyte proliferation, but rather a reaction to one of the MHC antigens on the responder cell." (Page 5 of the Office Action mailed October 1, 2004). Appellants submit that the Examiner appears to have misinterpreted the intent of the assay. It is understood that, as the Examiner has stated, the MLR is based upon an allogenic response. Thus the mixing of the stimulator and responder cells is expected to lead to T cell proliferation even in the absence of any test protein. However, the point of the assay is not to measure the degree to which the stimulator cells induce proliferation of the responder cells. Rather, the point is to measure the extent to which the test protein can enhance the expected proliferation of the stimulated T cells.

This misunderstanding is further demonstrated in the Examiner's discussion of supposedly "essential" controls. The Examiner has asserted that "there are several controls which the art recognizes as being essential for meaningful results for this assay, including autologous controls, a control to determine maximum response, screening for possible HLA antibodies and growth support capabilities" as well as internal controls to account for inherent variability of individual cellular responses. (Page 5 of the Office Action mailed October 1, 2004). Appellants submit that these controls are only needed when the purpose of carrying out the MLR assay is to evaluate the properties of the stimulator cells. As shown, for example, in Figure 16-4 of "Basic and Clinical Immunology, cited by the Examiner, the comparisons to mismatched (maximum response) and autologous (background) controls allow one to determine the degree of HLA class II antigen similarity between the stimulator cells and the responder cells. Such determinations, however, are not relevant to the MLR assay of Example 74.

The purpose of the assay disclosed in the instant specification, as discussed above, is to characterize not the stimulator cells, but the test proteins, such as PRO217. The precise extent to which the stimulator cells stimulate the responder cells is not significant; what matters is the degree to which the test protein increases this response. The extent to which the test protein increases the response of the T cells is measured by comparison to a negative control reaction, which uses either cell culture medium, or a non immunostimulant molecule, CD4-IgG, as a negative control. Because the response in the test reaction is compared to a negative control reaction, and because both reactions use the same stimulator and responder cells at the same time, additional controls to determine the precise properties of these cells are not required.

2. *The art recognizes the MLR as an in vitro assay useful for identifying compounds with immunomodulatory activity in vivo*

In support of the assertion that "the MLC assay, which is art recognized for determining histocompatibility, does not appear to be predictive of general immune response *in vivo*," the Examiner has cited references by Kahan *et al.*, Picotti *et al.* and Campo *et al.* (See page 5 of the Office Action mailed July 15, 2003). All three references study allograft rejections and immunosuppression of graft rejection using test compounds studied *in vitro*.

As a preliminary matter, Appellants submit that, as discussed above, the evidentiary standard to be used throughout *ex parte* examination of a patent application is a preponderance of



the totality of the evidence under consideration. Accordingly, Appellants submit that in order to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that **it is more likely than not** that one of ordinary skill in the art would doubt the truth of the statement of utility. With respect to asserted therapeutic utilities based upon *in vitro* data, an applicant "does not have to prove that a correlation exists between a particular activity and an asserted therapeutic use of a compound as a matter of statistical certainty."<sup>18</sup> The law requires only that one skilled in the art should accept that such a correlation is **more likely than not to exist**. Appellants respectfully submit that when the proper evidentiary standard is applied, a correlation must be acknowledged.

The Examiner cited Kahan *et al.* as stating that "no *in vitro* immune assay predicts or correlates with *in vivo* immunosuppressive activity; there is no surrogate immune parameter as a basis of immunosuppressive efficacy and/or for dose extrapolation from *in vitro* systems to *in vivo* conditions." (Page 4 of the Office Action mailed July 15, 2003). Appellants respectfully note that the asserted utility for the claimed PRO217 polypeptides is as an immunostimulant, not an immunosuppressor. The Examiner has asserted that "if one of ordinary skill in the art concluded that an *in vitro* immune assay was not predictive or correlative of immunosuppression, they are also likely to conclude that the same assay is not predictive or correlative with immunostimulation, absent evidence to the contrary." (Page 2 of the Advisory Action mailed November 19, 2003). Appellants submit that, as discussed above, the art as a whole clearly establishes that the mixed lymphocyte reaction (MLR) is a widely used *in vitro* assay for identifying immunomodulatory compounds, as demonstrated by the examples of tepoxalin, tautomycetin, and IL-12. Further, Picotti *et al.*, cited by the Examiner, provides evidence that a molecule which does not show the predicted activity in the specific pathway of graft versus host interaction, may still have general immunomodulatory activity.

The Examiner cited Picotti *et al.* as demonstrating that "IL-12 enhances alloantigen-specific immune function as determined by MLC, but this result *in vitro* does not result in a measurable response *in vivo* (i.e. failure to accelerate graft rejection)." Appellants first note that the asserted utility of PRO217 is not accelerated allograft rejection, which is hardly a process that

---

<sup>18</sup> M.P.E.P. 2107.03

medical practitioners would wish to accelerate. Thus the fact that IL-12 does not accelerate allograft rejection is not relevant to the utility of PRO217. Nor is the failure of IL-12 to accelerate allograft rejection an indication that IL-12 does not possess general immunostimulant properties *in vivo*. Picotti *et al.* confirm that "IL-12 is also a key cytokine involved in promoting cell mediated immune responses *in vivo*" (page 1459, col. 1). The fact that a molecule such as IL-12 that has known *in vivo* immunostimulant properties does not accelerate graft rejection supports Appellants' argument that graft rejection is a specific pathway that does not necessarily reflect general immunoregulatory function. Picotti *et al.* draw a similar conclusion, suggesting that "the magnitude of Th1-driven alloimmune response may not correlate directly to the severity of graft rejection," perhaps because Th2-driven immune responses are more relevant to graft rejection (page 1459, col. 2).

The Examiner has further asserted that Campo *et al.* "demonstrate that while zinc suppresses alloreactivity in MLC, it does not decrease T-cell proliferation *in vitro* nor produce immunosuppressive effects *in vivo*. (Page 5 of the Office Action mailed July 15, 2003). Appellants respectfully point out that the Examiner has misinterpreted this statement, due to the fact that the authors refer to two different types of immunosuppressive effects. Campo *et al.* set out to look for an inhibitor of MHC *in vitro* which would have the fewest side effects *in vivo* (see Abstract). The authors note that high concentrations of zinc "impair **all** T cell and monocyte function" (page 20; emphasis added). The authors took this impairment as an indicator of toxicity, and therefore intentionally used concentrations of zinc below that at which all T-cell function was impaired, in order to identify a concentration range that would not result in toxic effects. However, that does not mean that Campo *et al.* found zinc to have no immunosuppressive activity *in vivo*. In fact, the authors conclude, based upon their MLC results, that "zinc **could become an immunosuppressant in transplantation medicine** without toxic side effects" (page 21; emphasis added). Thus Campo *et al.* supports Appellants' position that those of skill in the art would interpret the results of MLC assays as having physiological relevance.

Appellants note that the Examiner has failed to point out several instances within these cited references wherein the authors stated that the MLR is an important method with a good predictive value. For example, Campo *et al.* teach that "the human mixed lymphocyte culture

(MLC) is an important method to test donor-recipient compatibility in bone marrow transplantation. It could be shown that cytokine release, especially IFN- $\gamma$ , **has a very good predictive value with regard to the transplantation outcome**, as cytokines play a major role in the generation of an alloreactive immune response and for the induction of graft rejection *in vivo*.....Landolfo *et al.* inhibited T-cell reactivity by the addition of anti-IFN- $\gamma$  **both *in vitro* and *in vivo***" (see page 18; emphasis added). Further, Picotti *et al.* showed that the IL-12R $\beta$ 1 subunit was critical for IL-12 driven enhanced alloimmune response ***in vitro* and *in vivo*** (see abstract). Thus, while there are instances of unpredictability using the MLR assay, there are many studies showing predictable results, including studies from Picotti, Landolfo and the IFN- $\gamma$  study. Finally, Campo *et al.* teaches that "cyclosporin A, FK506, and other substances are used to prevent graft rejection. ***In vitro* experiments revealed an inhibition of the MLC**" (page 16). Thus the teachings of Campo *et al.* confirm that inhibition of the MLR is observed for known immunoinhibitory molecules, that are in actual clinical use.

In summary, Appellants respectfully submit that the Examiner has not shown that a lack of correlation between results of the MLR assay *in vitro* and immunomodulatory activity *in vivo* is typical. In fact, Picotti *et al.* and Campo *et al.* support Appellants' position that it is more likely than not that the *in vitro* MLR assay can be successfully used to identify compounds having immunomodulatory activity *in vivo*. The Patent Office has failed to meet its initial burden of proof that Appellants' claims of utility are not substantial or credible.

**D. The Fong Declaration supports "real world" utility for proteins that test positive in the MLR assay**

The Examiner has asserted that "[t]he [Fong] Declaration under 37 CFR 1.132 filed 12 July 2004 is insufficient to overcome the holding of lack of utility based on results of the MLR assay." In particular, the Examiner takes issue with Dr. Fong's statement that "[t]he MLR assay of the present application is designed to measure the ability of a test substance to "drive" the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously." The Examiner

states that "[t]his is not what the instant specification asserts at pages 208-209. There is no mention in the instant specification about boosting the immune system 'to respond to a particular antigen that may not have been immunologically active previously.'" The Examiner asserts that "Dr. Fong is reading the results of the Peterson et al. reference into the disclosure of the instant specification," and that because this reference was not available at the time the instant application was filed, "reliance on the methods and results of this reference is improper." (Page 6 of the Office Action mailed October 1, 2004).

Appellants submit that the statements of Dr. Fong regarding the purpose of the MLR assay described in the instant specification are not based upon the Peterson *et al.* reference, but upon evidence regarding the properties of antigens and antigen presenting cells that was well known in the immunological art at the time the instant application was filed.

The specification discloses that the stimulator cells used in the MLR assay were treated with 3000 Rads of radiation. As explained in the Fong Declaration,

This irradiation is done in order to create a sample of cells that has mainly dendritic cells. It is known that the dendritic cell population among the PBMCs are differentially affected by irradiation. At low doses (500-1000 Rad), the proliferation of most cells, including the B cells in the PBMCs, is preserved, however, at doses above 2000 Rad, this function of B cells is abolished. Dendritic cells on the other hand, maintain their antigen presentation function even at a 3000 Rad dose of radiation.

Thus one of ordinary skill in the art, upon reading that the cells were treated with 3000 Rads, would have understood that, as a consequence of that treatment, the stimulator cells would be predominantly dendritic cells (DCs).

It was well known at the time of filing that, as disclosed in Steinman *et al.*, "[t]he best studied function of DCs is to convert antigens into immunogens for T cells" (Abstract). Appellants note that while the article by Steinman *et al.* was published in 2000, it is a review article that summarizes previous findings in the field, and cites articles on dendritic cells from 1997 and 1998 (page 586, col. 2). Thus Steinman *et al.* provide an accurate indication as to what was known in the art at the instant application's asserted priority date of September 1998.

It was also the case that "protein antigens often are known for a tumor-like melanoma, or for a virus like HIV-1 whose genetic sequence has been available," but that **these antigens needed to become immunogenic, that is, capable of inducing a T cell response** (Steinman *et*

*al.*, page 585, col. 1; emphasis added). The use of DCs in therapeutic treatment for melanoma was already being tested in clinical trials around the priority date of the instant application, as evidenced, for example, by Thurner *et al.*, whose results were completed and published by 1999. Steinman *et al.* further disclose that "[i]n order for an antigen to become a strong immunogen, one needs to provide a stimulus for the final maturation of the DCs," explaining that most DCs in the body **"are in an immature state and lack features leading to a strong T cell response"** (page 585, col. 2; emphasis added).

Thus one of skill in the art would have understood at the time of filing that (i) molecules which enhanced the proliferation of stimulated T-cells would increase the ability of DCs to convert antigens to immunogens, and (ii) such stimulatory molecules would allow antigens that were not usually immunogenic, such as the melanoma or viral antigens described above, to become immunogenic. Therefore, while the specification does not use the precise language that the purpose of the MLR assay was to identify molecules capable of boosting the immune system "to respond to a particular antigen that may not have been immunologically active previously," the structure of the assay, which is designed to find molecules that increase DC-induced T-cell proliferation, is clearly intended to find precisely such molecules. This conclusion would have been apparent to the skilled artisan based solely upon knowledge about DCs and their role in antigen presentation that was widely known in the art at the time of filing.

The Examiner has also disputed the relevance of the Gubler *et al.* article, cited by Dr. Fong in his Declaration as providing an example in which the MLR assay was used to identify a molecule, IL-12, that was proven to also have *in vivo* immunostimulant activity. The Examiner has asserted that "a review of Gubler *et al.* does not reveal the use of MLR in evaluating the biological effects of IL-12" and adds that "further work of researchers regarding IL-12 was not based on the results of a single assay, being the MLR, but rather by a body of work which provides for a number of biological activities of IL-12, which are not disclosed for the claimed invention". (Page 7 of the Office Action mailed October 1, 2004).

Gubler *et al.* identified CLMF (Cytokine Lymphocyte Maturation Factor), a heterodimeric lymphokine, and designated it as interleukin 12. Gubler *et al.* reported the molecular cloning and expression of CLMF (see column 1, last line and Materials and Methods), and performed two biological assays: (i) the T-cell growth factor assay (see Table 1 and Fig. 3

(upper panel) and (ii) the LAK (lymphokine activated killer) cell induction assay. In the T-cell growth factor assay, PHA-activated lymphoblasts prepared from human PBMCs were used to measure lymphoblast proliferation in a tritiated thymidine assay very similar to the instant MLR assay (see legend of Table 1). Table 1 summarizes the results and demonstrates that the two subunits, 35 kDa and 40 kDa of CLMF together showed the highest incorporation (58,615 cpm and 38,361 cpm incorporation for 1:20 and 1:100 dilution). As Gubler *et al.* discloses in column 1, page 4143: "we initiated a search for novel cytokines that would synergize with suboptimal concentrations of recombinant IL-2 to activate cytotoxic lymphocytes *in vitro* and thus might have synergistic immunoenhancing effects when administered together with recombinant IL-2 *in vivo*. This led to the identification of a factor, designated CLMF".

Therefore, while Gubler *et al.* did not use the same MLR assay as disclosed in the instant specification, they used a similar *in vitro* assay of T-cell proliferation, confirming Appellants' assertion that such *in vitro* systems are predictive of *in vivo* efficacy. Further, Appellants submit that the "body of work" performed by Gubler *et al.* was CLMF cDNA cloning, expression, and computer searches for homology, which are routine experiments done to characterize any novel protein and do not represent "a number of biological activities." The only other biological assay performed in this study was the "LAK cell induction assay" discussed above. The activation of lymphocytes in an *in vitro* T-cell proliferation assay similar to the MLR assay was sufficient for the authors to conclude that CLMF/IL-12 was an immunoenhancing agent that could be administered *in vivo*.

The Examiner asserts that there is allegedly "no evidence of record which correlates an activity of at least 180% of control as predictive of an activity of IL-12. It is not clear from what data this conclusion is derived. Therefore, the Declaration is not persuasive to overcome the holding of a lack of utility for the claimed invention based on the MLR assay" (Pages 7-8 of the Office Action mailed October 1, 2004).

The case law has clearly established that in considering affidavit evidence, the Examiner must consider all of the evidence of record anew.<sup>19</sup> "After evidence or argument is submitted by the applicant in response, patentability is determined on the totality of the record, by a

---

<sup>19</sup> *In re Rinehart*, 531 F.2d 1084, 189 U.S.P.Q. 143 (C.C.P.A. 1976) and *In re Piasecki*, 745 F.2d. 1015, 226 U.S.P.Q. 881 (Fed. Cir. 1985).

preponderance of the evidence with due consideration to persuasiveness of argument"<sup>20</sup> Furthermore, the Federal Court of Appeals held in *In re Alton*, "We are aware of no reason why opinion evidence relating to a fact issue should not be considered by an examiner"<sup>21</sup>. Appellants also respectfully draw the Examiner's attention to the Utility Examination Guidelines<sup>22</sup> which state, "Office personnel must accept an opinion from a qualified expert that is based upon relevant facts whose accuracy is not being questioned; it is improper to disregard the opinion solely because of a disagreement over the significance or meaning of the facts offered." The statement in question from an expert in the field (the Fong Declaration) states that "(i)t is my considered scientific opinion that a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity of at least 180% of the control is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant." Therefore, barring evidence to the contrary regarding the above statement in the Fong Declaration, this rejection is improper under both the case law and the Utility guidelines.

For the reasons given above, Appellants respectfully submit that the results of the MLR assay as shown in Example 74 of the present specification, and first disclosed in U.S. Provisional Application No. 60/100,858, filed September 17, 1998, provide a specific, substantial and credible utility under 35 U.S.C. §101 for the claimed invention. Accordingly, Appellants respectfully request that the subject matter of the instant claims be granted the September 17, 1998, priority date of U.S. Provisional Application No. 60/100,858.

**ISSUE II: Claims 39-43 and 50-51 satisfy the enablement requirement of 35 USC §112, first paragraph.**

Claims 39-43 and 50-51 stand rejected under 35 U.S.C. §112, first paragraph, allegedly "because the specification, while being enabling for an isolated polypeptide having at least 80% amino acid sequence identity to the polypeptide of SEQ ID NO:4 or the mature form thereof, which

---

<sup>20</sup> *In re Alton*, 37 U.S.P.Q.2d 1578 (Fed. Cir 1966) at 1584 quoting *In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992)).

<sup>21</sup> *In re Alton*, *supra*.

<sup>22</sup> Part IIB, 66 Fed. Reg. 1098 (2001).

isolated polypeptide inhibits VEGF stimulated proliferation of adrenal cortical capillary endothelial cells, does not reasonably provide enablement for a polypeptide not identical to at least the mature form of SEQ ID NO:4 which is capable of stimulating proliferation of T-lymphocytes." (Page 8 of the Office Action mailed October 1, 2004).

The Examiner has asserted that "the basis for this limitation is found in Example 74, which has been shown not to support utility for the claimed invention, and therefore, is likewise, not enabled." (Page 7 of the Office Action mailed July 15, 2003).

In this regard, Appellants refer to the arguments and information presented above in response to the issue of utility, wherein those arguments are incorporated by reference herein. Appellants submit that, as discussed above, the MLR assay demonstrates utility for the PRO217 polypeptide for the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable, including viral infections such as HIV and Epstein-Barr, and cancers such as melanoma. Based on such a utility, one of skill in the art would know exactly how to use the claimed polypeptides for the treatment of conditions where enhancement of an immune response is beneficial, without any undue experimentation.

Appellants note that the claimed variants all share the functional limitation that "the polypeptide is capable of stimulating proliferation of T-lymphocytes." Example 74 of the present application provides detailed protocols for the MLR assay, including the extensive step-by-step guidance from Current Protocols in Immunology, which is explicitly incorporated into the specification by reference. By following the disclosure in the specification, one skilled in the art can easily test whether a variant PRO217 polypeptide is capable of stimulating proliferation of T-lymphocytes. The specification further describes methods for the determination of percent identity between two amino acid sequences. (See page 67, line 34, to page 69, line 24). In fact, the specification teaches specific parameters to be associated with the term "percent identity" as applied to the present invention. The specification further provides detailed guidance as to changes that may be made to a PRO polypeptide without adversely affecting its activity (page 112, line 37 to page 115, line 8). This guidance includes a listing of exemplary and preferred substitutions for each of the twenty naturally occurring amino acids (Table 6, page 114). Accordingly, one of skill in the art could identify whether a variant PRO217 sequence falls within the parameters of the claimed invention. Once such an amino acid sequence is identified,



the specification sets forth methods for making the amino acid sequences (see page 112, line 37 to page 116, line 35) and methods of preparing the PRO polypeptides (see page 116, line 37 and onward).

Therefore, Appellants respectfully submit that the specification provides ample guidance such that one of skill in the art could readily test a variant polypeptide to determine whether it is capable of stimulating proliferation of T-lymphocytes by the methods set forth in Example 74. Furthermore, one of ordinary skill in the art has a sufficiently high level of technical competence to identify sequences with at least 80% identity to SEQ ID NO:4. Accordingly, one of ordinary skill could practice the claimed invention without undue experimentation.

The claims currently recite polypeptide sequences associated with a specific biological activity. This biological activity together with the well defined relatively high degree of sequence identity and general knowledge in the art at the time the invention was made, sufficiently defines the claimed genus such that, one skilled in the art, at the effective date of the present application, would have known how to make and use the claimed polypeptide sequences without undue experimentation. As the M.P.E.P. states, "[t]he fact that experimentation may be complex does not necessarily make it undue, if the art typically engages in such experimentation."<sup>23</sup>

As discussed above, a considerable amount of experimentation is permissible, if it is merely routine. Applicants submit that the identification of variant PRO217 polypeptides having at least 80% identity to SEQ ID NO:4, wherein the polypeptide is capable of stimulating proliferation of T-lymphocytes, can be performed by techniques that were well known in the art at the priority date of this application, and that the performance of such work does not require undue experimentation.

Accordingly, Appellants respectfully request reconsideration and reversal of the enablement rejection of Claims 39-43 and 50-51 under 35 U.S.C. §112, first paragraph.

---

<sup>23</sup> M.P.E.P. §2164.01 citing *In re Certain Limited-charge Cell Culture Microcarriers*, 221 U.S.P.Q. 1165, 1174 (Int'l Trade Comm'n 1983), *aff' sub nom. Massachusetts Institute of Technology v. A.B. Fortia*, 774 F.2d 1104, 227 U.S.P.Q. 428 (Fed. Cir. 1985).

**ISSUE III: Claims 39-43 are not anticipated under 35 U.S.C. §102 by Hsieh *et al.* or Brewer *et al.*, WO 98/54963**

Claims 39-43 stand rejected under 35 U.S.C. §102(a) as allegedly being anticipated by Hsieh *et al.* (Nature 398:431-436, published April 1, 1999) which discloses an amino acid sequence having 99.7% sequence identity to SEQ ID NO:4 of the present application.

Claims 39-43 further stand rejected under 35 U.S.C. §102(b) as allegedly being anticipated by Brewer *et al.* (WO 98/54963, published December 10, 1998), which discloses a amino acid sequence having over 99% identity to SEQ ID NO:4 of the present application.

Appellants submit that, as discussed above regarding the utility and enablement requirements of 35 U.S.C. §101 and 35 U.S.C. §112, first paragraph, (Issue I and Issue II), the results of the MLR assay (Example 74) establish a credible, substantial and specific asserted utility for the claimed PRO217 polypeptides. These results were first disclosed in U.S. Provisional Application Serial No. 60/100,858, filed on September 17, 1998. As discussed above, the disclosure of the instant application, which is similar to that of the earlier-filed application (U.S. Provisional Application Serial No. 60/100,858), provides the support required under 35 U.S.C. §112 for the subject matter of the instant claims. Accordingly, Appellants submit that the subject matter of the instant claims is disclosed in the manner provided by 35 U.S.C. §112 in U.S. Provisional Application Serial No. 60/100,858. Therefore, the effective filing date of this application is September 17, 1998, the filing date of U.S. Provisional Application Serial No. 60/100,858.

The journal article by Hsieh *et al.* was published on April 1, 1999, which is over six months after the effective filing date of the instant application; hence Hsieh *et al.* is not prior art.

The PCT patent application by Brewer *et al.*, WO 98/54963, was published on December 10, 1998, which is over two months after the effective filing date of the instant application; hence Brewer *et al.* is not prior art.

The Examiner has asserted that "a review of the instant application and this [MLR] assay do not lead to a conclusion of utility based on this assay, and therefore, priority to this provisional application is not afforded." (Page 2 of the Office Action mailed July 15, 2003).

In this regard, Appellants refer to the arguments and information presented above under Issue I and Issue II with respect to utility and enablement. These arguments are incorporated by

reference herein. Appellants respectfully submit that as described above under Issue I, the data from the MLR assay disclosed in Example 74 provides a specific, substantial and credible utility for the claimed invention and, therefore, the present specification teaches one of ordinary skill in the art "how to use" the claimed invention without undue experimentation, as described above.

Accordingly, Appellants respectfully request reconsideration and reversal of the rejection of Claims 39-43, 52 and 54-58 under 35 U.S.C. §102(b) as being anticipated by Hsieh *et al.* or Brewer *et al.*

**ISSUE IV: Claims 44-46 and 49 are not made obvious under 35 U.S.C. §103(a) by Hsieh *et al.* or Brewer *et al.*, WO 98/54963**

Claims 44-46 and 49 stand rejected under 35 U.S.C. §102(a) as anticipated by, or in the alternative, under 35 U.S.C. §103(a) as obvious over Hsieh *et al.* (Nature 398:431-436; published April 1, 1999). Claims 44-46 and 49 further stand rejected under 35 U.S.C. §102(b) as anticipated by, or in the alternative, under 35 U.S.C. §103(a) as obvious over Brewer *et al.* (WO 98/54963, published December 10, 1998).

As discussed above under Issue III, the instant application is entitled to the priority date of September 17, 1998. These arguments are incorporated by reference herein. Therefore, neither Hsieh *et al.* nor Brewer *et al.* is prior art.

Accordingly, Appellants respectfully request reconsideration and reversal of the rejection of Claims 44-46 and 49 under 35 U.S.C. §103(a) as being anticipated by or obvious over Hsieh *et al.* or Brewer *et al.*

## CONCLUSION


For the reasons given above, Appellants submit that the MLR assay disclosed in Example 74 of the specification provides at least one patentable utility for the PRO217 polypeptides of Claims 39-46 and 49-51, and that one of ordinary skill in the art would understand how to use the claimed polypeptides, for example in therapeutic applications where enhancement of an immune response is beneficial, such as the treatment of viral infections or cancer. Therefore, Claims 39-46 and 49-51 meet the requirements of 35 USC §101 and 35 USC §112, first paragraph. Further, this patentable utility for the claimed polypeptides was first disclosed in U.S. Provisional Application Serial No. 60/100,858, filed on September 17, 1998, priority to which is claimed in the instant application. Accordingly, the instant application has an effective priority date of September 17, 1998, and therefore Hsieh *et al.*, published on April 1, 1999, and Brewer *et al.*, WO 98/54963, published December 10, 1998, are not prior art and do not anticipate the claims under 35 USC §102(a) or (b), or render the claims obvious under 35 USC §103(a).

Accordingly, reversal of all the rejections of Claims 39-46 and 49-51 is respectfully requested.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39780-1618 P2C7).

Respectfully submitted,

Date: April 28, 2006

By:   
Barrie Greene (Reg. No. 46,740)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2203815 v1  
4/28/06 9:52 AM (39780.1618)

## 8. CLAIMS APPENDIX

### Claims on Appeal

39. An isolated polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO:4;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256;
- wherein the polypeptide is capable of stimulating proliferation of T-lymphocytes.
40. The isolated polypeptide of Claim 39 having at least 85% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO:4;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256;
- wherein the polypeptide is capable of stimulating proliferation of T-lymphocytes.
41. The isolated polypeptide of Claim 39 having at least 90% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO:4;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256;
- wherein the polypeptide capable of stimulating proliferation of T-lymphocytes.
42. The isolated polypeptide of Claim 39 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:4;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256;
- wherein the polypeptide is capable of stimulating proliferation of T-lymphocytes.

43. The isolated polypeptide of Claim 39 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:4;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256;
- wherein the polypeptide is capable of stimulating proliferation of T-lymphocytes.

44. An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO:4;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide; or
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.

45. The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO:4.

46. The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO:4, lacking its associated signal peptide.

49. The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209256.

50. A chimeric polypeptide comprising a polypeptide according to Claim 44 fused to a heterologous polypeptide.

51. The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

## 9. EVIDENCE APPENDIX

1. Kahan, Barry D., "Immunosuppressive therapy," *Curr. Opin. Immunol.* 4:553-560 (1992).
2. Picotti, J.R. et al., "Interleukin-12 (IL-12)-driven alloimmune responses in vitro and in vivo," *Transplantation* 67:1453-1460 (1999).
3. Campo, C.A. et al., "Zinc inhibits the mixed lymphocyte culture," *Biological Trace Element Research*, 79:15-22 (2001)
4. Basic& Clinical Immunology, 8th edition, Sites, D.P. et al., Eds, Appelton & Lange, Norwalk, CT, 1994, pp. 30-31; 208-209; 246-247; 280.
5. Fung-Leung, W-P. et al., "Tepoxalin, a novel immunomodulatory compound, synergizes with CsA in suppression of graft-versus-host reaction and allogenic skin graft rejection," *Transplantation* 60:362-368 (1995).
6. Shim, J-H. et al., "Immunosuppressive effects of tautomycetin *in vivo* and *in vitro* via T cell-specific apoptosis induction," *Proc. Natl. Acad. Sci. USA* 99:10617-10622 (2002).
7. Declaration of Sherman Fong, Ph.D. under 35 C.F.R 1.132, with attached Exhibits A-E:
  - A. Current Protocols in Immunology, Vol. 1, Richard Coico, Series Ed., John Wiley & Sons, Inc., 1991, Unit 3.12
  - B. Steinman, R.M., "The dendritic cell advantage: New focus for immune-based therapies," *Drug News Perspect.* 13:581-586 (2000).
  - C. Gubler, U. et al., "Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor," *Proc. Natl. Acad. Sci. USA* 88:4143-4147 (1991).



D. Peterson, A.C. et al., "Immunization with melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma," *J. Clin. Oncol.* **21**:2342-2348 (2003).

E. Thurner, B. et al., "Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma," *J. Exp. Med.* **190**:1669-1678 (1999).

Items 1-4 were made of record by the Examiner in the Office Action mailed July 15, 2003.

Items 5-6 were submitted with Appellants' Response filed September 8, 2003, and noted as considered by the Examiner in the Advisory Action mailed November 19, 2003.

Item 7 was submitted with Appellants' Request for Continued Examination and Preliminary Amendment filed July 12, 2004, and noted as entered on the record by the Examiner in the Final Office Action mailed October 1, 2004.

**10. RELATED PROCEEDINGS APPENDIX**

None.

SV 2203815 v1  
4/28/06 9:52 AM (39780.1618)

# Immunosuppressive therapy

Barry D. Kahan

The University of Texas Medical School, Houston, Texas, USA

Although Cyclosporin A has improved transplant outcome, its use has serious limitations due to its narrow therapeutic window. New approaches to broaden this window exploit alternative drug formulations, pharmacokinetic profiling and new immunosuppressive agents, such as Rapamycin and Brequinar, which act in a synergistic fashion. There is no evidence to suggest that the pharmacological alternative to Cyclosporin A, FK-506, displays a broader therapeutic window, although it may be tenfold more potent. Similarly, despite the specificity of the IgG2a mouse anti-human CD3 monoclonal antibody, it displays a significant range of clinical side effects, delayed therapeutic action and frequently stimulates generation of human anti-mouse monoclonal antibodies. Recent advances in monoclonal antibody technology seek not only to produce antibodies against determinants involved in alloactivation, but also to 'humanize' the antibodies for reduced side effects. The availability of this array of potential agents highlights the need to develop guidelines for clinical trial methodologies to address the unique needs and demands of organ transplantation.

Current Opinion in Immunology 1992, 4:553-560

## Introduction

After thirty years of vigorous but relatively unproductive research, the field of immunosuppressive drugs awakened following the approval of two agents that, in contrast to the non-selective drugs Azathioprine (Aza) and corticosteroids, display relatively specific actions on T cells. One of these, the fungal undecapeptide Cyclosporin A (CsA), not only improved clinical outcomes and broadened the clinical settings in which transplants were successful, but also provided a unique tool for dissecting activation mechanisms leading to lymphokine synthesis. Subsequent approval of the other agent, the IgG2a mouse monoclonal antibody (mAb) OKT-3, heralded the use of reagents that bind selective T-cell surface markers to modulate the immune response. The past decade has witnessed striking progress in the development of new pharmacological agents (Fig. 1). One group inhibits lymphokine biosynthesis, FK-506 or signal transduction, Rapamycin (RAPA). A second group is the nucleotide synthesis inhibitors; Mizoribine [1] and RS61443, a morpholinoethyl-ester analog of mycophenolic acid (MPA) [2•], block purine salvage pathways with the generation of guanosine monophosphate, and the quinoline carboxylic acid Brequinar (BQR) blocks the *de novo* synthesis of pyrimidines [3•]. A third group,

new mAbs, recognizes specific surface epitopes on T cells and antigen-presenting cells (Fig. 2). Immunosuppressive activity has been documented [4-9] with several mAbs that bind various determinants as shown in Table 1. Prolonged graft survival has also been achieved with antibodies, or preferably their F(ab')<sub>2</sub> fragments, directed towards class I [10] or class II MHC antigens. A refinement of mAb technology is the production of immunotoxins. Ricin  $\alpha$ -chain toxin linked to mouse anti-human CD5 IgG1 mAb has been used by Haverly (personal communication) to treat steroid-resistant graft versus host disease in human bone marrow transplantation. This array of new agents proffers an unprecedented opportunity to design effective, yet minimally toxic, regimens to improve the outcome of transplantation in man.

## Limitations of existing immunosuppressive regimens

Currently, clinical regimens are based upon the use of CsA, the immunosuppressant benefits of which are seriously limited by side effects. In attempts to augment its efficacy, the corticosteroid Prednisone (Pred), Aza,

### Abbreviations

ALG—anti-lymphocyte sera; Aza—Azathioprine; BQR—Brequinar; CMV—cytomegalovirus; CsA—Cyclosporin A; CTL—cytotoxic T lymphocyte; DTH—delayed type hypersensitivity; ICAM—intercellular adhesion molecule; IL—interleukin; LFA—lymphocyte function-associated antigen; mAb—monoclonal antibody; MHC—major histocompatibility complex; MPA—mycophenolic acid; MZB—mizoribine; NF-AT—nuclear factor of activated T cells; Pred—Prednisone; RAPA—Rapamycin; TCR—T-cell receptor; Th—T-helper.




Fig. 1. Classification of immunosuppressive drugs based upon their site of action in the cell cycle. In the first group, corticosteroid, and possibly deoxyspergualin, inhibit antigen-presenting cells. In the second group, Cyclosporin A (CsA) and FK-506 inhibit lymphokine (LK) biosynthesis during the G<sub>0</sub> phase and Rapamycin inhibits signal transduction during the G<sub>1</sub> phase. In the third group (the nucleoside synthesis inhibitors), Mizorbine (MZB) and RS61443 (a morpholinoethyl-ether analog of mycophenolic acid, MPA) inhibit purine synthesis pathways leading to the generation of guanosine monophosphate, whereas Brequinar (quinoline carboxylic acid) inhibits the *de novo* synthesis of pyrimidines. IL, interleukin; R, receptor.




Fig. 2. Epitope targets of monoclonal antibodies. ICAM, intercellular adhesion molecule; IL, interleukin; MHC, major histocompatibility complex; R, receptor; TCR, T-cell receptor.

Table 1. Determinants recognized by immunosuppressive monoclonal antibodies

Monoclonal antibody	Determinant	Reference
IgM T1089.1A-31	Determinants common to α/β chains of all human T-cell receptors	[4]
IgG2b BMA 031	CD4	[5]
OKT4A	CD7	[6]
SDZ CHH 380	α chain or α/β complex of interleukin-2 receptor	[7]
3383.1	Intercellular adhesion molecule-1 (or CD54)	[8]
B1RR-1	Lymphocyte function-associated antigen-1	[9]
25.3		

equine or rabbit polyclonal anti-lymphocyte sera (ALG) and/or mouse OKT-3 mAbs have been combined in empirical regimens that are often tailored to individual patients. To address one limitation of CsA, nephro- and/or hepato-toxicity during the initial post-transplant phase of induction immunosuppressive therapy, which delays allograft and patient recovery, pharmacokinetic control

programs have been used either to pre-select CsA doses [11] or to combine ALG or OKT-3 with Aza/Pred in order to delay treatment with CsA. However, immediate, rather than delayed, administration of CsA to patients displaying good initial renal function avoids the disadvantages of ALG/OKT-3 induction, namely an increased risk of cytomegalovirus (CMV) infection, additional expense and/or delayed hospital discharge awaiting satisfactory CsA levels after treatment with CsA. However, patients at extraordinarily high immunological risk, due to rejection of previous allografts within three months, or with marginally-functioning organs may preferably be treated with ALG or OKT-3 induction as a possible means to delay the onset of their first rejection episodes. Two possible alternatives for induction therapy are the CsA analogs that may display reduced nephrotoxicity, namely Cyclosporin G [12], which substitutes norvaline at position 2, and IMM-125 with a hydrophilic substituent at position 9.

To date, no large randomized study has shown that the induction regimen alters the clinical outcome; rather, a small cohort reported by Belitsky *et al* [13] showed no difference between ALG versus initial CsA therapy, the two options for induction therapy. There may be several reasons for this. Firstly, the polyclonal reagents, such as

rabbit or equine Minnesota ALG and anti-thymocyte globulin, regardless of their source, opsonize T cells, leading to their removal from the circulation. This depletion obviates T-cell mediated attack on the allograft. Among other factors that must be considered is that the central intravenous lines required for polyclonal administration may be accidentally contaminated, producing septicemia. Further, there are no indices of the efficacy of the polyclonal sera. Peripheral blood T-cell numbers above the target range of 50–150/ml tend only to be useful reflections of the appearance of human host anti-equine antibodies, not immunological resistance to therapy. The other induction therapy using OKT-3, which covers and/or modulates CD3 epitopes on the T-cell surface, offers the advantages of both peripheral intravenous administration and readily available fluorescence-activated cell sorting (FACS) tests for antibody efficacy. The clinician monitors patient peripheral blood lymphocyte T-cell epitopes for (a) cells with exposed CD3 epitopes that were not bound by OKT-3 *in vivo* by their capacity to bind fluorescenated OKT-3 *in vitro*, (b) the total number of circulating T cells with fluorescenated anti-CD2, a pan T-cell marker, and (c) the proportion of OKT-3-coated cells detected with a goat anti-mouse IgG reagent. A satisfactory therapeutic effect is observed when the patient has <25% OKT-3<sup>+</sup> cells *in vitro* and 60–75% CD2<sup>+</sup> T cells, about 40% of which are coated with mouse IgG which binds to OKT-3. While OKT-3 represents an advance in immunosuppressive therapy, it has several serious limitations: (a) severe first-dose reactions, including chills, fever, myalgias and, in the worst cases, pulmonary oedema apparently due to lymphokine release (particularly tumor necrosis factor and interleukin (IL)-2); (b) longer-term adverse effects such as aseptic meningitis; (c) a delay in the therapeutic effect for as long as 7 days after initiation of treatment; (d) induction of human anti-mouse antibodies, generally of the anti-idiotypic variety, but not uncommonly of broader reactivity. (e) a frequent incidence of rebound re-rejection episodes upon completion of the therapeutic course; and (f) a tendency toward CMV infections in 40% of treated patients. In addition, both polyclonal and mAb reagents may produce excessive immunosuppression, resulting in increased incidences of CMV infection and/or of lymphomas and other neoplasms, as well as allograft thrombosis. Thus, selection of a CsA versus an antibody induction regimen must balance the risks of nephrotoxicity versus that of excessive immunosuppression.

The use of CsA has reduced the risk of acute rejection, but a rational approach to CsA administration is confused by the tremendous variability between individuals in drug pharmacokinetics and pharmacodynamics [14], which, in turn, generates a fear of irreversible renal injury in case the CsA dose is excessive. Three approaches have been used to address this problem: (a) combining reduced CsA doses with subtherapeutic amounts of Aza [15]; (b) monitoring the parent compound CsA based upon its trough concentration prior to the next drug dose [16]; and (c) adjusting CsA doses prospectively based upon average concentrations calculated from serial measurements of the area under the concentration-time curve

[11]. Since drug absorption presents the greatest variability in pharmacokinetics, attempts have been made to increase CsA bioavailability by co administration of Vitamin E [17]. In addition, the manufacturer has produced a new micro-emulsion formulation that increases the bioavailability by twofold above that of the existing oral solution or capsule preparation, which show equivalent bioavailability in studies comparing both formulations [18]. The critical issue seems to be the drug concentration in the allograft. While direct intra-arterial infusion has been used for experimental models of renal or cardiac allografts, good drug uptake in man can be achieved by presenting CsA as an aerosol in absolute ethanol when it has a mean particle diameter of 1.2 microns [19].

Optimal use of CsA demands the measurement of drug concentrations/activities at the level of its lymphocyte receptor or target signal transduction molecule(s), which may be calcineurin (an enzyme that may be involved in a common step associated with T-cell and IgE receptor signaling pathways) [20<sup>o</sup>] or the nuclear factor of activated T-cells (NF-AT). However, a major limitation may be the failure of CsA to inhibit lymphocyte activation via the CD28 surface marker [21], an important co-stimulatory pathway that together with T-cell receptor (TCR) stimulation blocks induction of anergy in T-cell clones [22]. Fortunately, rejection episodes under CsA prophylactic therapy tend to be readily reversed by corticosteroid therapy, and the majority of steroid-resistant episodes are overcome with polyclonal ALG and/or OKT-3 therapy. Corticosteroids are believed to represent the Achilles' heel of transplantation because of the wide distribution and pleiotropic effects of the glucocorticoid receptor superfamily found in the cytoplasm. These are DNA binding dimeric transcription factors with a zinc finger structure that recognize enhancer (or negative regulator) elements bearing the GRE motif (GTACAnnnT-GTTCT, where n = any nucleotide). One important negative regulatory element is the AP-1 binding site, normally the focus for fos-jun heterodimers [23]. An alternative approach to the reduction of IL-1 $\beta$  generation, an action typical of corticosteroids, is to inhibit the enzyme that cleaves the inactive 31 kD precursor between Asp<sup>116</sup> and Ala<sup>117</sup> to release the 153 carboxyl-terminal amino acids that constitute IL-1 $\beta$  [24]. Another immunosuppressive effect may be achieved by the upregulation of the synthesis of transforming growth factor- $\beta$  by steroids [25]. Withdrawal of steroid treatment months to years after the transplant may be successful in patients who did not reject the transplant [26<sup>o</sup>].

Preliminary data suggest that a ten-day course of the IgM mouse anti-human  $\alpha$   $\beta$  TCR mAb T10B9.1A-31 [4], but not BMA031 (C Groth, personal communication), not only produces equivalent therapeutic effects to those of OKT-3, but is less toxic in terms of incidence of fever and neurological and respiratory symptoms, as well as of subsequent infections. Furthermore, T10B9 therapy is not associated with as great a rise in serum creatinine during treatment as OKT-3, suggesting a more rapid attenuation of the allo-immune response. However, the repeated use of xenogeneic antibodies during the induc-

tion phase as well as for anti-rejection therapy may be complicated by the development of neutralizing human anti-mouse antibodies.

A major goal of maintenance immunosuppressive therapy is prophylaxis against chronic rejection. To date, not only has CsA/Pred therapy failed to reduce the incidence of this complication from the 8–10% level observed under the Aza/Pred combination, but there is no way to determine if the failure is due to its inherently modest inhibition of B-cell responses or to physicians' tendency to limit CsA therapy to minimal, possibly ineffective, doses in order to mitigate a renal injury. Thus, despite the improvement in initial graft survival, transplants continue to be lost in the longer term, with half-lives of about seven years for cardiac and 11.5 years for renal transplant in humans. A recent study of the effects of immunosuppressive drugs on coronary vascular disease in heterotopic rat cardiac allografts suggests that RAPA particularly, CsA to a lesser extent, but definitely not FK-506, inhibit pathological endothelial and smooth muscle lesions in arteries and arterioles, which seem to be the critical lesions in the progression of chronic rejection [27].

### New pharmacological agents

Both the macrolide FK-506 and the undecapeptide CsA interrupt lymphokine synthesis by inhibiting generation of the  $\text{Ca}^{2+}$  dependent regulatory proteins NF-AT, NFIL-2A, NFIL-2B, and NF- $\kappa\text{B}$ , but not c-fos, which is necessary for IL-2 generation. Presumably, both drugs also affect serine protease gene transcripts, an excellent marker of rejection [28]. The inhibition of cytotoxic T lymphocytes (CTLs), even in the presence of optimal amounts of IL-2, is a prominent effect of CsA [29] and, apparently, FK-506. Despite the assumption that CsA and FK-506 produce similar inhibitory effects, at least three differences have been observed: first, FK-506 displays a flatter inhibition curve than CsA with a wider discrepancy in potency at the 50% inhibition than at the 95% inhibition level; secondly, CsA leads to the generation of suppressive T cells, whereas FK-506 does not; and thirdly, although both drugs inhibit  $\text{CD4}^+$  T helper (Th) lymphocytes, which secrete IL-2, only CsA (and not FK-506) permits priming of  $\text{CD8}^+$  CTLs [30]. Furthermore, Bretscher and Havelle [31] suggest that CsA switches the immune response to the graft from a delayed type hypersensitivity (DTH) response to an IgG response by inhibiting the Th1 subset with the emergence of the Th2 subset, which actively induces IgG via IL-4 generation and inhibits Th1 cells and DTH via IL-10. Both CsA and FK-506 spare transcription of the down-regulatory lymphokine IL-10. While CsA inhibits transcription of IL-6, this factor is not affected by FK-506.

The coming year should witness publication of a vast array of randomized trials comparing the clinical outcome of liver and renal transplants in patients treated with FK-506 versus CsA. So far, a preliminary non-randomized study of liver recipients showed that FK-506 therapy displays greater neurotoxicity, equivalent nephrotoxicity,

but, possibly, less hypertension than does CsA therapy [32<sup>o</sup>]. A further claim that corticosteroids do not have to be used with FK-506 cannot be assessed due to two factors: firstly, the protocol stipulated higher Pred doses in the CsA cohort than those used with FK-506; and secondly, to date, there is no pharmacokinetic analysis of Pred concentrations in CsA versus FK-506 treatment groups in order to exclude a drug interaction. Additionally, the extremely poor results in the initial study, wherein allegedly CsA-resistant patients were converted to treatment with FK-506, actually reflected antagonism between the two drugs caused by (a) an adverse immunological interaction between the two agents that apparently have similar mechanisms of action [33] and (b) competitive pharmacokinetic interactions. Although FK-506 has not yet been shown to achieve clinical results even equivalent to those of CsA, eventual definition of its relative therapeutic window will depend upon Phase II studies to select well-tolerated drug doses for randomized trials versus CsA therapy.

When a second agent, RS61443, was added in doses of 2500–3500 mg per day to a CsA/Pred regimen, it seemed to reduce the incidence of acute rejection episodes. However, these high doses are likely to produce toxicity, particularly leukopenia and gastrointestinal complaints [2<sup>o</sup>]. Randomized placebo-controlled trials are underway to assess the efficacy of RS61443 versus Aza added to a CsA/Pred regimen. Other studies are examining the impact of a fourth agent, deoxyspergulin, to potentiate an ALG/Aza/Pred/CsA induction protocol.

The studies that claimed Aza displays pharmacological synergism with CsA failed to utilize rigorous experimental design or data analysis [34]. For instance, both *in vitro* analyses [35] and clinical results demonstrate that Aza acts in an additive manner rather than synergistically with CsA [36]. Similarly, *in vitro* analyses suggest that RS61443 [37], mizoribine [37], and thalidomide [38] also act in an additive manner with CsA. Although initial data suggested that BQR potentiates the effect of CsA [3<sup>o</sup>], recent experiments document true synergism [37]. However, CsA/RAPA combinations show the most impressive degree of synergy both *in vitro* and *in vivo* [39]. Once Phase I toxicity trials have been completed, it will be possible to assess whether BQR or RAPA displays the synergistic effects with CsA in human transplantation that are evident in rodents and large animal models.

### New monoclonal antibody reagents

Second generation mAbs are being designed to avoid the severe systemic reactions due to lymphokine release that follow initial doses of OKT-3. For example, the IgG2b anti-human  $\alpha\beta$  TCR mAb BMA 031 used for induction therapy (three 50 mg doses administered on alternate days) delays the onset of first rejection episodes and probably improves one-year graft survival (R Knight and BD Kahan, unpublished data). Similar benefits have been reported with mouse and rat mAbs produced against the activation-induced  $\alpha$ -chain, or to new epitopes resulting

from the formation of the  $\alpha\beta$  complex, of the IL-2 receptor [8].

However, treatment with these antibodies leads to a high incidence of human anti-mouse antibodies, which may attenuate the immunosuppressive effects. Recent work has explored approaches to construct either (a) 'chimeric' antibodies bearing human Fc segments joined to mouse F(ab')<sub>2</sub> fragments, or (b) 'humanized' mAbs with mouse idiotypes inserted onto human IgG isotypes (Fig. 3). Chimeric antibodies combine the variable regions of mouse antibodies with human antibody constant regions and, therefore, present fewer foreign amino acid sequences to the host. However, one-third of the structure is still of mouse origin. Furthermore, a clinical trial using a chimeric anti-CD7 mAb not only failed to achieve a superior level of immunosuppression induction, but also increased the incidence of vascular thromboses [7]. The latter effect may have been related to the adhesion of Fc receptors on platelets and polymorphonuclear leukocytes to the human Fc regions, bound to endothelium via mouse epitopes. On the other hand, 'humanized' antibodies combine only the smallest part of a mouse antibody that is required, the antigen combining site, with human variable region frameworks and constant regions. Due to the reduced affinity of 'humanized' antibodies for antigen epitopes, Co *et al* [40] recommended two innovations: firstly, selection of a human framework that is as homologous to the original mouse antibody as possible; and secondly, insertion of key residues from the mouse model into the construct in order to achieve a molecular conformation that is similar to the native idioype. The beneficial effects of chimeric and 'humanized' variants of mouse mAbs will be clarified only by randomized clinical trials.

Two alternative approaches seek to utilize mAbs directed against donor MHC antigens or against co-receptor molecules. In a study of non human primates,

OKT-4A IgG2A mAbs, which react with the CD4 co-receptor on Th cells, provoked fewer side effects than OKT-3 [6]. In an initial clinical trial of OKT-4A induction therapy (0.2 mg/kg/day), all six patients suffered rejections. These rejections were reversible, but left residual areas of dead tissue resulting from an obstruction of the blood supply in half the renal allografts. Unfortunately, OKT-4A also generated a strong human anti-mouse antibody response (J Barry, personal communication). Experimental animal models are currently being used to determine if antibody efficacy is related to T-cell deletion and is potentiated by simultaneous treatment with an anti-CD8 mAb. On the one hand, Fathman and colleagues [41] found that depleting anti-CD4 mAbs produced prolonged allo-unresponsiveness toward allogeneic pancreatic islets, an effect that was moderated by simultaneous treatment with anti-CD8<sup>+</sup> mAbs, suggesting the role of a regulator CD8<sup>+</sup> cell. On the other hand, Waldmann and colleagues [42] induced tolerance toward mouse heart transplants where the donor and recipient were not matched at MHC level using an anti-CD4 mAb that not only did not deplete T cells but also was potentiated by simultaneous administration of an anti-CD8 mAb.

A second approach to co-receptor molecules is based on the interaction of lymphocyte function-associated antigen (LFA)-1 on CTLs with the intercellular adhesion molecule (ICAM)-1 on monocytes. Expression of ICAM-1 is up-regulated following lymphokine release, which occurs during acute allograft rejection but not during other pathological events in the kidney [43•]. Prophylactic and therapeutic administrations of a mAb directed against the high molecular weight  $\alpha$  chain of human ICAM-1 alone delayed both the onset and progression of rejection episodes in primate renal allograft models. Using mouse mAbs directed against LFA-1, Stoppa *et al* [44] reversed steroid resistant acute graft versus host reactions in man. Indeed, the combination of anti-ICAM-1 and anti-LFA-1 mAbs produced allo-tolerance in mice that were not com-




Fig. 3. Types of monoclonal antibody. Chimeric antibodies combine the variable regions of mouse antibodies with human constant regions and, therefore, present fewer foreign amino acid sequences to the host. 'Humanized' antibodies combine only the smallest part of a mouse antibody that is required, the antigen binding site, with human variable region frameworks and constant regions.

patible at the MHC level [45•]. These promising results in animal models using mAbs directed against T-cell and monocyte co-receptors await confirmation in controlled clinical trials.

While clinical interventions to date have focused on using mAbs directed towards surface epitopes important for the afferent limb of the allo immune response, there is increasing evidence that anti-idiotypic antibodies, either exogenously introduced or endogenously, spontaneously generated, may regulate the induction of allo-immune responses. A recent study performed by Snider [46] suggested that immunization of hosts with antigen-antibody complexes confers a bias in the epitope, resulting in a less efficient antibody response that shows anti-idiotypic properties. This approach represents a particularly fertile ground for clinical exploration.

### Cytokine receptor analogs and antagonists

A new group of immunosuppressive agents are the cytokine receptor antagonists. The discovery and initial testing of an IL-1 receptor antagonist has been reviewed by Arend [47]. IgG-stimulated human monocytes naturally produce IL-1 receptor antagonist, a heterogenous array of glycoproteins of 15–25 kD, depending upon their degree of glycosylation. IL-1 receptor antagonist binds type I, but not type II, IL-1 receptors without activating cells and with considerably less avidity than native IL-1 $\alpha$  and IL-1. Type I IL-1 receptors are present on Th2 cells and fibroblasts; Type II IL-1 receptors are present on B cells, neutrophils, and macrophages. Although therapeutic trials of IL-1 receptor antagonist in rheumatoid arthritis and septic shock suggest some beneficial effects, Faherty *et al.* [48] failed to observe that IL-1 receptor antagonist inhibited induction of CTLs, cutaneous DTH, or T cell dependent humoral antibody responses. They also found that administration of a mAb to type II IL-1 receptor (35F5) was ineffective. Fanslow *et al.* [49•] recently extended their previous studies, which used constructs of the extra-membranous portion of the IL-1 receptor, by using similar constructs of the IL-4 receptor. In the initial studies, they prolonged heterotopic pinna, neonatal mouse heart allograft survival, but failed to prevent allo-sensitization, as documented by a rapid, secondary-type proliferative response upon *in vitro* one-way mixed lymphocyte reactions. In their recent studies, constructs of IL-4 receptor alone, or in combination with rat anti-mouse IL-4 receptor mAb, induced modest prolongation of heart allo-explants.

### Immunosuppressive drug trials

Of the numerous obstacles currently hindering the development of efficacious immunosuppressive regimens, the lack of methodology for clinical transplantation trials is of particular importance. To date, no series of Phase I and II toxicity and dose-finding trials has been conducted in

order to establish a foundation for clinical investigation. The introduction of Aza, steroids, and CsA, as well as the preliminary trials of FK-506, have relied upon empirical approaches. Important obstacles to comprehensive trials include the relatively small numbers of transplant cases, the use of unrefined end-points such as graft and patient survival, and the lack of well-established criteria for the diagnosis and grading of rejection episodes, deficits that obfuscate the use of this event as an intermediate end-point. In addition, no *in vitro* immune assay predicts or correlates with *in vivo* immunosuppressive efficacy; hence, there is no surrogate immune parameter as a basis of immunosuppressive efficacy and/or for dose extrapolation from *in vitro* systems to *in vivo* conditions.

Since present results with CsA-based regimens yield excellent graft survivals, extremely large numbers of patients must be entered into clinical trials to document improved efficacy of a new agent. Even more extensive efforts will be needed to exclude the possibility that the results with the new agent are not actually worse than those obtained with the existent CsA regimen. In light of the presently high success rates, the benefits of any new regimen must be based upon both the potency and the mitigation of side effects, as assessed by quantitative parameters, including glomerular filtration rates. The practice of clinical research in transplantation must proceed to develop principles of rigorous study design and precise analytical tools in order to most expeditiously evaluate the available array of new immunosuppressants described in this review.

### Acknowledgements

This study was supported by an award from the National Institute of Diabetes, Digestive and Kidney Diseases NIDDK38016-05. The author acknowledges the invaluable editorial assistance of Ms. B. Lee Ligon.

### References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
  - of outstanding interest
1. TURKA LA, DAYTON J, SINCLAIR G, THOMPSON CB, MITCHELL BS: Guanine Ribonucleotide Depletion Inhibits T Cell Activation: Mechanism of Action of the Immunosuppressive Drug Mizoribine. *J Clin Invest* 1991, 87:940–948.
  2. SOULINGER HW, DEIERIEN MH, BELZER FO, DIETHELM AG, KAUFFMAN RS: RS-61443-A Phase I Clinical Trial and Pilot Rescue Study. *Transplantation* 1992, 53:428–432.
- An open label evaluation of the efficacy of RS61443, a morpholinoethyl-ester analog of MPA, to prevent renal allograft rejection in humans. The study showed relatively low plasma levels of MPA when administered immediately after transplantation, a significantly reduced incidence in the number and severity of rejection episodes with increased MPA doses, and surprisingly, reversal of on going steroid-resistant allograft rejection episodes.
3. CRAMER DV, CHAPMAN FA, JAFFEE BD, JONES EA, KNOOP M, HIRSH-EIRAN G, MAKOWKA L: The Effect of a New Immunosuppressive Drug, Brequinar Sodium, on Heart, Liver, and



- Kidney Allograft Rejection in the Rat. *Transplantation* 1992, 53:303-308.
- Evaluation of the efficacy of BQR, an anticancer drug that inhibits the activity of dihydroorotate dehydrogenase and *de novo* pyrimidine biosynthesis. BQR prolonged heart, liver, and kidney allograft survival in the rat and inhibited contact sensitivity responses to dinitrofluorobenzene.
4. WARD TT, LUCAS BA, THOMPSON JS, BROWN SA, MUNCH L, PREDECK RJ, JEZEK D: Treatment of Acute Cellular Rejection with T10B9.1A.31 or OKT3 in Renal Allograft Recipients. *Transplantation* 1992, 53:80-86.
  5. HILDEBRAND G, ROTHGANG F, HAMMER C, ILNER WD, ST SCHLEIBNER, RACHENBERG J, GURLAND H J, LAND W: Experience with a New Monoclonal Antibody in Clinical Kidney Transplantation. *Transplant Proc* 1989, 21:1776-1777.
  6. WEE SL, STROKA DM, PREFFER FI, JOHNSON IK, COVINS RB, COSIMI AB: The Effects of OKT4A Monoclonal Antibody on Cellular Immunity of Nonhuman Primate Renal Allograft Recipients. *Transplantation* 1992, 53:501-507.
  7. AMLOT PL, CASTAGNE JP, SWENY P: A Chimeric CD7 Monoclonal Antibody (SDZCHH380) for Organ Transplant Prophylaxis. *Transplant Immunol Lett* 1991, 7:3-4.
  8. SOULIMOU JP, CANTAROVICH D, LE MAUF B, GIRAL M, ROBILAND N, HOURMANT M, HUN M, JACQUES Y: Randomized Controlled Trial of a Monoclonal Antibody Against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis Against Rejection of Renal Allografts. *N Engl J Med* 1990, 322:1175-1182.
  9. WEE SL, COSIMI AB, PREFFER FI, ROTHGANG R, FARNES R, CONTI D, COVINS RB: Functional Consequences of Anti-ICAM-1 (CD54) in Cynomolgus Monkeys with Renal Allografts. *Transpl Proc* 1991, 23:279-280.
  10. FINESTMAN D, COE C: Prevention of Xenograft Rejection by Masking Donor HLA Class I Antigens. *Science* 1991, 252:1700-1702.
  11. KAHAN BD, WELSH M, RUTZKY L, LEWIS R, KNIGHT R, KATZ S, NAPOU K, GREVEL J, VAN BUREN CT: The Ability of Pretransplant Test-dose Pharmacokinetic Profiles to Reduce Early Adverse Events After Renal Transplantation. *Transplantation* 1992, 53:445-451.
  12. OLIMAN S, LINDEMAN A, GAHLE H, WILCZIK H, GUNNAR T, REINHOLD F, SAWYER J, GROOT C G: A Randomized Pilot Study of Cyclosporine G in Renal Transplantation. *Transplant Int* 1992, 5, in press.
  13. BELITSKY P, MACDONALD AS, COHEN AD, CROCKER J, HIRSCH D, JINDAL K, LAWEN J: Comparison of Antilymphocyte Globulin and Continuous IV Cyclosporine A as Induction Immunosuppression for Cadaver Kidney Transplants: a Prospective Randomized Study. *Transplant Proc* 1991, 23:999-1000.
  14. LINDEMAN A: Therapeutic Monitoring of Cyclosporin — an Update. *Eur J Clin Pharmacol* 1991, 41:273-283.
  15. SIMMONS RL, CANAFAY DM, STRAND M, ASCHER NL, PAYNE WD, SUTHERLAND DER, NABARIAN JS: Management and Prevention of Cyclosporine Nephrotoxicity after Renal Transplantation: Use of Low Doses of Cyclosporine, Azathioprine and Prednisone. *Transplant Proc* 1985, 27(suppl 1):266-275.
  16. LINDEMAN A: Factors Influencing the Pharmacokinetics of Cyclosporine in Man. *Ther Drug Monit* 1992, 13:165-177.
  17. SOKOL RJ, JOHNSON KE, KARRER FM, NARKEWICZ MR, SMITH D, KAM I: Improvement of Cyclosporin Absorption in Children after Liver Transplantation by Means of Water-soluble Vitamin E. *Lancet* 1991, 338:212-215.
  18. HILDEBRANDS IB, HOITSMAN AJ, VAN DEN BERG JWC, KOENE RAP: Cyclosporin A Blood Levels During Use of Cyclosporin as Oral Solution or in Capsules: Comparison of Pharmacokinetic Parameters. *Transpl Int* 1991, 4:125-127.
  19. KERRAN RJ, DUNCAN AJ, YOUSEM SA, ZENATI M, SCHLAEPER M, DOWLING RD, ALARIE Y, BURCKHART GJ, GRIFFITH BP: Improved Immunosuppression with Aerosolized Cyclosporine in Experimental Pulmonary Transplantation. *Transplantation* 1992, 53:22-25.
  20. LIU J, FARMER JD, JR, LANE WS, FRIEDMAN J, WEISSMAN I, SCHREIBER SI: Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes. *Cell* 1991, 66:807-815.
- Reports that both CSA and FK-506, which lack structural similarities but have highly similar biological properties, interfere with the TCR mediated signaling pathway leading to transcription of early T-cell activated genes. Two drug-binding cis-trans prolyl isomerases, cyclophilin and FKBP, may mediate the actions of CSA and FK-506, respectively. These drug-isomerase complexes competitively bound to and inhibited the  $Ca^{2+}$ - and calmodulin-dependent phosphatase, calcineurin, suggesting that this enzyme is involved in a common step associated with T-cell and IgE receptor signaling pathways.
21. HENS AD, BRIGHT EC: The Effect of the CD28 Activation Pathway on the Immunosuppressive Action of Cyclosporine. *Transplantation* 1991, 51:1232-1240.
  22. HARDING FA, MCARTHUR JG, GROSS JA, RAULEY DH, ALLISON JP: CD28-mediated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T-cell Clones. *Nature* 1992, 356:607-609.
  23. FULLER PJ: The Steroid Receptor Superfamily: Mechanisms of Diversity. *FASEB J* 1991, 5:3092-3099.
  24. CERRETTI DP, KOSLOWSKY CJ, MONLEY B, NELSON N, VAN NEST K, GREENSTREET TA, MURCH CJ, KRONHEIM SR, DRUCK T, CANNIZZARO LA, HUBNER K, BLANK RA: Molecular Cloning of the Interleukin-1 Converting Enzyme. *Science* 1992, 256:97-100.
  25. AYANLARISUTMAN O, FERRERO AP, DIAZ A, JIMENEZ SA: Regulation of Transforming Growth factor-1 Gene Expression by Glucocorticoids in Normal Human T Lymphocytes. *J Clin Invest* 1991, 88:1574-1580.
  26. HREBEK DE, WHALEN CC, LAUTMAN J, BARTUCCI MR, MOIR EJ, MAYES JT, SCHULAK JA: Withdrawal of Steroids after Renal Transplantation — Clinical Predictors of Outcome. *Transplantation* 1992, 53:41-45.
- Reports that maintenance steroid therapy can be safely withdrawn from the majority of CSA and Azs-maintained transplant recipients, but withdrawal may increase the risk of acute allograft rejection. The timing of steroid withdrawal emerges as the significant clinical prediction of rejection associated with withdrawal; racial differences were also noted.
27. MEFFER BM, BILLINGHAM ME, MORRIS RE: Effects of Cyclosporin, FK506, Rapamycin on Graft-vessel Disease. *Lancet* 1991, 338:1297-1298.
  28. LIPMAN MI, STEVENS AC, DUFFACKLEY RC, HELDERMAN JH, MCCUNE TR, HARARON WF, SHAPIRO ME, ROSEN S, STROM TB: The Strong Correlation of Cytotoxic T Lymphocyte specific Serine Protease Gene Transcripts with Renal Allograft Rejection. *Transplantation* 1992, 53:74-79.
  29. MIYAGAWA S, STEPKOWSKI SM, LAWEN JG, RUTZKY LP, KAHAN BD: *In Vitro* Correlates of *In Vivo* Therapy with Cyclosporine to Immunosuppress Rejection of Heterotopic Rat Cardiac Allografts Across Strong (RT-1) Plus Weak (non RT-1) Histocompatibility Differences. *Transplantation* 1991, 52:851-857.
  30. BISHOP DK, LI W: Cyclosporin A and FK506 Mediate Differential Effects on T Cell Activation *In Vitro*. *J Immunol* 1992, 148:1049-1054.
  31. BRETSCHNER PA, HAVELLE C: Cyclosporin A Can Switch the Immune Response Induced by Antigen from a Humoral to a Cell-mediated Mode. *Eur J Immunol* 1992, 22:349-355.
  32. FENG J, ABU-ELMAGD K, JAIN A, GORDON R, TZAKIS A, TODEO S, TAKAYA S, ADJIANI M, DEMETRIAS A, BRONSTER O, ET AL: A Randomized Trial of Primary Liver Transplantation Under Immunosuppression with FK-506 vs Cyclosporine. *Transplant Proc* 1991, 23:2977-2983.

Reports a trial of treatment with FK 506 or CsA with a single dose of intravenous methylprednisolone during the operation. The results suggest that FK 506 is at least as effective as CsA, if not even more so, based on freedom from rejection, reduced incidence of hypertension and lower total dose of steroids and also does not produce greater side effects.

33. VATSALA A, GOTO S, YOSHIMURA N, STEPKOWSKI S, CHOI T C, KAHAN BD: The Immunosuppressive Antagonism of Low Doses of FK506 and Cyclosporine. *Transplantation* 1991, 52:121-128.
34. KAHAN BD: Synergism, How assessed and How Achieved. *Clin Transpl* 1991, 5:534-539.
35. VATSALA A, CHOI T-C, KAHAN BD: Analysis of the Interactions of Immunosuppressive Drugs with Cyclosporine in Inhibiting DNA Proliferation. *Transplantation* 1990, 49:463-472.
36. SQUIFFLET JP, SUTHERLAND DRR, RYNASIEWICZ JJ: Combined Immunosuppressive Therapy with Cyclosporin A and Zathio-prine. *Transplantation* 1982, 34:315-318.
37. KAHAN BD: Cyclosporine: New Strategies Obtain Improved Clinical Results. *Transplant Proc* 1993, in press.
38. KEENAN RJ, EIRAS G, BURCKART GJ, STUART RS, HARDESTY RL, VOGELSANG G, GRIFFITH BP, ZEEVI A: Immunosuppressive Properties of Thalidomide: Inhibition of *In Vitro* Lymphocyte Proliferation Alone and in Combination with Cyclosporine or FK506. *Transplantation* 1991, 52:908-910.
39. KAHAN BD, GIBBONS S, TEJPAL N, STEPKOWSKI SM, CHOI T C: Synergistic Interactions of Cyclosporine and Rapamycin to Inhibit Immune Performances of Normal Human Peripheral Blood Lymphocytes *In Vitro*. *Transplantation* 1991, 51:232-239.
40. CHU MS, AYDALONIC NM, CARON PC, AYDALONIC MV, SCHEINBERG DC, QUEEN C: Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen. *J Immunol* 1992, 148:1149-1154.
- Describes the cloning of the mouse M195H mAb light chain variable region cDNAs by a new method and reports that the 'humanized' IgG1 and IgG3 M95 antibodies, which have reshaped variable regions, have higher apparent binding affinity for the CD33 antigen than do the chimeric or mouse antibodies.
41. SEYDEL K, SHIZURU J, GROSSMAN D, WU A, ALTERS S, FATHMAN CG: Anti-CD8 Abrogates Effect of Anti-CD4-mediated Islet Allograft Survival in Rat Model. *Diabetes* 1991, 40:1430-1434.
42. CHEN Z, CORRIOLLO S, METCALFE S, WALDMANN H: Tolerance in the Mouse to Major Histocompatibility Complex-mismatched Heart Allografts, and to Rat Heart Xenografts, Using Monoclonal Antibodies to CD4 and CD8. *Eur J Immunol* 1992, 22:805-810.
43. MOCHENAAR W, BRUIJN JA, SCHRAMA E, FERRONE S, DALLA MR, ZWINDERMAN AH, HOEDEMAEKER PJ, VAN ES LA, VAN DER WOUDE FJ: T cell Receptors and ICAM-1 Expression in Renal Allografts During Rejection. *Transpl Int* 1991, 4:140-145.
- Studies of 62 biopsies taken from 38 kidneys were divided according to diagnosis into the following groups: rejection; other causes of dysfunction; and stable function. There was a significant association between detection of TCR sub-units  $\alpha/\beta$  (TCR2) and  $\gamma/\delta$  (TCR1) on infiltrating lymphocytes and ICAM-1 in renal tubular cells with acute rejection, suggesting that TCRs and ICAM-1 may be useful markers to differentiate acute rejection from renal graft dysfunction due to other causes.
44. STOPPA AM, MARANINCHI D, BIASI D, VIENS P, HIRN M, OLIVE D, REIFFERS J, MILPIED N, GASPARD MH, MAWAS C: Anti-LFA-1 Monoclonal Antibody (25.3) for Treatment of Steroid-resistant Grade III-IV Acute Graft-versus-host Disease. *Transpl Int* 1991, 4:3-7.
45. BOBE M, YAGITA H, OKUMURA K, IHARA A: Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1. *Science* 1992, 255:1125-1127.
- Reports that two mAbs antibodies, anti-ICAM-1 and anti-CD11a (anti-LFA-1), act synergistically to induce immunological tolerance. While each mAb alone inhibited *in vitro* cell-mediated cytotoxicity, they showed only a prolonging of graft survival. Modest effects on persistent graft acceptance depended upon the simultaneous administration of the two mAbs.
46. SNIDER DP: Immunization with Antigen Bound to Bispecific Antibody Induces Antibody that is Restricted in Epitope Specificity and Contains Anti-idiotypic. *J Immunol* 1992, 148:1163-1170.
47. ARFNO WP: Interleukin 1 Receptor Antagonist: A New Member of the Interleukin 1 Family. *J Clin Invest* 1991, 88:1445-1451.
48. FAHERTY DA, GAUDY V, PLODUNSKI JM, KAFFKA K, KILIAN P, THOMPSON RC, BENJAMIN WR: Failure of IL-1 Receptor Antagonist and Monoclonal Anti-IL-1 Receptor Antibody to Inhibit Antigen-specific Immune Responses *In Vivo*. *J Immunol* 1992, 148:766-771.
49. FACKLOW WC, CLIFFORD KN, PARK LS, RUBIN AS, VOICE RF, BECKMANN MP, WIDMER MB: Regulation of Alloreactivity *In Vitro* by IL-4 and the Soluble IL-4 Receptor. *J Immunol* 1991, 147:535-540.
- Reports that IL-4 is an important endogenous regulator of the allogeneic response *in vitro* and that the specific neutralization of IL-4 is responsible for the inhibition effects of soluble IL-4 receptor observed in the peripheral lymph node system. The results suggest a therapeutic value for IL-4 antagonists alone or in combination with other immunosuppressive regimens.

BD Kahan, Department of Surgery, Division of Immunology and Organ Transplantation, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.

# INTERLEUKIN-12 (IL-12)-DRIVEN ALLOIMMUNE RESPONSES IN VITRO AND IN VIVO

## REQUIREMENT FOR $\beta 1$ SUBUNIT OF THE IL-12 RECEPTOR<sup>1</sup>

JOSEPH R. PICCOTTI,<sup>2,3</sup> KEWANG LI,<sup>2</sup> SHERRI Y. CHAN,<sup>2</sup> ERNST J. EICHWALD,<sup>4</sup> AND  
D. KEITH BISHOP<sup>2,5</sup>

Department of Surgery, Section of General Surgery and Department of Microbiology and Immunology,  
University of Michigan School of Medicine, Ann Arbor, Michigan 48109, and Department of Pathology,  
University of Utah School of Medicine, Salt Lake City, Utah 84132

**Background.** Interleukin-12 (IL-12) mediates its biologic activities via binding high-affinity receptors on T and natural killer cells. Although emphasis has been placed on the requirement for IL-12R $\beta 2$  in IL-12 bioactivity, the role of IL-12R $\beta 1$  is less well defined. The current study evaluated the effects of exogenous IL-12 on alloantigen-specific immune responses and determined the requirement for IL-12R $\beta 1$  in IL-12-mediated alloimmunity.

**Methods.** The mouse heterotopic cardiac transplant model was employed to evaluate the effects of IL-12 on alloantigen-specific immune responses in vivo. In addition, IFN- $\gamma$  production in mixed lymphocyte cultures (MLC) supplemented with IL-12 was measured to assess the effects of IL-12 on Th1 function in vitro. Mice deficient in IL-12R $\beta 1$  (IL-12R $\beta 1^{-/-}$ ) were used to determine the requirement for this receptor component in IL-12-driven alloimmune responses.

**Results.** Addition of IL-12 to MLC consisting of wild-type splenocytes enhanced alloantigen-specific proliferative responses and Th1 development. In contrast, IL-12 did not alter these in vitro immune parameters in IL-12R $\beta 1^{-/-}$  MLC. Treatment of wild-type cardiac allograft recipients with IL-12 resulted in high concentrations of serum interferon- $\gamma$  (IFN- $\gamma$ ) and a 10-fold increase in IFN- $\gamma$  production by recipient splenocytes after restimulation in vitro. However, this fulminate Th1 response did not accelerate allograft rejection. Importantly, IL-12 had no effect on serum IFN- $\gamma$  or in vivo priming of Th1 in IL-12R $\beta 1^{-/-}$  recipients. Finally, administration of IL-12 to WT allograft recipients resulted in a bimodal alloantibody response: antibody production was suppressed at high doses of IL-12, and enhanced at lower doses.

**Conclusions.** IL-12 markedly enhances alloantigen-specific immune function; however, these exaggerated Th1-driven responses do not culminate in accelerated allograft rejection. Further, these data indicate that IL-12R $\beta 1$  is essential for the enhancement of both in

vitro and in vivo alloimmune responses by exogenous IL-12.

It is well established that interleukin-12 (IL-12<sup>o</sup>) is a critical cytokine involved in the regulation of Th1- and Th2-mediated immune responses in several experimental models (reviewed in 1 and 2). IL-12 has direct stimulatory and inhibitory effects on Th1 and Th2, respectively (3-6). Further, this cytokine promotes Th1 and inhibits Th2 development indirectly by inducing interferon- $\gamma$  (IFN- $\gamma$ ) production by activated T cells and natural killer cells (7-12). Th1 have been accepted as key regulators of allograft rejection, in that this cell type promotes both delayed-type hypersensitivity and cytotoxic T lymphocyte responses, which are believed to be the principle terminal effector mechanisms of acute allograft rejection (13, 14). An understanding of the role of IL-12 in graft rejection is just emerging. For example, IL-12 clearly augments alloreactive Th1 development in vitro (15). However, the presence of IL-12 is not mandatory for the development of acute cardiac allograft rejection (15, 16). Hence, an important question is whether enhanced Th1 function alters the rejection response. Given the IL-12/Th1 dogma, one would predict that IL-12 would augment alloreactive Th1 function, resulting in accelerated allograft rejection. The present study therefore was designed to test the hypothesis that IL-12-driven Th1 responses would exacerbate cardiac allograft rejection.

IL-12 mediates its biologic effects by interacting with a high-affinity receptor, which consists of at least two cloned components, IL-12R $\beta 1$  and IL-12R $\beta 2$  (17-19). IL-12R $\beta 1$  interacts with the p40 subunit of IL-12, whereas the p35 subunit of IL-12 is believed to bind to IL-12R $\beta 2$  (19, 20). Emphasis has been placed on the necessity for IL-12R $\beta 2$  in IL-12 signaling (21, 22). However, by utilizing IL-12R $\beta 1$  knockout mice (IL-12R $\beta 1^{-/-}$ ), Wu et al. (23) recently reported that the  $\beta 1$  subunit of IL-12R is essential for IL-12-driven proliferation and IFN- $\gamma$  production by mitogen-activated blasts, natural killer cell lytic activity, and IFN- $\gamma$  production in response to endotoxin. We have reported that the p40 subunit of IL-12 stimulates alloreactive CD8+ Th1 development both in vitro (24) and in vivo (15). These observations suggest that

<sup>1</sup> This work was supported by grant R01 AI31946 (D.K.B.) from the National Institutes of Health.

<sup>2</sup> Department of Surgery, Section of General Surgery, University of Michigan School of Medicine.

<sup>3</sup> Address correspondence and reprint requests to Joseph R. Piccotti, Ph.D., Transplant Immunology Research Laboratory, Section of General Surgery, A560 MSRB II, Box 0654, University of Michigan Medical Center, Ann Arbor, MI 48109-0654.

<sup>4</sup> Department of Pathology, University of Utah School of Medicine.

<sup>5</sup> Department of Microbiology and Immunology, University of Michigan School of Medicine.

\* Abbreviations: Con A, concanavalin A; ELISA, enzyme-linked immunosorbent assay; GVHD, graft-versus-host disease; H&E, hematoxylin and eosin; IFN- $\gamma$ , interferon- $\gamma$ ; IL, interleukin; IL-12R $\beta 1^{-/-}$ , mice deficient in  $\beta 1$  subunit of IL-12 receptor; mAb, monoclonal antibody; MLC, mixed lymphocyte culture; WT, wild-type.

IL-12R $\beta$ 1 may be needed for alloreactive Th1 development, and that signaling through IL-12R $\beta$ 1 may be sufficient to mediate IL-12's biologic activity on CD8<sup>+</sup> T cells. Hence, the present study employed IL-12R $\beta$ 1<sup>-/-</sup> mice to determine whether  $\beta$ 1 subunit of IL-12R is required for IL-12-induced alloantigen-specific immune responses. To our knowledge, this study is the first to investigate the effects of IL-12 treatment on alloreactive Th1 development in vivo and to establish a mandatory role for IL-12R $\beta$ 1 in IL-12-driven alloimmune responses.

## MATERIALS AND METHODS

**Mice.** Wild-type (WT) C57BL/6 and BALB/c mice between 6 and 12 weeks of age were obtained from Charles River Laboratories (Raleigh, NC). Generation of C57BL/6 IL-12R $\beta$ 1<sup>-/-</sup> mice has been described previously (23). These mice were generated on the 129/Sv background and back-crossed to C57BL/6 mice for five generations, then intercrossed to generate homozygotes.

**Medium.** The culture medium used in these studies was Dulbecco's minimum essential medium supplemented with 1.6 mM L-glutamine, 0.27 mM L-asparagine, 1.4 mM L-arginine HCl, 14  $\mu$ M folic acid, 10 mM HEPES buffer, 1.0 mM sodium pyruvate, 100 units/ml penicillin/streptomycin, 2% fetal calf serum (all obtained from Life Technologies, Grand Island, NY), and  $5 \times 10^{-5}$  M 2-mercaptoethanol (Sigma Chemical, St Louis, MO).

**Mitogen-driven cytokine production.** To investigate the requirement for the  $\beta$ 1 subunit of IL-12R in mitogen-stimulated IL-10 and IFN- $\gamma$  production, splenocytes ( $2 \times 10^6$  cells/ml) isolated from naive WT or IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 mice were incubated for 72 hr with 1  $\mu$ g/ml concanavalin A (Con A) (Sigma Chemical). Cultures were supplemented with 1 ng/ml murine recombinant IL-12 (rIL-12) (kindly provided by Dr. Maurice Gately, Hoffmann-La Roche Inc.) to assess the effect of exogenous IL-12 on Con A-stimulated cytokine production by splenocytes of WT and IL-12R $\beta$ 1-deficient mice. Resulting supernatants were harvested at 72 hr, and the concentrations of IL-10 and IFN- $\gamma$  measured by enzyme-linked immunosorbent assay (ELISA).

**In vitro alloimmune responses.** To assess alloantigen-specific Th1 development, splenocytes ( $1 \times 10^6$  cells/ml) isolated from naive WT or IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 mice were incubated for 5 days with irradiated (5000 rads) BALB/c splenocytes ( $1 \times 10^6$  cells/ml). Where indicated, 1 ng/ml of murine rIL-12 was added to primary mixed lymphocyte cultures (MLC) to assess the effect of exogenous IL-12 on alloantigen-driven Th1 function and to evaluate whether Th1 from IL-12R $\beta$ 1-deficient mice were responsive to IL-12 stimulation. The concentration of rIL-12 was selected from dose-response experiments in which the amount of rIL-12 needed for maximal enhancement of alloantigen-specific proliferation was 5–10 ng/ml (data not shown). Resulting cell populations were harvested, washed three times, and restimulated (at  $1 \times 10^6$  cells/ml) with irradiated BALB/c stimulator cells ( $1 \times 10^6$  cells/ml). MLC supernatants were collected after 24 hr (IL-4 and IL-10) or 72 hr (IFN- $\gamma$ ), and cytokine concentrations measured by ELISA.

In addition, splenocyte proliferative response to alloantigens was determined in cultures either left unmodified or supplemented with 1 ng/ml murine rIL-12. WT or IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 splenocytes ( $1 \times 10^6$  cells/ml) were stimulated for 5 days with irradiated BALB/c splenocytes ( $1 \times 10^6$  cells/ml) in 96-well U-bottom plates (Becton Dickinson, Lincoln Park, NY) in a final volume of 200  $\mu$ l (done in quadruplicate). Cultures were pulsed with 0.5  $\mu$ Ci/well [methyl-<sup>3</sup>H]thymidine (ICN, Costa Mesa, CA) for the final 8 hr of the incubation period. [methyl-<sup>3</sup>H]Thymidine incorporation was assessed on a Wallac 1205 Betaplate scintillation counter (Wallac, Turku, Finland).

**Heterotopic cardiac transplantation.** Intact BALB/c (H2<sup>d</sup>) hearts were anastomosed to the great vessels in the abdomens of WT or

IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 (H2<sup>b</sup>) mice as described by Corry et al. (25). In this model, the transplanted heart is perfused with the recipient's blood and resumes contractions until acutely rejected, which occurs in unmodified WT recipients of this strain combination in approximately 8–9 days (15, 24). Graft function was evaluated by daily abdominal palpation. Myocyte damage and intensity of graft-infiltrating cells were assessed by routine hematoxylin and eosin (H&E) staining of paraffin-embedded sections of transplanted allografts.

**Experimental groups.** Cardiac allograft recipients were divided into four groups: (1) recipients injected intraperitoneally with 1 mg of anti-CD8 monoclonal antibody (mAb) hybridoma 2.43, purified by Montana ImmunoTech Inc., Bozeman, MT) on days -2 and -1 before transplantation, (2) animals given daily intraperitoneal injections of murine rIL-12 (0.1 or 1.0  $\mu$ g) on days 1–6 after transplantation, (3) recipients injected with a combination of 2.43 anti-CD8 mAb plus rIL-12, and (4) unmodified (no treatment) mice, which served as controls. Depletion of CD8<sup>+</sup> cells (<2%) was verified by flow cytometry using anti-CD8:fluorescein isothiocyanate antibody (PharMingen).

**In vivo alloimmune responses.** To monitor in vivo Th1 development, splenocytes ( $1 \times 10^6$  cells/ml) obtained from allograft recipients were restimulated with irradiated BALB/c stimulator cells ( $1 \times 10^6$  cells/ml), and the concentration of IFN- $\gamma$  was measured by ELISA. As an additional measure of the in vivo activity of IL-12 on IFN- $\gamma$  production, sera IFN- $\gamma$  concentrations in WT and IL-12R $\beta$ 1<sup>-/-</sup> cardiac allograft recipients were measured by ELISA. Further, to assess the effect of IL-12 treatment on B cell function, sera alloantibody (IgM, IgG1, and IgG2a) levels were determined (see below).

**Cytokine ELISA.** Experimental samples (100  $\mu$ l) were added in triplicate to plates coated with 5  $\mu$ g/ml rat anti-mouse IFN- $\gamma$ , IL-4, or IL-10 capture antibodies (PharMingen). Standards were employed by preparing 2-fold dilutions of murine recombinant IFN- $\gamma$ , IL-4, and IL-10 (PharMingen), with a starting concentration of 25, 2.5, and 10 ng/ml, respectively. After a 1-hr incubation at room temperature, plates were washed three times with 0.05% Tween 20 in PBS. One hundred microliters of rat anti-mouse secondary biotinylated antibodies (1  $\mu$ g/ml) (PharMingen) was then added, and plates were incubated at room temperature for 45 min. Plates were then washed three times with 0.05% Tween 20 in PBS, and 100  $\mu$ l of avidin-peroxidase (Sigma Chemicals) was added. After a 30-min incubation at room temperature, plates were washed three times with 0.05% Tween 20 in PBS, and 100  $\mu$ l of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) substrate (Sigma Chemical) was then added to each well. After 20 min, absorbance was determined at 405 nm by an EL 800 microplate reader (Bio-Tek Instruments, Winooski, VT). Sample cytokine concentrations were calculated from a standard curve. The sensitivity of this assay is approximately 300 pg/ml for IFN- $\gamma$ , 100 pg/ml for IL-4, and 150 pg/ml for IL-10.

**Sera alloantibody determination.** P815 cells (H2<sup>d</sup>) were stained for flow cytometric analysis using dilutions of sera (1:50) obtained from cardiac allograft recipients as the primary antibody, followed by fluorescein isothiocyanate-conjugated isotype-specific anti-mouse IgM, IgG1, and IgG2a secondary antibodies (The Binding Site, San Diego, CA). Data are reported as the mean channel fluorescence determined on a Becton Dickinson FACScan.


**Statistics.** Statistical analyses in this study were done using a Student's *t* test performed by the program StatView 4.1.

## RESULTS

### Requirement for IL-12R $\beta$ 1 in T Cell Responses in Vitro

**Enhancement of mitogen-driven IFN- $\gamma$  and IL-10 production by IL-12 requires IL-12R $\beta$ 1.** IL-12 stimulates concomitant production of IL-10 and IFN- $\gamma$  by activated T cells (15, 26, 27). To determine whether  $\beta$ 1 subunit of IL-12R is required for production of these cytokines, C57BL/6 splenocytes isolated WT or IL-12R $\beta$ 1-deficient mice were stimu-

lated with Con A for 72 hr, and supernatant cytokine concentrations were determined by ELISA. Production of the Th1 cytokine IFN- $\gamma$  by Con A-stimulated splenocytes isolated from IL-12R $\beta$ 1<sup>-/-</sup> mice was readily detectable (Fig. 1A), although concentrations were lower than that seen in WT controls (IL-12R $\beta$ 1<sup>-/-</sup> = 1.03 ng/ml vs. WT = 5.24 ng/ml). Addition of exogenous rIL-12 significantly enhanced IFN- $\gamma$  production by mitogen-stimulated splenocytes obtained from WT mice (15.79 ng/ml). In contrast, IFN- $\gamma$  production by splenocytes from IL-12R $\beta$ 1<sup>-/-</sup> mice was not altered after the addition of rIL-12 (1.54 ng/ml).



**FIGURE 1.** Mitogen-driven cytokine production by splenocytes isolated from IL-12R $\beta$ 1<sup>-/-</sup> mice. Splenocytes ( $2 \times 10^6$  cells/ml) obtained from WT or IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 mice were stimulated *in vitro* with 1  $\mu$ g/ml Con A. Cultures were either left untreated or supplemented with murine rIL-12 (1 ng/ml). Supernatants were collected after 72 hr, and the concentrations of IFN- $\gamma$  (A) and IL-10 (B) were determined by ELISA. Results are expressed as the mean cytokine concentration in triplicate samples  $\pm$  SD. Data are representative of three separate experiments. In panel A, \*,  $P < 0.05$  (WT unmodified vs. IL-12R $\beta$ 1<sup>-/-</sup> unmodified), \*\*\*,  $P < 0.005$  (WT unmodified vs. WT IL-12-treated). In panel B, \*,  $P < 0.05$  (WT unmodified vs. WT IL-12-treated).

The requirement for IL-12R $\beta$ 1 in IL-12-driven IL-10 production also was assessed. Splenocytes isolated from IL-12R $\beta$ 1-deficient mice produced similar levels of IL-10 upon Con A stimulation when compared to WT cells (Fig. 1B). rIL-12 enhanced Con A-stimulated IL-10 production by WT splenocytes (2.70 ng/ml vs. 5.65 ng/ml). However, the  $\beta$ 1 subunit of IL-12R was required for this response, as IL-12 did not affect IL-10 secretion by mitogen-stimulated IL-12R $\beta$ 1<sup>-/-</sup> splenocytes.

***In vitro* alloreactive T helper cell development.** To evaluate the requirement for IL-12R $\beta$ 1 in IL-12-driven alloantigen-specific T cell development, naive splenocytes obtained from WT or IL-12R $\beta$ 1<sup>-/-</sup> mice were incubated for 5 days with irradiated BALB/c splenocytes in primary MLC, which were either left unmodified or supplemented with rIL-12. Resulting cell populations were restimulated with irradiated BALB/c splenocytes in the absence of rIL-12, and *in vitro* IFN- $\gamma$ , IL-4, and IL-10 production determined by ELISA (Table 1). Primed WT splenocytes secreted high levels of IFN- $\gamma$  upon restimulation with alloantigens. Splenocytes obtained from IL-12R $\beta$ 1<sup>-/-</sup> mice secreted IFN- $\gamma$  upon restimulation with alloantigens, albeit to a lesser degree than WT cells (WT = 21.32 ng/ml vs. IL-12R $\beta$ 1<sup>-/-</sup> = 5.72 ng/ml). The decrease in alloantigen-stimulated IFN- $\gamma$  production in IL-12R $\beta$ 1-deficient mice was not associated with a decrease in the cells' ability to proliferate in response to alloantigens (Fig. 2), in that [methyl-<sup>3</sup>H]thymidine incorporation by alloantigen-stimulated IL-12R $\beta$ 1<sup>-/-</sup> splenocytes was similar to that seen by WT cells (IL-12R $\beta$ 1<sup>-/-</sup> = 13,385 cpm vs. WT = 11,441 cpm). In both groups, IL-4, IL-10 (Table 1), and IL-5 (data not shown) were not detected in cultures that were not supplemented with exogenous rIL-12.

As shown in Table 1, exogenous rIL-12 markedly enhanced IFN- $\gamma$  production by WT splenocytes *in vitro* (21.32 ng/ml vs. 215.13 ng/ml), but failed to augment IFN- $\gamma$  secretion by cells obtained from IL-12R $\beta$ 1<sup>-/-</sup> mice (5.72 ng/ml vs. 6.80 ng/ml). Likewise, rIL-12 significantly enhanced WT splenocyte proliferation in the MLC (Fig. 2), but did not alter the proliferative ability of splenocytes isolated from IL-12R $\beta$ 1-deficient mice. Finally, the addition of exogenous rIL-12 to cultures

**TABLE 1.** IL-12 does not enhance alloantigen-specific Th1 development in IL-12R $\beta$ 1<sup>-/-</sup> mice *in vitro*<sup>a</sup>

Treatment	IFN- $\gamma$ (ng/ml)	IL-4 (ng/ml)	IL-10 (ng/ml)
Unmodified			
WT	21.32 $\pm$ 0.88	ND	ND
IL-12R $\beta$ 1 <sup>-/-</sup>	5.72 $\pm$ 0.24**	ND	ND
IL-12 (1 ng/ml)			
WT	215.13 $\pm$ 13.52***	ND	1.54 $\pm$ 0.21
IL-12R $\beta$ 1 <sup>-/-</sup>	6.80 $\pm$ 0.21	ND	ND

<sup>a</sup> Splenocytes ( $1 \times 10^6$  cells/ml) obtained from WT or IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 mice were incubated for 5 days with irradiated allogeneic splenocytes ( $1 \times 10^6$  cells/ml) in unmodified MLC or MLC supplemented with murine rIL-12 (1 ng/ml). Resulting cell populations were harvested and restimulated with alloantigens for cytokine determination. Supernatant concentrations of IFN- $\gamma$  (72 hr), IL-4 (24 hr), and IL-10 (24 hr) were measured by ELISA. Results are expressed as the cytokine concentration in triplicate samples (mean  $\pm$  SD). Data are representative of four separate experiments. ND indicates not detectable. \*\*,  $P < 0.01$ , WT unmodified vs. IL-12R $\beta$ 1<sup>-/-</sup> unmodified; \*\*\*,  $P < 0.005$ , WT unmodified vs. WT IL-12-treated.





FIGURE 2. The  $\beta 1$  subunit of IL-12 receptor is required for IL-12-induced stimulation of alloantigen-specific splenocyte proliferation. C57BL/6 splenocytes ( $1 \times 10^6$  cells/ml) were stimulated with irradiated allogeneic BALB/c splenocytes ( $1 \times 10^6$  cells/ml) in 96-well microtiter plates for 5 days. Cultures were pulsed with 0.5  $\mu$ Ci/well [methyl- $^3$ H]thymidine for the final 8 hr of the incubation period, and thymidine incorporation was determined by liquid scintillation spectrophotometry. Results are expressed as the mean cpm in quadruplicate samples  $\pm$  SD. Data are representative of three separate experiments. \*,  $P < 0.05$  (WT unmodified vs. WT IL-12-treated).

stimulated the secretion of IL-10 by alloantigen-stimulated WT splenocytes, but not IL-12R $\beta 1^{-/-}$  cells (Table 1). Collectively, these data indicate that the  $\beta 1$  subunit of IL-12R is required for the enhancement of several in vitro alloimmune responses by exogenous rIL-12, including increased alloantigen-stimulated T cell proliferation, and IFN- $\gamma$  and IL-10 production.

#### Effects of Exogenous IL-12 on Alloimmune Responses in Vivo

**Enhancement of serum IFN- $\gamma$  by IL-12 treatment.** To monitor the in situ effects of IL-12 treatment on IFN- $\gamma$  production in cardiac allograft recipients, serum IFN- $\gamma$  concentrations were measured on day 7 after transplantation (Fig. 3). In both WT and IL-12R $\beta 1^{-/-}$  allograft recipients, serum IFN- $\gamma$  was undetectable by ELISA on day 7 after transplantation. Treatment of WT recipients with rIL-12 markedly increased serum IFN- $\gamma$  in three independent experiments; however, this treatment regimen had little effect on the concentration of serum IFN- $\gamma$  in IL-12R $\beta 1^{-/-}$  allograft recipients.

**Effects of IL-12 on alloantigen-specific Th1 development in vivo.** Splenocytes obtained from cardiac allograft recipients were restimulated in vitro with donor alloantigens and supernatant concentrations of IFN- $\gamma$  were determined by ELISA. This assay detects in vivo primed Th1, in that splenocytes from naive, nontransplanted mice produce minimal or undetectable levels of IFN- $\gamma$  under these conditions (15, 16, 24). Restimulation of splenocytes from unmodified IL-12R $\beta 1^{-/-}$  allograft recipients with donor alloantigens resulted in the secretion of similar amounts of IFN- $\gamma$  compared



#### Treatment In Vivo

FIGURE 3. Treatment of WT, but not IL-12R $\beta 1^{-/-}$  allograft recipients with rIL-12 markedly increases serum IFN- $\gamma$ . WT or IL-12R $\beta 1^{-/-}$  C57BL/6 mice bearing BALB/c cardiac allografts were either left untreated or given daily intraperitoneal injections of 1.0  $\mu$ g of rIL-12 on days 1–6 after transplantation. On day 7, blood obtained from allograft recipients was pooled and serum collected after centrifugation. Serum IFN- $\gamma$  was determined by ELISA. Results are expressed as the mean cytokine concentration in triplicate samples  $\pm$  SD. Data are representative of three independent experiments. ND indicates not detectable. \*\*\*,  $P < 0.005$  (WT IL-12-treated vs. IL-12R $\beta 1^{-/-}$  IL-12-treated).

to that seen in WT recipients (IL-12R $\beta 1^{-/-}$  = 7.16 ng/ml vs. WT = 6.24 ng/ml) (Fig. 4). Treatment of WT recipients with IL-12 resulted in a 10-fold increase in the production of IFN- $\gamma$  (59.05 ng/ml). In contrast, IFN- $\gamma$  production by splenocytes obtained from IL-12R $\beta 1^{-/-}$  recipients treated with IL-12 in vivo was similar to untreated values (9.59 ng/ml), indicating that the  $\beta 1$  subunit of IL-12R is required for IL-12-mediated enhancement of in vivo sensitization of IFN- $\gamma$ -producing cells. Further, these results indicate that in vivo Th1 development can occur in a state of IL-12 unresponsiveness.

**Effects of exogenous IL-12 on cardiac allograft rejection.** As IL-12 treatment markedly enhanced Th1 responses in WT allograft recipients (Figs. 3 and 4), one might predict that IL-12 treatment would exacerbate allograft rejection. To test this possibility, cardiac allograft function was monitored by daily abdominal palpation in WT or IL-12R $\beta 1^{-/-}$  allograft recipients bearing BALB/c hearts. Cardiac allograft recipients were either left untreated or injected once daily with 1.0  $\mu$ g of rIL-12. Treatment of WT allograft recipients with this dose of rIL-12 ( $n = 10$ ) resulted in symptoms of cachexia including weight loss (mean decrease =  $2.0 \pm 0.7$  g in 1 week), ruffed fur, hunched posture, and decreased activity. In contrast, IL-12R $\beta 1^{-/-}$  allograft recipients exhibited no signs of IL-12-induced toxicity.

The mean cardiac allograft survival in unmodified WT recipients was approximately 8 days (data not shown; 15, 24).

IFN- $\gamma$  (ng/ml)

FIGURE 3. Treatment of WT, but not IL-12R $\beta 1^{-/-}$  allograft recipients with rIL-12 markedly increases serum IFN- $\gamma$ . WT or IL-12R $\beta 1^{-/-}$  C57BL/6 mice bearing BALB/c cardiac allografts were either left untreated or given daily intraperitoneal injections of 1.0  $\mu$ g of rIL-12 on days 1–6 after transplantation. On day 7, blood obtained from allograft recipients was pooled and serum collected after centrifugation. Serum IFN- $\gamma$  was determined by ELISA. Results are expressed as the mean cytokine concentration in triplicate samples  $\pm$  SD. Data are representative of three independent experiments. ND indicates not detectable. \*\*\*,  $P < 0.005$  (WT IL-12-treated vs. IL-12R $\beta 1^{-/-}$  IL-12-treated).

Cardiac allograft recipients bearing BALB/c hearts. Cardiac allograft recipients were either left untreated or injected once daily with 1.0  $\mu$ g of rIL-12. Treatment of WT allograft recipients with this dose of rIL-12 ( $n = 10$ ) resulted in symptoms of cachexia including weight loss (mean decrease =  $2.0 \pm 0.7$  g in 1 week), ruffed fur, hunched posture, and decreased activity. In contrast, IL-12R $\beta 1^{-/-}$  allograft recipients exhibited no signs of IL-12-induced toxicity.






FIGURE 4. Enhancement of in vivo sensitization of IFN- $\gamma$ -producing cells by IL-12 requires IL-12R $\beta$ 1. WT or IL-12R $\beta$ 1<sup>-/-</sup> C57BL/6 cardiac allograft recipients were either left untreated or injected daily with 1.0  $\mu$ g of rIL-12 on days 1–6 after transplantation. To assess in vivo Th1 development, splenocytes ( $1 \times 10^6$  cells/ml) obtained from cardiac allograft recipients were restimulated with irradiated BALB/c splenocytes ( $1 \times 10^6$  cells/ml). Supernatants were collected after 72 hr, and the concentration of IFN- $\gamma$  was determined by ELISA. Results are expressed as the mean concentration of IFN- $\gamma$  in triplicate samples  $\pm$  SD. Data are representative of three separate experiments. \*\*\*,  $P < 0.005$  (WT unmodified vs. WT IL-12-treated).

Cardiac allografts in IL-12R $\beta$ 1<sup>-/-</sup> recipients were rejected in a similar fashion to that seen in IL-12-deficient mice (15), in that grafts were uniformly rejected by day 7 ( $n=8$ ). As expected, treatment of IL-12R $\beta$ 1<sup>-/-</sup> allograft recipients with rIL-12 had no effect on the tempo of allograft rejection ( $n=6$ ). Interestingly, despite the overwhelming Th1 response induced by rIL-12 in WT allograft recipients (Figs. 3 and 4), treatment of these animals with rIL-12 did not appear to accelerate the tempo of graft rejection when compared to grafts of untreated WT recipients on day 7 after transplantation. For example, 7 of 10 (70%) allografts of WT recipients treated with rIL-12 were still functioning on day 7. A histologic evaluation of these grafts revealed similar parameters of early rejection compared to unmodified WT recipients. Specifically, histology was characterized by diffuse mononuclear cell infiltrates, viable myocytes as evidenced by visible nuclei, and relatively uninvolved vessels (Fig. 5). Hence, rIL-12 treatment did not accelerate the pathologic changes associated with acute rejection.

**Phenotype of alloantigen-reactive Th1 in WT allograft recipients treated with rIL-12.** To determine the phenotype of Th1 responsive to exogenous rIL-12, WT cardiac recipients were depleted in vivo of CD8<sup>+</sup> T cells (Fig. 6). Splenocytes obtained from CD8 depleted cardiac allograft recipients produced markedly less IFN- $\gamma$  upon in vitro restimulation with irradiated donor splenocytes (WT unmodified = 6.15 ng/ml vs.



FIGURE 5. Exogenous IL-12 does not exacerbate cardiac allograft rejection. C57BL/6 WT recipients of BALB/c cardiac allografts were either left untreated or injected intraperitoneally with murine rIL-12 (1.0  $\mu$ g) on days 1–6 after transplantation. On day 7, allografts were harvested for histologic evaluation. (A) H&E-stained section of allografts from WT recipients left untreated (original magnification,  $\times 400$ ). (B) H&E-stained section of allografts from WT recipients treated with rIL-12 (original magnification,  $\times 400$ ). Note in both experimental groups moderate mononuclear cell infiltrates, and relative health of myocytes and vessels. These characteristics are associated with the early phase of acute rejection before onset of myocyte necrosis and vascular damage, which is observed on days 8 or 9 after transplantation. Results are representative of at least 10 individual transplants for each experimental group.

WT anti-CD8 mAb-treated = 0.52 ng/ml). Similarly, Th1 that develop as a result of IL-12 stimulation in these experiments were predominantly CD8<sup>+</sup> T cells (Fig. 6), as depletion of CD8 cells resulted in a reduction in IFN- $\gamma$  production (WT IL-12-treated = 35.89 ng/ml vs. WT IL-12 plus anti-CD8 mAb-treated = 2.75 ng/ml).

#### IL-12 Treatment (1.0 $\mu$ g/Day) Inhibits Alloantibody Responses

Given our findings that treatment of WT cardiac allograft recipients with rIL-12 resulted in significant augmentation of serum IFN- $\gamma$  (Fig. 3) and in vivo priming of Th1 (Fig. 4), one would predict that IL-12 treatment should drive IgG2a alloantibody production. To test this possibility, sera alloantibody production was assessed on day 7 after transplanta-




FIGURE 6. Alloantigen-specific Th1 responding to exogenous rIL-12 are CD8<sup>+</sup> T cells. In these experiments, splenocytes were obtained from cardiac allograft recipients either left untreated or treated with anti-CD8 mAb, rIL-12, or a combination of anti-CD8 mAb plus rIL-12. Th1 function was assessed by IFN- $\gamma$  production after a 72-hr restimulation of recipient's splenocytes with irradiated BALB/c splenocytes. Results are expressed as the mean concentration of IFN- $\gamma$  in triplicate samples  $\pm$  SD. Data are representative of three separate experiments. \*\*\*,  $P < 0.005$  (WT unmodified vs. WT anti-CD8 mAb-treated; WT IL-12-treated vs. WT IL-12 plus anti-CD8 mAb-treated).

tion in WT cardiac allograft recipients either left unmodified or treated once daily with 1.0  $\mu$ g of rIL-12. In these experiments, sera IgG2a was undetectable in rIL-12-treated WT allograft recipients at this time point (data not shown). Further, treatment of WT recipients with rIL-12 resulted in reduced sera IgM alloantibody in three independent experiments, compared to untreated WT recipients (Table 2). This observation indicates that high doses of rIL-12 inhibit, rather than enhance, alloantibody production in this model. In contrast, treatment of IL-12R $\beta$ 1<sup>-/-</sup> allograft recipients with

rIL-12 resulted in a slight increase in sera IgM compared to unmodified knockout recipients.

#### Effects of Low-dose IL-12 (0.1 $\mu$ g/Day) on Alloantibody Responses

The reduction in sera IgM in WT allograft recipients after rIL-12 (1.0  $\mu$ g/day) treatment (Table 2) may have been caused by anti-proliferative or toxic effects on B cell function caused by rIL-12 and/or IFN- $\gamma$ . To test this possibility, WT cardiac allograft recipients were treated once daily with 0.1  $\mu$ g of rIL-12 and sera alloantibody levels were assessed on day 7 or 8 after transplantation. No alterations in the pathology of allograft rejection was observed in recipients treated with 0.1  $\mu$ g of rIL-12 compared to 1.0  $\mu$ g (data not shown). Further, treatment of WT allograft recipients with 0.1  $\mu$ g of rIL-12 resulted in significantly less IL-12-induced toxicity, serum IFN- $\gamma$  concentrations in these animals were undetectable by ELISA, and in vivo Th1 sensitization was similar to untreated allograft recipients (data not shown). These results suggested that the 0.1- $\mu$ g dose of rIL-12 was ineffective in vivo. However, unlike the higher dose of rIL-12 (1.0  $\mu$ g), treatment of WT cardiac allograft recipients with 0.1  $\mu$ g of rIL-12 resulted in an increase in sera IgG2a, but not IgG1 at both days 7 and 8 after transplantation (Table 3). Further, IL-12 treatment augmented sera IgM levels at both time points.

#### DISCUSSION

Bioactive IL-12 exists as a p70 heterodimer composed of p35 and p40 subunits (28, 29). Each subunit of IL-12 interacts with a distinct component of the IL-12R: p40 binds to IL-12R $\beta$ 1 and p35 interacts with IL-12R $\beta$ 2 (19, 20). Both receptor subunits are associated with members of the Janus kinase family (30), and therefore may facilitate IL-12-mediated signal transduction. However, most of the attention has been given to IL-12R $\beta$ 2, which associates with JAK2 (30). For example, recent evidence supports a requirement for IL-12R $\beta$ 2 expression in IL-12-induced phosphorylation of Stat4 (21, 22). Further, these studies revealed the importance of the  $\beta$ 2 subunit of IL-12R by demonstrating that the unresponsiveness of Th2 to IL-12 in both human (21) and mouse (22) is a result of loss of IL-12R $\beta$ 2 expression by these cells. These results indicate that the binding of the p40 subunit of

TABLE 2. High-dose rIL-12 inhibits IgM production in vivo<sup>a</sup>

	Serum IgM (mean channel fluorescence)	
	Unmodified	IL-12 Treatment
WT		
Experiment 1	37.18	9.85
Experiment 2	33.97	11.39
Experiment 3	78.51	27.37
IL-12R $\beta$ 1 <sup>-/-</sup>		
Experiment 1	17.36	31.52
Experiment 2	33.83	43.64
Experiment 3	21.67	35.96

<sup>a</sup> Serum was obtained on day 7 after transplantation from WT or IL-12R $\beta$ 1<sup>-/-</sup> cardiac allograft recipients. Animals were either left untreated or injected with 1  $\mu$ g of rIL-12 once daily. Anti-BALB/c IgM was assessed by flow cytometry using P815 (H2<sup>d</sup>) target cells as described under Materials and Methods. Data are reported as the mean channel fluorescence and represent three separate experiments for each group.

TABLE 3. Low-dose rIL-12 augments IgM and IgG2a production in vivo<sup>a</sup>

	Mean channel fluorescence		
	IgM	IgG1	IgG2a
Experiment 1 (day 7)			
Unmodified	11.90	2.06	2.58
IL-12	28.94	2.67	12.79
Experiment 2 (day 8)			
Unmodified	31.54	8.53	16.31
IL-12	46.57	9.72	49.00

<sup>a</sup> Serum was obtained on day 7 or 8 after transplantation from cardiac allograft recipients either left untreated or injected with 0.1  $\mu$ g of rIL-12 once daily. Isotype-specific anti-BALB/c alloantibody was assessed by flow cytometry using P815 (H2<sup>d</sup>) target cells as described under Materials and Methods. Data are reported as the mean channel fluorescence. Mean channel fluorescence for isotype controls were 1.65 (IgM), 1.67 (IgG1), and 1.57 (IgG2a).



IL-12 to IL-12R $\beta$ 1 is not sufficient to mediate the bioactivity of heterodimer IL-12. However, we have reported that p40 promotes alloantigen-specific CD8<sup>+</sup> Th1 development in the absence of heterodimer IL-12 (15). This observation suggests that IL-12 p40 mediates its stimulatory effect through IL-12R $\beta$ 1 alone, or that IL-12R $\beta$ 1 associates with a yet unidentified component of IL-12R on CD8<sup>+</sup> T cells. These possibilities have not been tested. Additional data are emerging that support a biologic role of p40 interacting with IL-12R $\beta$ 1 (1). Specifically, p35 knockout mice, which are capable of producing p40 in levels similar to WT mice (31), are less susceptible to infection with *Listeria* and *Cryptococcus neoformans* compared to p40 knockout mice. Hence, one goal of the current study was to assess the role of IL-12R $\beta$ 1 in alloimmune responses both in vitro and in vivo.

IL-12 is a potent stimulator of in vitro alloantigen-specific Th1 development, in that the addition of IL-12 to MLC consisting of WT responder splenocytes resulted in a 10-fold or greater increase in IFN- $\gamma$  production (Table 1; 15). Exogenous rIL-12 also markedly augments in vitro Th1 development in mice that are deficient in p35, p40 (15) or both subunits of IL-12 (JR Piccotti and DK Bishop, unpublished observations), indicating that T cells of these mice are equipped with a functional IL-12R. In contrast, IL-12 did not alter MLC IFN- $\gamma$  production by splenocytes of IL-12R $\beta$ 1<sup>-/-</sup> mice (Table 1). This result illustrates the requirement of  $\beta$ 1 subunit of IL-12R for IL-12-driven Th1 differentiation in vitro. It should be noted that, although IFN- $\gamma$  production by IL-12R $\beta$ 1<sup>-/-</sup> splenocytes in MLC was reduced compared to WT values (Table 1), this cytokine was readily detectable by ELISA, suggesting that IL-12 is not an absolute requirement for in vitro Th1 responses.

IL-12 is also a key cytokine involved in promoting cell-mediated immune responses in vivo (1, 2). However, what role IL-12 plays in transplant rejection remains unclear. It has been reported that IL-12 has a central role in the progression of acute graft-versus-host disease (GVHD) in mice (6, 32). In these studies, neutralizing IL-12 with a polyclonal anti-IL-12 antibody results in the amelioration of acute GVHD (32) and, conversely, treatment with exogenous IL-12 converts chronic GVHD into exacerbated acute GVHD (6, 32). Further, Williamson et al. (33) have reported that neutralizing IL-12 during the inductive phase of GVHD results in a Th1 to Th2 shift evidenced by a reduction in IFN- $\gamma$  and enhancement of IL-5 and IL-10 production by Con A-stimulated splenocytes. In contrast to these findings, neutralizing IL-12 in mouse vascularized cardiac allograft recipients promotes intragraft Th2 cytokine (IL-4 and IL-10) gene expression; however, these grafts are rejected in an accelerated fashion compared to untreated recipients (16). Importantly, in vivo Th1 priming is not inhibited by IL-12 neutralization, indicating that Th1 development can occur independent of IL-12 (16). This possibility is further supported by the observation that splenocytes of IL-12R $\beta$ 1<sup>-/-</sup> allograft recipients produce similar concentrations of IFN- $\gamma$  upon restimulation with donor splenocytes compared to WT recipients (Fig. 4). It does not appear that Th1 development in IL-12R $\beta$ 1<sup>-/-</sup> mice is a result of the interaction of endogenous IL-12 with the low-affinity IL-12R $\beta$ 2, as treatment of these animals with rIL-12 did not augment in vivo priming of IFN- $\gamma$ -producing cells (Figs. 3 and 4).

A second hypothesis tested in the current study was treatment of cardiac allograft recipients with IL-12 would accelerate the rejection process as a result of exacerbated Th1-driven immune responses. Administration of exogenous rIL-12 significantly augmented in vivo sensitization of IFN- $\gamma$ -producing cells in WT cardiac allograft recipients, as evidenced by increased sera IFN- $\gamma$  (Fig. 3) and enhanced production of IFN- $\gamma$  by splenocytes after restimulation with donor alloantigens in vitro (Fig. 4). However, this fulminate Th1 response in vivo did not result in anticipated acceleration of graft rejection when compared to untreated control recipients (Fig. 5). It is possible that induction of high systemic levels of IFN- $\gamma$  results in an inhibition of immune response as a result of IFN- $\gamma$ 's anti-proliferative properties on effector cell development (34). However, graft survival was not prolonged after rIL-12 treatment in the current study. This observation questions the overall importance of Th1 responses in this experimental model, and suggests that the magnitude of Th1-driven alloimmune response may not correlate directly to the severity of graft rejection. Indeed, Th2-driven immune responses are emerging as potential effector cells of rejection in both human and experimental transplantation (reviewed in 35).

Finally, we examined the influence of rIL-12 administration on allospecific B cell function. In an experimental system in which PVG.RT1<sup>u</sup> congenic rats were immunized with an isolated alloantigen, Gracie et al. (36) reported that treatment with murine rIL-12 (1.0  $\mu$ g/day for 5 days) after alloimmunization augments levels of allospecific IgG2b and IgG2c, while decreasing IgG1. The authors demonstrated that co-administration of neutralizing anti-IFN- $\gamma$  mAb abrogated this response, indicating that the enhancement of B cell function by IL-12 was dependent on IFN- $\gamma$ . When adjusted for body weight, this dose of rIL-12 in the rat is comparable to our 0.1- $\mu$ g dose in the mouse. In the current study, treatment of WT cardiac allograft recipients with 0.1  $\mu$ g of rIL-12/day for 6 days increased the level of sera IgG2a compared to untreated recipients on day 7 and 8 after transplantation (Table 3). However, administration of 1.0  $\mu$ g of rIL-12/day reduced allospecific B cell function, indicated by a decrease in sera IgM (Table 2) and absence of isotype switch to IgG2a. These observations suggest a biphasic response to IL-12 treatment in WT mouse cardiac allograft recipients likely dependent on the concentration of IFN- $\gamma$ .

In summary, this study illustrates that the  $\beta$ 1 subunit of mouse IL-12R is critical for IL-12-driven alloimmune responses both in vitro and in vivo, and that IL-12R $\beta$ 2 alone does not transduce IL-12 signaling. These observations are supported by recent reports, which have shown that humans deficient in IL-12R $\beta$ 1 exhibit severe impairment in their resistance to infections as a result of intracellular pathogens (37, 38). The generation of mice deficient in IL-12R $\beta$ 2 will provide an important animal model to evaluate whether  $\beta$ 1 subunit of IL-12R alone conveys IL-12 responsiveness in vivo. Specifically, these mice would be useful in determining the mechanism by which p40 subunit of IL-12 enhances CD8<sup>+</sup> Th1 development (15, 16). Finally, this study questions the importance of Th1-driven alloimmune responses in cardiac allograft rejection, as exacerbated Th1 responses induced by IL-12 failed to accelerate graft rejection in this model.

**Acknowledgments.** The authors thank Drs. Jeanne Magram and Maurice K. Gately for generously providing IL-12R $\beta$ 1<sup>-/-</sup> mice and murine rIL-12, and for their helpful discussions. The authors also thank Brooke Schuermann for technical support.

## REFERENCES

1. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. *Annu Rev Immunol* 1998; 16: 495.
2. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu Rev Immunol* 1995; 13: 251.
3. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4<sup>+</sup> T cells to enhance priming for interferon  $\gamma$  production and diminishes interleukin 4 inhibition of such priming. *Proc Natl Acad Sci USA* 1993; 90: 10188.
4. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK. Effects of IL-12 on helper T cell-dependent immune responses in vivo. *J Immunol* 1994; 152: 2172.
5. Marshall JD, Secrist H, DeKruyff RH, Wolf SF, Umetsu DT. IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4<sup>+</sup> T lymphocytes. *J Immunol* 1995; 155: 111.
6. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. *J Immunol* 1994; 153: 4040.
7. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4<sup>+</sup> T cells through IL-12 produced by *Listeria*-induced macrophages. *Science* 1993; 260: 547.
8. Oswald IP, Caspar P, Jankovic D, Wynn TA, Pearce EJ, Sher A. IL-12 inhibits Th2 cytokine responses induced by eggs of *Schistosoma mansoni*. *J Immunol* 1994; 153: 1707.
9. Pearlman E, Heinzel FP, Hazlett FE Jr, Kazura JW. IL-12 modulation of T helper responses to the filarial helminth, *Brugia malayi*. *J Immunol* 1995; 154: 4658.
10. Gazzinelli RT, Giese NA, Morse HC. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during acquired immunodeficiency syndrome (MAIDS). *J Exp Med* 1994; 180: 2199.
11. Zhou P, Sieve MC, Bennett J, et al. IL-12 prevents mortality in mice infected with *Histoplasma capsulatum* through induction of IFN $\gamma$ . *J Immunol* 1995; 155: 785.
12. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/c mice to *Mycobacterium tuberculosis* infection. *J Immunol* 1995; 155: 2515.
13. Hall BM. Cells mediating allograft rejection. *Transplantation* 1991; 51: 1141.
14. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an *in vivo* model of immune-mediated tissue destruction. *Annu Rev Immunol* 1992; 10: 333.
15. Piccotti JR, Li K, Chan SY, et al. Alloantigen-reactive Th1 development in IL-12-deficient mice. *J Immunol* 1998; 160: 1132.
16. Piccotti JR, Chan SY, Goodman RE, Magram J, Eichwald EJ, Bishop DK. IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection: evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. *J Immunol* 1996; 157: 1951.
17. Chua AO, Chizzonite R, Desai BB et al. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. *J Immunol* 1994; 153: 128.
18. Chua AO, Wilkinson VL, Presky DH, Gubler U. Cloning and characterization of a mouse IL-12 receptor- $\beta$  component. *J Immunol* 1995; 155: 4286.
19. Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two  $\beta$ -type cytokine receptor subunits. *Proc Natl Acad Sci USA* 1996; 93: 14002.
20. Presky DH, Minetti LJ, Gillesen S, et al. Evidence for multiple sites of interaction between IL-12 and its receptor. *Ann NY Acad Sci* 1996; 795: 390.
21. Rogge L, Barberis-Maino L, Biffi M, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. *J Exp Med* 1997; 185: 825.
22. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R  $\beta$ 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. *J Exp Med* 1997; 185: 817.
23. Wu C, Ferrante J, Gately MK, Magram J. Characterization of IL-12 receptor  $\beta$ 1 chain (IL-12R $\beta$ 1)-deficient mice: IL-12R $\beta$ 1 is an essential component of the functional mouse IL-12R. *J Immunol* 1997; 159: 1658.
24. Piccotti JR, Chan SY, Li K, Eichwald EJ, Bishop DK. Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4<sup>+</sup> and CD8<sup>+</sup> IFN- $\gamma$ -producing cells. *J Immunol* 1997; 158: 643.
25. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: The role of H-2D, H-2K, and non-H-2 antigens in rejection. *Transplantation* 1973; 16: 343.
26. Windhagen A, Anderson DE, Carrizosa A, Williams RE, Hafler DA. IL-12 induces human T cells secreting IL-10 with IFN $\gamma$ . *J Immunol* 1996; 157: 1127.
27. Jeannin P, Delneste Y, Seveso M, Life P, Bonnefoy J-Y. IL-12 synergizes with IL-2 and other stimuli in inducing IL-10 production by human T cells. *J Immunol* 1996; 156: 3159.
28. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. *Proc Natl Acad Sci USA* 1990; 87: 6808.
29. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. *J Exp Med* 1989; 170: 827.
30. Zou J, Presky DH, Wu C-Y, Gubler U. Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits  $\beta$ 1 and  $\beta$ 2 and JAK kinases. *J Biol Chem* 1997; 272: 6073.
31. Mattner F, Magram J, Ferrante J, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with *Leishmania major* and mount a polarized Th2 cell response. *Eur J Immunol* 1996; 26: 1553.
32. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft-versus-host disease in mice. *J Immunol* 1996; 157: 689.
33. Williamson E, Garside P, Bradley JA, More IAR, Mowat AM. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. *J Immunol* 1997; 159: 1208.
34. Konieczny BT, Dai Z, Elwood ET, et al. IFN- $\gamma$  is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. *J Immunol* 1998; 160: 2059.
35. Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? *Transplantation* 1997; 63: 619.
36. Gracie JA, Bradley JA. Interleukin-12 induces interferon- $\gamma$ -dependent switching of IgG alloantibody subclass. *Eur J Immunol* 1996; 26: 1217.
37. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. *Science* 1998; 280: 1432.
38. de Jong R, Altare F, Haagen I-A, et al. Severe mycobacterial and *Salmonella* infections in interleukin-12 receptor-deficient patients. *Science* 1998; 280: 1435.

Received 18 August 1998.

Accepted 4 December 1998.

## Zinc Inhibits the Mixed Lymphocyte Culture

CATHRIN A CAMPO,<sup>1</sup> NELE WELLINGHAUSEN,<sup>2</sup>  
CHRISTIAN FABER,<sup>1</sup> ANDREA FISCHER,<sup>1</sup> AND LOTHAR RINK<sup>1,\*</sup>

<sup>1</sup>*Institute of Immunology and Transfusion Medicine,  
University of Lübeck School of Medicine, Lübeck, Germany;*  
and <sup>2</sup>*Section of Infectious Diseases and Clinical Immunology,  
University of Ulm, Ulm, Germany*

Received June 13, 2000; Accepted July 10, 2000

### ABSTRACT

The mixed lymphocyte culture (MLC) is an established clinical method for bone marrow transplantation, as it serves as an in vitro model for allogenic reaction and transplantation. We previously showed that cytokine release into the supernatant is a more specific and sensitive parameter for cross-reactivity in the MLC than the common measurement of cell proliferation. Therefore we tried to find an inhibitor of the MLC in vitro with the least side effects in vivo, measuring interferon (IFN)- $\gamma$  as one of the most important cytokines in posttransplant medicine. Earlier studies showed that zinc is an important trace element for immune function with both stimulatory and inhibitory effects on immune cells. We found that slightly elevated zinc concentrations (three to four times the physiological level), which do not decrease T-cell proliferation in vitro nor produce immunosuppressive effects in vivo, suppress alloreactivity in the mixed lymphocyte culture. In this report we analyzed the mechanism whereby zinc influences the MLC to possibly find a nontoxic way of immunosuppression.

**Index Entries:** Mixed lymphocyte culture (MLC); mixed lymphocyte reaction (MLR); trace elements; zinc.

### INTRODUCTION

The mixed lymphocyte culture (MLC) is a well-established and important tool for determination of compatibility between host and donor

\*Author to whom all correspondence and reprint requests should be addressed.

in transplantation medicine, as it serves as an *in vitro* model for allogenic reaction (1,2). It is common to measure T-cell proliferation in the MLC, but it was recently shown that cytokines are more specific and sensitive parameters for the prediction of a possible graft rejection, as they play a critical role in the posttransplant response (3-5). The TH1-cytokine interferon- $\gamma$  (IFN- $\gamma$ ) was identified as the most important factor within the cytokine cascade in the MLC (6). It is known to induce cytotoxic T-lymphocytes (CTL) (7) by enhancing the expression of both major histocompatibility complex (MHC) class I and MHC class II molecules (8). The IFN- $\gamma$  response mainly depends on HLA-DR differences and it therefore well represents reactivity between two individuals in the MLC (9).

In transplantation medicine, cyclosporin A, FK506, and other substances are used to prevent graft rejection. *In vitro* experiments revealed an inhibition of the MLC (10), but, unfortunately, all of these immunosuppressants show a wide range of toxicities *in vivo*, such as nephrotoxicity, neurotoxicity, and, probably, carcinogenicity (11-13). As we are beginning to understand the molecular mechanisms of cyclosporin A and FK506 function better and better, one of the major aims is to find similar substances with less toxicity.

Zinc within the physiological range (12-16  $\mu\text{M}$ ) is an important trace element for immune function (14). Zinc deficiency *in vivo* could be linked to various clinical symptoms such as impaired immune response with regard to decrease in number, differentiation, and function of T-lymphocytes and natural killer (NK) cells as well as decreased activation of monocytes and phagocytosis by macrophages, resulting in a high incidence of bacterial, viral and fungal infections. These symptoms, in the most severe form shown in the hereditary disease acrodermatitis enteropathica caused by malabsorption of zinc, are completely reversible after adequate substitution of zinc (15). On the other hand, high concentrations of zinc (about eight times the physiological level) led to cytotoxic effects with impairment of all T-cell functions, and inhibition of monokine induction by superantigens such as zinc is also important for the binding of some bacterial superantigens to the  $\beta$ -chain of the MHC class II molecule (16,17). Optimal immune-cell function hence requires a well-balanced zinc level.

In the following study, we investigated whether zinc is able to impair alloreactivity in the MLC at concentrations with neither cytotoxic effects *in vitro* nor toxic side effects *in vivo*.

## MATERIALS AND METHODS

### *Preparation of Lymphocyte Cultures*

Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy donors by density centrifugation over Ficoll-Hypaque (Biochrom, Berlin, Germany), washed twice with phosphate-buffered saline (PBS, Gibco, Berlin, Germany) and resuspended in RPMI-1640 medium (Biochrom) supplemented with 10% heat-inactivated fetal calf

serum (FCS, low endotoxin, myoclonal quality; Life Technologies, Eggenstein, Germany), 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin (all obtained from Biochrom, Berlin, Germany). The cells were adjusted to a final concentration of  $2 \times 10^6$  cells/mL. Equal volumes of cell suspensions of two donors were seeded in samples to a final volume of 1 mL into pyrogen-free 24-well culture plates (Falcon, Heidelberg, Germany). For controls, 1 mL of the adjusted cell suspension was cultured separately. The cultures were incubated for 5 d at 37°C in a 5% humidified CO<sub>2</sub> atmosphere after addition of the appropriate amount of zinc.

### **Zinc Preparations**

Zinc sulfate (Sigma, Deisenhofen, Germany) was dissolved in sterile water to achieve a zinc stock solution of 10 mM. This solution was further diluted in unsupplemented protein-free medium (PFM, Ultradoma, BioWhittaker) at a ratio of 1 to 2 and then sterile filtered. To achieve the final concentrations, PFM was used. The zinc solution was added to the cultures in a volume of 10% of the final culture volume.

### **Determination of Cytokines**

The culture supernatants were harvested after 5 d and stored at -80°C. The quantification of the cytokine release into the supernatant was performed by enzyme-linked immunosorbent assay (ELISA) technique (for IFN-γ provided by Bender Med Systems, Vienna, Austria). Results were measured in picograms per milliliter at 450 nm using an ELISA plate reader (Anthos Labtec, Salzburg, Austria).

### **Flow Cytometry**

Propidium iodide (PI) staining was performed by using a stock solution of 1 mg/mL (PI, Sigma). Cells ( $1 \times 10^6$ /mL) were incubated with 10 µL of PI stock solution for 20–30 min to allow intercalation of PI in double-stranded DNA. Finally, PI staining was measured at a wavelength of 620 nm in a flow cytometer (Coulter, Krefeld, Germany).

### **Statistical Analysis**

The results are expressed as median values. The significance is taken by Student's *t*-test analysis.

## **RESULTS**

### **Influence of Zinc on Mixed Lymphocyte Cultures**

We harvested the supernatants of zinc-supplemented mixed lymphocyte cultures (MLC) on d 5, proven to be the maximum of the IFN-γ secretion (18). Analyzing IFN-γ release in 20 MLC experiments supplemented with different concentrations of zinc, we found expected amounts of IFN-




Fig. 1. IFN- $\gamma$  secretion in the MLC after zinc supplementation. Zinc concentrations up to 1 mM were added to mixed lymphocyte cultures; controls remained unsupplemented. Secretion of IFN- $\gamma$  in the culture supernatants was determined by ELISA after 5 d of culture. Median values of  $n = 20$  experiments are expressed in picograms per milliliter. Significance was calculated by the Student's  $t$ -test (\* $p = 0.0017$ ).

$\gamma$  (334 pg/mL) in the supernatant of control MLC without zinc addition, whereas increasing zinc concentrations led to a dose-dependent reduction of the IFN- $\gamma$  level. At 60  $\mu$ M, the IFN- $\gamma$  production was significantly diminished (48 pg/mL,  $p = 0.0017$ ); at 500  $\mu$ M, no IFN- $\gamma$  was detectable (Fig. 1).

In order to prove our hypothesis that this result—that zinc concentrations of 60  $\mu$ M inhibit the MLC—was the result of a specific effect in the MLC and not to a loss of T-cell vitality, we added zinc concentrations of up to 5 mM to PBMC and measured cell viability by flow cytometry after an incubation time of 48 h. Figure 2 shows that 93.2% of the cells are still vital after addition of 50  $\mu$ M zinc and 92.3% with medium supplementation of 100  $\mu$ M zinc compared to controls without zinc addition with 91.3% viability. Zinc concentrations as high as 250  $\mu$ M causes a reduction of cell survival of 33% (Fig. 2).

For further analysis of possible mechanisms responsible for this inhibition, we preincubated PBMC with 50  $\mu$ M zinc for 20 min and then co-cultured these two populations in the MLC. The results reveal a marked influence of the point of time at which zinc is added to the culture: Preincubation of PBMC led to a greater reduction of IFN- $\gamma$  than simultaneous zinc supplementation to the MLC (Fig. 3).

## DISCUSSION

The human mixed lymphocyte culture (MLC) is an important method to test donor-recipient compatibility in bone marrow transplantation. It could be shown that cytokine release, especially IFN- $\gamma$ , has a very good predictive value with regard to the transplantation outcome (3), as cytokines play a major role in the generation of an alloreactive immune response and




Fig. 2. Viability of PBMC after zinc supplementation. Zinc concentrations of up to 750  $\mu\text{M}$  were added to unstimulated PBMC; controls remained unsupplemented. Cell viability was determined by flow cytometry after an incubation time of 48 h. One representative experiment is shown, values are expressed in percent of the total cell population.




Fig. 3. Effect of preincubation of PBMC with zinc. Zinc in a concentration of 50  $\mu\text{M}$  was added to the MLC simultaneously (MLC + Zn); PBMC was preincubated with 50  $\mu\text{M}$  zinc for 20 min and then cocultured in a MLC (PBMC + Zn); controls remained unsupplemented. Medians of  $n = 10$  experiments are presented. Significance was calculated by the Student's  $t$ -test (\* $p = 0.01$ ).

for the induction of graft rejection *in vivo* (4,5). Taking this *in vitro* model, it has always been the aim to inhibit proliferation of immune cells in order to find a way to prevent graft rejection in transplantation medicine. Landolfo et al. inhibited T-cell reactivity by the addition of anti-IFN- $\gamma$  both *in vitro* and *in vivo* (19); others showed a reduced graft rejection rate by repeated injections of monoclonal anti-IFN- $\gamma$  antibodies in a skin-, heart-, or pancreas-tissue transplantation situation (20-22).

In vivo substances like cyclosporin A or FK506 are broadly applied, as they are capable of prolonging graft survival. In vitro, they show an inhibitory effect on T-cell proliferation in the MLC (10). Yet, all of these therapeutic agents cause major side effects (e.g., nephrotoxicity, neurotoxicity, and others), which lead to a limitation of their use (11-13).

Zinc is an essential trace element with great influence on immune function. The physiological plasma level of zinc ranges from 12 to 16  $\mu\text{M}$ . In our study, we applied zinc concentrations up to 100  $\mu\text{M}$ , which can be reached by pharmacological application of zinc in vivo without causing side effects (23).

We found that zinc concentrations of 60  $\mu\text{M}$ , four times the physiological level, inhibit alloreactivity in the MLC. It is unlikely that the reduction of IFN- $\gamma$  is the result of a loss of T-cell activity, as it could be shown earlier that T-cells are still able to proliferate in medium supplemented with zinc concentrations as high as 100  $\mu\text{M}$  (24). Furthermore, we analyzed the viability of the PBMC by flow cytometry, showing that a concentration of 250  $\mu\text{M}$  is required to reduce cell viability by 33% (Fig. 2).

Increased zinc levels of over 100  $\mu\text{M}$  cause unstimulated human PBMC to release cytokines (25). This stimulatory effect of zinc is only seen in the presence of accessory cells, especially monocytes, as mostly IL-1 proved to be an essential cosignal for T-cell activation by zinc. Higher concentrations of zinc impair all T-cell and monocyte function by inhibition of the IL-1 receptor type I-associated protein kinase (IRAK), thus blocking the intracellular signal transduction pathway at a very early stage (24).

In our study, we applied zinc in concentrations that neither show cytotoxic effects nor reach stimulatory level. Therefore, there seems to be a specific effect of zinc on the responding T-cells in the MLC.

The results of earlier studies proposed an oligoclonal pattern of T-cell stimulation in the MLC similar to T-cell activation by superantigens (3). Furthermore, a highly altered V $\beta$  repertoire of T-cells infiltrating long-term rejected kidney allografts were described (26). Superantigens bind directly and partially with high affinity to major histocompatibility complex (MHC)-class II proteins, especially to HLA-DR. T-Cell activation is achieved by the formation of a complex of the V $\beta$ -chain of the T-cell receptor (TCR), the MHC molecule, and the superantigen. This binding is regulated by zinc, as zinc itself does not interact with the MHC molecule directly (27). We previously showed that the HLA-DR and HLA-DQ-molecules have the greatest influence on cytokine release in the MLC and thus on the outcome of a transplantation in vivo (9).

There are two main possible explanations for the phenomenon described. First, zinc in the applied concentration could saturate the MHC and, therefore, prevent a binding between TCR and MHC. In order to prove this hypothesis, we preincubated PBMC with zinc and then cocultured these populations. If an extracellular mechanism were actually responsible for the inhibition of the MLC, we would expect no significant difference in IFN- $\gamma$  secretion in either setting. Preincubation of PBMC



resulted in a markedly lower IFN- $\gamma$  secretion than the culture of two PBMC populations with simultaneous zinc supplementation to the MLC (Fig. 3), so that it seems more likely that zinc interferes with the intracellular signal transduction in the MLC. Therefore, zinc may regulate the alloreactivity of T-cells and might be an explanation for increased preterm delivery and abortion in zinc-deficient pregnant women (28,29). As mentioned earlier, higher concentrations of zinc are able to block the intracellular signal transduction pathway by inhibition of IRAK. We propose that the stimulation of T-cells by an HLA-different cell population can be blocked by zinc via specific inhibition of phosphorylation processes, leading to a diminished signal transduction in the cell. This results, among other things, in reduced secretion of cytokines, which should lead to less graft rejection in vivo. Various protein kinases such as cAMP- and cGMP-dependent protein kinases as well as protein tyrosine kinases are involved in zinc-induced cell stimulation and zinc also influences gene expression of different immunologically relevant transcription factors such as nuclear factor (NF)- $\kappa$ B and metallothionein transcription factor (MTF-1) as well as others. Which alteration of signal transduction zinc exactly inhibits the MLC remains the subject of further investigation. Because the MLC is inhibited by very low zinc concentrations, this inhibitory effect seems to be a specific pathway.

In conclusion, zinc could become an immunosuppressant in transplantation medicine without toxic side effects, which still leaves the immune system with the ability for phagocytosis. The infection rate will therefore be reduced compared to current immunosuppression. However, this has yet to be proven in in vivo transplantation models.

## REFERENCES

1. P. Hayry, L. C. Andersson, S. Nordling, and M. Virolainen, Allograft response in vitro, *Transplant Rev.* 12, 91-140 (1972).
2. J. Klein and C. L. Chiang, Ability of H-2 regions to induce graft-vs-host disease, *J. Immunol.* 117, 736-740 (1976).
3. S. G. Danzer and L. Rink, Cytokines in mixed lymphocyte culture as a prospective parameter for transplantation, *Med. Klin.* 91, 494-500 (1996).
4. I. L. Noronha, M. Eberlein-Gonska, B. Hartley, S. Stephens, J. S. Cameron, and R. Waldherr, In situ expression of tumor necrosis factor-alpha, interferon-gamma and interleukin-2 receptors in renal allograft biopsies, *Transplantation* 54, 1017-1024 (1992).
5. A. M. Dickinson, L. Sviland, P. J. Hamilton, P. Usher, P. Taylor, G. Jackson, et al., Cytokine involvement in predicting clinical-graft-versus-host-disease in allogeneic bone marrow transplant recipients, *Bone Marrow Transplant.* 13, 65-70 (1994).
6. S. G. Danzer, C. a Campo, and L. Rink, Interferon-gamma plays a key role in the human mixed lymphocyte culture, *Bone Marrow Transplant.* 18, 991-996 (1996).
7. E. Maraskovsky, W. F. Chen, and K. Shortman, IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cell, *J. Immunol.* 143, 1210-1214 (1989).
8. G. H. Wong, I. Clark-Lewis, L. McKimm-Breschkin, A. W. Harris, and J. W. Schrader, Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines, *J. Immunol.* 131, 788-793 (1983).
9. S. G. Danzer, C. a Campo, B. Kunze, H. Kirchner, and L. Rink, Identification of HLA-DRB1 and HLA-DQB1 identical individuals by a cytokine-based mixed lymphocyte culture, *Lymphokine Cytokine Res.* 13(5), 303-308 (1994).

10. J. Woo, H. F. Sewell, and A. W. Thomson, The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis, *Scand. J. Immunol.* 31(3), 297-304 (1990).
11. B. Ryffel, The carcinogenicity of ciclosporin, *Toxicology* 73(1), 1-22 (1992).
12. H. Porschke, H. Streng, and C. Stauch, Polyneuropathy and central nervous system before and after heart transplantation. Is ciclosporin neurotoxic? *Dtsch. Med. Wochenschr.* 116(42), 1577-1582 (1991).
13. T. Kishimoto, T. Tsujino, T. Nakatani, T. Kim, A. Ohyama, W. Sakamoto, et al., Effect of ciclosporin on cardiac output and regional blood flow in rats: ciclosporin-induced nephropathy and its prevention with calcium channel blocker, *Nephron* 61(2), 204-210 (1992).
14. N. Wellinghausen, H. Kirchner, and L. Rink, The immunobiology of zinc, *Immunol. Today* 18(11), 519-521 (1997).
15. K. H. Neldner and K. M. Hambidge, Zinc therapy of acrodermatitis enteropathica, *N. Engl. J. Med.* 292, 879-882 (1975).
16. N. Wellinghausen and L. Rink, The significance of zinc for leukocyte biology, *J. Leukocyte Biol.* 64, 571-577 (1998).
17. C. Driessen, K. Hirv, H. Kirchner, and L. Rink, Zinc regulates cytokine induction by superantigens and lipopolysaccharides, *Immunology* 84, 272-277 (1995).
18. S. G. Danzer, H. Kirchner, and L. Rink, Cytokine interactions in human mixed lymphocyte culture, *Transplantation* 57, 1638-1642 (1994).
19. S. Landolfo, F. Cofano, M. Giovarelli, M. Prat, G. Cavallo, and G. Forni, Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo, *Science* 229, 176-179 (1985).
20. R. H. Didlake, E. K. Kim, K. Sheehan, R. D. Schreiber, and B. D. Kahan, Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat, *Transplantation* 45, 222-223 (1988).
21. J. C. Carel, R. D. Schreiber, L. Falqui, and P. E. Lacy, Transforming growth factor beta decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon gamma, *Proc. Natl. Acad. Sci. (USA)* 87, 1591-1595 (1990).
22. A. S. Rosenberg, D. S. Finbloom, T. G. Maniero, P. H. Van der Meide, and A. Singer, Specific prolongation of the MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody, *J. Immunol.* 144, 4648-4650 (1990).
23. N. Boukaiba, C. Flament, S. Archer, P. Chappuis, A. Piau, M. Fusselier, et al., A physiological amount of zinc supplementation: effect on nutritional, lipid and thymic status in an elderly population, *Am. J. Clin. Nutr.* 57, 566-572 (1993).
24. N. Wellinghausen, M. Martin, and L. Rink, Zinc inhibits interleukin-1-dependent T cell stimulation, *Eur. J. Immunol.* 27, 2529-2535 (1997).
25. C. Driessen, K. Hirv, L. Rink, and H. Kirchner, Induction of cytokines by zinc ions in human peripheral blood mononuclear cells and separated monocytes, *Lymphokine Cytokine Res.* 13(5), 15-20 (1994).
26. K. Gagne, S. Brouard, M. Giral, F. Seville, A. Moreau, M. Guillet, et al., Highly altered V $\beta$  repertoire of T cells infiltrating long-term rejected kidney allografts, *J. Immunol.* 164, 1553-1563 (2000).
27. J. D. Fraser, R. G. Urban, J. L. Strominger, and H. Robinson, Zinc regulates the function of two superantigens, *Proc. Natl. Acad. Sci. (USA)* 89(12), 5507-5511 (1992).
28. A. Favier and M. Favier, Consequences des deficits en zinc durant la grossesse pour la mere et le nouveau-ne, *Rev. Fr. Gynecol. Obstet.* 85, 13-27 (1990).
29. A. E. Favier, The role of zinc in reproduction. Hormonal mechanisms, *Biol. Trace Element Res.* 32, 363-382 (1992).

a LANGE medical book

# Basic & Clinical Immunology

---

eighth edition

Edited by

**Daniel P. Stites, MD**  
Professor and Chairman  
Department of Laboratory Medicine  
University of California, San Francisco

**Abba I. Terr, MD**  
Clinical Professor of Medicine  
Stanford University School of Medicine  
Stanford, California

**Tristram G. Parslow, MD, PhD**  
Associate Professor of Pathology  
and of Microbiology and Immunology  
University of California, San Francisco



**APPLETON & LANGE**  
Norwalk, Connecticut

Notice: The authors and the publisher of this volume have taken care to make certain that the doses of drugs and schedules of treatment are correct and compatible with the standards generally accepted at the time of publication. Nevertheless, as new information becomes available, changes in treatment and in the use of drugs become necessary. The reader is advised to carefully consult the instruction and information material included in the package insert of each drug or therapeutic agent before administration. This advice is especially important when using new or infrequently used drugs. The publisher disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this volume.



Copyright © 1994 by Appleton & Lange  
Paramount Publishing Business and Professional Group  
Copyright © 1991 by Appleton & Lange  
Copyright © 1987, 1984, 1982, 1980, 1978, 1976 by Lange Medical Publications

All rights reserved. This book, or any parts thereof, may not be used or reproduced in any manner without written permission. For information, address Appleton & Lange, 25 Van Zant Street, East Norwalk, Connecticut 06855.

94 95 96 97 98 / 10 9 8 7 6 5 4 3 2 1

Prentice Hall International (UK) Limited, *London*  
Prentice Hall of Australia Pty. Limited, *Sydney*  
Prentice Hall Canada, Inc., *Toronto*  
Prentice Hall Hispanoamericana, S.A., *Mexico*  
Prentice Hall of India Private Limited, *New Delhi*  
Prentice Hall of Japan, Inc., *Tokyo*  
Simon & Schuster Asia Pte. Ltd., *Singapore*  
Editora Prentice Hall do Brasil Ltd., *Rio de Janeiro*  
Prentice Hall, *Englewood Cliffs, New Jersey*

ISBN: 0835-0561-9  
ISSN: 0891-2076

Acquisitions Editor: Martin Wonsiewicz  
Production Editor: Jennifer Sinsavich

PRINTED IN THE UNITED STATES OF AMERICA

ISBN 0-8385-0561-9



9 780838 505618

different PTKs. Phosphorylation is a common mechanism of regulating protein function; indeed, many of the PTKs must themselves be phosphorylated before they can become active. Several important types of lymphocyte surface receptors (including membrane immunoglobulin and T cell receptor proteins) are physically linked to specific cytoplasmic PTK proteins, which become active when the receptor binds its target ligand. These receptor-associated PTKs, in turn, may then activate other types of PTKs through phosphorylation, so that almost immediately a host of different PTKs are recruited into the response. By phosphorylating still other types of substrates, such as proteins that control cytoskeletal organization, expression of specific genes, and entry into the cell cycle, these newly activated PTKs appear to be either directly or indirectly responsible for triggering all subsequent events in lymphocyte activation. At present, however, the functions of most individual PTKs are uncertain.

One almost immediate effect of the PTK cascade is to activate the enzymatic breakdown of a specific class of phospholipids (called phosphatidylinositides) within the cell. The products of this hydrolysis include 2 small organic molecules, **diacylglycerol (DAG)** and **inositol 1,4,5-trisphosphate (IP<sub>3</sub>)**, which are released into the cytoplasm and serve as second messengers to trigger additional changes in cellular physiology. Among the most notable changes is a rapid, marked increase in the concentration of **intracellular free calcium ions**, which flood into the cytosol from organellar storage pools and from the extracellular medium, reaching maximal concentrations within 1 minute after contact with the activating stimulus. Like PTK activation, these rapid calcium fluxes are thought to be critical for initiating the subsequent events in activation.

Within the first hour after stimulation, the rates of oxidative metabolism and of overall protein and RNA synthesis in the lymphocyte rise. The chromatin begins to decondense as previously silent genes are transcribed and the cell prepares to undergo mitosis. After 2–4 hours, specific proteins that are thought to regulate cell proliferation, such as the product of the proto-oncogene *c-myc*, become detectable in the nucleus. In parallel with these biochemical events, the morphology of the cell changes in a process known as **blast transformation**: its overall diameter increases to 15–30  $\mu\text{m}$  as both its nucleus and cytoplasmic enlarge; the nuclear chromatin becomes loose and pale-staining; and the cell acquires a prominent nucleolus (reflecting a high rate of RNA synthesis). Within 8–12 hours, the changes are sufficiently marked that the cell can be recognized under the light microscope as a **lymphoblast**—a lymphocyte poised to begin mitosis. DNA synthesis takes place at around 18–24 hours after stimulation. The first cell division occurs 2–4 hours later and, depending on the conditions, can be repeated 5 or more times in succession, at intervals as

brief as 6 hours. The effector cells produced as a result of each division mature completely within a few days and express the immune functions typical of their lineage for several days thereafter.


## REQUIREMENTS FOR ACTIVATION OF B OR T LYMPHOCYTES

What are the stimuli that can lead to lymphocyte activation *in vivo*? Certainly, the most important are the innumerable foreign **antigens** that are recognized and bound by membrane immunoglobulins or T cell receptor proteins. A few types of antigens are in themselves sufficient to activate B cells—these are usually highly polymeric proteins or polysaccharides that are able to interact simultaneously with many immunoglobulin proteins on the surface of a single cell. Such multivalent antigens act to **cross-link** the immunoglobulins to one another, so that eventually a great many immunoglobulins are gathered at one pole of the cell surface at the point of contact with antigen—a phenomenon known as **capping** (Fig 2–9A). This dense local aggregation of immunoglobulins, each of which is bound to antigen, transmits a very effective signal and is enough to trigger B cell activation.

Activation can also be induced under artificial conditions by cross-linking other types of surface molecules (Table 2–4). Among the agents used for this purpose are certain lectins (sometimes called **mitogens**), which can activate T and/or B cells by cross-linking surface glycoproteins. Similar results can be obtained by using multivalent antibody complexes to cross-link some T cell surface proteins (such as CD3) that are able to transmit signals to the cytoplasm. Alternatively, lymphocytes can be activated pharmacologically by being treated with agents that directly in-

Table 2–4. Mitogens and other conditions used to activate lymphocytes *in vitro*.

Mitogen or Condition	Specificity
<b>Lectins</b>	
Concanavalin A	T cells
<i>Helix pomatia</i> lectin	T cells
Phytohemagglutinin	T cells; few B cells
Pokeweed mitogen	T and B cells
Wheat germ agglutinin	T cells
<b>Artificial cross-linking of specific surface proteins</b>	
Immunoglobulins	B cells
T cell surface markers (eg, CD3)	T cells
<b>Pharmacologic agents</b>	
Phorbol myristyl acetate plus calcium ionophore (eg, ionomycin)	T and B cells



**Figure 2-9.** General requirements for lymphocyte activation. **A:** Some highly polymeric antigens that cross-link multiple antigen receptors are sufficient to activate B cells. **B:** Activation by a nonpolymeric antigen requires additional stimuli supplied by another cell type. Costimulators from the antigen-presenting cell (APC) are necessary to activate a Th cell, which in turn provides helper factors for B cells and/or interleukin-2 (IL-2) for Tc cells.

duce calcium fluxes and other important signaling events, thereby bypassing the surface receptors entirely. Such potent artificial activators are often used in clinical testing to study lymphocyte responses *in vitro*.

The majority of antigens encountered in nature, however, are not polymeric and so do not cross-link receptors. Even when many copies of such an antigen bind individual immunoglobulins on a B cell, they generate only an incomplete signal, which fails to activate the cell. B cells can be activated by these more common antigens only if they are simultaneously stimulated by a nearby activated helper T lymphocyte. This stimulation may be delivered by lymphokines secreted from the T cell, but is transmitted most efficiently through direct contact of the B cell with T cell surface proteins. In either case, the helper-cell-derived proteins (which will be referred to in this book as **helper factors**) interact with non-immunoglobulin receptors on the B cell to generate a second signal. The combined effects of the helper factors and the bound antigen then act synergistically to cause B cell activation.


In a similar manner, T lymphocyte responses to most antigens also require 2 types of stimuli simultaneously. The first is provided by the antigen, which, if appropriately displayed by MHC proteins on an antigen-presenting cell, can be recognized and bound by T cell receptors. When it binds an antigen-MHC complex, the T cell receptor sends a signal to the cell interior, but this signal alone is usually not enough to

cause activation. For helper T cells, full activation also requires contact with other specific ligands, known as **costimulators**, that are expressed on the surface of the antigen-presenting cell. Activation of a cytotoxic T cell, on the other hand, generally requires **IL-2**, a cytokine secreted by activated helper T cells.

In summary, it is important to recognize that activation of a lymphocyte is controlled not only by antigen binding but also by interactions with other cells (Fig 2-9B). All T cells must cooperate with antigen-presenting cells, whereas B cells and cytotoxic T cells depend on helper T lymphocytes. These interactions either require direct surface-to-surface contact or are mediated by highly labile cytokines that act only over extremely short distances. Owing to this interdependence among cell types, lymphocyte activation occurs most commonly and efficiently in the secondary lymphoid organs, where lymphocytes, antigens, and antigen-presenting cells encounter one another at close quarters.

## LYMPHOID ORGANS

Lymphocytes are normally present in the blood at a concentration of approximately 2500 cells/mm<sup>3</sup> and so account for roughly one-third of all peripheral white blood cells. Each individual lymphocyte, however, spends most of its life within solid tissues, entering the circulation only periodically to migrate from one resting place to another. Indeed, at any




**Figure 13-8.** Time-response curve for antigen stimulation of  $10^6$  lymphocytes. Responses of peripheral blood lymphocytes from 15 normal adults with delayed hypersensitivity to the antigen. Cells were cultured as described in the legend to Fig 13-7. Antigen concentration for all cultures was  $15 \mu\text{g/mL}$ . Maximal response occurred on days 5-7 of culture. Results are plotted as the mean  $\pm$  1 SD, for 15 individual determinations.

until the culture has been allowed to continue for 5-7 days. Fig 13-8 clearly illustrates both the usefulness of and the necessity for performing careful time- and dose-response kinetics in assessing human lymphocyte function.

### MIXED LYMPHOCYTE CULTURE & CELL-MEDIATED LYMPHOLYSIS

Mixed lymphocyte culture (MLC) is a special case of antigen stimulation in which T lymphocytes respond to foreign histocompatibility antigen on unrelated lymphocytes or monocytes. This test is performed as either a "one-way" or "2-way" assay (Fig 13-9). In the one-way MLC, the stimulating cells are treated with either irradiation ( $\sim 2000$  R) or mitomycin to prevent DNA synthesis without killing the cell. The magnitude of the response is then entirely the result of DNA synthesis in the nonirradiated or non-mitomycin-treated cells. In the 2-way MLC, cells from both individuals are mutually stimulating and responding. DNA synthesis represents the net response of both sets of cells, and the individual contributions cannot be discerned. The culture conditions, time of exposure,  $^3\text{H}$ -Tdr pulse labeling, and harvesting procedures are usually identical to those for antigen stimulation. Controls include coculture of syngeneic irradiated and nonirradiated pairs and coculture of allogeneic irradiated pairs. The first control provides baseline DNA synthesis, and the second ensures ade-



**Figure 13-9.** MLC and CML assays schematically represented. Cells (black and white bars) from separate individuals are cultured. In MLC, DNA synthesis in responding (noninactivated) cell is measured. In CML assay, the ability of "A" cells to kill  $^{51}\text{Cr}$ -labeled "B" cells is measured. See the text for further explanation. [ $^3\text{H}$ ]-Tdr initiated thymidine. (Reproduced with permission, from Bach FH, Van Rood JJ: The major histocompatibility complex. Genetics and biology. *N Engl J Med* 1976;295:806-872).

quate inactivation by irradiation (or mitomycin) of the stimulator cells.

In the use of MLC as a test for T cell function, difficulties in quantitation often arise owing to variations in stimulator cell antigens that determine the degree of genetic disparity between stimulator and responder cells. To overcome this difficulty and produce a more standardized test, frozen aliquots of viable pooled human allogeneic cells have been employed as stimulator cells.

The stimulating antigens on human cells are class I MHC molecules encoded by the HLA-D locus (see Chapter 5). Responding cells are primarily T lymphocytes with obligate macrophage cooperation. B cells can also respond in MLC, since a marked increase in immunoglobulin synthesis can be detected. MLC may be used as a histocompatibility assay (see Chapter 16) and as a test for immunocompetence of T cells, particularly in immunodeficiency disorders (see Chapters 20 and 21).

Cell-mediated lympholysis (CML) is an extension of the MLC technique in which cytotoxic effector cells generated during MLC are detected (Fig 13-9). This test involves an initial one-way MLC culture followed by exposure of stimulated cells to  $^{51}\text{Cr}$ -labeled target cells specifically lysed by sensitized killer lymphocytes. These target cells are HLA-identical to the stimulator cells in MLC. Cytotoxicity is measured as the percentage of  $^{51}\text{Cr}$  released in specific target cells compared with the percentage of  $^{51}\text{Cr}$  released from control (nonspecific) target cells. Several lines of evidence indicate that cells which proliferate in MLC and killer cells which participate



in CML assay are not identical. Killer cells are generated that have specificity for class I MHC antigens on target cells, whereas in class II MHC antigen differences determine the reaction. CML assays provide an additional measure of T cell function and can be used to estimate presensitization and histocompatibility in clinical transplantation (see also Chapter 16).

### CLINICAL APPLICATION OF T & B CELL ASSAYS

Counting of T and B cells in peripheral blood and tissue specimens has limited application in both the diagnosis and investigation of pathophysiologic mechanisms of many disease states. Functional assays are even more limited in value primarily to studies of immune deficiency diseases. Current applications include the following.

- (1) Diagnosis and classification of immunodeficiency diseases (see Chapters 18-22 and 52).
- (2) Determination of origin of malignant lymphocytes in lymphocytic leukemia and lymphoma (see Chapter 45).
- (3) Evaluation of immunocompetence and mechanisms of tissue damage in autoimmune disease, eg, systemic lupus erythematosus and rheumatoid arthritis (see Chapter 31).
- (4) Detection of changes in cellular immune competence in HIV and other infections that may be of prognostic value (see Chapter 52).
- (5) Monitoring of cellular changes following organ transplantation (see Chapter 57).

### NATURAL KILLER (NK) CELLS

Natural killer (NK) cells can be enumerated by specific monoclonal antibodies using methods identical to those for T and B cells (see Chapter 17). Several monoclonal antibodies are available that detect either Fc receptors (CD16) or specific differentiation antigens (CD56, CD57) present on these cells. Some NK cells also express antigens from the CD2 T cell family. Functional testing is done by measuring the ability of these nonimmune cells to kill special target cells such as erythroleukemia cell line K562. Cytotoxicity is usually performed by using the  $^{51}\text{Cr}$  release assay, similarly to cell-mediated lympholysis (Fig 13-9).

### MONOCYTE-MACROPHAGE ASSAYS

The morphologic identification of normal peripheral blood monocytes in stained peripheral blood

films ordinarily is quite simple. Monocytes are larger than granulocytes and most lymphocytes. They typically have round or kidney-shaped nuclei with fine, lightly stained granules. However, in suspension or even in tissue or blood specimens, additional markers may be required to differentiate monocytes from lymphocytes and primitive myeloid cells.

A reliable stain for monocytes is so-called nonspecific esterase, or  $\alpha$ -naphthol esterase, which is present in monocytes but absent in most myeloid and lymphocytic cells. Monoclonal antibodies directed at specific differentiation antigens such as CD14 are available.

Functional attributes of monocytes are discussed in detail in Chapter 1. In the clinical laboratory, phagocytosis of particles or antibody-coated heat-killed microorganisms is useful for functional identification of monocytes.

### NEUTROPHIL FUNCTION

Polymorphonuclear neutrophils (PMN) are bone marrow-derived leukocytes with a finite life span, which play a central role in defense of the host against infection. For many types of infections, the neutrophil plays the primary role as an effector or killer cell. However, in the bloodstream and extravascular spaces, neutrophils exert their antimicrobial effects through a complex interaction with antibody, complement, and chemotactic factors. Thus, in assessing neutrophil function, one cannot view the cell as an independent entity; its essential dependence on other immune processes, both cellular and humoral, must be taken into account.

Defects in neutrophil function can be classified as quantitative or qualitative. In quantitative disorders, the total number of normally functioning neutrophils is reduced below a critical level, allowing infection to ensue. Drug-induced and idiopathic neutropenia (see Chapter 33), with absolute circulating granulocyte counts of less than  $1000/\mu\text{L}$ , are examples of this sort of defect. In these situations, granulocytes are functionally normal but are present in insufficient numbers to maintain an adequate defense against infection. In qualitative neutrophilic disorders, the total number of circulating PMN is either normal or sometimes actually elevated, but the cells fail to exert their normal microbicidal functions. Chronic granulomatous disease is an example of this type of disorder (see Chapter 22). In patients with chronic granulomatous disease the normal or increased numbers of circulating neutrophils are unable to kill certain types of intracellular organisms.

Phagocytosis by PMN can be divided into 5 dis-



## CELLULAR ASSAYS FOR HISTOCOMPATIBILITY

In vivo, recognition of nonself antigens and destruction of cells bearing such markers is accomplished by cells of the immune system. Some of the clinically relevant class II HLA antigens that can trigger the immune response are not readily detected by the serologic methods discussed above. Instead, lymphocytes are used as discriminatory reagents for the HLA-Dw and -DP antigens and as indicators of histoincompatibility between donor and recipient. The functions of cellular recognition are utilized in the MLC, HTC, and primed lymphocyte typing (PLT) tests, and the dual functions of recognition and effector cell killing are used in the CML test.


### MLC Test (See Chapter 13)

This is also known as the mixed-lymphocyte reaction (MLR). When the lymphocytes of 2 HLA-disparate individuals are combined in tissue culture, the cells enlarge, synthesize DNA, and proliferate, whereas HLA-identical cells remain quiescent. The proliferation is driven primarily by differences in the class II HLA antigens between the 2 test cells.

On the basis of MLC testing, class II antigens were originally described as a series of lymphocyte-activating determinants, products of the HLA-"D" locus (-Dw1, -Dw2, etc). No D locus products have ever been isolated, however, although several distinct "D region" loci (-DR, -DQ, and -DP) and their alleles have been identified. Dw "antigens" are now considered to be immunogenic epitopes formed by combinations of D region determinants that can be recognized by T cells. Distinct Dw types may represent unique haplotype combinations of various D region products.

Reactivity in MLC probably reflects the initial immune recognition step of graft rejection in vivo. The more immunogenic the D locus difference, the greater the cellular response in MLC and the more likely the rejection of the graft. Normally, both cells will proliferate, forming the 2-way MLC. To monitor the response of a single responder cell (the one-way MLC), the partner cell (stimulator) is inactivated by radiation or drugs (such as mitomycin C) that inhibit DNA synthesis (Fig 16-4). A maximum proliferative response usually occurs after incubation at 37 °C for 5-6 days. The culture is then pulsed with [<sup>3</sup>H]thymidine for 5-12 hours to label the newly synthesized DNA. Finally, the cells are harvested, washed free of unbound radioactivity, and counted in a beta counter.

A properly composed MLC test includes a check-board of one-way combinations of each cell serving as both stimulator and responder with all other cells. Each cell must be controlled for its ability to both stimulate and respond to HLA-mismatched cells. Normally, 2-4 unrelated control cells of known class II HLA type are tested individually with each family



**Figure 16-4.** The MLC and CML tests. In the one-way MLC, responder PBLs are mixed 1:1 with irradiated stimulator cells and incubated at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. After 5 days, the culture is pulsed with [<sup>3</sup>H]thymidine ([<sup>3</sup>H]TdR) to label the nucleic acid in the responder cells. After 18 hours, cells are harvested and counted for internalized radioactivity. If the class II HLA antigens of the stimulator cells differ from those of the responder cells, the responder cells undergo blastogenesis, synthesize DNA, and proliferate. Increased sample radioactivity signals recognition of class II HLA differences. When responder and stimulator cells are class II identical, the proliferative responses are less than 20% of the maximum response to the mismatched controls and less than 2% over autologous (background) controls (Reproduced, with permission, from Bach FH, Van Rood JJ: The major histocompatibility complex: Genetics and biology. *N Engl J Med* 1976;295:806, 872.)

member. The maximum response of each cell is obtained by exposure to a pool of irradiated stimulator cells of diverse HLA types.

Autologous controls combining self with irradiated self are also run to normalize the response of each cell to stimulators. Each test should be run in triplicate. It is absolutely necessary to perform the entire familial MLC at one time owing to the inherent variability of individual cellular responses from day to day.

Results are expressed as a stimulation index (SI) or relative response (RR). The SI is the ratio of counts per minute of the test over the autologous test for that cell:

$$SI = \text{cpm of } \frac{\text{Responder vs Stimulator (irradiated)}}{\text{Responder vs Responder (irradiated)}}$$

A value of SI ≤ 2 is interpreted as HLA identity at HLA-D. The RR calculates the response in the experimental MLC relative to the maximum response of that cell elicited by the pool. Counts per minute of both are corrected by subtraction of the autologous control for the responder cell.

$$RR = \frac{\text{Responder vs Stimulator (Irradiated)} - \text{Autologous control}}{\text{Responder vs Pool (Irradiated)} - \text{Autologous control}} \times 100$$

cpm of

MLC testing can be useful in selecting the most compatible (least stimulatory) organ donor if several nonidentical family members (matched for zero or one haplotype) are available. The donor who is the least stimulatory to the patient is the preferred organ donor. The results of an intrafamilial MLC can address such questions as (1) Are 2 serologically identical DR antigens also functionally identical? (2) Is the individual with only one identifiable DR antigen a homozygote, or is the DR "blank" really a second DR antigen that was missed in the serologic testing? (3) Are the serologically assigned class II antigens consistent with the MLC results? If apparently HLA-identical individuals are reactive, there may have been a genetic recombination event.

The MLC test is frequently used to confirm apparent HLA identity in the living-related transplant situation and is especially useful if haplotyping could not be accomplished. When the HLA-identical recipient and donor are unrelated, as in voluntary bone marrow donation, MLC testing is extremely important in revealing hidden class II incompatibilities that could affect recipient tolerance to the graft and promote graft-versus-host disease.

### HTC Test

MLC nonreactivity indicates HLA-Dw identity, and therefore the MLC test can be used to type for specific Dw alleles. Since most individuals to be tested are heterozygous at the D region, it follows that the stimulator cell must be homozygous for a given Dw antigen to result in MLC nonresponsiveness. Such HTCs have been identified in the random population, but the best source for HTCs is among the progeny of first-cousin marriages. True HTCs are rare and precious reagents, and few laboratories can afford to maintain the large cell panel necessary for complete and accurate testing.

The lymphocytes to be Dw typed are set up as responders in multiple MLC tests, each test with a different inactivated stimulator HTC. HTC testing can discriminate among the various subtypes of serologically identified DR antigens and thus can provide a finer definition of true class II HLA compatibility.

### PLT Test

Lymphocytes already exposed (primed) to a specific antigen in a primary MLC will proliferate rapidly on reexposure to the same antigen. Thus, a primed cell can be used to test an unknown cell for the presence of the original stimulating antigen. With cells primed to class II HLA antigens, this assay can be used as an HLA typing test for D region antigens.

As in HTC typing, an extensive panel of specifically primed cells must be maintained for PLT testing. PLT was used to type for DP antigens, but this method has been supplanted by molecular typing methods and is now only rarely used.

### CML Test

In primary MLC, exposure to nonself class I and class MHC II antigens can result in the generation of cytotoxic T lymphocytes (CTL). CTL kill their targets through direct contact, probably by the release of toxic mediators that lead to cell lysis. CD4 and CD8 CTL can be found infiltrating kidney allografts during rejection and are considered to be important effector cells in graft loss (see Chapter 57). To test for the capacity to generate CTL, a primary MLC is run with the patient as the responder and prospective donor cells as inactivated stimulators. After the MLC, the patient's cells are harvested and then reexposed in culture to fresh donor target cells that have been loaded with  $^{51}\text{Cr}$  (Fig 16-4). Usually, the targets are preincubated with the mitogen phytohemagglutinin (PHA) for 6 days, since PHA-activated blast cells can incorporate more  $^{51}\text{Cr}$  than resting lymphocytes can. CTL and targets are plated in effector:target-cell ratios of 100:1, 50:1, and 10:1. Control wells include targets alone to measure the spontaneous release of label and test wells containing target cells that are treated with detergent to release the maximum incorporated label. The test requires 4 hours of incubation in a humidified  $\text{CO}_2$  atmosphere at  $37^\circ\text{C}$ . At the conclusion, the supernatant of each test well is sampled and counted. In the experimental wells, the amount of  $^{51}\text{Cr}$  released is corrected for the background level of spontaneously released label and compared with the maximum amount of label released:

$$\% \text{ Specific Release} = \frac{\text{cpm (Experimental)} - \text{cpm (Spontaneous)}}{\text{cpm (Maximum)} - \text{cpm (Spontaneous)}} \times 100$$

Elevated counts of 30–50% above spontaneous background are indicative of CTL activity.

Direct CML testing can be used to monitor post-transplant rejection by testing for the presence of activated circulating anti-donor CTL. The patient's PBL are placed directly in culture with  $^{51}\text{Cr}$ -labeled donor cells as targets. An elevated donor cell lysis compared with pretransplant levels is considered evidence of circulating CTL, which are particularly prevalent during rejection.

CML testing has applications in living-related renal and bone marrow transplantation. The preferred kidney donor will be the one who fails to stimulate the recipient to form CTL. In bone marrow transplantation, the recipient is at risk for immune attack by the

Table 20-1. Evaluation of cell-mediated immunity.

Test	Comment
Total lymphocyte count	Normal at any age: $>1200/\mu\text{L}$ .
Delayed hypersensitivity skin test	Used to evaluate specific immunity to antigens. Suggested antigens are <i>Candida</i> , mumps, purified protein derivative, and streptokinase-streptodornase (4 units/0.1 mL).
Lymphocyte response to mitogens (PHA), antigens, and allogeneic cells (mixed-lymphocyte culture)	Used to evaluate T cell function. Results are expressed as stimulated counts divided by resting counts (stimulated index).
Total T cells using monoclonal antibodies to CD3, CD2, or CD4 plus CD8	Used to quantitate the number of circulating T cells. Normal: $>60\%$ of total lymphocytes.
Monoclonal antibody to T cells and T cell subsets (CD4 and CD8)	Determines total number of T cells as well as T cell subsets, eg, helper/suppressor.
Cytokine production (IL-1, IL-2, lymphotoxin, tumor necrosis factor, etc)	Used to detect specific cytokine production from subsets of mononuclear cells as an index of function.
Helper/suppressor T cell function	Provides information on T cell regulation of immunity.

### Clinical Features

**A. Symptoms & Signs:** The most frequent presenting sign in patients with DiGeorge's syndrome occurs in the first 24 hours of life with hypocalcemia that is resistant to standard therapy. Various types of congenital heart disease have been described, including interrupted aortic arch, septal defects, patent ductus arteriosus, and truncus arteriosus. Renal abnormalities may also be present. Some patients have the characteristic facial appearance described above. Patients who survive the immediate neonatal period may then develop recurrent or chronic infection with various viral, bacterial, fungal, or protozoal organisms. Pneumonia, chronic infection of the mucous membranes with *Candida*, diarrhea, and failure to thrive may be present.

Spontaneous improvement of T cell immunity occasionally occurs. These patients are considered to have "partial" DiGeorge's syndrome, but the reason for the spontaneous improvement in T cell immunity is not known. Patients have also been suspected of having DiGeorge's syndrome on the basis of hypocalcemia and congenital heart disease with or without the abnormal facies but have been found to have normal T cell immunity. Subsequently, these patients may develop severe T cell deficiency.

**B. Laboratory Findings:** Evaluation of T cell immunity can be performed immediately after birth



Figure 20-1. Infant with DiGeorge's syndrome. Prominent are low-set and malformed ears, hypertelorism, and fish-shaped mouth. Also note the surgical scar from cardiac surgery.

in a patient suspected of having DiGeorge's syndrome. The lymphocyte count is usually low ( $<1200/\mu\text{L}$ ) but may be normal or elevated. In the absence of stress during the newborn period, a lateral-view x-ray of the anterior mediastinum may reveal absence of the thymic shadow, indicating failure of normal development. Delayed hypersensitivity skin tests to recall antigens are of little value during early infancy, because sufficient time has not elapsed for sensitization to occur. T cells are markedly diminished in number, and the peripheral blood lymphocytes fail to respond to phytohemagglutinin (PHA) and allogeneic cells.

Studies of antibody-mediated immunity in early infancy are not helpful, because immunoglobulins consist primarily of passively transferred maternal IgG. Although it is believed that some of these patients have a normal ability to produce specific antibody, the majority have some impairment of antibody formation. Sequential studies of both T cell and B cell immunity are necessary, since spontaneous remissions and spontaneous deterioration of immunity with time have been described.

A diagnosis of hypoparathyroidism is established by the demonstration of low serum calcium levels, elevated serum phosphorus levels, and an absence of parathyroid hormone. Congenital heart disease may be diagnosed immediately following birth and may be mild or severe. Other congenital abnormalities in-

Fig  
poch  
tra

In

ca  
cu  
ly  
m:  
vic  
In  
ab  
no  
mno  
of  
to  
ha  
sp  
ter  
ni:fe:  
ab  
hy  
an

Di

0041-1237/05/0004-362\$03.00/0  
TRANSPLANTATION  
Copyright © 1995 by Williams & Wilkins

Vol. 60, 362-368, No. 4, August 27, 1995  
Printed in U.S.A.

## TEPOXALIN, A NOVEL IMMUNOMODULATORY COMPOUND, SYNERGIZES WITH CSA IN SUPPRESSION OF GRAFT-VERSUS-HOST REACTION AND ALLOGENEIC SKIN GRAFT REJECTION

WAI-PING FUNG-LEUNG,<sup>1</sup> BARBARA L. POPE, ERIKA CHOURMOUZIS, JULIE A. PANAKOS, AND CATHERINE Y. LAU

The R.W. Johnson Pharmaceutical Research Institute, Don Mills, Ontario M3C 1L9, Canada

Tepoxalin, a dual 5-lipoxygenase and cyclooxygenase inhibitor with nonsteroidal antiinflammatory effects, has recently been shown to suppress NF- $\kappa$ B transactivation and inhibit T cell proliferation via a mechanism very different from cyclosporine (CsA). In this report, we demonstrate that this novel immunosuppressive effect of tepoxalin is manifested in *in vivo* transplantation models. Tepoxalin suppressed murine spleen cell proliferation in a mixed lymphocyte reaction (MLR) with an  $IC_{50}$  of 1.3  $\mu$ M. Coadministration of tepoxalin and CsA in MLR cultures showed an additive inhibitory effect. Oral administration of tepoxalin at 12 mg/kg/day to mice suppressed local graft-versus-host (GVH) responses by about 40% ( $n=10$ ). Combination of tepoxalin and CsA at suboptimal doses synergized their immunosuppressive effects on GVH responses ( $n=20$ ). In skin transplantation, the median survival time of allogeneic BALB/cByJ (H-2<sup>d</sup>) mouse skin grafted onto C3H/HeJ (H-2<sup>k</sup>) mice was 10.5 days ( $n=8$ ), and was prolonged to 15.0 days ( $n=9$ ) for recipient mice administered tepoxalin at 50 mg/kg/day. Coadministration of suboptimal doses of tepoxalin (12.5 mg/kg/day) and CsA (50 mg/kg/day) prolonged skin graft rejections dramatically (55% of the grafts survived for more than 40 days,  $n=9$ ). Taken together, these results demonstrate that tepoxalin is a potent immunomodulatory compound that, when combined with CsA, provides synergistic immunosuppressive activity. The fact that tepoxalin and CsA act on different transcription factors, NF- $\kappa$ B and NFAT respectively, might explain the synergistic suppressive effects when both compounds were used. Tepoxalin could be an important addition to the cohort of immunosuppressive therapies currently used in solid organ and bone marrow transplantations.

The immune response in transplantation, which results in graft rejection and graft-versus-host (GVH)\* response, is primarily triggered by T cells through recognition of alloantigens (1-4). Suppression of immune response could be achieved using agents interfering with T cell activation and effector functions. The use of cyclosporine (CsA) as an immunosuppressant in transplantation has been documented (5, 6). CsA inhibits T cell activation by inhibiting the nuclear translocation of the nuclear factor NFAT (7, 8). However, CsA has associated toxicities and side effects when used at

therapeutic doses (9). Compounds that suppress T cell-mediated immune response with mechanisms different from that of CsA will undoubtedly be valuable additions to the cohort of the current regimens.

Tepoxalin (5-[4-chlorophenyl]-N-hydroxy-[4-methoxyphenyl]-N-methyl-1-H-pyrazole-3-propanamide) was discovered originally as a dual inhibitor of 5-lipoxygenase (LO) and cyclooxygenase (CO) and exhibits potent nonsteroidal antiinflammatory activities in animal models of adjuvant arthritis (10-12). Recently we found that tepoxalin also inhibits OKT3-induced T cell proliferation via a mechanism very different from that of CsA (13). CsA is known to block IL-2 production after activation of T cells through TCR/CD3, whereas tepoxalin inhibits IL-2 induced signal transduction (13). An in-depth investigation of the mechanism of action reveals that tepoxalin inhibits predominantly NF- $\kappa$ B activation (14), whereas CsA is most effective in blocking NFAT transactivation (7, 8). Because of these different mechanism of actions, a possible additive/synergistic effect of the combined tepoxalin and CsA treatment is expected. In this report, we demonstrate that tepoxalin is indeed effective in suppressing mixed lymphocyte reactions (MLR), GVH responses, and allogeneic skin graft rejections in mice. The synergistic effect of tepoxalin and CsA in immunosuppression was also studied. The possible mechanism of tepoxalin in immunosuppression and its potential clinical application are discussed.

### MATERIALS AND METHODS

**Mice.** Inbred C57BL/6J, C3H/HeJ, and BALB/cByJ mice and B6D2F<sub>1</sub>J mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Those used in experiments were male mice at about 6-10 weeks of age that weighed 18-25 g.

**Preparation of test compounds.** Tepoxalin, naproxen, and zileuton were synthesized by the R.W. Johnson Pharmaceutical Research Institute (Raritan, NJ). CsA (Sandimmune i.v.) was from Sandoz (Quebec, Canada). For MLR experiments, stock solutions of tepoxalin, naproxen, and zileuton were prepared in DMSO at 30 mM and diluted to working concentrations in culture medium at the time of experiments. DMSO at concentrations equivalent to those of the test compounds were used as controls in MLR assays. For experiments of GVH responses and skin graft rejections, micronized tepoxalin and naproxen were suspended in 0.5% methylcellulose (Sigma, St. Louis, MO) at concentrations of 5 mg/ml or lower. The vehicle control was the equivalent volume of 0.5% methylcellulose. Zileuton was dissolved in 50% polyethylene glycol 200 (Sigma, St. Louis, MO), and the corresponding vehicle control was the equivalent volume of polyethylene glycol 200. CsA was diluted in saline. All compounds were dissolved in vehicle just prior to administration to mice at volumes of 0.01 ml per gram body weight.

<sup>1</sup> Address correspondence to Dr. Wai-Ping Fung-Leung, The R.W. Johnson Pharmaceutical Research Institute, 3535 General Atomics Court, Suite 100, San Diego, California 92121.

\* Abbreviations: CsA, cyclosporine; CO, cyclooxygenase; GVH, graft-versus-host; LO, 5-lipoxygenase; MLR, mixed lymphocyte reaction.

27, 1995

**Lymphocyte proliferation assays.** Single-cell suspensions from spleens were washed once with PBS and then resuspended in RPMI 1640 medium supplemented with 5% fetal bovine serum and 2-mercaptoethanol. Responder spleen cells ( $2.5 \times 10^6$ ) from B6D2F<sub>1</sub> mice (H-2<sup>b</sup>) were stimulated by  $2.5 \times 10^5$  irradiated (2000 rad) spleen cells from B6D2F<sub>1</sub> mice (H-2<sup>b</sup>). The responder and stimulator cells were cocultured in 250  $\mu$ l medium containing various concentrations of the tested compounds in the 96-well plates (flat bottom wells, Corning Inc., NY). After 5 days of stimulation, [<sup>3</sup>H]-thymidine was added to the cultures (0.5  $\mu$ Ci per well) for 4 hr. Cells were harvested using a Tmtec Harvester 96, MACH II (Packard Inc., Orange, CT) and samples were counted using a Wallac 1470 Betaplate scintillation counter (Pharmacia, Uppsala, Sweden).

**Cell viability test.** Cell viability was assessed with the MTT assay. Spleen cells from C57BL/6J mice were prepared in RPMI 1640 medium supplemented with 5% fetal bovine serum and 50  $\mu$ M 2-mercaptoethanol. Spleen cells ( $2 \times 10^6$ /well) were stimulated with immobilized anti-CD3 (Pharmingen) in the presence of tepoxalin or its vehicle DMSO in 96-well culture plates (Corning Inc., NY). The MTT assay was conducted by using the Celltiter 96 kit (Promega Corp.), which is based on the conversion of a tetrazolium salt by viable cells to a detectable blue formazan.

**GVH-versus-host reactions.** The GVH assay was based on the method of Dorsh and Roeser (15). Spleen cells from C57BL/6J mice were injected subcutaneously into the footpads of B6D2F<sub>1</sub> mice. Each footpad was injected with  $8 \times 10^6$  spleen cells in 50  $\mu$ l. Seven days later, the draining popliteal lymph nodes were removed, minced of fat and weighed. Mice injected in the footpads with saline were used as negative controls. Lymph nodes of these mice were indistinguishable from those injected with syngeneic spleen cells. Tepoxalin was administered orally and CaA was given subcutaneously to mice daily started one day before footpad injection unless otherwise specified.

**Skin graft transplantation.** C3H/HeJ mice (H-2<sup>k</sup>) were anesthetized by intraperitoneal injection of 2.5% avertin (0.016 ml/g body weight). A grafting bed (about 0.3 cm  $\times$  1 cm) on the mouse tail was prepared by peeling off skin carefully to avoid bleeding. Tail skin of similar size was peeled from BALB/cByJ mice (H-2<sup>d</sup>) and then placed on the graft site in an opposite orientation according to the hair growth direction. The grafted skin was protected by a plastic tubing (diameter 0.5 cm, length 3 cm) held in place by wound clips for 5 days. Skin grafts were examined and scored daily. A graft was scored as being rejected when more than 80% of the graft was necrotic. CaA was given subcutaneously to mice daily starting one day before skin transplantation until rejection of grafts. Tepoxalin was given orally one day before transplantation and then daily starting one day after transplantation until graft rejection.

**Data presentation and statistics.** Data were analyzed using one-tailed Dunnett's tests. A parametric version was used if data were normally distributed as assessed by the Wilk-Shapiro test. Data which did not meet the assumptions of normality were tested using a nonparametric version of the Dunnett's test.

## RESULTS

**Inhibition of MLR proliferations by tepoxalin.** We recently reported that tepoxalin suppresses T cell proliferation and inhibits the activity of the transcription factor NF $\kappa$ B (13, 14). Cell activation and proliferation are critical for the initiation of an antigen specific immune response. The transcription factor NF $\kappa$ B is also known to be involved in regulating the expression of many target genes in an immune response (15, 17). The possible immunosuppressive effect of tepoxalin was therefore studied. To determine whether tepoxalin is capable of inhibiting the immune response against alloantigens, tepoxalin at various concentrations was tested in MLR proliferation assays. The assay was set up by stimulating

C57BL/6J (H-2<sup>b</sup>) mouse spleen cells with irradiated B6D2F<sub>1</sub> (H-2<sup>b/d</sup>) mouse spleen cells. As shown in Figure 1, tepoxalin inhibited cell proliferation in a dose-dependent fashion with an IC<sub>50</sub> of 1.3  $\mu$ M. The inhibitory effect was not related to cell toxicity. Tepoxalin at concentrations of 25  $\mu$ M or less did not affect the viability of anti-CD3 stimulated mouse spleen cells after 24 hr of treatment (Table 1). Since tepoxalin is a dual CO/LO inhibitor (10), the possible link of its suppression of MLR proliferation to its inhibition of CO and/or LO was studied. To address this question, the well-known CO inhibitor naproxen and the LO inhibitor zileuton were tested in parallel at doses 10-fold higher than their IC<sub>50</sub> for suppression of CO or LO in mice, respectively. Neither of these compounds, nor the combination of both of them, had an inhibitory effect on MLR proliferation (Fig. 1).

To further understand the mechanism of action of tepoxalin, the kinetics of tepoxalin in inhibiting MLR proliferation was compared to that of the known immunosuppressant, CsA. As shown in Table 2, the inhibitory effect was not diminished when tepoxalin was added 24–72 hr after the initiation of MLR. In contrast, CsA was effective only if it was added at the beginning of the cocultures. To determine whether tepoxalin and CsA were synergistic in inhibiting MLR proliferation, the two agents were tested in combination. Tepoxalin at 0.5  $\mu$ M, 1  $\mu$ M, or 2  $\mu$ M was tested in combination with varying concentrations of CsA (Fig. 2). CsA alone inhibited the response in a dose-related manner with an IC<sub>50</sub> of 22 nM. Tepoxalin alone inhibited proliferation by 26% at 0.5  $\mu$ M, by 55% at 1  $\mu$ M, and by 87% at 2  $\mu$ M. When tepoxalin and CsA were present at suboptimal concentrations, the inhibition was clearly additive. This additive effect was less significant at concentrations of the two drugs that were strongly inhibitory on their own.

**Suppression of GVH responses by tepoxalin.** The immunosuppressive effect of tepoxalin as demonstrated in MLR as-




FIGURE 1. Inhibition of MLR proliferations by tepoxalin. Spleen cells from C57BL/6J mice were cocultured in triplicate wells with irradiated spleen cells from B6D2F<sub>1</sub> mice as described in *Materials and Methods*. Varying concentrations of tepoxalin, naproxen, zileuton, or naproxen + zileuton were added to the cultures at the initiation of cultures. [<sup>3</sup>H]-thymidine uptake was measured on day 5. Control cultures contained DMSO diluted in a manner similar to that of the compounds. Uptake of [<sup>3</sup>H]-thymidine in vehicle controls was about 90,000 cpm. Percentages of control responses are calculated as percentages of (cpm of treated cultures/cpm of vehicle controls).



TABLE 1. The effective doses of tepoxalin in immunosuppression is not toxic to cells<sup>a</sup>

Tepoxalin ( $\mu$ M)	Cell viability <sup>b</sup>
100	52.0%
50	76.4%
25	96.5%
12.5	103.0%
6.25	115.5%
3.12	118.4%
1.56	136.5%

<sup>a</sup> Viability of anti-CD3 stimulated C57BL/6J spleen cells treated with tepoxalin for 24 hr was tested in the MTT viability assay.

<sup>b</sup> Cell viability is presented as the percentage of viable cells in tepoxalin treated sample compared with that treated with an equivalent amount of the vehicle, DMSO.

TABLE 2. Inhibitory effect of tepoxalin and CsA on MLR proliferations (% control response)<sup>a</sup>

	Concentration ( $\mu$ M)	Time of Treatment			
		0 hr	24 hr	48 hr	72 hr
Tepoxalin	1.25	64.0	52.0	67.0	30.6
	2.5	17.2	12.7	19.2	15.1
	5.0	4.7	5.2	7.8	9.0
Cyclosporine	0.021	40.6	65.0	97.1	133.6
	0.042	18.6	99.5	93.2	148.0
	0.084	5.7	64.1	84.4	119.2

<sup>a</sup> Different concentrations of compounds added in MLR cultures at different time points were studied. MLR assays were set up as described in *Materials and Methods*. The MLR proliferations treated with compounds were compared with their vehicle controls. <sup>b</sup> <sup>3</sup>H-thymidine uptake by proliferating cells in MLR assays was measured. Percentages of control responses are calculated as percentages of (cpm of treated cultures/cpm of vehicle controls).

says suggests its potential use as an immunosuppressant in clinical therapy. This possible application was verified with *in vivo* murine models of transplantation. A local GVH response was performed by injecting spleen cells from the parental C57BL/6J (H-2<sup>b</sup>) mice into the footpads of B6D2F1/J (H-2<sup>d</sup>) mice. GVH responses were demonstrated by the enlargement of the draining popliteal lymph nodes in recipient mice. The lymph nodes of recipient mice increased significantly by day 2 and continued to increase in size with time. The degree of the local GVH response was measured by weighing the draining popliteal lymph nodes. The lymph nodes of tepoxalin-treated mice did enlarge on day 2 but did not change significantly later on. After 7 days of the local GVH response, lymph nodes from tepoxalin-treated mice were slightly hyperplastic, but were significantly less so than that of the untreated controls (Fig. 3A). GVH responses in mice administered tepoxalin orally at 12–50 mg/kg/day were reduced by about 40% of that in the positive control group. Consistent with the findings in mice, tepoxalin was also effective in rats, with a 30% suppression of this local GVH response at 12 mg/kg/day (data not shown). The immunosuppressive agent CsA administered subcutaneously to mice at 50 and 75 mg/kg/day was shown to suppress GVH response by 42% and 71%, respectively (Fig. 3B). The results suggest that the immunosuppressive effect of tepoxalin at 12 mg/kg/day is comparable to that of CsA at 50 mg/kg/day. To assess whether the inhibitory effect of tepoxalin on GVH responses





FIGURE 2. Additive inhibitory effects of tepoxalin and CsA in MLR proliferations. Proliferation of C57BL/6J mouse spleen cells after 5 days stimulation with irradiated B6D2F1 spleen cells in medium containing tepoxalin at 0.5  $\mu$ M, 1  $\mu$ M, and 2  $\mu$ M plus varying concentrations of CsA was assayed as described in *Materials and Methods*. The proliferative response in cultures containing no drugs was 80,000 cpm.

could be obtained with other CO or LO inhibitors, naproxen and zileuton were again tested in GVH assays. No inhibition was seen with zileuton, naproxen, or a combination of the two compounds (Fig. 3C).

Since tepoxalin appears to act late in MLR assays, the effect of tepoxalin administered early and late in GVH responses was also studied. Similar to the findings in MLR proliferations, tepoxalin given to mice for a minimum of 3 days was sufficient to suppress GVH responses to an extent similar to those treated with tepoxalin throughout the 7-day course of the GVH response (Fig. 4). This short treatment with tepoxalin could be at the early (day -1 to day 1 or 4) or the late (day 4 to day 6) stage of the GVH response. The inhibitory effect of tepoxalin at the late stage of immune responses suggests its mechanism of action to be different from that of CsA. The possible synergism in immunosuppression by tepoxalin and CsA was therefore studied in GVH assays. A much stronger suppression of the GVH response was indeed found in mice treated with both tepoxalin and CsA rather than those treated with either one of the two drugs (Fig. 5). This synergistic effect was particularly significant when a low dose of tepoxalin (6 mg/kg/day) was combined with CsA.


**Prolongation of skin allograft survival by tepoxalin.** The time course of skin allograft rejection in mice is affected by the efficiency of the following two mechanisms: (1) the activation of T cells through recognition of specific alloantigens, and (2) the effector mechanisms mediating tissue destruction. To study the effect of tepoxalin on skin allograft survival, experimental allograft rejection was performed by grafting allogeneic BALB/cByJ (H-2<sup>d</sup>) mouse tail-skin onto C3H/HeJ (H-2<sup>k</sup>) recipient mice. For the first 6 days after transplantation, allografts appeared normal and their gross appearance was not different from that of syngeneic grafts. The rejection process became apparent by day 6, with signs of swelling and erythema, and quickly culminated into complete graft necrosis. Different doses of tepoxalin were tested in skin graft rejection assays. As shown in Figure 6, rejection of allografts

August 27, 1995




**FIGURE 3.** Suppression of GVH responses by tepoxalin. A local GVH response was triggered by subcutaneous injection of parental C57BL/6J spleen cells into footpads of B6D2F<sub>1</sub>/J mice, and was measured by weighing the draining lymph nodes as described in *Materials and Methods*. Mice injected with saline were used as negative controls. Drugs were given to mice from day -1 to day 6 of the GVH response. (A) GVH responses in mice administered different doses of tepoxalin or vehicle control (0.5% methylcellulose) orally. Ten mice were used per group. The values from mice treated with tepoxalin at 12, 25, and 50 mg/kg/day are significantly different from the vehicle control group (Dunnett's test). Similar results were obtained from more than three repeated experiments. (B) GVH responses in mice given Csa (50 and 75 mg/kg) or vehicle control (saline) subcutaneously. Five mice were used per group. (C) GVH responses in mice given naproxen, zileuton, or the combination of the two drugs at 50 mg/kg/day orally. Mice as vehicle controls for naproxen were treated with equivalent volumes of 0.5% methylcellulose; for zileuton, they were treated with 50% polyethylene glycol 200; and for the combination of drugs, they were treated with both 0.5% methylcellulose and 50% polyethylene glycol 200. Five mice were used per group. The column bars represent the standard errors. Asterisks indicate a *P* value of <0.05.

in the placebo-treated group started on day 7. About 50% of the allografts in the placebo group were rejected on day 10. Tepoxalin at doses of 12.5 and 25 mg/kg/day did not have a significant effect in prolonging graft rejection. When tepoxalin at 50 mg/kg/day was administered to mice, a significant prolongation of skin graft rejection was observed. The median survival time of skin grafts, defined as the time point at which 50% of the grafts are rejected, was 10.5 days in the



**FIGURE 4.** Effective suppression of mouse GVH response by short treatments with tepoxalin. The GVH response was induced by injection of C57BL/6J spleen cells into the footpads of B6D2F<sub>1</sub>/J mice and was measured by weighing the draining lymph nodes as described in *Materials and Methods*. Mice injected with saline instead of spleen cells were used as negative controls. Tepoxalin (25 mg/kg) was administered orally to mice at different time schedules as shown. GVH responses in mice treated with vehicle (0.5% methylcellulose) were used as positive controls. Five mice were used per group. The column bars represent the standard errors.



**FIGURE 5.** Synergistic suppression of mouse GVH responses by tepoxalin and Csa. The GVH response was induced by injection of C57BL/6J spleen cells into the footpads of B6D2F<sub>1</sub>/J mice and was measured by weighing the draining lymph nodes as described in *Materials and Methods*. Mice were treated with Csa (50 mg/kg) or tepoxalin (6 or 12 mg/kg) alone, or the combination of tepoxalin (6 or 12 mg/kg) and Csa (50 mg/kg). Mice injected with spleen cells and treated with vehicles were used as positive controls. Mice injected with saline instead of spleen cells were used as negative controls. Twenty mice were used per group. The column bars represent the standard errors. Asterisks indicate a *P* value of <0.05. Similar results were obtained from repeated experiments.

placebo-treated group and was 15.0 days for the group of mice treated with tepoxalin at 50 mg/kg/day (*P* < 0.05). Furthermore, a combination of tepoxalin and Csa at low doses showed a dramatic prolongation of allogeneic skin graft rejection (Fig. 7). About 52% of the mice treated daily with




FIGURE 6. Prolongation of skin graft rejection by tepoxalin. BALB/cByJ mouse tail skin was grafted onto the tail of C3H/HeJ mice and rejection of the grafted skin was scored as described in *Materials and Methods*. Different doses of tepoxalin were administered orally to C3H/HeJ recipient mice the day before and after skin transplantation, and then daily until skin grafts were rejected. Mice given the vehicle (0.5% methylcellulose) orally were used as controls. About ten mice were used per group. Data presented were taken from one of the three repeated experiments. Results obtained from all three experiments were similar. Prolongation of skin rejection in mice treated with tepoxalin 50 mg/kg was significant ( $P < 0.05$ , Dunnett's  $t$  test).




FIGURE 7. Enhanced prolongation of allogeneic skin graft rejection by tepoxalin and CsA. BALB/cByJ mouse tail skin was grafted onto the tail of C3H/HeJ mice as described in *Materials and Methods*. Tepoxalin (12.5 mg/kg) alone, CsA (50 mg/kg) alone, or tepoxalin (12.5 mg/kg) plus CsA (50 mg/kg) were administered to C3H/HeJ mice the day before and after skin transplantation, and then daily until skin grafts were rejected. Tepoxalin was given orally and CsA was given subcutaneously. For recipient mice with skin grafts surviving for more than 40 days, drug administration was discontinued from day 40, as shown by arrows. About ten mice were used per group. Enhanced prolongation of skin rejection was also observed for the combination of tepoxalin (25 mg/kg) and CsA (50 mg/kg) (data not shown).

tepoxalin (12.5 mg/kg/day) and CsA (50 mg/kg/day) retained the allogeneic skin grafts on day 40 after transplantation. To determine whether immunotolerance to skin grafts is generated by the combined drug treatment, drug dosing was discontinued after day 40 of transplantation. Skin graft rejection was noticeable on day 16 and all the grafts were rejected

on day 24 after drug cessation (Fig. 7). The results suggest that the combination of tepoxalin and CsA potentiates the immunosuppressive effect, but does not induce immunotolerance to the grafts.

## DISCUSSION

In this report, we demonstrate that tepoxalin is effective in suppressing the immune responses in murine models of GVH reaction and allogeneic skin graft rejection. This immunosuppressive activity is not seen with other inhibitors of CO or LO.

To study the mechanism of immunosuppression by tepoxalin, we used the *in vitro* mixed lymphocyte reaction, which measures the proliferative response of parental strain C57BL/6J spleen cells when stimulated by B6D2F<sub>1</sub>/J spleen cells. Tepoxalin inhibited the alloantigen-driven proliferative response in a dose-related manner with an  $IC_{50}$  of 1.3  $\mu$ M and a complete inhibition at 5  $\mu$ M. A similar inhibition was seen with CsA, which had an  $IC_{50}$  of approximately 22 nM and a complete inhibition at about 200 nM. However, there were differences in the kinetics of the inhibitions seen with the two compounds. Tepoxalin exerted the same degree of inhibition if added any time up to 72 hr after the set-up of MLR cultures. CsA was only inhibitory if added at the initiation of the MLR cultures. IL-2 production by T cells occurs early following activation, reaching peak levels by 24 hr of culture (18, 19). CsA has been known for its inhibitory effect on IL-2 production (7, 20, 21) and is therefore expected to affect T cells during the first 24 hr of activation. The fact that tepoxalin inhibits proliferation late in MLR assays suggests its inhibition of later events in T cell activation. One possibility is that the IL-2-mediated signal transduction pathway is affected by tepoxalin, which has been shown on human lymphocytes in our previous report (13).

GVH disease is a common problem in bone marrow transplantation that leads to frequent morbidity and mortality (22). Skin grafts trigger strong immune responses and have been one of the most difficult grafts in transplantation (3). The immunosuppressive activity of tepoxalin was demonstrated in murine models of GVH responses and allogeneic skin graft rejections. Tepoxalin was found to inhibit GVH responses at 12 mg/kg/day and to prolong skin graft rejections at 50 mg/kg/day. The possibility that tepoxalin blocks a later event in immune response is again implicated by its suppression of GVH reaction even when it was administered to mice 4 days after the initiation of the response.

Tepoxalin is known to be a dual CO and LO inhibitor with potent antiinflammatory effects (10). One of the obvious questions to ask is whether its immunosuppression is due to the inhibition of the CO or LO enzymes. The involvement of CO and LO in the modulation of immune responses remains controversial. Arachidonic acid metabolites produced by these enzymes, such as prostaglandins and leukotrienes, have many biological activities, including the modulation of inflammation and immune response (23-29). Indeed several inhibitors of LO have been shown to prolong graft rejection in transplantation (30-33). However, it was noticed that those LO inhibitors with immunosuppression activity are also potent antioxidants with inhibitory effects on NF- $\kappa$ B activity (34, 35). Therefore the immunoregulatory effects of these



August 27, 1995

compounds may not be directly related to inhibition of LOX. We compared the effect of tepoxalin with other known LOX/CO inhibitors in our studies. Naproxen (CO inhibitor) or zileuton (LO inhibitor), or their combination, did not have any effect on MLR proliferations or GVH responses. We have reported recently that tepoxalin is distinct from other CO and LO inhibitors in its inhibition of NF $\kappa$ B activities (14). NF $\kappa$ B is a pleiotropic transactivator of many target genes involved in immune or inflammatory responses (16, 17). The immunosuppressive effect of tepoxalin may be attributed to its inhibition of NF $\kappa$ B and not related to the general inhibition of arachidonic acid metabolism.

Taken together, these data show that tepoxalin is an effective immunosuppressive agent. Since the mechanism of tepoxalin appears to be different from CsA in immunosuppression, it suggests a possible combinational use of the two compounds in immunosuppressive therapy. Moreover, tepoxalin is devoid of ulcerogenic actions in gastrointestinal systems that are the common side effects of other NSAID drugs (11, 12). The LD<sub>50</sub> of tepoxalin in mice and rats was more than 400 mg/kg, which is over 10-fold higher than the effective doses used in *in vivo* immunosuppression. Tepoxalin could therefore be an important addition to the existing immunosuppressive therapeutic drugs to enhance the efficacy of treatment and to reduce drug toxicity in transplantation and autoimmunity.

**Acknowledgments.** We thank Dr. John Booth, Anna Bahnerli, and Linda Traeger for their assistance in manuscript preparation, and Anthony Branco and John DiCicco for maintenance of the animal facility.

## REFERENCES

- Korngold R, Sprent J. Lethal graft-versus-host disease across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. *J Exp Med* 1978; 148: 1687.
- Ascher NL, Hoffman RA, Hanto DW, Simmons RL. Cellular basis of allograft rejection. *Immunol Rev* 1984; 77: 217.
- Mason DW, Morris PJ. Effector mechanisms in allograft rejection. *Annu Rev Immunol* 1986; 4: 119.
- Hall BM. Cells mediating allograft rejection. *Transplantation* 1991; 51: 1141.
- Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. *Lancet* 1978; 2: 1323.
- Starzl TE, Iwatsuki S, van Thiel DH, et al. Evolution of liver transplantation. *Hepatology* 1982; 2: 614.
- Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. *Science* 1989; 246: 1617.
- Flanagan WM, Cortes B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 1991; 352: 803.
- Klintmalm GR, Iwatsuki S, Starzl TE. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. *Transplantation* 1981; 32: 488.
- Argentieri D, Anderson DW, Ritchie DM, Rosenthal ME, Capetola RJ. Tepoxalin (RWJ-20485) inhibits prostaglandin (PG) and leukotriene (LT) production in adjuvant arthritis rats and in dog knee joints challenged with sodium urate and immune complexes. *FASEB J* 1990; 4: A1122.
- Wallace JL, Cirino G, Cicala C, Anderson DW, Argentieri D, Capetola RJ. Comparison of the ulcerogenic properties of tepoxalin with those of non-steroidal anti-inflammatory drugs (NSAIDs). *Agents Actions* 1991; 34: 247.
- Wallace JL, McCafferty D-M. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy? *Gastroenterology* 1993; 105: 1630.
- Zhou L, Ritchie D, Wang EY, Barbons AG, Argentieri D, Lau CY. Tepoxalin: a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. *J Immunol* 1994; 151: 6168.
- Kazmi SMI, Plante RK, Visconti V, Taylor GR, Zhou L, Lau CY. Suppression of NF $\kappa$ B activation and NF $\kappa$ B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. *J Cell Biochem* 1994; 58: 1.
- Dorach SE, Roser B. A quantitative lymph node weight assay for allogeneic interactions in the rat. *AJERAK* 1974; 52: 253.
- Baeuerle PA. The inducible transcription activator NF $\kappa$ B: regulation by distinct protein subunits. *Biochim Biophys Acta* 1991; 1072: 63.
- Grilli M, Chiu JJ, Lenardo MJ. NF- $\kappa$ B and Rel: participants in a multifactorial transcriptional regulatory system. *Int Rev Cytol* 1993; 148: 1.
- Lindstein T, June CH, Ledbetter JA, Stalla G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. *Science* 1989; 244: 339.
- Shaw J, Moerovitch K, Bleackley RC, Paetkau V. Mechanisms regulating the level of IL-2 mRNA in T lymphocytes. *J Immunol* 1988; 140: 2243.
- Elliott JF, Lin Y, Mixal SB, Bleackley RC, Harnish DG, Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. *Science* 1984; 226: 1439.
- Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. *Annu Rev Immunol* 1992; 10: 519.
- Ferrari JL, Deeg HJ. Graft-versus-host disease. *N Engl J Med* 1991; 324: 667.
- Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T cell mitogenesis by prostaglandin: existence of a prostaglandin-producing suppressor cell. *J Exp Med* 1977; 146: 1719.
- Anderson CB, Jaffee BM, Graff RJ. Prolongation of murine skin allografts by prostaglandin E1. *Transplantation* 1977; 23: 444.
- Ford-Hutchinson A, Bray M, Doig M, Shipley M, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. *Nature* 1980; 286: 264.
- Rappaport RS, Dodge GR. Prostaglandin E inhibits the production of human interleukin 2. *J Exp Med* 1982; 155: 943.
- Chouaib S, Fradelizi D. The mechanism of inhibition of human IL-2 production. *J Immunol* 1982; 129: 2463.
- Synder DS, Beller DI, Unanue ER. Prostaglandins modulate macrophage Ia expression. *Nature* 1982; 299: 163.
- Johnson HM, Torres BA. Leukotrienes: positive signals for regulation of gamma-interferon production. *J Immunol* 1984; 132: 413.
- Iyobe T, Izumi R, Shimizu K. The immunosuppressive effect of 5-lipoxygenase inhibitor on liver allotransplantation in rats. *Transplantation* 1993; 56: 518.
- Konishi K, Watanabe T, Yabushita K, Hirose H, Izumi R, Miyazaki I. Effect of lipoxygenase inhibitor (nordihydroguaiaric acid, NDGA) on canine pancreatic allografts. *Transplant Proc* 1991; 23: 1681.
- Horichi H, Izumi R, Konishi K, et al. Effect of 5-lipoxygenase inhibitor on canine pancreatic allotransplantation. *Transplant Proc* 1991; 23: 1679.
- Weir MR, Li XW, Gomolka D, Peppler R, O'Bryan-Tear GG, Moran MA. The immunosuppressive properties of enisoprost

368

TRANSPLANTATION

Vol. 60, No. 4

and a 5-lipoxygenase inhibitor (BC-45662). Transplantation 1991; 52: 1053.

34. Israel N. Redox status of cells influences constitutive or induced NF $\kappa$ B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. *J Immunol* 1992; 149: 3386.
35. Fedyk ER, Phipps RP. Reactive oxygen species and not lipoxy-

genase products are required for mouse B-lymphocyte activation and differentiation. *Int J Immunopharmacol* 1994; 16: 533.

Received 28 November 1994.

Accepted 7 March 1995.

0041-1337/95/6004-368\$03.00/0

TRANSPLANTATION

Copyright © 1995 by Williams &amp; Wilkins

Vol. 60, 368-374, No. 4, August 27, 1995  
Printed in U.S.A.

## COMBINED THERAPY WITH INTERLEUKIN-4 AND INTERLEUKIN-10 INHIBITS AUTOIMMUNE DIABETES RECURRENCE IN SYNGENEIC ISLET-TRANSPLANTED NONOBESE DIABETIC MICE

ANALYSIS OF CYTOKINE mRNA EXPRESSION IN THE GRAFT<sup>1</sup>

ALEX RABINOVITCH,<sup>2,3,4,5</sup> WILMA L. SUAREZ-PINZON,<sup>4</sup> OLE SORENSEN,<sup>4</sup> R. CHRIS BLEACKLEY,<sup>2,6</sup>  
ROBERT F. POWER,<sup>7</sup> AND RAY V. RAJOTTE<sup>8</sup>

Departments of Medicine, Immunology, Biochemistry, Laboratory Medicine and Pathology, and Surgery, and the Muttart Diabetes Research and Training Centre, University of Alberta, Edmonton, Alberta, Canada

Syngeneic pancreatic islet grafts in nonobese diabetic (NOD) mice elicit a cell-mediated autoimmune response that destroys the insulin-producing  $\beta$  cells in the islet graft. IL-4 and IL-10 are cytokines that inhibit cell-mediated immunity. In this study, we evaluated the effects of IL-4 and IL-10 on the survival of syngeneic pancreatic islets transplanted into diabetic NOD mice. Islet grafts survived beyond 18 days and normoglycemia was maintained in 87% (10 of 15) of mice treated with IL-4 plus IL-10, but in none (0 of 20) of vehicle-injected (control) mice. Also, 40% (6 of 15) of the mice treated with IL-4 plus IL-10 were normoglycemic at 30 days after transplantation, compared with 14% (1 of 7) of the mice treated with IL-4 alone, 8% (1 of 13) of the mice treated with IL-10 alone, and none (0 of 20) of the control mice. Histological examination of grafts at 10 days after transplantation revealed peri-islet accumulations of mononuclear leukocytes and intact islet  $\beta$  cells in grafts from IL-4 plus IL-10-

treated mice, whereas islets were infiltrated by leukocytes and the  $\beta$  cell mass was greatly reduced in grafts from control mice. Polymerase chain reaction (PCR) analysis of cytokine mRNA expression in the grafts revealed higher levels of IL-2, IFN $\gamma$ , and IL-10 mRNA in grafts of diabetic compared with normoglycemic control mice, whereas IFN $\gamma$  and TNF $\alpha$  mRNA levels were significantly decreased in grafts of IL-4 plus IL-10-treated mice compared with either normoglycemic or diabetic control mice. These results suggest that T helper (Th)1 cells and their cytokine products (IL-2, IFN $\gamma$ , and TNF $\alpha$ ) may promote islet  $\beta$  cell destructive insulinitis and autoimmune diabetes recurrence in syngeneic islet-transplanted NOD mice, and that administration of IL-4 plus IL-10 may inhibit diabetes recurrence by suppressing Th1 cytokine production in the islet grafts.

Insulin-dependent diabetes mellitus (IDDM)\* results from destruction of the insulin-producing pancreatic islet  $\beta$  cells by the host's own immune system. Whereas it is not known what may initiate this autoimmune response against islet  $\beta$  cells, there is abundant evidence that IDDM is T cell-dependent (1, 2). However, it is unclear which T cells are involved and how they may lead to islet  $\beta$  cell destruction. A variety of immune/inflammatory cells infiltrate the pancreatic islets and constitute the insulinitis lesion (3, 4). There is evidence in human patients with IDDM (5-8) and in animals with spontaneous IDDM resembling the human disease—the nonobese diabetic (NOD) mouse and the biobreeding (BB) rat (9-22)—that islet  $\beta$  cell destruction may involve heterogeneous effec-

<sup>1</sup> This work was supported by a Diabetes Interdisciplinary Research Program grant from the Juvenile Diabetes Foundation International, and by grants from the Medical Research Council of Canada and the MacLachlan Fund of the University of Alberta Hospitals.

<sup>2</sup> Alex Rabinovitch and R. Chris Bleackley are supported by Medical Scientist Awards of the Alberta Heritage Foundation for Medical Research.

<sup>3</sup> Address correspondence to: Alex Rabinovitch, M.D., Department of Medicine, 430 Heritage Medical Research Centre, University of Alberta, Edmonton, Alberta, Canada, T6G 2S2.

<sup>4</sup> Department of Medicine.

<sup>5</sup> Department of Immunology.

<sup>6</sup> Department of Biochemistry.

<sup>7</sup> Department of Laboratory Medicine and Pathology.

<sup>8</sup> Department of Surgery.

\* Abbreviations: BB, Biobreeding; CFA, complete Freund's adjuvant; IDDM, insulin-dependent diabetes mellitus; NOD, nonobese diabetic; PCR, polymerase chain reaction; Th, T helper.

# Immunosuppressive effects of tautomycetin *in vivo* and *in vitro* via T cell-specific apoptosis induction

Jae-Hyuck Shim<sup>\*,†</sup>, Heung-Kyu Lee<sup>\*,†</sup>, Eun-Ju Chang<sup>\*</sup>, Wook-Jin Chae<sup>\*</sup>, Jin-Hwan Han<sup>\*</sup>, Duck-Jong Han<sup>\*</sup>, Tomohiro Morio<sup>§</sup>, Jung-Jin Yang<sup>¶</sup>, Alfred Bothwell<sup>||</sup>, and Sang-Kyou Lee<sup>\*,\*\*</sup>

<sup>\*</sup>Department of Biotechnology, College of Engineering and Bioproducts Research Center, Yonsei University, 120-749 Seoul, Korea; <sup>†</sup>Department of Surgery and Pathology, College of Medicine, University of Ulsan and Asan Medical Center, 138-040 Seoul, Korea; <sup>¶</sup>Department of Computer Science, Catholic University of Korea, 420-743 Puchon, Korea; <sup>§</sup>Department of Pediatrics, Tokyo Medical and Dental University, School of Medicine, Tokyo 113-8519, Japan; and <sup>||</sup>Section of Immunobiology, Yale University, School of Medicine, New Haven, CT 06520

Edited by Charles A. Janeway, Jr., Yale University School of Medicine, New Haven, CT, and approved June 11, 2002 (received for review October 2, 2001)

Tautomycetin (TMC) was identified as an immunosuppressor of activated T cells. Inhibition of T cell proliferation with TMC was observed at concentrations 100-fold lower than those needed to achieve maximal inhibition with cyclosporin A (CsA). TMC specifically blocked tyrosine phosphorylation of intracellular signal mediators downstream of Src tyrosine kinases in a T cell-specific manner, leading to apoptosis due to cleavage of Bcl-2, caspase-9, caspase-3, and poly(ADP-ribose) polymerase, but not caspase-1. In TMC-treated rats that received a heterotopic cardiac allograft, the graft survived more than 160 days, comparable to graft survival in allografted rats treated with CsA. Thus, TMC, whose mechanism of action is different from that of CsA or FK506, can be used as a potent T cell-specific immunosuppressor.

Organ transplantation to replace diseased organs has become the standard treatment in terminal organ failure, such as in renal, hepatic, or cardiac diseases (1). In most cases, induction of T cell-mediated immune responses to the highly polymorphic MHC molecules on nucleated cells in the grafted organ is the major barrier to successful transplantation (2). Improvement in graft survival is accomplished by precise HLA typing capability, greater surgical experience and skill, and the potential of cloned animals as organ donors. But genetic differences at loci other than MHC still trigger rejection. Therefore, continuous efforts to discover effective and specific immunosuppressive agents have been intense.

The systematic study of products from bacteria and fungi has led to the development of immunosuppressive drugs such as cyclosporin A (CsA), FK506 (tacrolimus), and rapamycin (3). CsA and FK506 block T cell activation by preventing the induction of IL-2 gene expression, whereas rapamycin blocks the signaling pathway triggered by IL-2 receptor (4). They exert their pharmacological effects by binding to the immunophilins, and the immunophilin and drug complex binds and inhibits the Ser/Thr phosphatase calcineurin, which is activated when intracellular calcium ion level rises on T cell activation (5, 6). Rapamycin has a different mode of action from either CsA or FK506. Like FK506, rapamycin binds to the FK506-binding protein family of immunophilins. However, the complex of rapamycin/immunophilin has no effect on calcineurin activity but instead blocks the signaling pathway triggered by the IL-2 receptor. These drugs are effective immunosuppressive agents, but they are not free of problems. Because calcineurins are found in many cells, these drugs are expected to be deleterious in many other tissues, such as kidney and liver (7). Therefore, it is important to develop new immunosuppressors with minimal toxicity that target molecules specifically involved in immune responses. It would also be helpful to have more than two different immunosuppressive drugs with different pharmacological effects.

In this study, we identified tautomycetin (TMC) as an activated T cell-specific immunosuppressor. Being different from CsA and FK506 in its mechanism of action, TMC inhibited the induction of tyrosine phosphorylation of T cell-specific signaling mediators in T cell receptor (TcR) proximal signal transduction pathway, leading to induction of apoptosis. In *in vivo* studies, TMC was at least as effective as CsA in the heterotopic cardiac transplant animal model.

## Materials and Methods

**Cell Culture and Reagents.** Human peripheral blood lymphocytes from healthy volunteers were isolated by standard Ficoll-Hypaque gradient centrifugation. The cell lines HeLa, Jurkat, and CD8- $\zeta$  Jurkat transfectant were cultured in standard medium containing FBS. Jurkat transfectants were regularly treated with medium containing 2.2 mg/ml of Geneticin (GIBCO/BRL). OKT3 and -8 mAb were purified from supernatants secreted from OKT3 and -8 hybridomas (American Type Culture Collection) by Gamma Bind plus Sepharose from Pharmacia Biotech. The following antibodies were used: anti-p-Tyr (4G10; Upstate Biotechnology, Lake Placid, NY), anti-p-Tyr agarose conjugated beads (Upstate Biotechnology), anti-ICE (Upstate Biotechnology), anti-Fyn (Upstate Biotechnology), anti-phospho-ERK-1/-2 (New England Biolabs), anti-Cpp32 (Transduction Laboratories, Lexington, KY), anti-Caspase-9 (PharMingen), anti-CD3 $\zeta$  (ID4; PharMingen), anti-CD28 (PharMingen), and anti-CD69 (FN50; PharMingen). Antibodies of anti-Bcl-2 (100), anti-Cbl (C-15), anti-LAT (Q-20), anti-poly(ADP-ribose) polymerase (PARP) (H-250), anti-PLC $\gamma$ -1 (530), anti-SLP-76 (K-20), anti-Vav (C-14), and anti-ZAP70 (LR) were purchased from Santa Cruz Biotechnology. Phorbol 12-myristate 13-acetate and Concanavalin A (ConA) were obtained from Sigma. CsA was generously provided by Chong Kun Dang (Seoul, Korea), and tautomycin was purchased from WAKO Biochemicals (Osaka).

**Separation and Purification of TMC.** *Streptomyces* sp. CK-4412, isolated from forest soil on Cheju Island, Korea, was cultured at 28°C for 65 h in Erlenmeyer flasks containing a medium composed of soluble starch, 3%; soybean flour, 1.5%; corn steep liquor, 1.5%; polypeptone, 0.2%; Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, 0.1%; CaCO<sub>3</sub>, 0.5%; and allophosite, 1%. After centrifugation, the supernatant (6.9 liters) was extracted with EtOAc, and the extracts were evaporated *in vacuo*. The extracts were then applied to LH-20 and silica gel column developed with the solvent, CHCl<sub>3</sub>:*n*-hexane:acetone:AcOH (10:5:3:0.1). Active fraction called CKD-722 was collected and concentrated *in vacuo* to give a yellowish oily material, and further purification and identification were performed with HPLC by using an octadecyl silane (ODS) column, NMR, and electrospray ionization-MS analysis.

**Murine Mixed Lymphocyte Reaction (MLR) Assays and IL-2 ELISA.** For murine MLR assays, the immunosuppressive activity of active fractions and TMC was assessed with mixed lymphocyte reactions, as previously described (8). For IL-2 ELISA, 1  $\times$  10<sup>5</sup> human primary T cells were activated by using 1  $\mu$ g/ml of OKT3 and 0.5

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: TMC, tautomycetin; CsA, cyclosporin A; PI, propidium iodide; MLR, mixed lymphocyte reaction; BcR, B cell receptor; TcR, T cell receptor; PARP, poly(ADP-ribose) polymerase.

<sup>†</sup>J.-H.S. and H.-K.L. contributed equally to this work.

<sup>\*\*</sup>To whom reprint requests should be addressed. E-mail: sjrlee@yonsei.ac.kr.

$\mu\text{g}/\text{ml}$  of anti-CD28 mAb for a given time in microwell plates. Supernatants were harvested, and IL-2 ELISA was performed according to the manufacturer's protocol. Briefly, 100  $\mu\text{l}$  of diluted capture Ab was coated in 96-microwell plates for 12 h at 4°C and blocked for 1 h at room temperature. Reaction was performed by using detection Ab and horseradish peroxidase-conjugated avidin. Wells were washed seven times, and tetramethyl-benzidine (TMB) substrate was added to each well. Fifty microliters of stop solution was added, and absorbance was measured at 450 nm within 30 min. For correction, the following equation was used:

Corrected value of absorbance = absorbance at 570 nm – absorbance at 450 nm.

**Immunoprecipitation and Immunoblot Analysis.** After incubation of  $3 \times 10^7$  CD8- $\zeta$  transfectants, primary human T or B cells at 37°C for 5 min with crosslinked OKT8 mAb (1  $\mu\text{g}/1 \times 10^6$  cells), OKT3 mAb (1  $\mu\text{g}/1 \times 10^6$  cells) and anti-CD28 mAb (0.5  $\mu\text{g}/1 \times 10^6$  cells) or anti-BcR mAb (1  $\mu\text{g}/1 \times 10^6$  cells), respectively, cells were solubilized in lysis buffer (10 mM Tris/50 mM NaCl/5 mM EDTA/50 mM NaF/30 mM sodium pyrophosphate/100  $\mu\text{M}$   $\text{Na}_3\text{VO}_4$ /200  $\mu\text{M}$  PMSF/10  $\mu\text{g}/\text{ml}$  of leupeptin/5  $\mu\text{g}/\text{ml}$  of aprotinin, 1% Nonidet P-40). Tyrosine-phosphorylated proteins were immunoprecipitated with 4G10 mAb coupled to agarose beads (Upstate Biotechnology), and immunoprecipitates or total cell lysates were fractionated by SDS/PAGE and transferred to Immobilon-P (Millipore). Membrane was blocked in TTBS buffer [100 mM Tris-HCl (pH 7.5)/150 mM NaCl/0.1% Tween-20] with 4% BSA, then immunoblotted with the indicated antibodies. The membrane was washed and incubated with horseradish peroxidase-conjugated secondary antibodies, and developed with enhanced chemiluminescence (Amersham Pharmacia).

**Heterotopic Cardiac Allograft.** The microsurgical technique of heart transplantation in rat was done by double anastomosis. With ether anesthesia, the abdomen of the Lewis rat was opened and bled by cutting the abdominal aorta and its chest opened. After perfusion of heart through the ascending aorta with cold saline solution, the heart was removed from the mediastinum after the division of the trachea and placed in a beaker containing cold saline. The abdomen of the recipient Wistar rat was opened by midline incision. The Lewis heart was placed within the abdominal cavity, and end-to-side anastomosis was done by sewing the pulmonary artery and aorta to the inferior vena cava and abdominal aorta of the Wistar, respectively. Soon after perfusion, regular beating of the heart followed the ventricular fibrillation. The intestine was returned to the abdomen, and the abdominal wall was closed.

**Apoptosis Assays.** Cell death was confirmed by detecting DNA fragmentation. Briefly,  $5 \times 10^6$  cells were lysed in  $\times 2$  lysis buffer (200 mM Hepes, pH 7.5/2% Triton X-100/400 mM NaCl/20 mM EDTA) and incubated with RNase at 37°C for 1 h. DNA was extracted with phenol and precipitated with 5 M ammonium acetate and 2.5 volume of 100% ethanol and then analyzed by electrophoresis on 2% agarose gel. Also, for cell viability analysis,  $1 \times 10^6$  cells were determined by staining with propidium iodide (PI) and analyzed on a FACScan (Becton Dickinson).

**Transient Transfection.** Jurkat TAg cell lines were transiently transfected with 5  $\mu\text{g}$  of plasmid DNA by using Superfect transfection reagent (Qiagen, Hilden, Germany). Cells ( $3 \times 10^6$ ) were washed once with PBS and plated to a 60-mm dish. Plasmid DNA was incubated for 10 min at room temperature in serum-free medium containing Superfect. After the DNA-Superfect complexes were added dropwise to the cells in a 60-mm dish, the cells were incubated in fresh medium for 36 h.

## Results

**Identification of TMC as an Immunosuppressor.** We isolated a large number of actinomycete strains from forest soil on the volcanic





Fig. 1. Structure of TMC.

Cheju Island in Korea. Appropriate dilutions of culture broth after centrifugation were included in mouse MLR to examine their inhibitory effects on T cell proliferation. The culture broth of *Streptomyces* sp. CK-4412 showing the strongest inhibition of T cell proliferation in MLR was prepared on a large scale and then applied to an LH-20 and silica gel chromatography column. The active fraction, called CKD-722, was collected and further purified by HPLC by using an ODS column. CKD-722 prepared in MeOH showed characteristic UV absorption at 268 nm, and the main absorption band in IR spectrum appeared at 1,825, 1,760, 1,730, and 1,700  $\text{cm}^{-1}$ . From the analysis of electrospray ionization mass spectrometry ( $m/z$  661,  $M + \text{CH}_3\text{OH} + \text{Na}$ ) and  $^1\text{H}$  and  $^{13}\text{C}$  NMR, CKD-722 was identified as TMC (Fig. 1). TMC was originally found as a new antifungal antibiotic produced by *Streptomyces griseochromogenes* (8).

**Inhibition of T Cell Proliferation and Activation by TMC.** The inhibitory effect of TMC on T cell proliferation was confirmed in the MLR between splenocytes of BALB/c and mitomycin C-treated splenocytes of C57BL/6 in the presence of serial dilutions of TMC or CsA, the most frequently used immunosuppressor. The level of inhibition of MLR by TMC was 100-fold higher than that by CsA, and the  $\text{IC}_{50}$  of TMC and CsA were 7.8 and 417 nM, respectively (Fig. 2A). Similar levels of proliferation inhibition were observed in mouse splenocytes stimulated with the mitogen Con A (Fig. 2B). Also, similar kinetics of inhibition by TMC or CsA was observed in rat splenocytes. Induction of IL-2 gene expression, CD69, and IL-2R $\alpha$  chain surface expression has been well documented as valuable markers for TcR-distal activation events (9). The potency of TMC in the IL-2 secretion assay in human primary T cells is similar to that of CsA in contrast to its more potent inhibitory activity than that of CsA in murine MLR and murine spleen cell proliferation in response to Con A. This result demonstrated that TMC possesses immunosuppressive activity to inhibit the proliferation of T cells by inhibition of IL-2 secretion (Fig. 2C). In contrast to cells pretreated with CsA, the surface expression of CD69 or IL-2R $\alpha$  chain was not induced in Jurkat T cells pretreated with TMC after TcR stimulation (data not shown). These results indicated that TMC has the capacity to inhibit the intracellular signaling pathway leading to T cell activation and proliferation, and its mechanism of action might be different from that of CsA.


**TMC Inhibits T Cell-Specific Tyrosine Phosphorylation Induction in TcR-Proximal Signaling.** The membrane-proximal signaling events initiated by the TcR complex are activation and recruitment of protein tyrosine kinases and subsequent phosphorylation of cellular proteins (10, 11). To identify the signaling event targeted by TMC in the TcR-mediated signaling pathway, inhibition of tyrosine phosphorylation of various intracellular substrates by TMC was examined in primary human T cells. TMC blocked the phosphorylation of tyrosine residues on several specific cellular proteins in T cells stimulated by immobilized OKT3 mAb (Fig. 3A). The inhibition of tyrosine phosphorylation by TMC is dose- and time-dependent (data not shown), and induction of tyrosine phosphorylation was not influenced by CsA as expected. This result raises the possibility that TMC may block tyrosine phosphorylation of intracellular signal mediators like genistein or herbimycin (12). To rule out this possibility, induction of tyrosine phosphorylation of intracellular proteins was examined in the human primary B cells after



**Fig. 2.** Inhibition of proliferation and activation of T cells by TMC. (A) MLR was set up by culturing splenocytes of BALB/c mouse with mitomycin C-treated allogenic spleen cells of mouse C57BL/6 in the presence of TMC (●), CsA (○), or cremophor-EL only (◻). (B) Spleen cells from BALB/c were stimulated with Con A (Sigma) for 48 h in the presence of TMC (●), CsA (○), or cremophor-EL only (◻), and then [<sup>3</sup>H] thymidine incorporation was measured. (C) Human primary T cells ( $1.0 \times 10^5$ ) were pretreated with TMC (1 μg/ml, ●), CsA (1 μg/ml, ○), or cremophor-EL only (◻), and then stimulated with OKT3 mAb (10 μg/ml) and anti-CD28 mAb (0.5 μg/ml) at 37°C for 24 h.

B cell receptor (BcR) stimulation by anti-BcR mAb (13). As shown in Fig. 3B, TMC, CsA, or solubilizing reagent cremophore-EL did not affect the BcR-induced tyrosine phosphorylation of intracellular signaling molecules. As expected, genistein inhibited the induction of tyrosine phosphorylation in both T and B cells on receptor stimulation (data not shown). Specificity of TMC on activated T cells was further confirmed in Fig. 4B, where activated or resting human primary T and B cells were used. Therefore, TMC specifically inhibits the tyrosine phosphorylation of T cell-specific intracellular signal mediators involved in the T cell activation-signaling pathway.


To identify the target molecule affected by TMC, we examined tyrosine phosphorylation induction of several key molecules participating in TcR-proximal or -distal signaling events in the presence of TMC by using the CD8-ζ Jurkat transfectant. In this transfectant, induction of tyrosine phosphorylation of intracellular proteins was observed on stimulation of CD8-ζ chimera by OKT8 mAb, whose pattern was qualitatively and quantitatively similar to that induced



**Fig. 3.** T cell-specific inhibition of tyrosine phosphorylation on intercellular signal mediators by TMC. (A) Human primary T cells were pretreated with TMC (1 μg/ml) or CsA (1 μg/ml) for 5 h. Then cells were stimulated with immobilized OKT3 mAb (10 μg/ml) and rabbit anti-mouse IgG (10 μg/ml) for the indicated times. (B) Human primary B cells were pretreated with TMC (1 μg/ml), CsA (1 μg/ml), or solubilizing reagent (cremophore) for 5 h and then stimulated with goat anti-human IgM F (ab')<sub>2</sub> (10 μg/ml) for the indicated times. The lysates of cells were subjected to 10% SDS/PAGE under reducing conditions and then immunoblotted with anti-phosphotyrosine Ab 4G10. (C) CD8-ζ Jurkat transfectants or primary human B cells were pretreated for 5 h with or without TMC (1 μg/ml) and then stimulated with OKT8 mAb (10 μg/ml) and rabbit anti-mouse IgG (10 μg/ml) or goat anti-human IgM F (ab')<sub>2</sub> (10 μg/ml) for 5 min, respectively. Immunoprecipitates or total lysates were resolved by SDS/PAGE and immunoblotted with the indicated antibodies. Treatment of cells with these drugs for 5 h did not induce cell death. An equal amount of protein was loaded in each well, which was confirmed by Ponceau S staining and immunoblotting with the anti-ZAP-70 mAb.

by TcR crosslinking (14, 15). In the presence of TMC, the intracellular domain of ζ chain, ZAP-70 tyrosine kinase, immune-specific adapters such as LAT and SLP76, ubiquitous adapter c-Cbl, PLC-γ, Vav, and MAP kinase ERK were not tyrosine phosphorylated, which have been characterized to be downstream of Lck and Fyn in TcR signaling cascade (Fig. 3C) (16). Surprisingly, tyrosine

**Fig. 4.** T cell-specific induction of apoptosis by TMC. (A) The primary T and B lymphocytes and HeLa cells were incubated for 10 h with the medium alone or various concentrations of TMC. Cells were lysed, and DNA fragmentation was analyzed by electrophoresis. (B) The primary human T lymphocytes were preincubated without (○) or with (●) immobilized OKT3 mAb (10  $\mu$ g/ml), and B lymphocytes were preincubated without (▽) or with (▼) goat anti-human IgM F(ab')<sub>2</sub> for 3 h, and then treated with TMC (1  $\mu$ g/ml) for 5 h. Cell viability was determined by staining with PI and measurement by flow cytometry. (C) Jurkat T cells were incubated with various concentrations of TMC for 5 h. Cell lysates were subjected to SDS/PAGE under reducing condition (anti-PARP blot, anti-caspase-3 blot, anti-caspase-9, and anti-Bcl-2 blot), and native PAGE under nonreducing conditions (anti-caspase-1 blot), and then immunoblotted with the indicated antibodies. As positive controls for the cleavage of these molecules, cells were stimulated with NIH 3T3 transfectant stably expressing human FasL. (D) Jurkat T cells ( $3 \times 10^6$ ) stably expressing high level of SV40T antigen were transfected by using Superfect transfection reagent with null vector (gray) or bcl-2 expression vector (black). Cells were treated for 5 h with TMC (1 or 10  $\mu$ g/ml) after transfection and then analyzed by PI staining assay. (E) The primary human T lymphocytes purified from peripheral blood using Ficoll were pretreated with TMC (1  $\mu$ g/ml) for 5 h. Cells were then stimulated with immobilized OKT3 mAb (10  $\mu$ g/ml) for 5 min. Lysates were immunoprecipitated with anti-p-Tyr-conjugated agarose beads, and the precipitates were immunoblotted with anti-PI-3K/p85 mAb. For anti-phospho-Akt, anti-phospho-Bad, and anti-PI-3K/p85 blots, the lysates were immunoblotted with the indicated antibodies. An equal amount of protein was added in each lane, which was confirmed by Ponceau S staining and immunoblotted with the anti-PI-3K/p85 mAb.



phosphorylation of Lck and Fyn and their kinase activity was not influenced, suggesting that TMC targets a signal mediator between ZAP-70 and Lck or Fyn tyrosine kinase in TcR-mediated signal transduction cascade. A similar pattern of tyrosine phosphorylation inhibition was observed with primary human T cells stimulated by OKT3, and anti-CD28 mAb in the presence of TMC (Fig. 6, which is published as supporting information on the PNAS web site, www.pnas.org). However, Lyn tyrosine kinase specifically induced on BcR stimulation was not influenced by TMC.

**T Cell-Specific Induction of Apoptosis by TMC.** Triggering programmed cell death in activated T lymphocytes is one of the most important regulatory mechanisms of the immune response (17). TMC induced DNA fragmentation of primary T cells using concentrations as low as 1.7 nM. Primary B cells showed minimal cell

death at high concentrations of TMC, and apoptosis was not observed in HeLa cells in the presence of TMC (Fig. 4A). Induction of apoptosis was quantitatively confirmed by PI and annexin V staining, and CD4<sup>+</sup> and CD8<sup>+</sup> T cells did not show any difference in the level of apoptosis induction by TMC (Fig. 7, which is published as supporting information on the PNAS web site). The purified activated human T cells showed much higher sensitivity to TMC than resting T cells or activated or resting B cells (Fig. 4B). This result is consistent with the mechanism of action of TMC, which inhibits tyrosine phosphorylation induction of T cell-specific intracellular signal mediators.

Two independent apoptotic-signaling pathways triggered by the ligation of death receptors or various forms of cellular stress have been proposed, and these two pathways converge on the activation of downstream caspase-3, -6, -7, -9 (18). To investigate the molec-



**Table 1. *In vivo* immunosuppressive effect of tautomycin on graft survival after heterocardiatic transplantation in rat**

Drug	Concentration, mg/kg	Injection	Survival days	No. of rats
Cremophor-EL only	5	i.p.	9	4
	5	i.p.	10	3
CsA/cremophor-EL	5	i.p.	>100	2
Tautomycin/PBS	0.05	i.p.	10	3
TMC/PBS	0.05	i.p.	>160	12
TMC/ME	0.03	i.v.	>160	8

The Lewis rat heart was transplanted in the abdominal cavity of the Wistar rat by microsurgical anastomosis. After the heterotopic heart transplantation, the recipient was given CsA (5 mg/kg of rat weight optimally formulated in cremophor-EL solution) for 40 days, tautomycin (0.05 mg/kg of rat weight and solubilized in PBS), or TMC (0.03 or 0.05 mg/kg of rat weight and solubilized in PBS or in microemulsion form (ME) for 30 days. Graft survival was monitored by examining the heartbeat through the abdominal wall, and anatomical examination was done on 100th or 160th day after heterocardiatic transplantation.

ular mechanism of apoptosis induction by TMC, cleavage of downstream effector caspases and their key substrates was examined (Fig. 4C). Bcl-2, which was known to bind to mitochondria and inhibit the release of cytochrome c, was cleaved as a consequence of TMC treatment in a dose-dependent fashion, and overexpression of Bcl-2 in Jurkat TAG cell line abrogated the apoptotic effect of TMC (Fig. 4D) (19). Similar kinetics of cleavage was observed in downstream caspase-9, caspase-3-like protease, and PARP. However, caspase-1-like protease (20), which was cleaved by natural Fas ligand stimulation, was not affected by TMC treatment. Z-VAD-fmk, which was known to inhibit the function of caspase-1 and -8, inhibited the TMC-induced apoptosis in a dose-dependent manner (Fig. 8, which is published as supporting information on the PNAS web site). This finding suggested involvement of caspase-8 in TMC-mediated apoptosis induction via mitochondria. These results indicated that T cell-specific induction of apoptosis by TMC is in part mediated by Bcl-2 cleavage, leading to the release of cytochrome c, which facilitates binding of Apaf-1 to caspase-9 in its presence and subsequent activation of caspase-8 and -3 in apoptosis induction signaling pathways.

In recent studies, the serine/threonine kinase Akt is emerging as a key molecule involved in regulating cell survival in a variety of models (21). To investigate the involvement of PI-3 kinase, Akt, and BAD in T cell-specific apoptosis induction by TMC, the induction of phosphorylation of PI-3 kinase, Akt, and BAD was examined in the presence of TMC by using the primary T cells stimulated by immobilized OKT3 mAb. As shown in Fig. 4E, TMC significantly inhibited the phosphorylation of Akt and BAD, suggesting that these three molecules might be responsible for the possible functional crosstalk between inhibition of T cell activation and induction of T cell-specific apoptosis by TMC.

**Immunosuppressive Effect of TMC *in Vivo*.** To assess the *in vivo* immunosuppressive effect of TMC, we measured allograft survival in rats treated with either TMC or CsA after heterotopic cardiac transplantation (22). The mean graft survival without administration of any immunosuppressor or solubilizing reagent was only 9.5 days, compared with more than 100 days for an isograft. The recipient was treated with CsA (5 mg/kg of rat weight) optimally formulated in cremophor-EL polyethoxyethylated castor oil solution for 40 days or with several different doses of TMC solubilized in PBS or in microemulsion form for 30 days after heterocardiatic transplantation. As shown in Table 1, graft survival was prolonged for more than 100 days in the CsA-treated group. The grafted heart survived for more than 160 days in groups of rats treated with TMC using a dose as low as 0.03 mg/kg, and the level of graft survival was observed in a dose-dependent manner. On histological examination on the 160th day after transplantation, the cardiac muscle cells,

vascular architecture, and renal tubes were well preserved, and T cell infiltration was minimal in the recipient. Biochemical analysis of GOP, GTP, glucose, and creatine levels in blood after administration of TMC up to 5 mg/kg in rats for 30 days did not show any significant liver and kidney toxicity (see Table 2, which is published as supporting information on the PNAS web site). In contrast to TMC, tautomycin did not show any immunosuppressive effect in *in vivo* heart allograft transplantation. These results demonstrated that the *in vivo* immunosuppressive activity of TMC is as effective as CsA in an *in vivo* organ transplantation model, and the immunosuppressive effect of TMC can be improved even more if the pharmacological formulation of TMC is optimized.

## Discussion

A new *Streptomyces* strain was isolated from the soil of volcanic Cheju Island, which produces a novel immunosuppressive molecule. The active compound was purified through various chemical methods and identified as TMC, which was originally found as an antifungal antibiotic. A comparable level of inhibition of T lymphocyte proliferation induced by mouse MLR or the mitogen Con A was observed with a 100-fold lower concentration of TMC than CsA. Although the induction of IL-2 gene expression was inhibited by both TMC and CsA, TMC showed the inhibition of the surface expression of CD69 or IL-2R $\alpha$  chain. These findings suggested that TMC has the capacity to inhibit the intracellular signaling pathway leading to T cell activation and proliferation, and its mechanism of action is different from that of CsA.

Among the intracellular signaling events proximal to the TcR complex, TMC inhibited T lymphocyte activation by blocking the tyrosine phosphorylation induction of the T cell-specific signal mediator in a dose- and time-dependent manner on TcR stimulation. This inhibitory effect of TMC was not observed in primary B cells when BcR was engaged by anti-BcR mAb. Further analysis of the tyrosine phosphorylation state of individual key signaling molecules in the T cell activation pathway demonstrated that TMC inhibited T lymphocyte activation by blocking the tyrosine phosphorylation induction of T cell-specific signal mediators located between Lck or Fyn tyrosine kinase and ZAP-70 tyrosine kinase. The molecule downstream of these two kinases might be the target of TMC. A recent study supported the concept that TcR antagonism can occur through the generation of an inhibitory signal within the TcR complex, and the inhibitory effect can be exerted through the action of proteins that specifically bind partially phosphorylated  $\zeta$ . Binding proteins could be unknown inhibitory phosphatases brought into the vicinity of TcR or unknown positively acting kinases present in a limited amount. Alternatively, one of these binding proteins might be the target molecule of TMC.

Surprisingly, the T cell-specific inhibition of tyrosine phosphorylation induction by TMC triggered T cell-specific apoptosis via Bcl-2, caspase-9, caspase-3, and PARP cleavage, but not via caspase-1 activation. Protection of TMC-induced apoptosis by Bcl-2 overexpression confirmed this pathway. However, partial protection, not complete abrogation, of TMC-induced apoptosis by Bcl-2 overexpression might suggest the possible roles of other members of the Bcl-2 gene family in TMC-mediated apoptosis induction via mitochondria. Inhibition of phosphorylation of PI-3 kinase, Akt, and BAD by TMC demonstrated that Akt and BAD might be important signal communicators between TMC-mediated inhibition of T cell activation and apoptosis induction. The observation that the activated human primary T cells showed much higher sensitivity to TMC than resting T cells or activated or resting B cells is consistent with the results that TMC inhibited the tyrosine phosphorylation induction of T cell-specific signaling molecules.

Both TMC and tautomycin exist naturally in two tautomeric forms, which resulted in similar chemical names being coined. Tautomycin, which is known to be a specific inhibitor of serine/threonine protein phosphatases PP1 and PP2A, shares a partial

structural moiety with TMC due to its tautomeric property (23). However, the functional moieties in tautomycin necessary for its inhibitory activity to PP1 and PP2A (C22-C26) and apoptosis-inducing activity (C1-C18) do not exist in TMC. Higher concentrations ( $10^3 \mu\text{g/ml}$ ) of tautomycin were required to exert a similar level of apoptosis by TMC, and T cell-specific apoptosis induction was not observed with tautomycin. In contrast to TMC, tautomycin did not show any immunosuppressive activity in *in vivo* heart allograft transplantation.

Two recent papers (24, 25) demonstrated that protein phosphatase PP1 is targeted to microtubules by the microtubule-associated protein  $\tau$ , and associates with and activates the actin-binding protein cofilin in human T lymphocytes, and regulate its polymerization through phosphorylation. Phosphorylation of cytoskeleton or its associated proteins plays an important role in T cell activation. These results strongly support the inhibitory effect of TMC on T cell activation. PP1 exists *in vivo* as multiple holoenzymes composed of catalytic subunit and several targeting or regulatory subunits, and the action of PP1 *in vivo* is thought to be controlled by the regulatory subunits. In our results, TMC might act on the unknown regulatory subunits of PP1 in T cell-specific manner.

Several possible mechanisms by which TMC induces activated T cell-specific apoptosis can be suggested. TMC might not act on the apoptotic machinery directly, but by preventing the early T cell activation pathway, it creates a form of intracellular stress and then activates mitochondria-mediated apoptosis signaling. Alternatively, inhibition of activation of an intracellular target molecule on T cell stimulation directly triggers the apoptosis signal transduction pathway via caspase-3 and -8. Thus TMC induces the cleavage of the anti-apoptotic protein Bcl-2 and the release of cytochrome *c* from mitochondria and then activation of caspase-9 complexed with Apaf-1 leading to caspase-3 activation, the executioner for apoptotic cell death. Another possibility is that inhibition of T cell activation by TMC may block the activation of Akt, the cell survival signal, leading to the activation of the pro-apoptotic molecule, BAD, by preventing its phosphorylation (Fig. 5). The *in vivo* immunosuppressive effect of TMC was tested in the heterotopic cardiac allograft rat model, and 100-fold lower concentrations of TMC than CsA increased graft survival up to more than 160 days, which is quite comparable to the *in vivo* effect of CsA. Administration of TMC up to 5 mg/kg in rats did not show any significant liver and kidney toxicity, high glucose level in biochemical analysis of blood, or histological abnormality such as renal tubular damage (Table 2).

In conclusion, we identified an immunosuppressor, TMC, from a *Streptomyces* strain from the soil of volcanic Cheju Island that acts very specifically on activated T cells. Its mechanism of action is different from that of CsA and FK506, and the level of cytotoxicity




Fig. 5. Proposed mechanism of action of TMC. TMC inhibits the tyrosine phosphorylation of T cell-specific intracellular signal mediator between ZAP-70 and Lck or Fyn tyrosine kinase in TcR-mediated signal transduction cascade. Inhibition of tyrosine phosphorylation by TMC induces activation of caspase-3 that can cleave the antiapoptotic protein Bcl-2 and then activation of caspase-9 complexed with Apaf leading to subsequent PARP cleavage and DNA fragmentation. Alternatively, inhibition of T cell activation may block the activation of Akt leading to activation of proapoptotic molecule, Bad.

of TMC on various organs was much lower than that of CsA when administered *in vivo*. The microemulsion preparation of TMC used in these experiments may be a suboptimal formulation, so there may be considerable room for improvement of the immunosuppressive effects. Furthermore, it can be also used in combination therapy with much lower doses of the current immunosuppressors and as a bioprobe to dissect the complex intracellular signaling pathways in T cell activation. Studies are being undertaken to identify the specific target molecules of TMC in the signal transduction pathway of T cell activation, as well as its chemical modification and optimal drug formulation for efficient clinical administration.

We thank Steve Maher for comments on the manuscript and all members of Immune Cell Engineering Laboratory, Department of Biotechnology, Yonsei University, for their spiritual help. This study was supported in part by a research grant to S.K.L. from Bioproducts Research Center of Yonsei University (1995G0402); by a grant from the 2001 Good Health R&D project, Ministry of Health and Welfare, Korea; and by a grant from Basic Science Research Funds from Korea Science and Engineering Foundation (R01-1999-00138).

- Deeg, H. J. (1994) *Transfus. Sci.* 15, 243–254.
- Krensky, A. M., Weiss, A., Crabtree, G., Davis, M. M. & Parham, P. (1990) *N. Engl. J. Med.* 322, 510–517.
- Gerber, D. A., Bonham, C. A. & Thomson, A. W. (1998) *Transplant. Proc.* 30, 1573–1579.
- Chung, J., Kuo, C. J., Crabtree, G. R. & Blennis, J. (1992) *Cell* 69, 1227–1236.
- Flanagan, W. M., Cortes, B., Bram, R. J. & Crabtree, G. R. (1991) *Nature (London)* 352, 803–807.
- Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G. & Schreiber, S. L. (1990) *Proc. Natl. Acad. Sci. USA* 87, 9231–9235.
- Hong, J. C. & Kahan, B. D. (2000) *Semin. Nephrol.* 20, 108–125.
- Cheng, X. C., Ubukata, M. & Isono, K. (1990) *J. Antibiotics* 43, 890–896.
- Altman, A., Isakov, N. & Baier, G. (2000) *Immunol. Today* 21, 567–573.
- Kane, L. P., Lin, J. & Weiss, A. (2000) *Curr. Opin. Immunol.* 12, 242–249.
- Acuto, O. & Cantrell, D. (2000) *Annu. Rev. Immunol.* 18, 165–184.
- Graber, M., June, C. H., Samelson, L. E. & Weiss, A. (1992) *Int. Immunol.* 4, 1201–1210.
- Kasprowicz, D. J., Kohn, A. P., Berton, M. T., Chrucinski, A. J., Sharpe, A. & Sanders, V. M. (2000) *J. Immunol.* 165, 680–690.
- Irving, B. A. & Weiss, A. (1991) *Cell* 64, 891–901.
- Lim, J. H., Kim, S. W., Song, Y. S. & Lee, S. K. (1998) *Mol. Cell* 8, 408–415.
- Rudd, C. E. (1999) *Cell* 96, 5–8.
- Budd, R. C. (2001) *Curr. Opin. Immunol.* 13, 356–362.
- Los, M., Wesselborg, S. & Schulze-Osthoff, K. (1999) *Immunity* 10, 629–639.
- Reed, J. C. (1997) *Nature (London)* 387, 773–776.
- Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M. & Lazebnik, Y. A. (1995) *Nature (London)* 376, 37–43.
- Jones, R. G., Parsons, M., Bonnard, M., Chan, V. S., Yeh, W. C., Woodgett, J. R. & Ohashi, P. S. (2000) *J. Exp. Med.* 191, 1721–1734.
- Han, D. J., Khang, S. K., Pai, S. T. & Yoon, D. W. (1990) *Microsurgery* 11, 127–132.
- Kawamura, T., Matsuzawa, S., Mizuno, Y., Kikuchi, K., Oikawa, H., Oikawa, M., Ubukata, M. & Ichihara, A. (1998) *Biochem. Pharmacol.* 55, 995–1003.
- Liao, H., Li, Y., Bratigan, D. L. & Gundersen, G. G. (1998) *J. Biol. Chem.* 273, 21901–21908.
- Ambach, A., Saunus, J., Konstandin, M., Wesselborg, S., Meuer, S. C. & Samstag, Y. (2000) *Eur. J. Immunol.* 30, 3422–3431.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:

Docket No.:

Serial No.:

Group Art Unit:

Filing Date:

Examiner:

For:

**DECLARATION OF SHERMAN FONG, Ph.D. UNDER 37 C.F.R. § 1.132**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Sherman Fong, Ph.D. declare and say as follows: -

1. I was awarded a Ph.D. in Microbiology by the University of California at Davis, CA in 1975.
2. After postdoctoral training and holding various research positions at Scripps Clinic and Research Foundation, La Jolla, CA, I joined Genentech, Inc., South San Francisco, CA in 1987. I am currently a Senior Scientist at the Department of Immunology/Discovery Research of Genentech, Inc.
3. My scientific Curriculum Vitae is attached to and forms part of this Declaration.
4. I am familiar with the Mixed Lymphocyte Reaction (MLR) assay, which has been used by me and others under my supervision, to test the immune stimulatory or immune inhibitory activity of novel polypeptides discovered in Genentech's Secreted Protein Discovery Initiative project.
5. The MLR assay is a well known and widely used proliferative assay of T-cell function, the basic protocols of which are described, for example, in Current Protocols in Immunology Vol. 1, Richard Coico, Series Ed., JohnWiley & Sons, Inc., 1991, Unit 3.12. (Exhibit A). This publication is incorporated by reference in the description of the MLR protocol in the present application.

6. The T-lymphocytes or "T-cells" of our immune system can be induced to proliferate by a variety of agents. The MLR assay is designed to study a particularly important induction mechanism whereby responsive T-cells are cultured together (or "mixed"), with other lymphocytes that are "allogeneic", e.g. lymphocytes that are taken from different individuals of the same species. In the MLR protocol of the present application, a suspension of PBMCs that includes responder T-cells, is cultured with allogeneic PBMCs that predominantly contain dendritic cells. According to the protocol, the allogeneic "stimulator" PBMCs are irradiated at a dose of 3000 Rad. This irradiation is done in order to create a sample of cells that has mainly dendritic cells. It is known that the dendritic cell population among the PBMCs are differentially affected by irradiation. At low doses (500-1000 Rad), the proliferation of most cells, including the B cells in the PBMCs, is preserved, however, at doses above 2000 Rad, this function of B cells is abolished. Dendritic cells on the other hand, maintain their antigen presentation function even at a 3000 Rad dose of radiation. (See, e.g. Current Protocols in Immunology, *supra*, at 3.12.9). Accordingly, under the conditions of the MLR assay used to test the PRO polypeptides of the present invention, the stimulator PBMCs remaining after irradiation are essentially dendritic cells.
7. Dendritic cells are the most potent antigen-presenting cells, which are able to "prime" naive T cells *in vivo*. They carry on their surface high levels of major histocompatibility complex (MHC) products, the primary antigens for stimulating T-cell proliferation. Dendritic cells provide the T-cells with potent and needed accessory or costimulatory substances, in addition to giving them the T-cell maturing antigenic signal to begin proliferation and carry out their function. Once activated by dendritic cells, the T-cells are capable of interacting with other antigen presenting B cells and macrophages to produce additional immune responses from these cells. For further details about the properties and role of dendritic cells in immune-based therapies see, e.g. Steinman, Drug News Perspect. 13(10):581-586 (Exhibit B).
8. The MLR assay of the present application is designed to measure the ability of a test substance to "drive" the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously.

9. Such immune stimulants find important clinical applications. For example, IL-12 is a known immune stimulant, which has been shown to stimulate T-cell proliferation in the MLR assay. IL-12 was first identified in just such an MLR [Gubler et al. PNAS 88, 4143 (1991) (Exhibit C)]. In a recent cancer vaccine trial, researchers from the University of Chicago and Genetics Institute (Cambridge, MA) have demonstrated the efficacy of the approach, relying on the immune stimulatory activity of IL-12, for the treatment of melanoma. [Peterson et al. Journal of Clinical Oncology 21 (12). 2342-48 (2003) (Exhibit D)] They extracted circulating white blood cells carrying one or more markers of melanoma cells, isolated the antigen, and returned them to the patients. Normally patients would not have an immune response to his or her own human antigens. The patients were then treated with different doses of IL-12, an immune stimulant capable of inducing the proliferation of T cells that have been co-stimulated by dendritic cells. Due to the immune stimulatory effect of IL-12, the treatment provided superior results in comparison to earlier work, where patients' own dendritic cells were prepared from peripheral blood mononuclear cells (PBMCs), treated with antigens, then cultured *in vitro* and returned to the patient to stimulate anti-cancer response. [Thurner et al. J. Exp. Med. 190 (11), 1669-78 (1999) (Exhibit E)].

10. It is my considered scientific opinion that a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity at least 180% of the control, as specified in the present application, is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant. Some PRO polypeptides do the reverse, and give inhibition of T-cell proliferation in the MLR assay. It is my considered scientific opinion that a PRO polypeptide shown to inhibit T-cell proliferation in the MLR assay where the activity is observed as 80% or less of the control, as specified in the present application, would be expected to find practical utility when an inhibition of the immune response is desired, such as in autoimmune diseases.

Dated: 6/16/04

By: Sherman Fong

Sherman Fong, Ph.D.

**Sherman Fong, Ph.D.**

Senior Scientist  
Department of Immunology  
Genentech Inc.  
1 DNA Way.  
South San Francisco, California 94080-4990

19 Basinside Way  
Alameda, California 94502

Work Telephone: (650) 225-2783  
Home Telephone: (510) 522-5411

FAX: (650) 225-8221

Education:

- 1978 - 1980 Postdoctoral Fellow in Immunology, Research Institute of Scripps Clinic,  
Scripps Clinic and Research Foundation, La Jolla, California
- 1975 - 1978 Postdoctoral Fellow in Immunology, University of California at  
San Francisco, San Francisco, California
- 1970 - 1975 Ph.D. in Microbiology, University of California at  
Davis, California
- 1966 - 1970 B.A. in Biology/Microbiology, San Francisco State  
University, San Francisco, California

Professional Positions:

Currently: Senior Scientist, Department of Immunology/Discovery Research, Genentech, Inc., South San Francisco, California

8/00-8/01 Acting Director, Department of Immunology, Genentech, Inc. South San Francisco, California

10/89 Senior Scientist in the Department of Immunology/Discovery Research, Genentech, Inc.  
South San Francisco, California

3/89 - 10/89 Senior Scientist and Immunobiology Group Leader, Department of Pharmacological  
Sciences, Immunobiology Section/Medical Research and Development, Genentech, Inc., S. San Francisco,  
California

9/87 - 3/89 Scientist, Department of Pharmacological Sciences, Immunopharmacology Section/Medical  
Research and Development, Genentech, Inc., S. San Francisco, California

1/82 - 9/87 Assistant Member (eq. Assistant Professor level), Department of Basic and Clinical Research,  
Division of Clinical Immunology, Scripps Clinic and Research Foundation, La Jolla, California

6/80 - 12/81 Scientific Associate in the Department of Clinical Research, Division of Clinical  
Immunology, Scripps Clinic and Research Foundation, La Jolla, California

7/78 - 6/80 Postdoctoral training in the laboratory of Dr. J. H. Vaughan, Chairman, Department of Clinical  
Research, Division of Clinical Immunology, Scripps Clinic and Research Foundation, La Jolla, California

2/75 - 6/78 Postdoctoral training in the laboratory of Dr. J. W. Goodman, Department of Microbiology  
and Immunology, School of Medicine, University of California, San Francisco, California

7/71 - 12/74 Research Assistant and Graduate Student, Department of Medical Microbiology, School of Medicine, University of California, Davis, California, under Dr. E. Benjamini

Awards:

Recipient: National Institutes of Health Postdoctoral Fellowship Award (1975).

Recipient: Special Research Award, (New Investigator Award), National Institute of Health (1980).

Recipient: P.I., Research Grant Award, National Institute of Health (1984).

Recipient: Research Career Development Award (R01), National Institutes of Health (1985).

Recipient: P.I., Multi-Purpose Arthritis Center Research Grant, NIH (1985)

Recipient: P.I., Research Grant Award, (R01 Renewal), National Institute of Health (1987).

Scientific Associations:

Sigma Xi, University of California, Davis, California Chapter

Member, The American Association of Immunologists

Committee Service and Professional Activities:

Member of the Immunological Sciences Study Section, National Institutes of Health Research Grant Review Committee, (1988-1992).

Advisory Committee, Scientific Review Committee for Veteran's Administration High Priority Program on Aging, 1983.

Ad Hoc member of Immunological Sciences Study Section, National Institutes of Health, 1988.

Ad Hoc Reviewer: Journal of Clinical Investigations, Journal of Immunology, Arthritis and Rheumatism, International Immunology, Molecular Cell Biology, and Gastroenterology

Biotechnology Experience

Established at Genentech in 1987-1989 within the Immunobiology Laboratory, in the Department of Pharmacological Sciences, group to study the immunogenicity of recombinant hGH (Protropin®) in hGH transgenic mice.

Served as Immunologist on the Biochemical Subteam for Protropin® Project team.

Served as Immunologist on the Met-less hGH and Dnase project teams, two FDA approved biological drugs: second generation hGH Nutropin® and Pulmozyme® (DNase).

Served immunologist in 1989-1990 on the CD4-IgG project team carrying out in vitro immunopharmacological studies of the effects of CD4-IgG on the in vitro human immune responses to mitogens and antigens and on neutrophil responses in support of the filing of IND to FDA in 1990 for use of CD4-IgG in the prevention of HIV infection. Product was dropped.

In 1989-1991, initiated and carried research and development work on antibodies to CD11b and CD18 chains of the leukocyte  $\beta 2$  integrins. Provided preclinical scientific data to Anti-CD18 project team

supporting the advancement of humanized anti-CD18 antibody as anti-inflammatory in the acute setting. IND filed in 1996 and currently under clinical evaluation.

1993-1997, Research Project Team leader for small molecule  $\alpha 4\beta 1$  integrin antagonist project. Leader for collaborative multidisciplinary team (N=11) composed of immunologists, molecular/cell biologists, protein engineers, pathologists, medicinal chemists, pharmacologists, pharmaceutical chemists, and clinical scientists targeting immune-mediated chronic inflammatory diseases. Responsible for research project plans and execution of strategy to identify lead molecules, assessment of biological activities, preclinical evaluation in experimental animals, and identification of potential clinical targets. Responsible for identification, hiring, and working with outside scientific consultants for project. Helped establish and responsible for maintaining current research collaboration with Roche-Nutley. Project transferred to Roche-Nutley.

1998-present, worked with Business Development to identify and create joint development opportunity with LeukoSite (currently Millennium) for monoclonal antibody against  $\alpha 4\beta 7$  integrin (LDP-02) for therapeutic treatment for inflammatory bowel disease (UC and Crohn's disease). Currently, working as scientific advisor to the core team for phase II clinical trials for LDP-02.

Currently, Research Project Team Biology Leader (1996-present) for small molecule antagonists for  $\alpha 4\beta 7$ /MAdCAM-1 targeting the treatment of human inflammatory bowel diseases and diseases of the gastrointestinal tract. Responsible for leading collaborative team (N=12) from Departments of Immunology, Pathology, Analytical Technology, Antibody Technology, and Bio-Organic Chemistry to identify and evaluate lead drug candidates for the treatment of gastrointestinal inflammatory diseases.

Served for nearly fifteen years as Ad Hoc reviewer on Genentech Internal Research Review Committee, Product Development Review Committee, and Pharmacological Sciences Review Committee.

Worked as Scientific advisor with staff of the Business Development Office on numerous occasions at Genentech, Inc. to evaluate the science of potential in-licensing of novel technologies and products.

2000-2001 Served as Research Discovery representative on Genentech Therapeutic Area Teams (Immunology/Endocrine, Pulmonary/Respiratory Disease Task Force)

Invited Symposium Lectures:

Session Chairperson and speaker, American Aging Association 12th Annual National Meeting, San Francisco, California, 1982.

Invited Lecturer, International Symposium, Mediators of Immune Regulation and Immunotherapy, University of Western Ontario, London, Ontario, Canada, 1985.

Invited Lecturer, workshop on Human IgG Subclasses, Rheumatoid Factors, and Complement. American Association of Clinical Chemistry, San Francisco, California, 1987.

Plenary Lecturer, First International Waaler Conference on Rheumatoid Factors, Bergen, Norway, 1987.

Invited Lecturer, Course in Immunorheumatology at the Universite aux Marseilles, Marseilles, France, 1988.

Plenary Lecturer, 5th Mediterranean Congress of Rheumatology, Istanbul, Turkey, 1988.

Invited Lecturer, Second Annual meeting of the Society of Chinese Bioscientist of America, University of California, Berkeley, California, 1988.

Lecturer at the inaugural meeting of the Immunology by the Bay sponsored by The Bay Area Bioscience Center. The  $\beta 2$  Integrins in Acute Inflammation, July 14, 1992.

Lecturer, "Research and Development -- An Anatomy of a Biotechnology Company", University of California, Berkeley, Extension Course, given twice a year--March 9, 1995 to June 24, 1997.

Lecturer, "The Drug Development Process -- Biologic Research - Genomics", University of California, Berkeley Extension, April 21, 1999, October, 1999, April 2000, October, 2000.

Lecturer, "The Drug Development Process -- Future Trends/Impact of Pharmacogenomics", University of California Berkeley Extension, April 2001, October 2001, April 2002.

Invited Speaker, "Targeting of Lymphocyte Integrin  $\alpha 4 \beta 7$  Attenuates Inflammatory Bowel Diseases", in Symposium on "Nutrient effects on Gene Expression" at the Institute of Food Technology Symposium, June, 2002.

Patents:

Dennis A. Carson, Sherman Fong, Pojen P. Chen.

U.S. Patent Number 5,068,177: Anti-idiotypic Antibodies induced by Synthetic Polypeptides, Nov. 26, 1991

Sherman Fong, Caroline A. Hebert, Kyung Jin Kim and Steven R. Leong.

U.S. Patent Number 5,677,426: Anti-IL-8 Antibody Fragments, Oct. 14, 1997

Claire M. Doerschuk, Sherman Fong, Caroline A. Hebert, Kyung Jin Kim, Steven R. Leong. U.S. Patent Number 5,686,070: Methods for Treating Bacterial Pneumonia, Nov. 11, 1997

Claire M. Doerschuk, Sherman Fong, Caroline A. Hebert, Kyung Jin Kim, Steven R. Leong. U.S. Patent 5,702,946: Anti-IL-8 Monoclonal Antibodies for the Treatment of Inflammatory Disorders, Dec. 30, 1997

Sherman Fong, Caroline A. Hebert, Kyung Jin Kim, Steven R. Leong.

U.S. Patent Number 5,707,622: Methods for Treating Ulcerative Colitis, Jan. 13, 1998

Sherman Fong, Napoleone Ferrara, Audrey Goddard, Paul Godowski, Austin Gurney, Kenneth Hillan, and Mickey Williams. U.S. Patent Number 6,074,873: Nucleic acids encoding NL-3, June 13, 2000

Sherman Fong, Napoleone Ferrara, Audrey Goddard, Paul Godowski, Austin Gurney, Kenneth Hillan, and Mickey Williams. U.S. Patent Number 6,348,351 B1: The Receptor Tyrosine Kinase Ligand Homologues. February 19, 2002

Patent Applications:

Sherman Fong, Kenneth Hillan, Toni Klassen

U.S. Patent Application: "Diagnosis and Treatment of Hepatic Disorders"

Sherman Fong, Audrey Goddard, Austin Gurney, Daniel Tumas, William Wood

U.S. Patent Application: Compositions and Methods for the Treatment of Immune Related Diseases.

Sherman Fong, Mary Gerritsen, Audrey Goddard, Austin Gurney, Kenneth Hillan, Mickey Williams, William Wood. U.S. Patent Application: Promotion or Inhibition of Cardiovasculogenesis and Angiogenesis

Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin Gurney, Mary Napier, Daniel Tumas, William Wood. US Patent Application: Compounds, Compositions and Methods for the Treatment of Diseases Characterized by A33-Related Antigens

Chen, Filvaroff, Fong, Goddard, Godowski, Grimaldi, Gurney, Hillan, Tumas, Vandlen, Van Lookeren, Watanabe, Williams, Wood, Yansura

US Patent Application: IL-17 Homologous Polypeptides and Therapeutic Uses Thereof

Ashkenazi, Botstein, Desnoyers, Eaton, Ferrara, Filvaroff, Fong, Gao, Gerber, Gerritsen, Goddard, Godowski, Grimaldi, Gurney, Hillan, Kljavin, Mather, Pan, Paoni, Roy, Stewart, Tumas, Williams, Wood  
US Patent Application: Secreted And Transmembrane Polypeptides And Nucleic Acids Encoding The Same



Publications:

1. Scibienski R, Fong S, Benjamini E: Cross tolerance between serologically non-cross reacting forms of egg white lysozyme. *J Exp Med* 136:1308-1312, 1972.
2. Scibienski R, Harris M, Fong S, Benjamini E: Active and inactive states of immunological unresponsiveness. *J Immunol* 113:45-50, 1974.
3. Fong S: Studies on the relationship between the immune response and tumor growth. Ph D Thesis, 1975.
4. Benjamini E, Theilen G, Torten M, Fong S, Crow S, Henness AM: Tumor vaccines for immunotherapy of canine lymphosarcoma. *Ann NY Acad Sci* 277:305, 1976.
5. Benjamini E, Fong S, Erickson C, Leung CY, Rennick D, Scibienski RJ: Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin C treated cells. *J Immunol* 118:685-693, 1977.
6. Goodman JW, Fong S, Lewis GK, Kamin R, Nitecki DE, Der Balian G: T lymphocyte activation by immunogenic determinants. *Adv Exp Biol Med* 98:143, 1978.
7. Goodman JW, Fong S, Lewis GK, Kamin R, Nitecki DE, Der Balian G: Antigen structure and lymphocyte activation. *Immunol Rev* 39:36, 1978.
8. Fong S, Nitecki DE, Cook RM, Goodman JW: Spatial requirements of haptenic and carrier determinants for T-dependent antibody responses. *J Exp Med* 148:817, 1978.
9. Fong S, Chen PP, Nitecki DE, Goodman JW: Macrophage-T cell interaction mediated by immunogenic and nonimmunogenic forms of a monofunctional antigen. *Mol Cell Biochem* 25:131, 1979.
10. Tsoukas CD, Carson DA, Fong S, Pasquali J-L, Vaughan JH: Cellular requirements for pokeweed mitogen induced autoantibody production in rheumatoid arthritis. *J Immunol* 125:1125-1129, 1980.
11. Pasquali J-L, Fong S, Tsoukas CD, Vaughan JH, Carson DA: Inheritance of IgM rheumatoid factor idiotypes. *J Clin Invest* 66:863-866, 1980.
12. Fong S, Pasquali J-L, Tsoukas CD, Vaughan JH, Carson DA: Age-related restriction of the light chain heterogeneity of anti-IgG antibodies induced by Epstein-Barr virus stimulation of human lymphocytes in vitro. *Clin Immunol Immunopathol* 18:344, 1981.
13. Fong S, Tsoukas CD, Frincke LA, Lawrance SK, Holbrook TL, Vaughan JH, Carson DA: Age-associated changes in Epstein-Barr virus induced human lymphocyte autoantibody responses. *J Immunol* 126:910-914, 1981.
14. Tsoukas CD, Fox RI, Slovin SF, Carson DA, Pellegrino M, Fong S, Pasquali J-L, Ferrone S, Kung P, Vaughan JH: T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. *J Immunol* 126:1742-1746, 1981.
15. Fong S, Tsoukas CD, Pasquali J-L, Fox RI, Rose JE, Raiklen D, Carson DA, Vaughan JH: Fractionation of human lymphocyte subpopulations on immunoglobulin coated petri dishes. *J Immunol Methods* 44:171-182, 1981.
16. Pasquali J-L, Tsoukas CD, Fong S, Carson DA, Vaughan JH: Effect of Levamisole on pokeweed mitogen stimulation of immunoglobulin production in vitro. *Immunopharmacology* 3:289-298, 1981.

17. Pasquali J-L, Fong S, Tsoukas CD, Hensch PK, Vaughan JH, Carson DA: Selective lymphocyte deficiency in seronegative rheumatoid arthritis. *Arthritis Rheum* 24:770-773, 1981.
18. Fong S, Fox RI, Rose JE, Liu J, Tsoukas CD, Carson DA, Vaughan JH: Solid-phase selection of human T lymphocyte subpopulations using monoclonal antibodies. *J Immunol Methods* 46:153-163, 1981.
19. Pasquali J-L, Fong S, Tsoukas CD, Slovin SF, Vaughan JH, Carson DA: Different populations of rheumatoid factor idiotypes induced by two polyclonal B cell activators, pokeweed mitogen and Epstein-Barr virus. *Clin Immunol Immunopathol* 21:184-189, 1981.
20. Carson DA, Pasquali J-L, Tsoukas CD, Fong S, Slovin SF, Lawrence SK, Slaughter L, Vaughan JH: Physiology and pathology of rheumatoid factors. *Springer Semin Immunopathol* 4:161-179, 1981.
21. Fox RI, Fong S, Sabharwal N, Carstens SA, Kung PC, Vaughan JH: Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. *J Immunol* 128:351-354, 1982.
22. Seybold M, Tsoukas CD, Lindstrom J, Fong S, Vaughan JH: Acetylcholine receptor antibody production during leukoplasmaapheresis for Myasthenia Gravis. *Arch Neurol* 39:433-435, 1982.
23. Tsoukas CD, Fox RI, Carson DA, Fong S, Vaughan JH: Molecular interactions in human T-cell-mediated cytotoxicity to Epstein-Barr virus. I. Blocking of effector cell function by monoclonal antibody OKT3. *Cell Immunol* 69:113-121, 1982.
24. Sabharwal UK, Vaughan JH, Fong S, Bennett P, Carson DA, Curd JG: Activation of the classical pathway of complement by rheumatoid factors: Assessment by radioimmunoassay for C4. *Arthritis Rheum* 25:161-167, 1982.
25. Fox RI, Carstens SA, Fong S, Robinson CA, Howell F, Vaughan JH: Use of monoclonal antibodies to analyze peripheral blood and salivary gland lymphocyte subsets in Sjogren's Syndrome. *Arthritis Rheum* 25:419, 1982.
26. Fong S, Miller JJIII, Moore TL, Tsoukas CD, Vaughan JH, Carson DA: Frequencies of Epstein-Barr virus inducible IgM anti-IgG B lymphocytes in normal children and in children with Juvenile Rheumatoid Arthritis. *Arthritis Rheum* 25:959-965, 1982.
27. Goodman JW, Nitecki DE, Fong S, Kaymakalan Z: Antigen bridging in the interaction of T helper cells and B cells. *Adv Exp Med Biol* 150:219-225, 1982.
28. Goodman JW, Nitecki DE, Fong S, Kaymakalan Z: Antigen bridging in T cell-B cell interaction: Facts or fiction. In: *Protein Conformation as Immunologic Signal*. EMBO Workshop, Portonere, Italy, 1982.
29. Tsoukas CD, Carson DA, Fong S, Slovin SF, Fox RI, Vaughan JH: Lysis of autologous Epstein-Barr virus infected B cells by cytotoxic T lymphocytes of rheumatoid arthritis patients. *Clin Immunol Immunopathol* 24:8-14, 1982.
30. Fong S, Vaughan JH, Tsoukas CD, Carson DA: Selective induction of autoantibody secretion in human bone marrow by Epstein-Barr virus. *J Immunol* 129:1941-1945, 1982.
31. Sabharwal UK, Fong S, Hoch S, Cook RD, Vaughan JH, Curd JG: Complement activation by antibodies to Sm in systemic lupus erythematosus. *Clin Exp Immunol* 51:317-324, 1983.

32. Tsoukas CD, Carson DA, Fong S, Vaughan JH: Molecular interactions in human T cell mediated cytotoxicity to EBV. II. Monoclonal antibody OKT3 inhibits a post-killer-target recognition/adhesion step. *J Immunol* 129:1421-1425, 1982.
33. Welch MJ, Fong S, Vaughan JH, Carson DA: Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. *Clin Exp Immunol* 51:299-305, 1983.
34. Fong S, Vaughan JH, Carson DA: Two different rheumatoid-factor producing cell populations distinguished by the mouse erythrocyte receptor and responsiveness to polyclonal B cell activators. *J Immunol* 130:162-164, 1983.
35. Fox RI, Hueniken M, Fong S, Behar S, Royston I, Singhal SK, Thompson L: A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states. *J Immunol* 131:762-767, 1983.
36. Fong S: Solid-phase panning for the fractionation of lymphoid cells. In: *Cell separation: methods and selected applications*. Pretlow TG, Pretlow TP (eds.) pp. 203-219. Academic Press, New York, 1983.
37. Carson DA, Fong S: A common idiotype on human rheumatoid factors identified by a hybridoma antibody. *Mol Immunol* 20:1081-1087, 1983.
38. Fong S, Gilbertson TA, Carson DA: The internal image of IgG in cross-reactive anti-idiotypic antibodies against human rheumatoid factors. *J Immunol* 131:719-724, 1983.
39. Fox RI, Adamson TC, Fong S, Young C, Howell FV: Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjogren syndrome. *Diagn Immunol* 1:233-239, 1983.
40. Fox RI, Adamson III TC, Fong S, Robinson CA, Morgan EL, Robb JA, Howell FV: Lymphocyte phenotype and function in pseudolymphoma associated with Sjogren's syndrome. *J Clin Invest* 72:52-62, 1983.
41. Fong S, Gilbertson TA, Chen PP, Vaughan JH, Carson DA: Modulation of human rheumatoid factor-specific lymphocyte responses with a cross-reactive anti-idiotypic bearing the internal image of antigen. *J Immunol* 132:1183-1189, 1984.
42. Chen PP, Houghten RA, Fong S, Rhodes GH, Gilbertson TA, Vaughan JH, Lerner RA, Carson DA: Anti-hypervariable region antibody induced by a defined peptide. A new approach for studying the structural correlates of idiotypes. *Proc Natl Acad Sci USA* 81:1784-1788, 1984.
43. Fox RI, Fong S, Tsoukas CD, Vaughan JH: Characterization of recirculating lymphocytes in rheumatoid arthritis patients: Selective deficiency of natural killer cells in thoracic duct lymph. *J Immunol* 132:2883-2887, 1984.
44. Chen PP, Fong S, Normansell D, Houghten RA, Karras JG, Vaughan JH, Carson DA: Delineation of a cross-reactive idiotype on human autoantibodies with antibody against a synthetic peptide. *J Exp Med* 159:1502-1511, 1984.
45. Fong S, Carson DA, Vaughan JH: Rheumatoid factor. In: *Immunology of Rheumatic Diseases*. Gupta S, Talal N (eds.): Chapter 6. pp. 167-196. Plenum Publishing Corp., New York, 1985.

46. Fong S: Immunochemistry. In: Immunology as applied to Otolaryngology. Ryan AF, Poliquis JF, Harris A (eds.): pp. 23-53. College Hill Press, San Diego, 1985.
47. Fong S, Chen PP, Vaughan JH, Carson DA: Origin and age-associated changes in the expression of a physiologic autoantibody. *Gerontology* 31:236-250, 1985.
48. Chen PP, Fong S, Houghten RA, Carson DA: Characterization of an epibody: An anti-idiotypic which reacts with both the idiotype of rheumatoid factors (RF) and the antigen recognized by RFs. *J Exp Med* 161:323, 1985.
49. Chen PP, Goni F, Fong S, Jirik F, Vaughan JH, Frangione B, Carson DA: The majority of human monoclonal IgM rheumatoid factors express a primary structure-dependent cross-reactive idiotype. *J Immunol* 134:3281-3285, 1985.
50. Lotz M, Tsoukas CD, Fong S, Carson DA, Vaughan JH: Regulation of Epstein-Barr virus infections by recombinant interferon. Selected sensitivity to interferon-gamma. *Eur J Immunol* 15:520-525, 1985.
51. Chen PP, Kabat EA, Wu TT, Fong S, Carson DA: Possible involvement of human D-minigenes in the first complementarity-determining region of kappa light chains. *Proc Natl Acad Sci USA* 82:2125-2127, 1985.
52. Goldfien RD, Chen PP, Fong S, Carson DA: Synthetic peptides corresponding to third hypervariable region of human monoclonal IgM rheumatoid factor heavy chains define an immunodominant idiotype. *J Exp Med* 162:756-761, 1985.
53. Fong S, Chen PP, Gilbertson TA, Fox RI, Vaughan JH, Carson DA: Structural similarities in the kappa light chains of human rheumatoid factor paraproteins and serum immunoglobulins bearing a cross-reactive idiotype. *J Immunol* 135:1955-1960, 1985.
54. Chen PP, Goni F, Houghten RA, Fong S, Goldfien RD, Vaughan JH, Frangione B, Carson DA: Characterization of human rheumatoid factors with seven anti-idiotypes induced by synthetic hypervariable-region peptides. *J Exp Med* 162:487-500, 1985.
55. Fong S, Gilbertson TA, Hueniken RJ, Singhal SK, Vaughan JH, Carson DA: IgM rheumatoid factor autoantibody and immunoglobulin producing precursor cells in the bone marrow of humans. *Cell Immunol* 95:157-172, 1985.
56. Fong S, Chen PP, Goldfien RD, Jirik F, Silverman G, Carson DA: Recurrent idiotypes of human anti-IgG autoantibodies: their potential use for immunotherapy. In: *Mediators of Immune Regulation and Immunotherapy*. Singhal SK, Delovitch TL (eds.): pp. 232-243. Elsevier Science Publishing Co., New York, 1986.
57. Fox RI, Chen PP, Carson DA, Fong S: Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjogren's syndrome. *J Immunol* 136:477-483, 1986.
58. Jirik FR, Sorge J, Fong S, Heitzmann JG, Curd JG, Chen PP, Goldfien R, Carson DA: Cloning and sequence determination of a human rheumatoid factor light-chain gene. *Proc Natl Acad Sci USA*, 83:2195-2199, 1986.
59. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughan JH: Release of lymphokines following Epstein-Barr virus infection in vitro. I. The sources and kinetics of production of interferons and interleukins in normal humans. *J Immunol*, 136:3636-3642, 1986.

60. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughan JH: Release of lymphokines following infection with Epstein-Barr virus in vitro. II. A monocyte dependent inhibitor of interleukin-1 downregulates the production of interleukin-2 and gamma interferon in rheumatoid arthritis. *J Immunol*, 136:3643-3648, 1986.
61. Fong S, Chen PP, Gilbertson TA, Weber JR, Fox RI, Carson DA: Expression of three cross reactive idiotypes on rheumatoid factor autoantibodies from patients with autoimmune diseases and seropositive adults. *J Immunol*, 137:122-128, 1986.
62. Fong S, Gilbertson TA, Chen PP, Karras JG, Vaughan JH, Carson DA: The common occurrence of internal image type anti-idiotypic antibodies in rabbits immunized with monoclonal and polyclonal human IgM rheumatoid factors. *Clin Exp Immunol*, 64:570-580, 1986.
63. Fox RI, Carson DA, Chen P, Fong S: Characterization of a cross reactive idioype in Sjogren's syndrome. *Scand J Rheum* S61:83-88, 1986.
64. Silverman GJ, Carson DA, Solomon A, Fong S: Human kappa light chain subgroup analysis with synthetic peptide-induced antisera. *J Immunol Methods* 95:249-257, 1987.
65. Goldfien R, Chen P, Kipps TJ, Starkebaum G, Heitzmann JG, Radoux V, Fong S, Carson DA: Genetic analysis of human B cell hybridomas expressing a rheumatoid factor-associated cross-reactive idioype. *J Immunol* 138:940- 944, 1987.
66. Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, Silverman G, Radoux V, Fong S: Rheumatoid factors and immune networks. *Annu Rev Immunol* 5:109-126, 1987.
67. Kipps TJ, Fong S, Tomhave E, Chen PP, Goldfien RD, Carson DA: High frequency expression of a conserved kappa variable region gene in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 84:2916-2920, 1987
68. Fong S, Chen PP, Fox RI, Goldfien RD, Silverman GJ, Radoux V, Jirik F, Vaughan JH, Carson DA: Rheumatoid factors in human autoimmune disease: Their origin, development and function. *Path Immunopath Res* 5:407-449, 1987.
69. Goldfien RD, Fong S, Chen P, Carson DA: Structure and function of rheumatoid factor: Implications for its role in the pathogenesis of mixed cryoglobulinemia. In: *Antiglobulins, cryoglobulins and glomerulonephritis, Proceedings of 2nd International Milano Meeting of Nephrology*. Ponticelli C, Minetti L, D'Amico G (eds.) Martinus Nijhoff, Dordrecht pp. 17-27, 1986.
70. Silverman GJ, Carson DA, Patrick K, Vaughan JH, Fong S: Expression of a germline human kappa chain associated cross reactive idioype after in vitro and in vivo infection with Epstein-Barr virus. *Clin Immunol Immunopathol* 43:403-411, 1987.
71. Silverman GJ, Fong S, Chen PP, Carson DA: Clinical update: Cross reactive idioype and the genetic origin of rheumatoid factors. *J Clin Lab Anal*, 1:129-135, 1987.
72. Chen PP, Fong S, Carson DA: Molecular basis of reactivity of epibodies. In: *Elicitation and use of anti-idiotypic antibodies and their biological applications*. Bona C (ed.), CRC Press, Boca Raton, Fla, in press.
73. Fong S, Chen PP, Carson DA, Fox, RI: Rheumatoid factor in Sjogren's syndrome. In: *Sjogren's Syndrome: Clinical and Immunological Aspects*. Talal N, Moutsopoulos HM, Kassan SS (eds.), Springer-Verlag, New York, pp. 203-217, 1987.

74. Chen PP, Fong S, Carson DA: The use of defined peptides in characterizing idiotypes. *Int Rev Immunol* 2:419-432, 1987.
75. Chen PP, Fong S, Goni F, Houghten RA, Frangione B, Liu F, Carson DA: Analyses of human rheumatoid factors with anti-idiotypes induced by synthetic peptides. *Monogr Allergy* 22:12-23, 1987.
76. Carson DA, Chen PP, Radoux V, Jirik F, Goldfien RD, Silverman GJ, Fong S: Molecular basis for the cross-reactive idiotypes on human anti-IgG autoantibodies (rheumatoid factors) In: *Autoimmunity and Autoimmune Disease*. Ciba Foundation Symposium 129 pp. 123-130, 1987.
77. Radoux V, Fong S, Chen PP, Carson DA: Rheumatoid factors: current concepts. In: *Advances in Inflammation Research*. Lewis, A. (Ed), Raven Press, New York, pp.295-304, 1987.
78. Kipps TJ, Fong S, Chen PP, Miller WE, Piro LD, Carson DA: Immunoglobulin V gene utilization in CLL. In: *Chronic lymphocytic leukemia: recent progress and future direction*, Alan R Liss, Inc., New York, pp. 115-126, 1987.
79. Fong S, Chen PP, Fox RI, Goldfien RD, Radoux V, Silverman GJ, Crowley JJ, Roudier J, Carson DA: The diversity and idiotypic pattern of human rheumatoid factors in disease. *Concepts in Immunopath* 5: 168-191, 1988.
80. Fox RI, Fong S, Chen PP, Kipps TJ: Autoantibody production in Sjogren's syndrome: a hypothesis regarding defects in somatic diversification of germline encoded genes. *In Vivo* 2: 47-56, 1988.
81. Chen PP, Fong S, Goni F, Silverman GJ, Fox RI, Liu M-K, Frangione B, Carson DA: Cross-reacting idiotypes on cryoprecipitating rheumatoid factor. *Springer Seminar Series in Immunopath* 10: 35-55, 1988.
82. Chen PP, Fong S, Carson DA: Rheumatoid factor. *Rheumatic Diseases of North America* 13:545-568, 1987.
83. Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik FR, Goldfien RD, Fox RI, Silverman GJ, Fong S. Idiotypic and genetic studies of human rheumatoid factors. *Arthritis Rheum* 30: 1321-1325, 1987.
84. Fong S, Chen PP, Crowley JJ, Silverman GJ, Carson DA: Idiotypic characteristics of rheumatoid factors. *Scand J Rheumatol, Suppl.* 75: 58-65, 1988.
85. Crowley JJ, Goldfien RD, Schrohenloher RE, Spiegelberg HL, Silverman GJ, Mageed RA, Jefferis R, Koopman WJ, Carson DA, Fong S: Incidence of three cross reactive idiotypes on human rheumatoid factor paraproteins. *J Immunol* 140: 3411-3418, 1988.
86. Fong S, Chen PP, Crowley JJ, Silverman GJ, Carson DA: Idiotypes and the structural diversity of human rheumatoid factors. *Springer Seminar Series in Immunopath* 10: 189-201, 1988.
87. Silverman GJ, Goldfien, Chen PP, Mageed RA, Jefferis R, Goni F, Frangione B, Fong S, Carson DA. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors: implications for structural and genetic basis of autoantibodies in humans. *J Clin Invest* 82: 469-475, 1988.
88. Fox RI, Chan E, Benton L, Fong S, Friedlander M. Treatment of primary Sjogren' syndrome with hydroxychloroquine. *American Journal of Medicine* 85 (suppl 4A): 62-67, 1988.
89. Fong S. La Diversite Structurale Des Facteurs Rhumatoides Humains. In *Immunorhumatologie*. Roux H, Luxembourg A, Roudier J, (Eds.). Solal, editeurs, Marseille, pp 162-166, 1989.

90. Fu, Y., Arkin, S., Fuh, G., Cunningham, B.C., Wells, J.A., Fong, S., Cronin, M., Dantzer, R., Kelley, K. Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor. *J. Clin. Invest* 89: 451-457, 1992.
91. Weber, J.R., Nelson, C., Cunningham, B.C., Wells, J.A., Fong, S. Immunodominant structures of human growth hormone identified by homolog-scanning mutagenesis. *Mol. Immunol.* 29: 1081-1088, 1992.
92. Bushell, G., Nelson, C., Chiu, H., Grimley, C., Henzel, W., Burnier, J., Fong, S. The role of cathepsin B in the generation of T cell antigenic epitopes of human growth hormone. *Mol. Immunol.* 30:587-591, 1993.
93. Bednarczyk, J.L., Wygant, J.N., Szabo, M.C., Molinari-Storey, L., Renz, M., Fong, S., McIntyre, B.W. Homotypic leukocyte aggregation triggered by a monoclonal antibody specific for novel epitope expressed by the integrin  $\beta 1$  subunit: Conversion of non-responsive cells by transferring human  $\alpha 4$  subunit cDNA. *J. Cell. Biochem.* 51: 465-478, 1993.
94. Berman, P.W., Nakamura, G., Riddle, L., Chiu, H., Fisher, K., Champe, M., Gray, A., Ward, P., Fong, S. Biosynthesis and function of membrane bound and secreted forms of recombinant Mac-1. *J. Cell. Biochem.* 52:183-195, 1993.
95. Crowe, D.T., Chiu, H., Fong, S., Weissman, I.L. Regulation of the avidity of integrin  $\alpha 4\beta 7$  by the  $\beta 7$  cytoplasmic domain. *J. Biol. Chem.* 269:14411-14418, 1994.
96. Renz, M.E., Chiu, H.H., Jones, S., West, C., Fox, J., Kim, J.K., Presta, L.G., Fong, S. Structural requirements for adhesion of soluble recombinant murine VCAM-1 to  $\alpha 4\beta 1$ . *J. Cell Biol.* 125:1395-1406, 1994.
97. Chiu, H. H., Crowe, D. T., Renz, M. E., Presta, L. G., Jones, S., Weissman, I. L., and Fong, S. Similar but non-identical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  under different activity states. *J. Immunol.* 155:5257-5267, 1995.
98. Viney, J. L., Jones, S., Chiu, H., Lagrimas, B., Renz, M., Presta, L., Jackson, D., Hillan, K., Fong, S. Mucosal Addressin Cell Adhesion Molecule-1. A structural and functional analysis demarcates the integrin binding motif. *J. Immunol.* 157: 2488-2497, 1996.
99. Fong, S., Jones, S., Renz, M.E., Chiu, H.H., Ryan, A.M., Presta, L. G., and Jackson, D. Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1)—Its binding motif for  $\alpha 4\beta 7$  and role in experimental colitis. *Immunologic Research* 16: 299-311, 1997.
100. Jackson, D.Y., Quan, C., Artis, D.R., Rawson, T., Blackburn, B., Struble, M., Fitzgerald, G., Chan K., Mullin, S., Burnier, J.P., Fairbrother, W.J., Clark, K., Beresini, M., Chiu, H., Renz, M., Jones, S., and Fong, S. Potent  $\alpha 4\beta 1$  Peptide Antagonists as Potential Anti-Inflammatory Agents. *J. Med. Chem.* 40: 3359-3368, 1997.
101. Viney, J.L. and Fong, S.  $\beta 7$  Integrins and Their Ligands in Lymphocyte Migration to the Gut. *Chemical Immunology: 'Mucosal T Cells'*. *Chemical Immunology* 71:64-76, 1998.
102. Bradley, L.M., Malo, M.E., Fong, S., Tonkonogy, S.L., and Watson, S.R. Blockade of both L-selectin and  $\alpha 4$  Integrins Abrogate Naïve CD4 Cell Trafficking and Responses in Gut-Associated Lymphoid Organs. *International Immunology* 10, 961-968, 1998.

103. Quan, C., Skelton, N., Clark, K., Jackson, D.Y., Renz, M., Chiu, H.H., Keating, S.M., Beresini, M.H., Fong, S., and Artis D.R. Transfer of a Protein Binding Epitope to a Minimal Designed Peptide. *Biopolymers (Peptide Science)*;47,265-275, 1998.

104. Hillan, K.J., Hagler, K.E., MacSween, R.N.M., Ryan, A.M., Renz, M.E., Chiu, H.H., Ferrier, R.K., Bird, G.L., Dhillon, A.P., Ferrell, L.D., Fong, S. Expression of the Mucosal Vascular Addressin, MAdCAM-1, in Inflammatory Liver Disease. *Liver* 19, 509-518, 1999

105. Pender, S.L.F., Salmela, M.T., Monteleone, G., Schnapps, D., McKenzie, C., Spencer, J., Fong, S., Saarialho-Kere, U., and MacDonald, T.T. Ligation of alpha 4 beta 1 integrin on human intestinal mucosal mesenchymal cells selectively upregulates membrane type-1 matrix metalloproteinase and confers a migratory phenotype. *American Journal of Pathology* 157, 1955-1962, 2000.

106. Liang, T.W., DeMarco, R., Gurney, A., Hooley, J., Huang, A., Klassen, T., Mrsny, R., Tumas, D., Wright, B.D., and Fong, S. Characterization of Human Junctional Adhesion Molecule (huJAM): Evidence for involvement in cell-cell contact and tight junction regulation. *American Journal of Physiology; Cell Physiology* 279, C1733-C1743, 2000.

107. Liang, T.W., Chiu, H.H., Gurney, A., Sidle, A., Tumas, D.B., Schow, P., Foster, J., Klassen, T., Dennis, K., DeMarco, R.A., Pham T., Frantz, G., Fong, S. VE-JAM/JAM 2 interacts with T, NK, and dendritic cells through JAM 3. *J.Immunology* 168, 1618-1626, 2002.

107. Dupree, N., Artis, D.R., Castanedo, G., Marsters, J., Sutherlin, D., Caris, L., Clark, K., Keating, S., Beresini, M., Chiu, H., Fong, S., Lowman, H., Skeleton, N., and Jackson, D. Selective  $\alpha 4 \beta 7$  Antagonists and Their Potential as Anti-Inflammatory Agents. *J. Med. Chem.* 45, 3451-3457, 2002.

108. Castanedo, G.M., Sailes, F.C., Dubree, N., Nicholas, J., Caris, L., Keating, S., Chiu, H., Fong, S., Marsters, J., Jackson, D.Y., Sutherlin, D.P. The Solid Phase Synthesis of Dual  $\alpha 4 \beta 1 / \alpha 4 \beta 7$  Antagonists: Two Scaffolds with Overlapping Pharmacophores. *Bioorganic and Medicinal Chemistry Letters* 12, 2913-2917, 2002.



# **CURRENT PROTOCOLS IN IMMUNOLOGY**

**VOLUME 1**

## **EDITORIAL BOARD**

**JOHN E. COLIGAN**

National Institute of Allergy and Infectious Diseases

**ADA M. KRUISBEEK**

Netherlands Cancer Institute

**DAVID H. MARGULIES**

National Institute of Allergy and Infectious Diseases

**ETHAN M. SHEVACH**

National Institute of Allergy and Infectious Diseases

**WARREN STROBER**

National Institute of Allergy and Infectious Diseases

## **SERIES EDITOR**

**Richard Coico**

City University of New York Medical School



**John Wiley & Sons, Inc.**

Copyright © 1991–1994 by Current Protocols  
Copyright © 1994–2001 by John Wiley & Sons, Inc.  
All rights reserved.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

While the authors, editors, and publisher believe that the specification and usage of reagents, equipment, and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they accept no legal responsibility for any errors or omissions, and make no warranty, express or implied, with respect to material contained herein. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. This is particularly important in regard to new or infrequently employed chemicals or experimental reagents.

*Library of Congress Cataloging in Publication Data:*

Current protocols in immunology / edited by John E. Coligan ... [et al.].

p. cm.

Kept up to date by quarterly supplements.

4 vols. Includes index.

ISBN 0-471-52276-7

1. Immunology—Laboratory manuals I. Coligan, John E.

[DLM: 1. Clinical Protocols. 2. Immunologic Techniques. QW 525 C976]

QR183.C87 1991

616.07'0'072—dc20

DNLM/DLC

for Library of Congress

Printed in the United States of America

10

90-15726  
CIP

# Proliferative Assays for T Cell Function

UNIT 3.12

A number of agents can specifically or nonspecifically induce T cell activation, resulting in cytokine production, cytokine receptor expression, and ultimately proliferation of the activated T cells. Although proliferation is not a specific effector function of T lymphocytes—in contrast to helper function for B lymphocytes (UNIT 3.10) or cytotoxicity (UNIT 3.11)—proliferation assays are reliable, simple, and easy to perform and have been widely used to assess the overall immunocompetence of an animal. In addition, the assays described in this unit form the basis for identifying the appropriate cellular population that might be used to obtain T cell clones (UNIT 3.13) or T cell hybridomas (UNIT 3.14).

The assays have been divided into two groups on the basis of whether they are used to stimulate primed or unprimed T lymphocytes. The first basic protocol describes the use of agents that are capable of activating unprimed T lymphocytes in culture either by pharmacologic means (calcium ionophore and phorbol ester stimulation), by direct cross-linking of the T cell receptor (TCR) on a large percentage of responder cells (anti-CD3, anti-TCR- $\gamma\delta$ , or anti-TCR- $\alpha\beta$  monoclonal antibodies), by cross-linking the receptors on certain subpopulations of T cells with monoclonal antibodies specific for the V regions of  $\beta$  chains of the TCR (anti-V $\beta$ ) or with enterotoxins specific for certain V $\beta$ -chain regions, or by indirectly cross-linking the TCR (lectins or monoclonal antibodies to non-TCR antigens). The first alternate protocol describes the use of plate-bound antibodies specific for the TCR to stimulate proliferation. The second alternate protocol describes the activation of unprimed T cells to cell-associated antigens in the mixed leukocyte reaction (MLR). The first support protocol describes the preparation and use of T cell-depleted accessory or stimulator cells and the second support protocol describes methods for blocking accessory cell proliferation. Finally, the second basic protocol describes the induction of a T cell proliferative response to soluble protein antigens or to cell-associated antigens against which the animal has been primed in vivo.

The assays in this unit employ murine T lymphocytes. Induction of proliferative responses of murine B lymphocytes is described in UNIT 3.10. Related assays for use with human peripheral blood lymphocytes are described in UNIT 7.9.

**NOTE:** All solutions and equipment coming into contact with cells must be sterile, and proper sterile technique should be used accordingly.

## ACTIVATION OF UNPRIMED T CELLS

Unprimed T cells can be induced to proliferate by a variety of agents, including pharmacological agents, anti-CD3/TCR or anti-Thy-1 monoclonal antibodies, enterotoxins and lectins. The commentary briefly describes the specificities of these agents, while Table 3.12.1 lists sources and concentrations for use in this protocol. Although this procedure is intended to measure proliferation of T cells specifically, in many cases induction of T cell proliferation is dependent on the presence of non-T cells that function as accessory cells. The latter provide additional costimulatory signals for T cell proliferation as well as cross-link (via their Fc receptors) monoclonal antibodies bound to cell-surface antigens. The requirement for non-T accessory cells varies with the nature of the stimulatory ligand and can range from absolute dependence to accessory cell-independent T cell activation (see Table 3.12.1). The activation is calculated after determining the difference in incorporation of [ $^3$ H]thymidine between stimulated and control cells.

## BASIC PROTOCOL

In Vitro Assays  
for Mouse B and  
T Cell Function

### 3.12.1

**Table 3.12.1** Agents Used to Activate Unprimed T Cells in Proliferative Assays

Agent <sup>a</sup>	Source/ cat. no. <sup>b</sup>	Concentration	Accessory cells <sup>c</sup>	Mode of action, etc.
PMA	SIG P8139	1-10 ng/ml	No	Use with ionomycin or A23187; pharmacologic
Ionomycin	CAL 407950	200-500 ng/ml	No	Use with PMA; pharmacologic
A23187	CAL 100105	100-500 ng/ml	No	Use with PMA; pharmacologic
PHA	WD HA16	1-5 µg/ml	Yes	Indirect TCR cross-linking
Con A	PH 17-0450-01	1-10 µg/ml	Yes	Indirect TCR cross-linking
Anti-Thy-1	PG mAb-G7	1-50 µg/ml	Yes <sup>c</sup>	Indirect TCR cross-linking
Anti-CD3	PG HM-CD3	0.1-5 µg/ml	Yes <sup>c</sup>	Use plate-bound or soluble; direct TCR cross-linking
Anti-TCR-αβ	PG HM-AB-TCR	0.1-10 µg/ml	Yes <sup>c</sup>	Use plate-bound or soluble; direct TCR cross-linking
Anti-TCR-γδ	PG HM-GD-TCR-1; HM-GD-TCR-3	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Anti-Vβ-8.1, 8.2 <sup>c</sup>	PG MM-Vβ-TCR-1	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Anti-Vβ-6 <sup>c</sup>	PG RM-Vβ-TCR-2	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Anti-Vβ-11	PG RM-Vβ-TCR-3	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Staph tox A	TT AT101	1-10 µg/ml	Yes <sup>c</sup>	Vβ-1,3,10,11,17-receptor specificity
Staph tox B	TT BT202; SIG S4881	1-100 µg/ml	Yes <sup>c</sup>	Vβ-3,7,8,17-receptor specificity
Staph tox E	TT ET404	1-10 µg/ml	Yes <sup>c</sup>	Vβ-11,15,17-receptor specificity

<sup>a</sup>Abbreviations: PMA, phorbol 12-myristate 13-acetate; PHA, phytohemagglutinin; Con A, concanavalin A; Staph tox A, B, & E, *Staphylococcus enterotoxins* A, B, & E.

<sup>b</sup>Supplier addresses and phone numbers are provided in APPENDIX 5. Abbreviations: CAL, Calbiochem; PG, Pharmingen; PH, Pharmacia LKB; SIG, Sigma; TT, Toxin Technology; WD, Wellcome Diagnostics.

<sup>c</sup>When using anti-CD3 and anti-TCR antibodies in soluble form (rather than plate-bound), accessory cells are required. When using Staph enterotoxins, accessory cells must express appropriate MHC class II molecules. Accessory cell dependence is not absolute with anti-Thy-1 antibodies.

## Materials

Complete RPMI-5 and RPMI-10 media (APPENDIX 2)

Responder cells: lymphocytes from nonimmunized mouse thymus, spleen, or lymph nodes (UNIT 3.1)

Activating agent(s) (Table 3.12.1)

Phosphate-buffered saline (PBS; APPENDIX 2)

Accessory cells: unfractionated mouse spleen cell suspension, irradiated or treated with mitomycin C (second support protocol) or T cell-depleted (first support protocol)

[<sup>3</sup>H]thymidine (APPENDIX 3)

15- and 4-ml disposable, polystyrene conical tubes with screw caps

Low-speed centrifuge with Sorvall H-1000B rotor (or equivalent)

1-, 5-, and 10-ml disposable polystyrene pipets

96-well flat- or round-bottom microtiter plates with lids (Costar #3596 or #3799)

25- to 100- $\mu$ l single- and multichannel pipettors with disposable tips

Additional reagents and equipment for removing organs (UNIT 1.9), preparing single-cell suspensions (UNIT 3.1), and counting, labeling, and harvesting cells (APPENDIX 3)

1. Prepare responder leukocyte suspensions from thymus, spleen, or lymph node in complete RPMI-5 as described in UNIT 3.1.

*The size of the intended experiment dictates the number of organs to be collected. See annotation to step 3 for an indication of cell number required, and UNIT 3.1 for number of cells per organ. Spleen, thymus, and lymph node can be used as responder cells, while only spleen is a source of accessory cells. Purified T cells or subpopulations of T cells (i.e., CD4<sup>+</sup> or CD8<sup>+</sup>) cells may also be used. See UNITS 3.1-3.6 for enrichment/depletion methods.*

2. Centrifuge single-cell suspensions in 15-ml conical tubes for 10 min in Sorvall H-1000B rotor at  $-1000$  rpm ( $200 \times g$ ), room temperature, and discard supernatant.
3. Resuspend cell pellet in complete RPMI-5. Count responder cells and adjust to  $-10^6$  cells/ml with complete RPMI-10.

*While this concentration ( $1 \times 10^6$  cells/ml or  $2 \times 10^5$  cells/well) will give satisfactory responses with most cell populations, it is useful to compare 2, 4, and  $8 \times 10^5$  cells per well in initial pilot experiments. If unfractionated spleen or lymph node cells are used as the responder population, sufficient accessory cells are present and there is no need to supplement the cultures with additional cells. However, if highly purified T cells or T cell subpopulations are used as responders, it will be necessary to add non-T accessory cells depending on the nature of the activating agent (see Table 3.12.1). This is most easily accomplished by adding increasing numbers ( $0.1$ ,  $0.5$ , and  $1.0 \times 10^5$ ) of syngeneic spleen (accessory) cells in  $0.1$  ml to  $2 \times 10^5$  T cells in  $0.1$  ml (see first support protocol). Also, a meaningful comparison of the responsiveness of different cell populations requires titrations of both the activating agents as well as the responding cell populations, and a kinetic experiment.*

4. Prepare working solutions of activating agents in 4-ml conical tubes at room temperature as follows. For MAb, toxin, or lectin, make a series of four dilutions from 1 mg/ml stock solutions—e.g., 100, 30, 10, and 3  $\mu$ g/ml in PBS. For the pharmacological agent, make single dilutions of 100 ng/ml solution of PMA and 1  $\mu$ g/ml A23187 (or 4  $\mu$ g/ml ionomycin) in PBS.

*If MAb in supernatant or ascites form are being used, at least four dilutions should also be used. Working solutions should be used immediately, since the various proteins, especially MAb, may bind to the plastic.*

In Vitro Assays  
for Mouse B and  
T Cell Function

See Table 3.12.1 for V $\beta$  specificities of staphylococcal enterotoxins. It is essential to verify that the mouse strain employed expresses the MHC class II surface molecules for which the enterotoxin has a specific binding affinity. See Marrack and Kappler (1989) for further discussion of various enterotoxins and their specificities.

5. Add 20  $\mu$ l of each dilution of activating reagent (MAb, enterotoxin or lectin) to each of three wells of a 96-well flat- or round-bottom microtiter plate. Include control wells with 20  $\mu$ l of PBS only. Add 20  $\mu$ l PMA or calcium ionophore at the single concentration indicated in step 4, as the dose-response curve for these agents is extremely narrow.

*A series of four dilutions will form one row of each microtiter plate, allowing for efficient organization of the plates.*

6. To the wells of the 96-well microtiter plate containing activating agent, add  $2 \times 10^5$  cells in 0.2 ml.

7. Place microtiter plates in a humidified 37°C, 5% CO<sub>2</sub> incubator for 2 to 4 days.

*Optimum culture periods for stimulating cells will vary depending on cell type and laboratory conditions and must be determined empirically (see critical parameters).*

8. Add [<sup>3</sup>H]thymidine to each well. Return the plates to CO<sub>2</sub> incubator to pulse 18 to 24 hr. Harvest cells using a semiautomated sample harvester and measure cpm in  $\beta$  scintillation counter.

- 9a. Compute the data as the difference in cpm of stimulated (experimental) and control (no activating agent added) cultures. This is done by subtracting the arithmetic mean of cpm from triplicate control cultures from the arithmetic mean of cpm from corresponding stimulated cultures. The results are referred to as " $\Delta$  cpm."

- 9b. Alternatively, compute the data as the ratio of cpm of stimulated and control cultures. This is done by dividing the arithmetic mean of cpm from stimulated cultures by the arithmetic mean of cpm from control cultures. The results are referred to "SI" (stimulation index).

*The second method (step 9b) has the disadvantage that small changes in background values will result in large changes in SI and should be interpreted with caution. In most publications,  $\Delta$  cpm rather than SI values are preferred.*

#### ALTERNATE PROTOCOL

#### ACTIVATION OF UNPRIMED T CELLS WITH PLATE-BOUND ANTIBODIES

Although it is possible to induce T cell activation with monoclonal antibodies to the CD3/TCR complex in solution during culture, such activation depends on cross-linking of the antibody by Fc receptor-bearing accessory cells. This protocol describes the use of monoclonal antibodies to the CD3/TCR complex by coupling them to the wells of the microtiter plates. The T cell proliferative response induced under these conditions does not require the presence of significant numbers of accessory cells, although the responses obtained may be suboptimal (Jenkins et al., 1990).

Use of this protocol is recommended for use with those antibodies to the CD3/TCR complex which bind poorly to the Fc receptor present on murine accessory cells and which do not induce T cell activation in soluble form. Although all monoclonal antibodies readily couple to plastic under these conditions, it is very difficult to induce a proliferative response with certain antibodies such as the G7, anti-Thy-1 monoclonal antibody. In such cases, the conditions described in the basic protocol should be followed.

### Additional Materials

PBS (APPENDIX 2), room temperature and 4°C

1 mg/ml purified anti-CD3 or anti-TCR MAb in PBS (for nonspecific activation of T cells) or 1 mg/ml purified anti-V $\beta$  or anti-TCR- $\gamma\delta$  MAb in PBS (for activation of T cells with specific receptors; see Table 3.12.1)

1. In 4-ml conical polystyrene tubes, prepare a series of four dilutions of MAb from sterile 1 mg/ml stock solutions—e.g., 100, 10, 1, and 0.1  $\mu$ g/ml—using room temperature PBS.

*Sources and recommended concentrations of monoclonal antibodies can be found in Table 3.12.1; since MAb will bind to plastic, the working dilutions should be used immediately.*

*The ability of anti-TCR antibodies to cross-link receptor molecules varies depending on the purity of the MAb preparation and the affinity of the MAb for the TCR/CD3 complex. Optimum dilutions will have to be determined in dose-response experiments. Alternatively, preparations of ascites fluid from the MAb can be tested at different dilutions (e.g., 1:100, 1:200, 1:400, and 1:800), but use of purified antibody will allow for better standardization of the assay.*

*Because the efficacy of MAb-induced activation depends on the amount of antibody bound to the bottom of the wells, it is crucial to make the dilutions in a buffer without any additional source of proteins such as FCS or albumin; these would compete with the binding of the antibody, and therefore reduce the responsiveness. For this reason, it is also not recommended to perform the assay with culture supernatants of the appropriate hybridomas.*

2. Add 30  $\mu$ l of each concentration of MAb solution to each of three wells of a 96-well round-bottom microtiter plate. Include control wells of 30  $\mu$ l PBS only.

*A series of four dilutions will form one row of each plate, allowing for efficient organization of the plates. Consistently better responses are seen with round-bottom (compared with flat-bottom) plates in antibody-mediated experiments.*

*Most often, optimal responses are seen with 10  $\mu$ g/ml antibody. There is no point in adding more than the indicated amount of antibody, since the maximum amount that can bind to surface of the wells is ~2 to 3  $\mu$ g (A.M.K., unpub. observ.).*

3. Cover the plate and gently tap its side to ensure complete covering of the bottom of the wells. Incubate plates 90 min at 37°C. During incubation, proceed to step 4.

*During this incubation, the antibodies bind to the plastic in the wells for subsequent cross-linking of the T cell receptors on responding T cells. Plates can also be prepared the night before an experiment and kept in the refrigerator overnight, after the 37°C incubation.*

4. Prepare responder cell suspensions as in steps 1 to 3 of the basic protocol.

*Highly purified T cell populations can be used in these studies as the proliferative response induced is accessory cell-independent. However, the presence of non-T accessory cells does not interfere with the proliferative response.*

5. Wash the wells of the incubated plates by adding 200  $\mu$ l cold PBS and inverting the plates with a flick of the hand on a stack of paper towels placed in a tissue culture hood. Repeat washing procedure two more times to remove excess antibody.

6. To the wells of the washed plates, add  $\sim 2 \times 10^5$  cells in 0.2 ml.

*If cells are not ready at this stage, plates may be kept in the refrigerator overnight after 100  $\mu$ l PBS has been added. Presumably, longer storage periods should be acceptable, but our experience is limited to  $\leq 4$  day periods. The PBS should be removed before the cells are added.*

Most cell populations will give peak responsiveness at this cell dosage, but pilot experiments should be performed to establish optimal conditions.

7. Proceed as in steps 7 to 9 of the basic protocol, but incubate cultures for 2 to 3 days before adding [ $^3\text{H}$ ]thymidine.

*Kinetic assays should be performed to determine the optimum culture period.*

## ALTERNATE PROTOCOL

### T CELL PROLIFERATION IN MIXED LYMPHOCYTE CULTURES

In the mixed lymphocyte culture (MLC) or reaction (MLR), suspensions of responder T cells are cultured with allogeneic stimulator lymphocytes. The activating stimulus is the foreign histocompatibility antigen (usually MHC class I or class II molecules) expressed on the allogeneic stimulator cells. Responder cells need not be primed because a sufficiently high number of T cells in the MLC will respond to the stimulator population. If the stimulator cell population contains T cells, their uptake of [ $^3\text{H}$ ]thymidine must be prevented by irradiation or treatment with mitomycin C; alternatively the stimulator cell suspension can be depleted of T cells (see support protocols).

#### Additional Materials

Responder cells: lymphocytes from nonimmunized mouse thymus, spleen, or lymph nodes (UNITS 1.9 & 3.1) or purified T cells or T cell subpopulations (UNITS 3.1-3.6)

Stimulator cells: allogeneic mouse spleen cells that differ from the responder cells at H-2 or Mls loci, irradiated or treated with mitomycin C (second support protocol) or T cell-depleted (first support protocol)

1. Prepare responder cell populations as in steps 1 to 3 of the basic protocol. Although unfractionated cell populations can be used as responders in certain situations, it may be preferable to use purified T cells or T cell subsets.

*To estimate the MLR of a cell population, it is necessary to perform a dose-response assay with different numbers of responder cells. Typically, three replicate wells are set up containing each of the following:  $0.5 \times 10^5$ ,  $1 \times 10^5$ , and  $4 \times 10^5$  cells (optimal responses are usually obtained with the latter two densities). The setup for these four cell densities will occupy one row (12 wells) of a microtiter plate.*

*For thymocytes, it may be necessary to use  $8 \times 10^5$  cells per well because the frequency of responding T cells is lower; the lowest number of responder cells could then be  $1 \times 10^5$  and the doses in between would be 2 and  $4 \times 10^5$ . Using this range of higher numbers of responder cells may also be preferred when experimental manipulations are expected to reduce the frequency of responding T cells.*

2. To a 96-well microtiter plate, add  $5 \times 10^4$  to  $4 \times 10^5$  responder cells in 0.1 ml to each well. For each experimental group, set up three replicate wells.

*Stimulation of leukocytes for proliferation in 96-well microtiter plates can be run in parallel with cytotoxic T lymphocyte (CTL) generation (UNIT 3.11), which is performed in 24-well microtiter plates. For example, cells can be diluted to  $4 \times 10^6$  cells/ml and added to 24-well plates in 1.0 ml/well for CTL generation and to 96-well plates in 0.1 ml/well for proliferation.*

3. Prepare a single-cell suspension of irradiated or mitomycin C-treated stimulator cells. Alternatively, prepare a suspension of T-cell depleted stimulator cells. Add 0.1 ml to each well of the plates containing responder cells.

*The optimum number of stimulator cells must be determined for each MLC and for different responder cells. For a range of responder cells from  $0.5$ – $4 \times 10^5$ , test stimulator cells at densities of 2, 4, and  $8 \times 10^6$ /ml (i.e., 2, 4, and  $8 \times 10^5$ /well). It should be noted that the stimulator cell suspension provides both the specific antigen to be recognized by the responder T cells as well as nonspecific accessory cells. If*



highly purified T cells are used as the responder population, it is therefore not necessary to supplement the cultures with non-T accessory cells syngeneic to the responder T cells.

Separate wells with control cultures should be set up that include—for each dose of responder and stimulator cells—replicate wells of responder cells with irradiated or mitomycin C-treated syngeneic stimulator cells. Values obtained from these controls reflect “background” proliferation values (see step 9 of basic protocol). Other negative controls often included are wells with stimulator cells alone and wells with responder cells alone. These are not used for the calculation of the data, but are useful to compare with the background proliferation values; the latter should not be much higher (<2-fold) than those obtained with stimulator or responder cells alone. Higher background values indicate potential autoreactivity.

4. Follow steps 7 to 9 of the basic protocol, but incubate the cultures for 3 to 6 days.

*Optimum culture periods for stimulating cells will vary depending on cell type and laboratory conditions, and must be determined empirically (see critical parameters).*

## DEPLETION OF T CELLS FROM ANTIGEN-PRESENTING/STIMULATOR CELL SUSPENSIONS

### SUPPORT PROTOCOL

Although normal unfractionated spleen cell populations can be used as a source of accessory cells, in certain types of experiments it may be preferable to use spleen cell populations from which the T cells have been removed. This procedure ensures that none of the observed proliferative responses of the responder population result from T cell factors derived from the accessory cell population. For example, even T cells whose cell division has been blocked (second support protocol) can produce cytokines. In the following steps, T cell-depleted spleen cell suspensions are prepared using a lytic monoclonal antibody to the T cell antigen, Thy-1. Because almost all the antigen presentation or stimulator cell activity in spleen resides in the non-T cell fraction, this procedure also leads to enrichment of functional antigen-presenting cell function. Further enrichment of antigen-presenting cells (APC) by flotation of the T cell-depleted spleen cells on Percoll gradients is also described. Other procedures leading to enrichment of APC are described elsewhere; the method described in UNIT 3.7 does not deplete T cells and therefore is not recommended here; the method described in UNIT 3.15 leads to higher levels of enrichment that are not required in the protocols presented here.

### Additional Materials

- Spleen cells from nonimmunized mice
- Hanks balanced salt solution (HBSS; APPENDIX 2)
- Low-Tox rabbit complement (Cedarlane #CL3051), reconstituted with ice-cold distilled water and filter-sterilized
- Anti-Thy-1.2 ascites (HO-13-4; ATCC #TIB 99) or anti-Thy-1.1 ascites (HO-22-1; ATCC #TIB 100; alternatively, see Table 3.4.1 for other anti-Thy-1 MAb and UNIT 2.6 for production of ascites)
- 70% Percoll solution (UNIT 3.8 and reagents and solutions)

1. Centrifuge the spleen cell suspension derived from single spleen down to a pellet.

*The spleen cells should always be from nonprimed animals and should be syngeneic to the responder T cells unless they are to be used as stimulator cells in the MLC.*

2. To the pellet, add 0.9 ml HBSS, 0.1 ml complement, and 25  $\mu$ l anti-Thy-1 ascites.

*If cells from more than a single spleen are needed, the procedure should be scaled up accordingly.*

In Vitro Assays  
for Mouse B and  
T Cell Function

3.12.7

*The choice of anti-Thy-1 reagent to be used depends on the strain of animal from which the spleen was derived. The great majority of commonly available mouse strains (except AKR) express the Thy-1.2 allele.*

3. Incubate the mixture at 45 min in a 37°C water bath.
4. Centrifuge 10 min in Sorvall H-1000B rotor at ~1000 rpm (200 × g), room temperature, and discard supernatant. Resuspend pellet in HBSS and wash two more times.
5. Count viable cells (APPENDIX 3) and resuspend in complete RPMI-10 or PBS for inactivation as in the second support protocol, or in HBSS to prepare low-density accessory cells (see below).

*The T cell-depleted spleen cell population is comprised of B cells, macrophages, and dendritic cells. Further enrichment of cells with enhanced accessory cell function can be obtained by fractionation of this population on Percoll.*

6. Dilute 70% Percoll solution to 55% by mixing 23.58 ml of the 70% Percoll with 6.42 ml HBSS. Resuspend T cell-depleted spleen cells from step 5 in HBSS at  $20 \times 10^6$  cells/ml.
7. Layer 3 ml cell suspension over 3 ml of 55% Percoll solution in a 15-ml conical centrifuge tube.
8. Spin 13 min in H-1000B rotor at 3000 rpm (1900 × g), room temperature.
9. Remove cells that band at the Percoll/HBSS interface with a 5-in. Pasteur pipet and wash 3 times in HBSS as in step 4.
10. Count viable cells and resuspend in complete RPMI-10 for inactivation according to the second support protocol.

*The population obtained from steps 6 to 10 is comprised of large cells including macrophages, dendritic cells, and activated B lymphocytes. This population of cells is enriched in accessory cell function. When used in either of the basic protocols with purified T responder cells, fewer of the Percoll-purified cells should be needed to provide accessory function.*

## SUPPORT PROTOCOL

### BLOCKING CELLULAR DIVISION OF ACCESSORY/STIMULATOR CELLS

There are two situations in which inhibition of accessory or stimulator cell division should be blocked. When purified T cells rather than unfractionated lymphoid populations are used in the basic protocol, cultures are frequently supplemented with accessory cells syngeneic to the responder T cells. If accessory cell DNA synthesis is inhibited, one can then be certain that the resultant proliferative response is comprised entirely of responder T cells and does not contain a component of recruited B cell proliferation derived from the accessory cell populations. In the MLR, the stimulator cells are spleen cells from mice that differ from the responder cells in *H-2* and/or *Mls* gene expression (see APPENDIX 1, Tables A.1C.1 and A.1F.1) and they can also recognize alloantigens on the responder cells. This responsiveness of stimulator cells against responder cells in an MLR (so-called back-stimulation) must be prevented by blocking cellular division. This can be done by treatment of stimulator cells with mitomycin C (a DNA cross-linking reagent) or by g irradiation. Many investigators prefer mitomycin C treatment when antigenic differences encoded for by *Mls* genes are to be measured, or when an irradiation source is not available. For more information on the loci encoding *Mls* genes, see Tables A.1F.2 and A.1F.3.

#### Mitomycin C Treatment

##### Additional Materials

Mitomycin C (Sigma #M-0503; store in dark)

1. In a 15-ml aluminum foil-wrapped tube, prepare a solution of mitomycin C in PBS at 0.5 mg/ml and filter sterilize.

*Since mitomycin C is very light-sensitive, it is necessary to prepare a fresh stock solution each day for each experiment.*

2. Prepare spleen cell suspension as described in steps 1 and 2 of the basic protocol at a concentration of  $5 \times 10^7$  cells/ml in PBS.
3. Add mitomycin C to a final concentration of 50  $\mu$ g/ml (100  $\mu$ l/ml of cell suspension) and wrap the tube in aluminum foil. Incubate 20 min at 37°C.
4. Add an excess of complete RPMI-5 (i.e., fill tube with ~12 ml) and centrifuge 10 min in Sorvall H-1000B rotor at 1200 rpm (300  $\times$  g). Discard supernatant and repeat washing procedure two more times.

*Three washes are crucial, because any traces of mitomycin C left among the cells will reduce proliferative responses when the cells are added to an MLC.*

5. Resuspend pellet in complete RPMI-10. Count cells with hemacytometer. Adjust to desired concentration as described in the annotation to step 6 of the basic protocol.

### Irradiation Treatment

Prepare a spleen cell suspension as described in steps 1 to 3 of the basic protocol, at a final concentration of  $5\text{--}10 \times 10^6$  cells/ml in complete RPMI-10. Using a source of ionizing irradiation ( $^{60}\text{Co}$  or  $^{137}\text{Cs}$   $\gamma$ -irradiator; e.g., Gammacell 1000, Nordion), deliver 1000 to 2000 rad of irradiation to the cells.

This dose range of irradiation is suitable for most immunologic applications employing spleen cell suspensions. However, antigen presentation by different spleen cells is differentially affected by irradiation (Ashwell et al., 1984): at low doses (500 to 1000 rad), antigen-presenting function of B cells is preserved; after doses of 1100 to 2000 rad, a substantial decline is observed; and doses >2000 rad abolish the participation of B cells as APC. Macrophages and dendritic cells, on the other hand, maintain antigen presentation through doses of 3000 rad. To ensure that B cells do not participate in the responses measured, some investigators prefer to use doses of 2000 rad. However, responsiveness to *Mls* antigens can best be measured with stimulator cells that received doses of <1000 rad, since B cells present *Mls* more effectively. Alternatively, *Mls* responsiveness can be measured after mitomycin C treatment of stimulator cells, since it also preserves the antigen-presentation function of B cells.

When transformed cell lines are used as antigen-presenting or accessory cells, higher doses must be used to ensure blockage of cell division. The appropriate dose will have to be determined empirically for each cell line, but is likely to be at least 5000 rad; some transformed cell lines require as much as 10,000 to 12,000 rad, and may be more sensitive to mitomycin C treatment.

### ACTIVATION OF PRIMED T CELLS

Proliferative responses to viruses, protein antigens, minor transplantation antigens, and the male H-Y antigen require in vivo immunization followed by in vitro stimulation. Furthermore, enhanced proliferative responses to those antigens that will generate primary in vitro responses (i.e., MHC antigens) can be obtained by in vivo priming. Multiple immunizations usually elevate in vitro responses.

To immunize animals for in vitro secondary responses to soluble protein antigens or peptides, dissolve antigens and emulsify in complete Freund's adjuvant (UNIT 2.5). For strong responses by draining lymph node cells, immunize animals in a hind footpad. For

### BASIC PROTOCOL

In Vitro Assays  
for Mouse B and  
T Cell Function

### 3.12.9

strong responses by spleen cells, immunize intraperitoneally. Tail-base immunization also can be used as an efficient route of immunization; follow procedure for intradermal injection. To prime animals against cellular antigens, inject intraperitoneally with  $1-5 \times 10^7$  cells that express the antigen. Immunization protocols are described in UNIT 1.6.

Within 2 to 3 weeks after in vivo priming, in vitro responsiveness of primed T cells can usually be measured. This assay is often used as a preparation for subsequent in vitro cloning procedures (UNIT 3.14) and T cell hybridoma preparation (UNIT 3.13).

### Materials

Complete RPMI-10 medium (APPENDIX 2)

Responder cells: Purified T cells isolated from lymph nodes (UNITS 3.1-3.6) of in vivo primed mice

Antigen: 1 mg/ml sterile protein antigen(s) (UNIT 3.13), in PBS or suspension of irradiated or mitomycin C-treated stimulator cells expressing alloantigens at  $8 \times 10^6$  cells/ml (UNIT 3.11, support protocol) in complete RPMI-10 medium (APPENDIX 2)

Accessory cells: suspension of irradiated or mitomycin C-treated (or T cell-depleted) spleen cells syngeneic to the responding T cells at  $5 \times 10^6$  cells/ml in complete RPMI-10 medium

4-ml conical tubes

96-well flat-bottom microtiter plates with lids

1. Follow steps 1 to 3 of the first basic protocol for preparation of responder cells.
2. Prepare 4-fold dilution series of the antigens in 4-ml conical tubes, using complete RPMI-10.

*The following dilutions are recommended: 100, 10, 1, and 0.1  $\mu\text{g/ml}$  protein antigens and 8, 4, 2, and  $1 \times 10^5$  cells/ml of stimulator cells in complete medium.*

3. Add antigens to 96-well flat-bottom microtiter plates, at 30  $\mu\text{l/well}$  for protein antigens or 100  $\mu\text{l/well}$  for cellular antigens. For each experimental group, set up three replicate wells and include control wells with medium only (no antigen).

*By using four concentrations of antigens and three replicate wells for each dose, one row of a microtiter plate will cover the entire tested range.*

4. Add responder T cells in 0.1 ml to each well.

*Purified T cells are recommended; otherwise extremely high background values may be obtained. This appears to be due in part to proliferation of recruited cells (T and non-T) that are not antigen-specific. If unfractionated lymph node cells from recently primed mice are used, add  $1-2 \times 10^5$  cells per well and proceed to step 6.*

5. If purified lymph node T cells specific for protein antigens are used, add 0.1 ml of accessory spleen cells syngeneic to the donor of the responder T cells at  $5 \times 10^5$  cells per well.

*Purified T cells require an exogenous source of accessory non-T cells. Accessory cells function both as antigen-presenting cells and as a source of undefined "second signals." They are not required for cell preparations primed against cellular antigens, because accessory cell function is provided by the stimulator cells.*

6. Proceed as in steps 7 to 9 of the basic protocol.

*Culture periods before labeling can vary widely and kinetic assays should be performed. In general, for T cells from primed mice, it is likely that the response will peak at day 4 or 5.*

## REAGENTS AND SOLUTIONS

### *Percoll solution*

#### *Diluent:*

45 ml 10× PBS, pH 7.4 (APPENDIX 2)

3 ml 0.6 M HCl

132 ml H<sub>2</sub>O

Filter sterilize

#### *70% Percoll solution:*

63 ml Percoll (Pharmacia LKB #170891-01)

37 ml sterile diluent (above)

Final osmolality should be 310 to 320 osM

## COMMENTARY

### Background Information

Proliferative assays for measuring T cell function have certain advantages and disadvantages compared to the cytotoxic T lymphocyte (CTL) assay described in UNIT 3.11 or the lymphokine production assays in UNITS 3.15 & 6.3. Advantages are that proliferative assays are less time-consuming, less labor-intensive, less cell-consuming, and less expensive than "true" effector T cell function assays. A disadvantage is that antigen specificity is not as easily demonstrated in proliferative assays as in CTL assays, unless antigen-specific clones of proliferating cells are used. Furthermore, the proliferative assay only detects dividing cells instead of measuring true effector T cell function.

It is not clear which T cell function is measured in proliferative assays; the proliferative response should therefore be used solely as general indicators of T cell reactivity. Data obtained in proliferative assays might variously reflect proliferation of CTL, lymphokine-producing T cells, or nonactivated "bystander" cells, and will be severely affected by the function of non-T cells such as accessory cells (see below). Since the majority of T cells respond to and produce IL-2 upon activation, differences in responsiveness in a proliferative assay in part reflect differences in IL-2 production by the responding T cells. Proliferative assays therefore become more meaningful when combined with the lymphokine detection assays presented in UNITS 3.15 & 6.3. Since responsiveness to IL-2 is also determined by the levels and functionality of IL-2 receptors, further information will be added by including measurements of IL-2 receptors (UNIT 6.1) or by flow cytometry (UNIT 5.4). Yet, as a first approximation of cellular activation, proliferative assays are valuable.

### Critical Parameters and Troubleshooting

Parameters affecting the magnitude of T cell proliferative responses include cell concentration, type of medium, source of serum, incubator conditions (CO<sub>2</sub> level and humidity), type and concentration of activating agent, type of responding T cells, type of accessory/stimulator cells, mouse strain, and culture time. Optimal conditions for individual laboratories and experiments must be derived empirically with respect to these variables, but general guidelines are provided below.

A number of agents can be employed in the first basic protocol to induce T cell proliferation (Table 3.12.1). T cells may be activated by pharmacologic means by producing an elevation of intracellular free calcium with a calcium ionophore combined with activation of protein kinase C with a phorbol ester. The most direct means of inducing T cell activation involves stimulation with monoclonal antibodies that interact with the CD3/TCR complex—i.e., anti-CD3, anti-TCR- $\alpha\beta$  or - $\gamma\delta$ , as well as anti-V $\beta$  antibodies that are capable of interacting with a subset of cells bearing a specific TCR. A vigorous T cell proliferative response of defined subsets can also be induced with certain bacterial toxins known as staphylococcal enterotoxins. These toxins are often referred to as "superantigens" (Marrack and Kappler, 1989) because they stimulate T cells via the variable (V) gene segment of the TCR. Different toxins have affinities for different V $\beta$  chains and these specificities make them valuable reagents for activating T cells. The activating capacity of toxins is also dependent on their ability to bind to MHC class II molecules (i.e., responding T cells react with the toxin/class II complex); thus, responsiveness varies with the

In Vitro Assays  
for Mouse B and  
T Cell Function

mouse strain used. Lectins such as phytohemagglutinin (PHA) and concanavalin A (Con A) have been widely used for many years to activate T cells. Although the precise mechanism of action of these agents is unknown, it is likely that lectins activate T cells by indirectly cross-linking the TCR because TCR-negative cells will not respond to these agents. Lastly, it is also possible to induce T cell activation with monoclonal antibodies to cell-surface antigens other than the TCR; this protocol employs the G7 monoclonal antibody, one of the most effective of the anti-Thy-1 activators (Gunter et al., 1984).

When comparing the reactivity of different cell populations, it is essential to perform dose-response assays for responder T cells and activating agents and for both responder and stimulator T cells (in MLR), since each population may yield optimal responses at different cell numbers. This may reflect differences in frequency of responding cells, and hence may indicate a need to perform limiting dilution assays (UNIT 3.15). Since peak responsiveness of different populations of T cells may occur at different times, it is also essential to perform kinetic experiments—i.e., compare responsiveness at days 2, 3, 4, and 5.

Differences in responsiveness need not necessarily be due to differences in the frequency of responding T cells, but may also indicate differences in the efficacy with which co-stimulatory activity or “second signals” are delivered by the accessory cells present in different cell populations. The type of interactions pertinent to the generation of primary responses by T cells is explained in the commentaries of UNITS 3.8, 3.11, & 3.13. Specific requirements for inducing activation with immobilized antibodies have been described (Staerz and Bevan, 1986; Hathcock et al., 1989; Jenkins et al., 1990). A responding cell population completely devoid of accessory cells (such as purified populations of splenic or lymph node T cells or cloned T cells) will yield fine responsiveness in an MLC, since accessory cell function is provided by the stimulator cells; however, the same population will generally not yield responses when mitogens, antigens, or enterotoxins are used. In such a setting, accessory cells may also function as antigen-presenting cells (APC). Addition of irradiated or mitomycin C-treated syngeneic sources of accessory cells (either whole spleen cells or purified APC; see first support protocol) can be used to restore responsiveness in purified T cells. The need for accessory cells can sometimes be

bypassed when anti-TCR monoclonal antibodies are coupled to plastic, or when certain anti-Thy-1 monoclonal antibodies are used; however, these conditions do not necessarily result in optimal responsiveness (Jenkins et al., 1990).

The level of [ $^3\text{H}$ ]thymidine incorporation should not be regarded only as a reflection of cellular proliferation: some nondividing cells will synthesize DNA and “cold” thymidine released by disintegrating cells will compete with incorporation of labeled thymidine. Therefore, measurements of DNA synthesis should be accompanied by counting viable cells over the length of the culture period if a true estimate of cellular proliferation is to be obtained. Of course, cell death of nonactivated cells will also interfere with the accuracy of this last parameter.

The sensitivity of proliferation assays is such that small errors in cell numbers will result in large differences in [ $^3\text{H}$ ]thymidine incorporation values. When values obtained in triplicate cultures correspond poorly (e.g., >5% difference in cpm values >1000), technical problems such as cell clumping, dilution, and pipetting should be considered. Excessively high values may be obtained from contaminated wells, as [ $^3\text{H}$ ]thymidine will be incorporated into replicating bacteria; therefore, it is good practice to check the wells from microtiter plates under an inverted microscope for contamination. Contamination may also interfere with proliferation of the activated lymphocytes.

It is also useful to check for blast formation by microscopic examination of the cultures: activated lymphocytes will tend to enlarge, and detection of blasts will give a general indication of successful activation.

The main problem that may occur with proliferative response assays is high levels of background [ $^3\text{H}$ ]thymidine incorporation in control cultures without antigens. This problem is frequently due to the fetal calf serum (FCS) used to supplement the cultures, which may be mitogenic for B cells. Different lots of FCS should be screened to select those that are nonstimulatory or only weakly stimulatory in the absence of other stimuli, and that support strong proliferative responses upon antigenic stimulation of T cells.

If flat-bottom microtiter plates are used in the procedure and weak responses occur, it may be useful to switch to round-bottom plates. Our laboratory has found consistently better responses in round-bottom plates when

thymocytes are used as responder cells or with slight alloantigenic differences between responding and stimulating cells. In addition, antibody-mediated experiments yield better results with round-bottom plates. Presumably, this reflects better cell contact obtained in such plates; optimal responses will almost certainly occur at different cell numbers than in flat-bottom plates and densities will have to be adjusted accordingly.

Although satisfactory responses to most alloantigens can be obtained with complete RPMI-10 medium, it may be necessary to compare different media. This need arises when the proliferative responses are weak (i.e., when [ $^3\text{H}$ ]thymidine values for activated cultures are <10-fold higher than those for control cultures) and may occur under various circumstances: weak alloantigenic differences between responder and stimulator cells, weak T cell proliferative function in the responder cells or diminished APC function in the stimulator cells due to experimental manipulations, or a low precursor frequency of responding T cells. Thymocytes in particular do not contain a high level of responding T cells. Frequently, proliferation can be improved when complete Clicks or Dulbeccos media are used (with additives as described in APPENDIX 2), presumably because these media contain additional nutrients and have an osmolality more compatible with mouse serum than RPMI.

When RPMI is used as medium, 5%  $\text{CO}_2$  will be sufficient, but for other media, a 7.5%  $\text{CO}_2$  concentration in the incubator will be more satisfactory. Generally, the buffering capacity of DMEM is insufficient at 5%, but fine at 7.5%. Much will also depend on the proliferative activity of the responding population of T cells (e.g., vigorous proliferation will reduce the pH in the cultures); it is therefore recommended to compare responsiveness in initial pilot experiments in incubators set at different  $\text{CO}_2$  concentrations.

The culture period required for stimulation—after which the cells are to be labeled—varies for different laboratories, media, and types of responding and stimulator cells. Conditions eliciting weak responses, such as those obtained with thymocytes or a weak alloantigenic difference, will require a longer culture period (5 to 6 days) than those which elicit a higher frequency of responding T cells (3 to 4 days). Because laboratory conditions vary, it will be necessary to run a kinetic assay to determine the optimal time for T cell prolifer-

ation. Addition of [ $^3\text{H}$ ] thymidine on days 2, 3, 4, 5, and 6 will provide a useful test; further extension of the culture period will not yield any improvements, due to exhaustion of nutrients in the medium.

### Anticipated Results

For proliferative assays described in the basic protocol, which activate the majority of the responding T cells, responses of 100,000 cpm should be obtained; in the MLR or following activation with monoclonal antibodies to subpopulations of T cells (anti-V $\beta$ ), responses up to 100,000 cpm may be observed; however, measurements of 20,000 cpm (with tight standard errors) can be quite satisfactory. Background values of <1000 cpm should be expected. Reported results (as described in step 9a) should be mean cpm of experimental wells minus background cpm ( $\Delta$  cpm).

### Time Considerations

The time required to set up proliferative assays is not more than a day, with the number of hours depending on the number of different groups of responder cells that must be prepared. The time required for incubation of cells ranges from 2 to 6 days, as noted above in critical parameters. Following an additional 18- to 24-hr incubation period for pulsing, harvesting the cells and measuring cpm will require several hours depending on the number of plates (~15 min for harvesting each plate and ~100 min for counting each plate at 1 min/sample).

### Literature Cited

- Ashwell, J.D., DeFranco, A.L., Paul, W.E., and Schwartz, R.H. 1984. Antigen presentation by resting B cells: Radiosensitivity of the antigen-presentation function and two distinct pathways of T cell activation *J. Exp. Med.* 159:861-869.
- Gunter, K.C., Malek, T.R., and Shevach, E.M. 1984. T cell activating properties of an anti-Thy-1 monoclonal antibody: Possible analogy to OKT3/Leu-4. *J. Exp. Med.* 159:716-730.
- Hathcock, K.S., Segal, D.M., and Hoder, R.J. 1989. Activation of Lyt2 $^+$  (CD8 $^+$ ) and Lyt2 $^-$  (CD4 $^+$ ) T cell subsets by anti-receptor antibody. *J. Immunol.* 142:2181-2186.
- Jenkins, M.K., Chen, C., Jung, G., Mueller, D.L., and Schwartz, R.H. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. *J. Immunol.* 144:16-22.
- Marrack, P. and Kappler, J. 1989. The staphylococcal enterotoxins and their relatives. *Science* 248:705-711.

Staerz, U.D. and Bevan, M.J. 1986. Activation of resting T lymphocytes by a monoclonal antibody directed against an allotypic determinant on the T cell receptor. *Eur. J. Immunol.* 16:263-268.

### Key References

Corradin, G., Etlinger, H.M., and Chiller, M. 1977. Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell dependent proliferative response with lymph node cells from primed mice. *J. Immunol.* 119:1048-1055.

Rosenwasser, L.J. and Rosenthal, A.S. 1978. Adherent cell function in murine T lymphocyte antigen recognition. I. A macrophage-dependent T cell proliferation assay in the mouse. *J. Immunol.* 120:1991-1998.

*Both of the above describe how specific proliferation of antigen-primed T cells can be measured.*

Strong, D.M., Ahmed, A.A., Thurman, G.B., and Sell, K.W. 1973. In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. *J. Immunol. Methods* 2:279-287.

*Details the MLC proliferation assay.*

---

Contributed by Ada M. Kruisbeek  
Netherlands Cancer Institute  
Amsterdam, The Netherlands

Ethan Shevach  
National Institute of Allergy and  
Infectious Diseases  
Bethesda, Maryland



*Dendritic cells are allowing scientists to overcome a longstanding obstacle to research in immunology by extending the playing field beyond antigens to immunogens and beyond models to pathogens that cause disease.*

## The Dendritic Cell Advantage: New Focus For Immune-Based Therapies

by Ralph M. Steinman

The focus of immune therapeutics has been on lymphocytes, the cellular mediators of immunity, and the suppression of lymphocyte function. The drug ciclosporin (cyclosporine) is an excellent and successful example. However, medicine needs therapies that enhance immunity or resistance to infections and tumors. Medicine also needs strategies, whether suppressive or enhancing, that are specific to the disease-causing stimulus or antigen. In contrast to lymphocytes, dendritic cells (DCs) provide a much earlier and antigen-specific means for manipulating the immune response. DCs capture antigens and then initiate and control the activities of lymphocytes, including the development of resistance to infections and tumors (reviewed in references 1-3).

### Summary

Dendritic cells (DCs) provide a much earlier and antigen-specific means for manipulating the immune response. The best-studied function of DCs is to convert antigens into immunogens for T cells. The "DC advantage" entails a myriad of functions. DCs are more than antigen-presenting cells; they are accessories or adjuvants or catalysts for triggering and controlling immunity. Another special feature of DCs is their location and movement in the body; DCs are stationed at surfaces where antigens gain access to the body. The events that make up the life history of DCs are now being unraveled in molecular terms. As research on DCs expands, more potential functions and more sites for their manipulation are becoming apparent. © 2000 Prous Science. All rights reserved.


The controlling role of DCs is best known for thymus-dependent lymphocytes or T cells which are important in many diseases, the most poignant being the AIDS epidemic (Table 1). DCs were identified in a few laboratories that were focusing on the induction of immunity from resting T cells. It was noted that immune tissues (spleen, lymph nodes, lymph. blood) had a small fraction of cells with unusual

"tree-like" or "dendritic" processes. These distinctive cells had not been recognized previously and they proved to have distinct functions. Most importantly, DCs were potent inducers of immunity even in animals, not just the test tube, and now even in patients (reviewed in references 1-3).

The DC field was held back by the fact that there were so few cells relative

**TABLE 1: HUMAN DISEASES THAT INVOLVE T CELLS**

- Rejection of organ transplants and graft-vs.-host disease in bone marrow transplantation
- Resistance to many infections including vaccine design
- Vaccines against tumors and immune therapies for existing tumors
- Allergy
- AIDS
- Autoimmune diseases like insulin-dependent (juvenile) diabetes, multiple sclerosis, rheumatoid arthritis and psoriasis



**Fig. 1.** A key function of dendritic cells. Antigens within tumors, transplants and infectious agents need to be presented by DCs to become immunogens, i.e., to make T cells begin to grow and exhibit their helper and killer functions.

to other players in the immune system such as B cells, T cells and macrophages. In reality, DCs are quite abundant for the job they have to do, namely, to initiate immune responses from antigen-specific T cells. In immune system organs like lymph nodes, DCs form an extensive network throughout the T cell-rich regions and physically outnumber any given antigen-reactive T cell by at least 100 to 1. The DC field was also held back because many thought that the cells were no different from macrophages, thus keeping investigators from working on the active DCs. In reality, DCs were identified on the basis of profound differences from macrophages, and their many distinct properties and functions were only uncovered by separating DCs from macrophages.

The best-studied function of DCs is to convert antigens into immunogens for T cells. The antigen receptors on T cells do not focus on intact proteins in microbes and tumors, but instead recognize fragmented or processed proteins, that is, peptides. The processing of protein antigens into peptides occurs within cells, and then the peptides are

displayed or presented at the cell surface affixed to products of the major histocompatibility complex (MHC). The ensuing interaction between a T-cell receptor (TCR) and its specific MHC-peptide complex allows a T cell to detect peptides formed within cells in transplants, tumors, sites of infection and self tissues attacked during autoimmune disease (Table 1). "Antigens" refers to specific substances recognized by the immune system, while "immunogens" refers to antigens that effectively induce responses either by themselves or together with enhancing materials called "adjuvants." For T cells in particular, antigens and immunogens are not one and the same (Fig. 1). Even preprocessed peptides and MHC-peptide complexes are weak immunogens. This was evident early on in the work of Peter Medawar, the great scientist who discovered the immune basis of transplantation. He spent many years trying to purify functioning transplantation antigens. These efforts were to little avail.

What was not known in Medawar's time is that transplantation antigens

(later shown to be MHC-peptide complexes) become immunogenic when presented by DCs.<sup>4</sup> In other words, transplantation antigens when presented on many cell types are weak immunogens, but on DCs they become powerful inducers of immunity.<sup>4</sup> The same is true of peptides that become much more immunogenic when presented on DCs. DCs activate T cells by getting them to divide and express their helper and killer functions. Then the activated T cells interact with other antigen-presenting cells to eliminate the antigen in question. DCs are also called "nature's adjuvant," because prior adjuvants were artificial substances used to enhance immunity. The DC advantage entails a myriad of functions, some of which will be considered below.

### Potency of dendritic cells in initiating immunity in tissue culture

What are some specific features of DCs that warrant attention? The first is their potency. Very small numbers of DCs are sufficient to trigger strong T-cell responses in test tubes. Immune assays are generally carried out with impure antigen-presenting cells, applied at a dose of one presenting cell for every T cell, the latter often preactivated. In contrast, roughly one DC per 30-100 T cells is more than sufficient to induce optimal responses, including responses by resting T cells. A single DC can simultaneously activate 10-20 T cells nestled within its sheet-like processes. Therefore, DCs are more than antigen-presenting cells; they are accessories or adjuvants or catalysts for triggering and controlling immunity.

It has always been clear that the accessory function of DCs did not depend exclusively on their capacity to process antigens to form MHC-peptide complexes. This is because the stimuli that were used to define the potency and immune-activating role of DCs did not require that the DCs process an applied antigen. Such stimuli included major transplantation antigens, mitogens, contact allergens, anti-

T-cell antibodies and superantigens. Furthermore, once resting T cells were activated by DCs, the T cells responded vigorously to antigens presented by other cell types, showing that the latter were not deficient in forming ligands for the antigen receptor on T cells, but instead lacked accessory properties.

The word "accessory" has since been replaced by the terms "professional" and "co-stimulatory," but the basic concept is unchanged by shifting terminology. T cells need stimuli other than their specific trigger or ligand (MHC-peptide complexes) to begin to grow and function, for example, to produce the interleukins and killer molecules mentioned above. DCs are potent in providing the needed accessory or co-stimulatory functions. For example, DCs produce an adhesion molecule called DC-SIGN that binds to a target on resting T cells called ICAM-3,<sup>5</sup> and DCs express very high levels of a stimulatory molecule called CD86 that binds to CD28 on resting T cells.<sup>6</sup> These are but two examples of the specialized activities of DCs. These cells do not operate as a single magic bullet.

### Position of dendritic cells *in vivo*

Another special feature of DCs is their location and movement in the body. As criteria were developed to identify DCs, it became feasible to go back into the animal and patient to look for the corresponding cells in different tissues. DCs are stationed at surfaces where antigens gain access to the body (Fig. 2, left). The skin and the airway have been the best studied. DCs are found in afferent lymphatic vessels, special channels that allow cells to move from peripheral tissues to lymphoid organs, primarily the T-cell areas (Fig. 2, middle and right). This migration is most readily observed in models of skin transplantation and contact allergy, which are the two most powerful immune responses known.

DC migration is likely to be very important. The body's pool of T cells primarily traffics through the T-cell areas of lymph nodes, rather than




Fig. 2. Distribution of dendritic cells *in situ*. DCs at body surfaces and in solid organs can pick up antigens, move to the lymphoid tissues to find antigen-specific T cells and initiate immunity. Molecular mechanisms are being uncovered that govern the mobilization, maturation, migration and mortality of these DCs. In the lymph node, T lymphocytes are selected for expansion and differentiation into helper and killer T cells. The activated T cells then leave the lymph node to return to the body surface or peripheral organ to eliminate the antigen.

through tissues where antigens are usually deposited. So when DCs capture antigens in the skin, airway or another peripheral tissue, their migration to the T-cell areas gives them a chance to select the corresponding rare specific T cells from the assembled repertoire (Fig. 2). The selected T cells then increase in numbers (clonal expansion) and function, enabling the specific immune response to begin. The initial frequency of T cells that recognize an antigen is very small. Only one in 10,000–100,000 of T cells in the repertoire responds to a specific MHC-peptide complex. Therefore, it is so precise and efficient for DCs to be able to pick up an antigen in the periphery and then initiate the immune response from rare T-cell clones in lymphoid organs.

The events that make up the life history of DCs (Figs. 2 and 3) are now being unraveled in molecular terms. For example, scientists are figuring out how to expand antigen-capturing precursors to DCs using flt3 ligand and granulocyte colony-stimulating factor (G-CSF). Key players for the mobilization of DCs from the periphery to lymph nodes are the multidrug resistance receptors, usually studied for their capacity to mediate resistance to chemotherapeutic agents rather than

movement of DCs. Migration of DCs is controlled by chemokines produced in the lymphatic vessels and lymphoid organs (Fig. 2). These act on DC chemokine receptors to orchestrate their movement to the T-cell areas. Then within the lymphoid tissue, several members of the tumor necrosis factor (TNF) and TNF-receptor families, such as TRANCE and CD40 ligand, trigger DC production of cytokines like interleukin-12. The TNF family also maintains DC viability. Otherwise the cells die within a day or two. Each of these components of DC function provides targets for manipulating immunity.

### Priming of T-cell immunity via dendritic cells

#### Animal studies

During the early research on DCs, several labs administered antigens to experimental animals and then tried to identify the cells that had captured the antigens in a form that was immunogenic. Regardless of the route of antigen administration (blood, muscle, skin, intestine and airway), DCs were the major reservoir of immunogen.




Fig. 3. The life history of dendritic cells. DCs arise from proliferating progenitors, primarily in the bone marrow, and this can be driven by cytokines like flt-3 ligand and G-CSF. Precursors are formed, such as the monocytes in blood, which then give rise to immature DCs. The immature DCs are capable of producing large amounts of antigen-presenting MHC products and capturing antigens. Multidrug resistance receptors are newly recognized players in the mobilization of immature DCs. DCs mature in response to various stimuli such as infection and inflammation, and migrate under the influence of chemokines to the lymphoid tissues. There the DCs die within a day unless their lifespan is prolonged by TNF-family molecules expressed by the activated T cells.

Next, DCs were used as nature's adjuvant to immunize animals. The DCs were taken from mice or rats, exposed to antigens *ex vivo* and injected back into immunologically naive recipients. The animals became immunized to the antigens that had been captured by the DCs, and the immunization took place in the lymph nodes draining the site of DC injection. Genetic proof was provided that the DCs were priming the animal directly and not simply handing off their antigen to other cells.<sup>7,8</sup>

DC-based immunization is really very different from all prior attempts at cell therapy. Immunology has had extensive experience with "passive immunization," whereby a recipient is given large numbers of cells that are activated prior to injection. It is hard to produce such large numbers of cells, and their lifespan, diversity and efficacy are all finite. In contrast, when relatively small numbers of antigen-charged DCs are used to induce immunity, this produces "active immunization." Now the animals (and patients, see below) can make their own diverse and longer lasting immune response to the antigen-bearing DCs.

#### Human studies

The above experiments made it clear that DCs, pulsed *ex vivo* with antigens, actively immunized animals and raised the exciting possibility that scientists would be able to induce resis-





Fig. 4. The use of dendritic cells as adjuvants for enhancing immunity to tumors and infectious agents in humans. This new form of immune therapy begins with the isolation of DC precursors from the patient, usually from blood. The precursors develop *ex vivo* (in relatively simple tissue culture systems) into large numbers of more mature DCs. During this time, the DCs are charged with antigens from the tumor or infection. Then the DCs are reinfused to elicit immunity and thereby resistance to the disease.

tance to tumors, infections and transplants in patients. For example, could one expose patients' DCs *ex vivo* to antigens in their tumors and then reinfuse the antigen-bearing DCs to elicit tumor-specific immunity (Fig. 4)? This approach is actually not terribly complicated, but one first had to overcome a major obstacle and learn to generate large numbers of DCs. These techniques became available in the 1990s. They have energized the field and, accordingly, clinical trials for the immunization of humans against cancer have begun on most continents.

It is evident that DCs can serve as adjuvants for humans, converting antigens into immunogens.<sup>9,10</sup> Even in advanced cancer, immune responses already have been observed that are similar to or better than immune responses obtained with other approaches. However, this approach is still in its preliminary stages, since a good deal of science remains to be developed. On the one hand, there are critical unknowns in terms of overall DC biology. Many of the clinical studies to date, for example, have overlooked key features that could improve DC function, such as the need for DCs



to be sufficiently mature (see below) to be effective *in vivo*. Also, DC biology has to be placed in the context of specific tumors and pathogens and patients for DC-based therapies to be optimized.

To summarize and further illustrate the role of DCs in the context of human disease (Table I), consider the need to harness T cells to resist tumors and chronic infections. Protein antigens often are known for a tumor-like melanoma, or for a virus like HIV-1 whose genetic sequence has been available for more than 15 years. However, this knowledge about antigens from melanoma and HIV-1 antigens remains to be converted into methods that provide better immunogens either for immune therapy of melanoma or for the design of HIV-1 vaccines. This is because some important facts of immunological life are being overlooked. When antigens are injected, they also need to gain access to the right DCs to become immunogens (Fig. 1).

### Delivering antigens to dendritic cells

Broadly speaking, a central goal is to learn how to deliver or "target" antigens to DCs and simultaneously to differentiate or "mature" the cells to their most potent state. These two challenges, antigen targeting and DC maturation, prove to be intertwined.

Targeting means that the antigen should be in a form that the DCs can recognize. Without such recognition, the uptake and subsequent processing of antigen to form MHC-peptide complexes is suboptimal. DCs have a number of special mechanisms for capturing antigens and converting these into MHC-peptide complexes (Table II). For example, DCs have a receptor called DEC-205 whose binding partners or ligands are still unknown. Nonetheless, it is clear that DEC-205 greatly increases the capacity of DCs to form MHC-peptide complexes.<sup>11</sup> DCs also carry out a fascinating process called "cross-presentation." DCs can take up dying cells and effi-

TABLE II: DENDRITIC CELL SPECIALIZATION TO INCREASE MHC-PEPTIDE COMPLEX FORMATION

- Receptors for antigen uptake, e.g., DEC-205
- Processing of dying cells, nonreplicating microbes and immune complexes onto MHC class I ("cross-presentation")
- Regulation of antigen processing by maturation stimuli
- Clustering of T-cell receptor ligands with co-stimulators like CD86

ciently extract peptides from them, so antigens "cross" from the dying cell to the DC. The discoverers of this phenomenon called it "resurrecting the dead."<sup>12</sup> Cross-presentation allows DCs to efficiently form MHC-peptide complexes from dead cells in tumors, transplants and tissues under autoimmune attack.

Special uptake and processing mechanisms allow DCs to tailor a protein antigen, as well as the proteins in a complex microbe or tumor cell, into peptides that bind to an individual's MHC products. The latter are exceptionally polymorphic, differing genetically from one individual to another. As a result, the relevant immunizing peptides differ from one individual to another. One reason why peptides are not ideal immunogens is that they must be individualized. DCs, in contrast, can capture antigens with high efficiency and likewise extract peptides that are relevant for any individual.

A second DC advantage is that these cells have the many required accessory or co-stimulatory properties for converting the selected peptides ("antigens") into effective immunogens. A third DC advantage is that these cells position themselves in a way that leads to the identification of rare antigen-reactive T lymphocytes *in vivo* (Fig. 2). DCs thus overcome many of the difficult obstacles in initiating immunity.

In order for an antigen to be a strong immunogen, one needs to provide a stimulus for the final differentiation or maturation of the DCs (Fig. 3). Most DCs in the body are in an immature state and lack many features that lead to a strong T-cell response.

Immature DCs, for example, lack the CD86 and CD40 molecules that greatly boost the DC-T cell interaction. Immature DCs also lack a chemokine receptor called CCR7 that seems very important for proper migration and homing to lymph nodes to start immunity. For cancer immunology, it is unlikely that tumors provide maturation stimuli. Tumors may even block DC maturation induced by other stimuli. Therefore it is important to learn how to deliver tumor cells to DCs and bypass the normal obstacles to effective antitumor immunity.

Surprising recent evidence actually links DC maturation to the efficient formation of MHC-peptide complexes or TCR ligands (Table II). Immature DCs take up antigens, but they do not make abundant MHC-peptide complexes until they receive a maturation stimulus.<sup>13,14</sup> Maturation also up-regulates CD86 co-stimulators, but the CD86 actually travels together with the TCR ligands to the surface of the DCs. At the DC surface, the MHC molecules and CD86 remain clustered with each other, keeping the machinery for T-cell activation juxtaposed. This phenomenon will help explain the potency of DCs, because TCR ligands and co-stimulators are displayed together on the cell surface and in high levels.

### Control points beyond antigen targeting and maturation of DCs

Research on DCs is moving more vigorously, because the cells are more readily available and because their role in the immune system is considered essential. Nonetheless, researchers in this field are just beginning to find ways to manipulate DCs *in situ*. Putting together an antigen that targets

to DCs with a stimulus for DC maturation will be a major step in improving the conversion of antigens into immunogens, as in immune-based therapies against tumors and infectious agents.

Additional challenges and questions are evident:

- How can DC numbers be increased *in situ* and how can active DCs be mobilized to a cancer or site of chronic infection?
- Can DCs induce strong immune memory to make vaccination long lasting and effective (we have only been reviewing the role of DCs in the initiation of immunity)?
- Can DCs change the quality of the immune response? "Quality" refers to recent evidence for different types of DCs, especially a subset that induces Th1-type T cells for resistance to infectious agents and strong memory.
- Is it possible to move beyond DC-based immunization experiments and use DCs to either regulate or tolerate the immune system, as frequently required in transplantation and autoimmune diseases?
- Can DCs influence elements of the immune system other than T cells; for example, B cells and the innate defenses provided by natural killer (NK) and NK-T cells?

The answer to all these questions is a preliminary "yes." As research on DCs expands, more potential functions and more sites for their manipulation are becoming apparent.

### Dendritic cells and better control of disease

DCs provide important avenues for the investigation of human disease. Many labs are exploiting DCs to identify antigens relevant for immunity against human pathogens. In these experiments, one introduces complex but clinically important antigens to DCs and then identifies which components are best presented to the immune system. We have recently used this approach to identify previously un-

known immune responses to the Epstein-Barr virus,<sup>15</sup> a virus we all carry that has the potential to cause cancer like Hodgkin's lymphoma. Other laboratories have been using DCs to identify new antigens in other infectious agents, in transplants and in cancers like melanoma.

Investigators are also manipulating DCs *ex vivo* and then reinfusing the cells to identify conditions leading to strong immunity in patients (Fig. 4). In particular, DC-mediated active immunization against cancer is being vigorously pursued, as mentioned above. Instead of manipulating DCs *ex vivo*, a more desirable goal would be able to alter DCs directly *in situ*. Some approaches are under way. An example is the injection of cytokines like IL-3 ligand and G-CSF to mobilize various precursor populations of DCs. One should also develop methods to control DC mobilization, migration and maturation. In sum, DCs are allowing scientists to overcome a longstanding obstacle to research in immunology by extending the playing field beyond antigens to immunogens and beyond models to pathogens that cause disease.

### References

1. Hart, D.N.J. Dendritic cells: Unique leukocyte populations which control the primary immune response. *Blood* 1997, 90: 3245-87.
2. Banchereau, J. and Steinman, R.M. Dendritic cells and the control of immunity. *Nature* 1998, 392: 245-52.
3. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecq, S., Liu, Y.-J., Pulendran, B. and Palucka, K. Immunobiology of dendritic cells. *Annu Rev Immunol* 2000, 18: 767-811.
4. Steinman, R.M. and Witmer, M.D. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. *Proc Natl Acad Sci USA* 1978, 75: 5132-6.
5. Geijtenbeek, T.B.H., Torensma, R., van Vliet, S.J., van Duinhoven, G.C.F., Adema, G.J., van Kooyk, Y. and Figdor, C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell* 2000, 100: 575-85.
6. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K.S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P.S., Ikchura, S., Muramatsu, S., Hodes, R.J. and Steinman, R.M. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells *in situ* and during maturation *in vitro*. *J Exp Med* 1994, 180: 1849-60.
7. Inaba, K., Metlay, J.P., Crowley, M.T. and Steinman, R.M. Dendritic cells pulsed with protein antigens *in vitro* can prime antigen-specific, MHC-restricted T cells *in situ*. *J Exp Med* 1990, 172: 631-40.
8. Liu, L.M. and MacPherson, G.G. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells *in vivo*. *J Exp Med* 1993, 177: 1299-307.
9. Dhodapkar, M., Steinman, R.M., Sapp, M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S.M., Dunbar, P.R., Cerundolo, V., Nixon, D.F. and Bhardwaj, N. Rapid generation of broad T-cell immunity in humans after single injection of mature dendritic cells. *J Clin Invest* 1999, 104: 173-80.
10. Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brückner, F.B., Steinman, R.M., Fink, A., Kämpgen, F. and Schuler, G. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 1999, 190: 1669-78.
11. Mahnke, K., Guo, M., Lee, S., Sepulveda, H., Swain, S., Nussenzweig, M. and Steinman, R.M. The dendritic cell receptor for endotoxin, DEC-205, can recycle and enhance antigen presentation major histocompatibility complex class II-positive lysosomal compartments. *J Cell Biol* 2000, 151: 673-84.
12. Altherr, M.L. and Bhardwaj, N. Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I. *Immunologist* 1998, 6: 194-8.
13. Inaba, K., Turley, S., Lyda, T., Yamakita, F., Shimoyama, S., Reis e Sousa, C., Gernain, R.N., Mellman, I. and Steinman, R.M. The formation of immunogenic MHC class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. *J Exp Med* 2000, 191: 927-36.
14. Turley, S.J., Inaba, K., Garrett, W.S., Ebersold, M., Untermaier, J., Steinman, R.M. and Mellman, I. Transport of peptide-MHC class II complexes in developing dendritic cells. *Science* 2000, 288: 522-7.
15. Munz, C., Bickham, K.L., Subklewe, M., Tsang, M.J., Chahroudi, A., Kurilla, M.G., Zhang, D., O'Donnell, M. and Steinman, R.M. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. *J Exp Med* 2000, 191: 1649-60.

Ralph M. Steinman, M.D., is Henry G. Kunkel Professor and Senior Physician, Laboratory of Cellular Physiology and Immunology, The Rockefeller University, 1230 York Ave., New York, New York 10021-6399, U.S.A.



## Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor

(heterodimeric lymphokine/T-cell growth factor/lymphokine-activated killer cells/coordinate gene regulation/interleukin-12)

UELI GUBLER<sup>\*†</sup>, ANNE O. CHUA<sup>\*</sup>, DAVID S. SCHOENHAUT<sup>\*</sup>, CYNTHIA M. DWYER<sup>‡</sup>, WARREN MCCOMAS<sup>\*</sup>, RICHARD MOTYKA<sup>\*</sup>, NASRIN NABAVI<sup>§</sup>, AIMEE G. WOLITZKY<sup>§</sup>, PHYLLIS M. QUINN<sup>§</sup>, PHILIP C. FAMILLETTI<sup>‡</sup>, AND MAURICE K. GATELY<sup>§</sup>

Departments of <sup>\*</sup>Molecular Genetics, <sup>†</sup>Bioprocess Development, and <sup>‡</sup>Immunopharmacology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ 07110

Communicated by John J. Burns, February 4, 1991

**ABSTRACT** Cytotoxic lymphocyte maturation factor (CLMF) is a disulfide-bonded heterodimeric lymphokine that (i) acts as a growth factor for activated T cells independent of interleukin 2 and (ii) synergizes with suboptimal concentrations of interleukin 2 to induce lymphokine-activated killer cells. We now report the cloning and expression of both human CLMF subunit cDNAs from a lymphoblastoid B-cell line, NC-37. The two subunits represent two distinct and unrelated gene products whose mRNAs are coordinately induced upon activation of NC-37 cells. Coexpression of the two subunit cDNAs in COS cells is necessary for the secretion of biologically active CLMF; COS cells transfected with either subunit cDNA alone do not secrete bioactive CLMF. Recombinant CLMF expressed in mammalian cells displays biologic activities essentially identical to natural CLMF, and its activities can be neutralized by monoclonal antibodies prepared against natural CLMF. Since this heterodimeric protein displays the properties of an interleukin, we propose that CLMF be given the designation interleukin 12.

The molecular cloning and expression of recombinant cytokines has made possible both significant advances in our understanding of the molecular basis of immune responses and the development of new approaches to the treatment of disease states. As an example, recombinant interleukin 2 (recombinant IL-2) has been shown to be capable of causing regression of established tumors in both experimental animals (1) and in man (2); however, its clinical use has been associated with significant toxicity (2). One potential approach to improving the therapeutic utility of recombinant cytokines is to use them in combination (3, 4). With this concept in mind, we initiated a search for novel cytokines that would synergize with suboptimal concentrations of recombinant IL-2 to activate cytotoxic lymphocytes *in vitro* and thus might have synergistic immunoenhancing effects when administered together with recombinant IL-2 *in vivo*. This led to the identification of a factor, designated cytotoxic lymphocyte maturation factor (CLMF), that synergized with recombinant IL-2 to facilitate the generation of both cytolytic T lymphocytes (CTLs) and lymphokine-activated killer (LAK) cells *in vitro* (5, 6). CLMF was subsequently purified to homogeneity from a human lymphoblastoid B-cell line (NC-37) and was shown to be a 75-kDa disulfide-bonded heterodimer composed of two subunits with molecular masses of 40 kDa and 35 kDa (7).<sup>†</sup> We now report the molecular cloning and expression of CLMF.

## MATERIALS AND METHODS

**cDNA Cloning.** A subline of NC-37 cells selected for its ability to produce high levels of CLMF (7), NC-37.98, was induced with phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 for 16 hr. Poly(A)<sup>+</sup> RNA was isolated, and random hexamer-primed cDNA libraries were established in phage  $\lambda$ gt10 by standard procedures. Mixed-primer polymerase chain reaction (PCR) using controlled ramp times (8) was performed as follows. PCR primers contained all possible codons and were 14 or 15 nucleotides long (Fig. 1) with a 5' extension of 9 nucleotides containing an *Eco*RI site for subcloning. Degeneracies varied from 1 in 32 to 1 in 4096; 0.5–4 pmol per permutation of forward and reverse primer was used in a 50- to 100- $\mu$ l PCR mixture with 40 ng of cDNA made from NC-37.98 cells that had been activated by culture with 10 ng of PMA and 25 ng of calcium ionophore A23187 per ml for 16 hr (40-kDa subunit) or with 3  $\mu$ g of human genomic DNA (35-kDa subunit). PCR cycling parameters were as follows. Initial denaturation was at 95°C for 7 min. Low-stringency annealing was performed by cooling to 37°C over 2 min, incubating 2 min at 37°C, heating to 72°C over 2.5 min, extending at 72°C for 1.5 min, heating to 95°C over 1 min, and denaturing at 95°C for 1 min. This cycle was repeated once. Thirty standard cycles (40-kDa subunit) or 40 standard cycles (35-kDa subunit) were performed as follows: 95°C for 1 min, 55°C for 2 min, and 72°C for 2 min. Final extension was at 72°C for 10 min. "Amplicons" of the expected size were gel-purified, subcloned, and sequenced. The 40-kDa subunit cDNAs were isolated by hybridizing the 54-mer amplicon in 5 $\times$  SSC (1 $\times$  SSC = 0.15 M NaCl/0.015 M sodium citrate, pH 7) containing 20% formamide at 37°C overnight. Filters were washed in 2 $\times$  SSC at 42°C for 30 min and exposed to x-ray film. The 35-kDa subunit cDNAs were isolated by hybridizing the 51-mer amplicon in 5 $\times$  SSC/20% formamide at 37°C overnight. The filters were washed in 2 $\times$  SSC at 40°C for 30 min and exposed to x-ray film. Positive clones were plaque-purified, their inserts were subcloned into the pBluescript plasmid, and their sequences were determined by using Sequenase.

**Expression.** cDNAs were separately engineered for expression in vectors containing the simian virus 40 early promoter essentially as described (9). COS cells were transfected with both CLMF subunit expression plasmids mixed together or

Abbreviations: CLMF, cytotoxic lymphocyte maturation factor; rCLMF and nCLMF, recombinant and natural CLMFs; CTL, cytolytic T lymphocyte; IL, interleukin; LAK, lymphokine-activated killer; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate; n, natural; PCR, polymerase chain reaction.  
<sup>†</sup>To whom reprint requests should be addressed.

<sup>‡</sup>The cDNA sequences reported in this paper have been deposited in the Genbank data base [accession nos. M38443 (35-kDa CLMF subunit) and M38444 (40-kDa CLMF subunit)].

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

```

1  MCPARSLLLV ATLVLDDHLS LARNLPVATP DPGMFPC^LHH SQNLLRAVS^N
51  MLQKARQ^TLE FY^PCTSEED HEDITKDKTS TVEAC^LPLEL TKNESCLNS^R
101  ETSFITNGSC LASRKTSFMM ALCLSSIIYED LKMYQVEFKT MNAKLLMDPK
151  RQIFLDQ^NML AVIDELMQAL NFNSETVPQK SSLEEPDFYK TKIKLCILL^H
201  AFRIRAVTID RVTSYLNAS

1  MCHQQLVISW FSLVFLASPL VAIWELKKDV YVVELDWYPD APGEMVVLTC
51  DTPEEDGITW TLDQSSEVLG SGKTLTIQVK EFGDAGQYTC HKGGEVLSHS
101  LLLLHKKEDG IWSTDILK^DQ KEPKNKTFLR CEAKNYSGRF TCWWLTIST
151  DLTF^SVKSSR GSSDPQGVTC GAATLSAERV RGDNKEYEYS VECQEDSAC^P
201  AAEE^SLPIEV MVD^AVHKLKY ENYTS^FFIR DIIKPDPPKN LQLKPLKNSR
251  QVEVSWEYPD TWSTPHSYFS LTFCVQVQ^GK SKREKKDRVF TDKTSATVIC
301  RKNASISVRA QDRYSSSSWS EWASVPCS

```

FIG. 1. Amino acid sequences of the 35-kDa (Upper) and 40-kDa (Lower) CLMF subunits as deduced from the respective cDNAs and shown in single-letter code. Signal peptides are overlined, cysteine residues are marked by a caret, and N-linked glycosylation sites (NXS, NXT, where X is another amino acid) are underlined. The peptide sequences used to generate PCR probes are overlined with arrows indicating the direction of amplification.

with each one separately by the DEAE-dextran method. Twenty-four hours after transfection, the serum-containing medium was replaced with medium containing 1% Nutridoma-SP (Boehringer Mannheim), and supernatant fluids were collected from the cultures after 40 hr. These fluids were stored at 4°C until tested in the bioassays.

**General Methods.** Standard molecular biological procedures were used as described (10). CLMF bioassays were performed as detailed (7).

**Computer Searches.** The National Biomedical Research Foundation protein data base (Release 26.0) as well as the Genbank and European Molecular Biology Laboratory databases (Releases 65.0 and 24.0, respectively) were searched for sequences homologous to CLMF cDNAs. The two subunit sequences were compared to each other using the ALIGN program (mutation data matrix, break penalty of 6; see ref. 11).

## RESULTS

Partial N-terminal amino acid sequences of the two CLMF subunits (7) were used to generate completely defined 51- to 54-base-pair (bp)-long oligonucleotide probes by means of mixed primer PCR. These probes were used to screen cDNA libraries made from RNA from activated NC-37.98 cells, and cDNAs encoding the two subunits were isolated and characterized. Both cDNAs encode secreted proteins with a classical hydrophobic N-terminal signal peptide immediately followed by the N terminus of the mature protein as determined by protein sequencing (7). Two independent cDNA clones for the 40-kDa subunit were shown to be identical. Both encode the mature 40-kDa subunit that is composed of 306 amino acids (calculated  $M_r = 34,699$ ) and contains 10 cysteine residues and four potential N-linked glycosylation sites (Fig. 1). Two of these sites are within isolated tryptic peptides derived from the purified 40-kDa CLMF subunit protein. Amino acid sequence analysis has shown that Asn-

222 is glycosylated, whereas Asn-125 is not (Fig. 1; F. Podlaski, personal communication). The mature 35-kDa subunit is composed of 197 amino acids (calculated  $M_r = 22,513$ ), with 7 cysteine residues and three potential N-linked glycosylation sites (Fig. 1). When purified CLMF is reduced with 2-mercaptoethanol and analyzed by SDS/PAGE, the 35-kDa subunit appears to be heterogeneous, suggesting that it may be heavily glycosylated (7). Two variants of 35-kDa subunit-encoding cDNAs were isolated. The first type had the sequence shown in Fig. 1. Additional isolates contained what is probably an allelic variation, replacing Thr-213 with a methionine residue.

Computer searches of sequence databases showed that the amino acid sequences of the two subunits are not related to any known protein. The subunit sequences are also not related to each other, since a comparison using the ALIGN program (11) gave a score of 1.27; only scores >3 are considered to indicate significant evolutionary relationship (12). The genes encoding the subunits appear to be unique, since low- and high-stringency hybridizations of genomic blots revealed identical banding patterns (data not shown). RNA blots showed the size of the 40-kDa subunit mRNA to be 2.4 kb, whereas the 35-kDa subunit was encoded by a 1.4-kb transcript (Fig. 2). Expression of the two mRNAs encoding the subunits was coordinately regulated upon induction (Fig. 2). When NC-37.98 cells were activated with PMA and calcium ionophore for 72 hr, mRNA encoding each of the CLMF subunits was minimally detectable at 6 hr after the beginning of induction but was readily detected at 24 hr and continued to accumulate until maximal levels were reached at 72 hr (normalized to GAPDH mRNA levels; see the legend to Fig. 2). In contrast, the mRNA for IL-2 in activated NC-37.98 cells was already at high levels at 6 hr and subsequently decreased, whereas the mRNAs for the low-affinity IL-2 receptor (p55) followed the induction pattern seen for the CLMF subunits. Scanning of RNA blots also revealed that steady-state mRNA levels for the 40-kDa





FIG. 2. RNA blots showing the coordinate induction of the 35-kDa (A) and 40-kDa (B) CLMF subunit mRNAs and IL-2 mRNA (C) and its p55 receptor mRNA (D). Poly(A)<sup>+</sup> RNA (5  $\mu$ g) from NC-37.98 cells activated with 10 ng of PMA and 25 ng of calcium ionophore A23187 per ml were loaded in each lane. Lanes from left to right in each panel show RNAs isolated 6, 24, 30, 48, and 72 hr after induction, respectively. (Upper) Four-day exposures. (Lower) Two-hour exposure of the same blots after stripping and rehybridization with a GAPDH probe. Marker sizes are in kb (BRL RNA ladder).

CLMF subunit were severalfold higher than those for the 35-kDa subunit expressed by the same cells. This finding parallels the observation that activated NC-37 cells secrete excess free 40-kDa subunit protein (7). The 3' untranslated sequences of both CLMF subunit mRNAs contain several copies of the octamer motif TTATTTAT (data not shown). This sequence is present in other transiently expressed mRNAs and is involved in regulating mRNA stability (13).

Coexpression of the 40-kDa and 35-kDa CLMF subunit cDNAs in COS cells was required to generate secreted biologically active CLMF (Table 1 and Fig. 3). COS cells transfected with cDNA encoding either the 40-kDa subunit alone or the 35-kDa subunit alone did not secrete biologically active CLMF (Table 1). Mixing media conditioned by COS

cells that had been separately transfected with one or the other of the two CLMF subunit cDNAs also did not give rise to bioactive CLMF (Table 1).

Two types of assays were used to compare rCLMF and nCLMF. The first assay measures the proliferation of phytohemagglutinin (PHA)-activated human peripheral blood lymphocytes, whereas the second assay evaluates the synergy between CLMF and suboptimal concentrations of IL-2 in the generation of LAK cells in hydrocortisone-containing cultures (7). The data in Fig. 3 show that rCLMF as expressed in COS cells and nCLMF as purified from NC-37 cells are essentially identical. Dose-response curves for rCLMF and nCLMF were superimposable in each of the two assays, and rCLMF was neutralized by a monoclonal antibody raised against nCLMF. Conditioned media from cultures of mock-transfected COS cells displayed no activity in these assays (Table 1 and data not shown).

## DISCUSSION

In a previous report (7), we described the purification of a heterodimeric cytokine, CLMF, that synergized with low amounts of IL-2 to cause the generation of LAK cells in the presence of hydrocortisone and stimulated the proliferation of activated T cells independent of IL-2. In the present report, we have used the N-terminal amino acid sequence information previously obtained to clone the two subunit cDNAs of CLMF. Protein purification of NC-37 cell line-derived CLMF had shown that the protein was composed of two disulfide-bonded subunits with different N-terminal amino acid sequences (7). However, it was not clear from our previous results whether the two subunits were processed from one common gene product and whether proteolytic posttranslational processing other than signal peptide cleavage was occurring. The molecular cloning and sequencing of

Table 1. Coexpression of both CLMF subunit cDNAs is required for secretion of biologically active CLMF by COS cells

Addition	Conc., units/ml	Dilution	<sup>3</sup> HThymidine incorporated by PHA-activated lymphoblasts, mean cpm $\pm$ 1 SEM
Cytokine*			
None	—		11,744 $\pm$ 514
nCLMF	200		68,848 $\pm$ 878
nCLMF	40		48,827 $\pm$ 605
nCLMF	8		26,828 $\pm$ 594
nCLMF	1.6		17,941 $\pm$ 196
Culture fluid from COS cells transfected with			
A. 35-kDa CLMF subunit cDNA		1:20	11,912 $\pm$ 660
		1:100	10,876 $\pm$ 232
B. 40-kDa CLMF subunit cDNA		1:20	11,699 $\pm$ 931
		1:100	11,666 $\pm$ 469
C. 35-kDa + 40-kDa CLMF subunit cDNAs		1:20	38,615 $\pm$ 587
		1:100	38,361 $\pm$ 828
		1:10 <sup>†</sup>	11,544 $\pm$ 483
1:1 mix of culture fluids A and B		1:50	10,503 $\pm$ 259
		1:20	11,503 $\pm$ 286
CM from mock-transfected control <sup>‡</sup>		1:100	10,751 $\pm$ 303

PHA-activated lymphoblasts were prepared from human peripheral blood mononuclear cells as described (7). Lymphoblast proliferation was measured in a 48-hr assay (7) in which  $2 \times 10^4$  lymphoblasts were incubated in 100- $\mu$ l cultures containing the indicated amounts of natural CLMF (nCLMF) or COS cell culture fluids. <sup>3</sup>HThymidine was added to each culture 18 hr prior to harvest. Conc., concentration.

\*nCLMF is purified NC-37-derived CLMF.

<sup>†</sup>1:10 dilution of the 1:1 mixture of culture fluids A and B was equivalent to a 1:20 final dilution of each of the individual culture fluids.

<sup>‡</sup>Conditioned medium (CM) from cultures of mock transfected COS cells.




FIG. 3. Comparison of biologic activities of nCLMF (circles) and recombinant CLMF (rCLMF, squares). nCLMF was purified from NC-37 cell-conditioned media; rCLMF was purified from conditioned media from cultures of COS cells transfected with cDNAs encoding the 40-kDa and 35-kDa human CLMF subunits. (Upper) T-cell growth factor assay. The ability of CLMF to stimulate the proliferation of human PHA-activated lymphoblasts in 48-hr cultures was assayed as described (7). CLMF preparations were mixed with neutralizing rat monoclonal anti-human CLMF antibody 4A1 (ref. 7; open symbols) or with normal rat IgG (Sigma; rlg, closed symbols) at a final concentration of 20  $\mu$ g of IgG/ml and were incubated for 30 min at 37°C prior to addition of PHA blasts. All values are means of triplicate determinations. (Lower) LAK cell induction assay. The ability of CLMF, alone or in combination with recombinant IL-2, to induce the generation of LAK cells in 4-day cultures was assessed as described (7). Low-density peripheral blood lymphocytes were incubated in the presence of various amounts of nCLMF or rCLMF with (closed symbols) or without (open symbols) recombinant IL-2 at 7.5 units/ml in the T-cell growth factor assay. Hydrocortisone sodium succinate (Sigma) was included at a concentration of 0.1 mM to minimize triggering of endogenous cytokine cascades. Lysis of <sup>51</sup>Cr-labeled Daudi cells was assessed at an effector/target ratio of 5:1. The data shown represent the means of quadruplicate determinations. The spontaneous <sup>51</sup>Cr release was 20%.

the corresponding cDNAs now has demonstrated that there is no common precursor for the two CLMF subunits; rather, they are encoded by completely different genes. The predicted and actual amino acid composition for the two subunits are strikingly similar; differences in predicted versus actual molecular weights are accounted for by glycosylation (F. Podlaski, personal communication). Thus, the only major posttranslational proteolytic event that appears to take place in the maturation of the CLMF subunits is signal peptide cleavage.

The kinetics of expression of the individual CLMF subunit mRNAs were examined and compared to the expression of mRNAs for IL-2 and the IL-2 receptor p55. Previously it had been observed that NC-37 cells, like certain murine (14) and marmoset (15) B-cell lines, secreted IL-2 when activated (M.K.G., unpublished results). RNA blots demonstrated that upon activation of NC-37 cells, both CLMF subunit mRNAs were coordinately induced with kinetics similar to the IL-2 receptor (p55) mRNAs. On the other hand, IL-2 mRNA levels peaked much earlier. Similar differences in induction kinetics were also seen at the level of IL-2 and CLMF bioactivity secreted from NC-37 cells (M.K.G., unpublished data). These kinetic differences are consistent with our previous observation that in a cytolytic lymphocyte response, IL-2 appears to act earlier than CLMF (5).

Transfection studies with COS cells established that only coexpression of both subunit cDNAs gives rise to secreted bioactive CLMF. Thus, it appears that the two proteins have to interact within the endoplasmic reticulum to assemble properly into bioactive secreted CLMF. By comparing the activity of rCLMF to that of nCLMF in the T-cell growth factor and LAK cell induction assays (Fig. 3) and assuming that the specific activity of rCLMF is similar to that of nCLMF ( $8 \times 10^7$  units/mg (7)), we estimate that the amount of rCLMF heterodimer produced in these experiments was 5–50 ng/ml. The finding that COS cells, which are fibroblast-like cells, are able to assemble correctly the two CLMF subunits to form bioactive CLMF indicates that this secretion and processing pattern is not limited to cells of the lymphoid lineage.

Western blot analysis using an anti-CLMF antibody specific for the 40-kDa subunit has allowed confirmation that (i) COS cells transfected with both CLMF subunit cDNAs secrete CLMF with the expected heterodimeric structure and (ii) COS cells transfected with the 40-kDa subunit cDNA alone secrete that subunit (F. Podlaski, personal communication). Since no bioactivity was detected in media conditioned by COS cells transfected with only the 40-kDa subunit, that subunit by itself appears either to have a much reduced specific activity compared with heterodimeric CLMF or to be completely inactive.

Because of the lack of a high-affinity antibody specific for the 35-kDa subunit, we have not yet been able to determine definitively whether COS cells transfected with only the 35-kDa subunit cDNA secrete that subunit. Since no bioactivity was detected in the media, secretion of a bioactive 35-kDa subunit by itself could be very inefficient; alternatively, similar to the 40-kDa subunit, the protein could be much less active or inactive altogether. Intracellular 35-kDa protein in the absence of the other subunit could be inherently unstable; there is precedence for this phenomenon, since it has been reported that 90% of the  $\beta$  chains of lutropin (LH), when expressed in the absence of  $\alpha$  chains, are retained in the endoplasmic reticulum and are slowly degraded (16). Simple mixing of media conditioned by COS cells transfected separately with either one of the two CLMF subunit cDNAs did not yield bioactive CLMF. One possible explanation would be that the cells do not secrete the 35-kDa CLMF subunit by itself. More likely, our experimental conditions did not allow proper heterodimer formation. One would expect that only

carefully controlled renaturation and oxidation conditions would allow the disulfide bond formation required for generation of bioactive CLMF.

Normal human peripheral blood lymphocytes under the appropriate induction conditions produce both CLMF subunit mRNAs and secrete the active protein (N.N. and M.K.G., unpublished data). There is some evidence suggesting that CLMF is produced predominantly by B cells. In preliminary experiments, B-cell mitogens have appeared to be more effective than T-cell mitogens in eliciting CLMF production from peripheral blood lymphocytes (M.K.G., unpublished results). When screening human cell lines for their ability to produce CLMF activity (7), we observed that four of eight B-cell lines tested produced CLMF after activation with PMA and calcium ionophore, whereas none of five T-cell lines produced CLMF. Nevertheless, three of these T-cell lines secreted large amounts of IL-2 and tumor necrosis factor activity after activation (M.K.G., unpublished results). Likewise, natural killer cell stimulatory factor (NKSF), a heterodimeric cytokine similar or identical to CLMF, was isolated from RPMI 8866 lymphoblastoid B cells (17). A recent report (18) has indicated that B lymphocytes can secrete a cytokine(s) distinct from IL-2 that facilitates virus-specific cytolytic T-lymphocyte responses. It is possible that CLMF may have been the cytokine active in those studies. Thus, although B lymphocytes have not traditionally been viewed as cytokine-producing helper cells, it is conceivable that CLMF production constitutes a novel mechanism whereby B lymphocytes contribute to the amplification of T-lymphocyte responses. In addition to the biologic activities described in this report, CLMF by itself has been shown (i) to activate NK cells in an 18–22 hr assay, (ii) to facilitate the generation of specific allogeneic CTL responses, and (iii) to stimulate the secretion of  $\gamma$  interferon by resting peripheral blood lymphocytes (M.K.G., unpublished results). It can also synergize with low concentrations of recombinant IL-2 in the latter two assays and in causing the proliferation of resting peripheral blood lymphocytes. In view of its production by peripheral blood lymphocytes and its diverse actions on lymphoid cells, it appears that CLMF constitutes a new interleukin. We propose that CLMF be

given the provisional designation IL-12. The availability of recombinant CLMF will now make possible a broader and more detailed characterization of its biology.

1. Rosenberg, S. A., Mule, J. J., Speiss, P. J., Reichert, C. M. & Schwartz, S. L. (1985) *J. Exp. Med.* 161, 1169–1188.
2. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C. & Reichert, C. M. (1985) *N. Engl. J. Med.* 313, 1485–1492.
3. Iigo, M., Sakurai, S., Tamura, T., Saijo, N. & Hoshi, A. (1988) *Cancer Res.* 48, 260–264.
4. Winklesake, J. L., Stampfl, S. & Zimmerman, R. J. (1987) *Cancer Res.* 47, 3948–3953.
5. Gately, M. K., Wilson, D. E. & Wong, H. L. (1986) *J. Immunol.* 136, 1274–1282.
6. Wong, H. L., Wilson, D. E., Jenson, J. C., Familletti, P. C., Stremlo, D. L. & Gately, M. K. (1988) *Cell Immunol.* 111, 39–54.
7. Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y.-C. E., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L., Truitt, T., Chizzonite, R. & Gately, M. K. (1990) *Proc. Natl. Acad. Sci. USA* 87, 6808–6812.
8. Compton, T. (1990) in *PCR Protocols*, eds. Innis, M. A., Gelfand, D. H., Sninsky, J. J. & White, T. J. (Academic, New York), pp. 39–45.
9. Cullen, B. (1987) *Methods Enzymol.* 152, 684–703.
10. Maniatis, T., Fritsch, E. F. & Sambrook, J. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
11. Dayhoff, M. O., Barker, W. C. & Hunt, L. T. (1983) *Methods Enzymol.* 91, 524–545.
12. Williams, A. F. (1987) *Immunol. Today* 8, 298–303.
13. Shaw, G. & Kamen, R. (1986) *Cell* 46, 659–667.
14. Taira, S., Matsui, M., Hayakawa, K., Yokoyama, T. & Naruchi, H. (1987) *J. Immunol.* 139, 2957–2964.
15. Brent, L. H., Miyawaki, T., Everson, M. P. & Butler, J. L. (1990) *Eur. J. Immunol.* 20, 1125–1129.
16. Corless, C. L., Matzuk, M. M., Ramabhadran, T. P., Krichevsky, A. & Boime, I. (1987) *J. Cell Biol.* 104, 1173–1181.
17. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, P., Perussia, B. & Trinchieri, G. (1989) *J. Exp. Med.* 170, 827–845.
18. Liu, Y. & Mullbacher, A. (1989) *Proc. Natl. Acad. Sci. USA* 86, 4629–4633.

# Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma

By Amy C. Peterson, Helena Harlin, and Thomas F. Gajewski

**Purpose:** Preclinical studies showed that immunization with peripheral blood mononuclear cells (PBMC) loaded with tumor antigen peptides plus interleukin-12 (IL-12) induced CD8<sup>+</sup> T-cell responses and tumor rejection. We recently determined that recombinant human (rh) IL-12 at 30 to 100 ng/kg is effective as a vaccine adjuvant in patients. A phase II study of immunization with Melan-A peptide-pulsed PBMC + rhIL-12 was conducted in 20 patients with advanced melanoma.

**Patients and Methods:** Patients were HLA-A2-positive and had documented Melan-A expression. Immunization was performed every 3 weeks with clinical re-evaluation every three cycles. Immune responses were measured by ELISpot assay before and after treatment and through the first three cycles, and were correlated with clinical outcome.

**Results:** Most patients had received prior therapy and had visceral metastases. Nonetheless, two patients achieved a

complete response, five patients achieved a minor or mixed response, and four patients had stable disease. The median survival was 12.25 months for all patients and was not yet reached for those with a normal lactate dehydrogenase. There were no grade 3 or 4 toxicities. Measurement of specific CD8<sup>+</sup> T-cell responses by direct ex vivo ELISpot revealed a significant increase in interferon gamma-producing T cells against Melan-A ( $P = .015$ ) after vaccination, but not against an Epstein-Barr virus control peptide ( $P = .86$ ). There was a correlation between the magnitude of the increase in Melan-A-specific cells and clinical response ( $P = .046$ ).

**Conclusion:** This immunization approach may be more straightforward than dendritic cell strategies and seems to have clinical activity that can be correlated to a biologic end point.

*J Clin Oncol* 21:2342-2348. © 2003 by American Society of Clinical Oncology.

MOST MELANOMA tumors express antigens that can be recognized by CD8<sup>+</sup> T cells.<sup>1,2</sup> Nonetheless, tumors frequently escape immune destruction, either from a failure to generate an optimal tumor antigen-specific T-cell response or from development of resistance to the T-cell response induced. One strategy to overcome the former hurdle is through active immunization, the opportunity for which has been facilitated by the molecular definition of melanoma antigens.<sup>3</sup> Specific CD8<sup>+</sup> T cells that are properly activated can home to tumor sites and kill tumor cells, to the extent to which they can overcome negative immunoregulatory pathways and tumor resistance.<sup>4</sup>

The optimal immunization strategy for inducing tumor antigen-specific CD8<sup>+</sup> effector T cells in humans remains undefined. However, antigen-presenting cell-based strategies have shown promise. Both monocyte-derived<sup>5,6</sup> and bone marrow-derived<sup>7</sup> dendritic cells (DCs) have been loaded with

melanoma tumor antigens and administered in the advanced-disease setting, with evidence for immunization and tumor regression in subsets of patients. However, DCs are cumbersome to generate and alternative approaches that are more straightforward yet equally as effective would be useful. One cofactor produced by DCs that contributes to their efficacy is interleukin-12 (IL-12), which facilitates the induction of interferon gamma (IFN- $\gamma$ )-producing cytolytic effector cells.<sup>8-10</sup> Endogenous IL-12 seems necessary for optimal rejection of immunogenic murine tumors<sup>11,12</sup> and provision of exogenous IL-12, either alone<sup>13</sup> or combined with tumor antigen-based vaccines,<sup>14-19</sup> can induce rejection of pre-established tumors in murine models. We previously have shown that coadministration of IL-12 with peripheral blood mononuclear cells (PBMCs) loaded with tumor antigen peptides induced specific cytolytic T-lymphocyte responses and tumor protection in mice, circumventing the need to generate dendritic cells.<sup>20</sup> The ease by which PBMC can be isolated from patients has made this an attractive approach for clinical translation. We recently conducted a phase I clinical study to determine the dose of recombinant human (rh) IL-12 necessary to induce T-cell responses in combination with antigen-loaded PBMCs, and found that doses from 30 to 100 ng/kg administered subcutaneously (sc) at the vaccine site were optimal and well tolerated.<sup>21</sup> The effective range of doses indicated that a straight dose of 4  $\mu$ g might be used.

In this article, we describe results of a phase II clinical study of immunization with Melan-A/MART-1<sup>3</sup> peptide-pulsed autologous PBMCs + rhIL-12 in HLA-A2-positive patients with

From the University of Chicago, Departments of Pathology and Medicine, Section of Hematology/Oncology, and the Ben May Institute for Cancer Research, Chicago, IL.

Submitted December 26, 2002; accepted March 26, 2003.

Supported by the Burroughs Wellcome Fund, Research Triangle Park, NC, and the Cancer Research Institute, New York, NY.

A.P. and H.H. contributed equally to this work.

Address reprint requests to Thomas F. Gajewski, MD, PhD, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637; email: tgajewski@medicine.bsd.uchicago.edu.

© 2003 by American Society of Clinical Oncology.

0732-183X/03/2112-2342/\$20.00

## MELAN-A + IL-12 VACCINE FOR MELANOMA

advanced melanoma. Immune responses were analyzed using a direct ex vivo ELISpot assay. We show that this vaccine approach had clinical activity and that the magnitude of increased T-cell response correlated with clinical outcome.

## PATIENTS AND METHODS

## Patient Enrollment and Eligibility

This was an open-label, nonrandomized, single-institution study of Melan-A peptide-pulsed autologous PBMCs + rhIL-12.<sup>4</sup> The protocol was approved by the University of Chicago Institutional Review Board and all patients signed written informed consent. Patients who were both HLA-A2-positive and showed Melan-A tumor expression by reverse transcriptase polymerase chain reaction (RT-PCR) were considered for inclusion. Additional inclusion criteria were life expectancy more than 12 weeks, Karnofsky performance status  $\geq 70$ , and adequate hematopoietic, renal, and hepatic function. Delayed-type hypersensitivity (DTH) skin testing was performed against mumps, *Candida*, and *Trichophyton*, not for eligibility but to correlate subsequently with clinical outcome and immunization potential. Patients were excluded if they had severe cardiovascular disease or arrhythmia, were pregnant or nursing, had biologic therapy received within 4 weeks, tested positive for hepatitis B surface antigen or human immunodeficiency virus (HIV), had clinically significant autoimmune disease or any illness requiring immunosuppressive therapy, had a psychiatric illness that would interfere with patient compliance and informed consent, had active gastrointestinal bleeding or uncontrolled peptic ulcer disease, or had uncontrolled brain metastases. Patients with treated brain metastases who were clinically and radiographically stable and did not require corticosteroids were allowed to enter onto the trial.

## Patient Characteristics

Twenty patients with metastatic melanoma were enrolled after giving written informed consent. Patient characteristics are outlined in Table 1. All patients had advanced disease; the majority had at least three sites of metastasis, 60% of which were visceral (ie, noncutaneous and nonpulmonary metastases). Approximately two thirds of the patients had received prior therapy, and 10 patients had an elevated lactate dehydrogenase (LDH) level, which is an important negative prognostic factor.<sup>22</sup> Only 45% were positive for at least one recall antigen (mumps, *Candida*, or *Trichophyton*) by DTH skin testing.

## RT-PCR Analysis

RNA was isolated from fresh tumor cells using guanidine and cesium chloride. cDNA was synthesized and PCR was performed for Melan-A and beta-actin using the primer pairs and reaction conditions described previously.<sup>21</sup> Control reactions without reverse transcriptase were performed to rule out a contribution of genomic DNA. PCR products were visualized using a 1.5% ethidium bromide-stained agarose gel. No formal quantitation was performed.

## Vaccine Preparation

Therapy consisted initially of three 21-day cycles. Vaccinations were given on the first day of each cycle and rhIL-12 was administered subcutaneously on days 1, 3, and 5. Approximately 100 to 150 mL of peripheral blood from patients was collected on day 1 of each cycle into heparinized 60-mL syringes using sterile technique. PBMCs were isolated over a Lymphoprep gradient (Lymphoprep; Axis-Shield PoC, Oslo, Norway), counted, washed, and resuspended in Dulbecco's phosphate-buffered saline (DPBS) at  $40 \times 10^6$  cells/mL. At least  $10 \times 10^6$  cells from each sample were cryopreserved to prepare CD8<sup>+</sup> and CD8<sup>-</sup> fractions for subsequent correlative immunologic studies. The Melan-A<sub>27-33</sub> peptide (AAGIGILTV) was produced according to good manufacturing practice standards by Multiple Peptide Systems (San Diego, CA) and provided in lyophilized vials. Aliquots of peptide were prepared at 5 mmol/L in dimethyl sulfoxide and stored at

Table 1. Patient Characteristics

Patient Characteristic	Patients (n = 20)	
	No.	%
Age, years		
Median	58	
Range	35-79	
Sex		
Male	9	45
Female	11	55
Karnofsky performance status (ECOG)		
90%-100% (0)	10	50
70%-80% (1)	9	45
60%-70% (2)	1	5
No. of metastatic sites		
1	2	10
2		None
$\geq 3$	18	90
Location of metastases		
Visceral	13	65
Brain (irradiated)	4	20
Prior therapy		
None	6	30
Chemotherapy or immunotherapy	7	35
As only prior therapy	5	25
Chemotherapy	1	5
As only prior therapy	1	5
Immunotherapy	4	20
As only prior therapy	1	5
Other*	2	10
As only prior therapy		None
Adjuvant IFN- $\alpha$	5	25
As only prior therapy	3	15
Elevated LDH	10	50
DTH recall positive	9	45

Abbreviations: ECOG, Eastern Cooperative Oncology Group; IFN- $\alpha$ , interferon  $\alpha$ -2b; LDH, lactate dehydrogenase; DTH, delayed-type hypersensitivity.

\*Experimental therapy other than a melanoma vaccine, immunomodulatory cytokine, or chemotherapy.

-80°C for up to 3 months. Peptide preparations were quality controlled for HLA-A2 binding, sterility, and identity by high-performance liquid chromatography and mass spectrometry. An aliquot of peptide was diluted to 20  $\mu$ mol/L in DPBS and mixed with an equal volume of patient PBMCs (final peptide concentration, 10  $\mu$ mol/L; target number of PBMCs,  $10^6$ ) followed by incubation at 37°C for 1 hour in 10 mL DPBS. The cells were then irradiated (20 Gy), washed in DPBS, and resuspended in 1 mL DPBS. The suspension of peptide-loaded PBMCs was injected sc using a 1-mL syringe and a 21-gauge needle, divided evenly into two sites. Preferred sites were those near draining lymph node basins but not near a tumor mass. The actual number of PBMCs administered per vaccine ranged from 78 to  $100 \times 10^6$ .

rhIL-12 was provided by Genetics Institute (Cambridge, MA) as a lyophilized powder of 10  $\mu$ g under vacuum. Each vial was intended for single use only and was stored as a powder in our research pharmacy at 2 to 8°C until reconstituted with sterile water for injection. Once reconstituted, rhIL-12 was loaded into 3-mL syringes and used within 4 hours. rhIL-12 (4  $\mu$ g) was administered sc with a 25-gauge needle just after pulsed PBMC inoculation and immediately adjacent to one of the two immunization sites on days 1, 3, and 5. The same approximate location was used for each injection of peptide-pulsed PBMCs and rhIL-12 for each cycle.

## Toxicity Assessment and Criteria for Clinical Response

Toxicities were determined using the National Cancer Institute common toxicity criteria scale version 2.0. A complete response (CR) was assigned if there was disappearance of all lesions without the appearance of any new

lesions; a partial response (PR) was defined as  $\geq 50\%$  reduction in total tumor volume; a minor response (MR) was defined as less than 50% reduction in total tumor volume; progressive disease (PD) was assigned if new lesions appeared, any tumor reappeared, or if a 25% increase in tumor area was observed; a mixed response was assigned if at least one tumor decreased in size with other or new tumors growing; stable disease (SD) was anything that did not fit the aforementioned criteria. When possible, cutaneous lesions were photographed.

### CD8<sup>+</sup> T-Cell Preparation

CD8<sup>+</sup> and CD8<sup>-</sup> fractions from PBMC were isolated at the time of preparation of each vaccine and cryopreserved until analysis in batch fashion. CD8<sup>+</sup> T lymphocytes were isolated by positive selection using CD8 microbeads and magnetic columns (MACS system; Miltenyi Biotech, Auburn, CA). The unbound CD8<sup>-</sup> fraction was cryopreserved for use as antigen-presenting cells for in vitro expansion of specific CD8<sup>+</sup> T cells. Although the primary ELISpot analysis was performed directly with thawed cells, a secondary assay was carried out after in vitro expansion. For in vitro expansion, CD8<sup>-</sup> cells were thawed from each time point and pooled, pulsed with 50  $\mu\text{mol/L}$  Melan-A peptide in serum-free Iscove's modified Dulbecco's medium (IMDM) with beta<sub>2</sub>-microglobulin, irradiated (3,000 rad), washed, and plated at  $2 \times 10^6$  cells/well in 24-well plates. CD8<sup>+</sup> T cells were thawed and cultured with the irradiated CD8<sup>-</sup> cells at  $4 \times 10^5$  cells/well in IMDM medium containing 10% human AB serum. After 5 days, the cells were collected and plated with a new batch of Melan-A-pulsed irradiated CD8<sup>-</sup> cells. After an additional 5 days the cells were collected and tested.

### ELISpot Assays

Briefly, 96-well membrane bottomed plates (MAHA S4510; Millipore, Bedford, MA) were coated with 15  $\mu\text{g/mL}$  of antihuman IFN- $\gamma$  antibody (Mabtech, Cincinnati, OH) in PBS. The plates were washed and CD8<sup>+</sup> T cells, either freshly thawed at  $5 \times 10^4$  cells/well or after in vitro expansion at  $5 \times 10^3$  cells/well, were plated in triplicate in IMDM medium with 10% human AB serum. T2 cells (transporter associated with antigen processing-deficient cell line, American Type Culture Collection no. CRI 1992) were pulsed for 1 hour at 37°C with 50  $\mu\text{mol/L}$  peptide (either derived from HIV [ILKEPVHGV], Epstein-Barr virus [EBV; GLCTLVAML], or Melan-A [AAGIGILTV]), washed, and plated at a 5-to-1 ratio to the T cells. A replicate of CD8<sup>+</sup> T cells was stimulated with PMA (phorbol 12-myristate 13-acetate) (50 ng/mL) + ionomycin (0.5  $\mu\text{g/mL}$ ) as a positive control. After 24 hours, the cells were removed by washing with PBS + 0.05% Tween (wash buffer), and biotinylated antihuman IFN- $\gamma$  antibody was added in PBS + 0.5% fetal calf serum. The plates were incubated for 2 to 4 hours at room temperature, washed, and streptavidin-alkaline phosphatase was added for 1 hour at room temperature. The plates were then washed, BCIP-NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro-blue tetrazolium) was added, and the plates were finally washed with water and allowed to air dry. Plates were scanned with an ELISpot reader (CTL Technologies, Cleveland, OH) and the number of spots per well was enumerated after the background was set on the basis of wells that had been incubated with medium alone; spot separation was adjusted using Immunospot software (CTL Technologies). For each sample, the number of T cells producing IFN- $\gamma$  in response to EBV or Melan-A peptides was determined by subtracting the number of spots seen in response to HIV peptide. The mean and SD were determined for each triplicate sample. After immunization, the time point at which peak frequencies among the first three cycles were observed was used for data analysis.

### Statistical Analysis

Comparisons between pre- and post-ELISpot frequencies were performed using a paired *t* test, and comparisons of augmented ELISpot frequencies between responders and nonresponders were made using an unpaired two-sided *t* test. Correlations between various dichotomous variables and clinical outcome were made using Fisher's exact test (two-sided). Survival data were determined using the Kaplan-Meier method, with differences among subgroups assessed by the log-rank test. All analyses were performed using SPSS software (version 8.0; SPSS Inc, Chicago, IL).

Table 2. Adverse Events

Adverse Event	Grade 1	Grade 2	Grade 3
Fatigue	16	0	0
Anorexia	6	0	0
Fever	7	0	0
Rash	3	0	0
Headache	3	0	0
Nausea	2	0	0
Injection site reaction	5	0	0
Neutropenia	1	2	0
Thrombocytopenia	2	0	0
Hepatic	5	2	0
Creatinine	1	0	0

NOTE. Adverse events were determined using the National Cancer Institute common toxicity criteria scale version 2.0.

## RESULTS

### Immunization Treatment and Toxicities

Each 3-week cycle consisted of immunization on day 1 and sc rhIL-12 administration on days 1, 3, and 5, as described in Methods. Three cycles constituted one course of therapy and patients were evaluated for response after each course. Patients were observed as inpatients in our General Clinical Research Center for the first 24 hours of each cycle.

Adverse reactions are listed in Table 2. All but one patient completed at least three cycles of therapy. There were no grade 3 to 4 toxicities; two patients had grade 2 neutropenia and two patients had grade 2 ALT or AST elevations, which were reversible. The most common adverse reactions were fatigue and fever.

### Clinical Outcome

Clinical response outcomes are listed in Table 3. Two patients had a CR, for an overall response rate of 10%. In addition, four patients (20%) had a mixed response, one patient (5%) had an MR, four patients (20%) had SD, and the remaining nine patients (45%) had PD. The sites of tumor response were diverse. The two patients who experienced a CR both had numerous metastases of 2 cm or less and a normal LDH. One patient was female, had multiple cutaneous lesions, and no prior therapy; the other patient was male, had multiple lung lesions, and had experienced prior treatment failure from chemioimmunotherapy. Neither patient experienced a recurrence with a mean follow-up time of 28 months at the time of data analysis. Of the five other patients who showed a decrease in size of at least one tumor mass, three had responses in skin, one had a response in bone, and one had a response in an adrenal lesion. Three of the four patients with SD had visceral metastases.

Table 3. Clinical Outcome

Best Response	No. of Patients	%
Complete response	2	10
Partial response	0	0
Minor response	1	5
Mixed response	4	20
Stable disease	4	20
Progressive disease	9	45

## MELAN-A + IL-12 VACCINE FOR MELANOMA




Fig 1. Interferon gamma ELISpot frequencies by CD8<sup>+</sup> T cells against Melan-A and (A) Epstein-Barr virus (EBV) (B) pre- and postimmunization. Control values with HIV peptide were subtracted out. Post- and pretreatment values were compared using a paired *t* test.

### Peptide-Specific T-Cell Responses by ELISpot

A carefully controlled IFN- $\gamma$  ELISpot assay was used to monitor the immune response to immunization. Cryopreserved CD8<sup>+</sup> T cells were thawed in batch fashion and stimulated in triplicate directly ex vivo with T2 cells loaded with peptides derived from either HIV, EBV, or Melan-A. The HIV values were subtracted from those obtained with either Melan-A or EBV as an internal control at each time point. Seventeen of the enrolled patients had adequate cryopreserved material with which to perform immunologic assessments.

As shown in Fig 1, some patients displayed a high frequency of Melan-A-specific CD8<sup>+</sup> T cells before vaccination, with as high as 1% of CD8<sup>+</sup> cells responding to this peptide. These T cells were functional because they produced IFN- $\gamma$ . The majority of patients showed an increase in the frequency of Melan-A-specific cells after immunization ( $P = .015$ ). In contrast, the frequencies of specific CD8<sup>+</sup> T cells responding to the EBV peptide did not vary significantly overall ( $P = .86$ ). Although the changes in T-cell frequency were modest, these results demonstrate an antigen-specific response after immunization with Melan-A peptide-pulsed PBMC + rhIL-12.

The changes in Melan-A-specific ELISpot frequencies were compared among patients who had a mixed response or better and those who had no clinical response. As shown in Fig 2, the mean increase in Melan-A-specific T cells for the clinical responders was  $112 \pm 45$  and for nonresponders was  $26 \pm 16$ , indicating that a greater absolute increase in Melan-A-specific T cells was associated with tumor regression ( $P = .046$ ).

### Survival and Associations Between Immunologic Parameters and Clinical Outcome

The overall median survival was 12.25 months and is shown in Fig 3A. Seven patients remained alive at the time of data analysis, with all patients followed beyond 12 months. Because the presence of elevated levels of serum LDH is a known




Fig 2. Comparison of increased Melan-A ELISpot frequencies after immunization between clinical responders and nonresponders. The absolute difference between Melan-A-specific ELISpot frequencies post- and pretreatment was compared between responders and nonresponders using a two-sided, unpaired *t* test.

negative prognostic factor,<sup>23</sup> survival was also compared in response to this vaccine on the basis of LDH level (Fig 3B). The median survival for patients with an elevated LDH level was 9.25 months, whereas the median had not yet been reached for those with a normal LDH ( $P = .005$ ). In addition, the median survival for patients who experienced a significant increase in Melan-A-specific T cells was not yet reached, compared with 8.5 months for patients without a significant increase in Melan-A-specific cells (Fig 3C;  $P = .120$ ).

Additional immunologic parameters that had been measured were also analyzed for associations with either clinical response or survival and are summarized in Table 4. Neither a positive recall DTH to standard antigens nor a relatively high number of EBV- or Melan-A-specific CD8<sup>+</sup> T cells before immunization correlated with either outcome. The median pretreatment Melan-A-specific T cell frequency was 23 in clinical nonresponders and -26 in responders. To increase the sensitivity of the assay to detect Melan-A-specific T cells, an in vitro expansion was performed on the preimmunization samples and analyzed by ELISpot as described in Methods. Ten patients showed high Melan-A-specific T cell frequencies after in vitro expansion. However, this also failed to correlate with clinical outcome. Finally, although a normal LDH level was associated with survival, it did not correlate with clinical response and also did not correlate with immune response. Collectively, these results reinforce the specificity of the result showing a significant association between an increased number of Melan-A-specific T cells and clinical outcome.

### Expression of Melan-A in Resected Tumors After Immunization

It was conceivable that some patients developed PD despite immunization because of outgrowth of Melan-A-negative tumor cells. Posttreatment tumor samples were obtained from progressing tumors from three patients and analyzed by RT-PCR. Although the new metastasis that developed in patient 1 was negative for






Fig 3. Overall survival for all patients (A), on the basis of serum lactate dehydrogenase greater than 200 U/L (B), and on the basis of increased Melan-A-specific interferon gamma-producing CD8<sup>+</sup> T cells (C) was determined using the Kaplan-Meier method. Differences between groups were compared using the log-rank test.

Melan-A expression, those samples from patients 4 and 6 retained detectable expression of Melan-A mRNA (Fig 1). These results indicate that, although outgrowth of antigen-negative tumors can occur, other mechanisms of resistance to immune destruction likely explain the lack of clinical response in other patients.

#### DISCUSSION

In this study we used Melan-A peptide-pulsed autologous PBMC + rhIL-12 as a vaccine to treat HLA-A2-positive patients with advanced melanoma. We observed a significant increase in Melan-A-specific IFN- $\gamma$ -producing CD8<sup>+</sup> T cells after immunization, and found a statistical association between clinical response and the magnitude of the specific T-cell increase. Although it is difficult to compare across individual, small phase II studies, these results are similar to those that have been reported using antigen-loaded dendritic cells, but with a strategy that may be more straightforward to execute.

Preparation of the peptide-loaded PBMCs typically took 5 hours from phlebotomy to injection, and quality control of the cell product was facilitated by the lack of an extended in vitro culture period and absence of exposure to culture medium or serum proteins that is required for dendritic cell preparations. Conversely, dendritic cell vaccines have been prepared in batches and cryopreserved in individual doses in some studies, which obviates the need to prepare a fresh vaccine at each time point. Cryopreservation of vaccines has not yet been examined with our current approach. A comparative trial between PBMC/rhIL-12 and dendritic cell-based vaccination may, therefore, be of interest as the technologies continue to develop. Our results

support the notion developed in preclinical models that IL-12 can contribute to effective antitumor immunity, and are consistent with the results of a recent adjuvant vaccine study using rhIL-12 in melanoma.<sup>24</sup>

We used a direct ex vivo ELISpot assay to assess antigen-specific T-cell responses in this study. Control experiments testing EBV reactivity from normal donors revealed that ELISpot analysis could be performed accurately on cryopreserved CD8<sup>+</sup> T cell samples immediately after thawing (H. Harlin and T. Gajewski, unpublished data). We found that background reactivity against the control HIV peptide varied among patients and to some extent among time points for an individual patient. The magnitude of increase in apparent Melan-A-reactive T cells would have been greater in some patients had the values obtained with the HIV control peptide not been subtracted. We believe that this experimental detail is critical because it normalizes the samples for background differences and provides an internal control for minor variation between individual vials of cryopreserved T cells. We also compared the Melan-A frequencies to those against an EBV control peptide, to determine whether the treatment was altering ELISpot results. We performed our analyses on purified CD8<sup>+</sup> T cells to control for variable numbers between patients and across time points. It is possible that we excluded subpopulations of CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and natural killer T cells that could have produced IFN- $\gamma$  in response to Melan-A. Nonetheless, our results revealed a measurable and significant increase in Melan-A-specific T cells posttreatment. Our currently employed ELISpot assay is distinct from the assay used in our phase I trial of peptide-pulsed



Table 4. Statistical Correlates With Response or Survival

Parameter	Correlation With Response (P)	Correlation With Survival (P)
Positive DTH recall	.642	.130
Strong EBV pro-Rx*	.131	.491
Increased EBV post versus pre†	.290	.644
Strong Melan-A pro-Rx†	.644	.481
Increased Melan-A post versus pre†	.046	.120
Strong in vitro expansion of Melan-A5	.304	.565
LDH levels < 200	.99	.005

NOTE. Associations with response were determined using Fisher's exact test (two sided), except the differences between pre- and posttreatment, which were determined using an unpaired *t* test. Associations with survival were determined using the Kaplan-Meier method and log-rank test. Significant values are indicated in boldface.

Abbreviations: DTH, delayed-type hypersensitivity; EBV, Epstein-Barr virus; Rx, immunization; LDH, lactate dehydrogenase; HIV, human immunodeficiency virus; IL-2, interleukin-2.

\*At least 90 spots per  $10^5$  CD8<sup>+</sup> T cells after subtraction of background against a control HIV peptide.

†Changes between post- and prevaccination samples were calculated as the difference between the absolute number of specific spots and compared using an unpaired *t* test between clinical responders and nonresponders.

‡At least 40 spots per  $10^5$  CD8<sup>+</sup> T cells after subtraction of background against a control HIV peptide.

§At least 90 spots per  $10^5$  CD8<sup>+</sup> T cells after subtraction of background against a control HIV peptide, after a 10-day in vitro expansion with Melan-A peptide-pulsed autologous CD8<sup>+</sup> cells and IL-2.

PBMC + rhIL-12 and in other trials<sup>21,25</sup> in which in vitro expansion had been performed before assessment of IFN- $\gamma$  production. Analysis of T-cell responses with minimal in vitro manipulation should most accurately reflect the status of those cells in vivo.

High frequencies of Melan-A-specific, IFN- $\gamma$ -producing CD8<sup>+</sup> T cells were observed in some patients at study entry when they clearly had progressively growing melanoma. This observation indicates that the absolute frequency of functional T cells against a tumor antigen does not correlate with the behavior of the tumor. We also found no statistical association between this high frequency and clinical outcome; in fact, the two patients who experienced a CR had undetectable Melan-A-specific T cells before therapy. Although high frequencies of T cells reacting with a Melan-A tetramer have been detected in some normal donors,<sup>26</sup> those cells had a naïve surface phenotype and did not produce high levels of IFN- $\gamma$ . What did correlate with clinical response in our current study is a meaningful increase in Melan-A-specific T cells posttreatment. These increases were modest (a net gain of 112 spots per  $10^5$  CD8<sup>+</sup> T cells on average), indicating either that a subtle alteration in the steady-state between the immune response and a growing tumor in favor of increased T-cell frequencies is sufficient to translate into tumor regression, or that another immune function that we are not measuring is contributing to the final event of tumor shrinkage. Tumor regressions without detectable increases in




Fig 4. Melan-A expression in tumors that persisted after immunization. Three patients underwent surgical resection of lesions (after discontinuing the study), which were analyzed for Melan-A expression by qualitative reverse transcriptase polymerase chain reaction. Controls were analyzed without reverse transcriptase or with beta-actin primers.

T-cell frequencies using standard assays have been observed in other studies.<sup>27</sup>

The median overall survival in our study was 12.25 months from treatment initiation, which is greater than the expected 6 to 9 months for this patient population. Although it was a relatively small study and subject to selection bias, most patients were pretreated and had visceral disease, one half of the patients had elevated serum LDH levels, and four patients had treated brain metastases. As has been seen in melanoma patients treated with standard therapies, we found that an elevated serum LDH level was a negative prognostic factor for survival. Whether this is reflective of tumor burden or the metabolic state of the tumor cells that have adapted to an anaerobic environment is unclear.

Some patients developed increases in Melan-A-specific T cells and developed progressive tumor growth despite retained expression of the antigen on posttreatment biopsies. This observation is similar to that seen in murine studies<sup>28</sup> and indicates mechanisms of tumor resistance downstream from initial T-cell priming, presumably within the tumor microenvironment. Potential explanations include poor T-cell trafficking to tumor sites, presence of negative regulatory cells, T-cell anergy or death, expression of inhibitory molecules by tumor cells, or downregulation of class I major histocompatibility complex or antigen-processing molecules.<sup>29,30</sup> Future studies should investigate definable mechanisms of tumor escape that allow tumor cells to resist elimination by antigen-specific T cells in vivo.

#### ACKNOWLEDGMENT

We thank Genetics Institute/Wyeth for rhIL-12, and T. Karrison, M. Sherman, S. Swiger, and M. Posner for important contributions.

#### REFERENCES

- Boon T, Cerottini JC, Van den Eynde B, et al: Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* 12:337-365, 1994
- Kawakami Y, Robbins PF, Wang RF, et al: Identification of tumor-regression antigens in melanoma. *Important Adv Oncol* 3-21, 1996

3. Coulie PG, Brichard V, Van Pel A, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 180:35-42, 1994
4. Gajewski TF, Fallarino F: Rational development of tumor antigen-specific immunization in melanoma. *Ther Immunol* 2:211-225, 1995
5. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 4:328-332, 1998
6. Thurner B, Haendle I, Roder C, et al: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 190:1669-1678, 1999
7. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res* 61:6451-6458, 2001
8. Gajewski TF, Renauld JC, Van Pel A, et al: Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. *J Immunol* 154:5637-5648, 1995
9. Mehrotra PT, Wu D, Crim JA, et al: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. *J Immunol* 151:2444-2452, 1993
10. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu Rev Immunol* 13:251-276, 1995
11. Fallarino F, Uyttenhove C, Boon T, et al: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. *J Immunol* 156:1095-1100, 1996
12. Fallarino F, Gajewski TF: Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Stat1. *J Immunol* 163:4109-4113, 1999
13. Brunda MJ, Luistro L, Warrior RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. *J Exp Med* 178:1223-1230, 1993
14. Hallez S, Detremmerie O, Giannouli C, et al: Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. *Int J Cancer* 81:428-437, 1999
15. Fallarino F, Ashikari A, Boon T, et al: Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. *Int Immunol* 9:1259-1269, 1997
16. Vagliani M, Rodolfo M, Covello F, et al: Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. *Cancer Res* 56:467-470, 1996
17. Cavallo F, Signorelli P, Giovarelli M, et al: Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. *J Natl Cancer Inst* 89:1049-1058, 1997
18. Rao JB, Chamberlain RS, Bronte V, et al: IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. *J Immunol* 156:3357-3365, 1996
19. Sumimoto H, Tani K, Nakazaki Y, et al: Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice. *Cancer Gene Ther* 5:29-37, 1998
20. Fallarino F, Uyttenhove C, Boon T, et al: Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. *Int J Cancer* 80:324-333, 1999
21. Gajewski TF, Fallarino F, Ashikari A, et al: Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. *Clin Cancer Res* 7:895s-901s, 2001
22. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. *Cancer* 88:1484-1491, 2000
23. Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. *J Clin Oncol* 16:1103-1111, 1998
24. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multipptide vaccine for resected metastatic melanoma. *J Clin Oncol* 19:3836-3847, 2001
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 4:321-327, 1998
26. Pittet MJ, Vahmori D, Dunbar PR, et al: High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. *J Exp Med* 190:705-715, 1999
27. Marchand M, van Baren N, Weynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 80:219-230, 1999
28. Wick M, Dubey P, Koeppen H, et al: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. *J Exp Med* 186:229-238, 1997
29. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. *Immunol Today* 16:487-494, 1995
30. Marincola FM, Jaffee EM, Hicklin DJ, et al: Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. *Adv Immunol* 74:181-273, 2000

# Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

By Beatrice Thurner,\* Ina Haendle,\* Claudia Röder,\*  
Detlef Dieckmann,\* Petra Kelkavoussi,† Helmut Jonuleit,§  
Armin Bender,\* Christian Maczek,\* Doris Schreiner,\*  
Peter von den Driesch,\* Eva B. Bröcker,‡ Ralph M. Steinman,||  
Alexander Enk,§ Eckhart Kämpgen,‡ and Gerold Schuler\*

From the \*Department of Dermatology, University of Erlangen-Nuremberg, D-91052 Erlangen, Germany; the †Department of Dermatology, University of Würzburg, D-97080 Würzburg, Germany; the §Department of Dermatology, University of Mainz, D-55131 Mainz, Germany; and the ||Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021

## Summary

Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma patients, who were progressive despite standard chemotherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were administered into the skin,  $3 \times 10^6$  DCs each subcutaneously and intradermally, followed by two intravenous injections of  $6 \times 10^6$  and  $12 \times 10^6$  DCs, respectively. Only minor (less than two equal to grade II) side effects were observed. Immunity to the recall antigen was boosted. Significant expansions of Mage-3A1-specific CD8<sup>+</sup> cytotoxic T lymphocyte (CTL) precursors were induced in 8/11 patients. Curiously, these immune responses often declined after the intravenous vaccinations. Regressions of individual metastases (skin, lymph node, lung, and liver) were evident in 6/11 patients. Resolution of skin metastases in two of the patients was accompanied by erythema and CD8<sup>+</sup> T cell infiltration, whereas nonregressing lesions lacked CD8<sup>+</sup> T cells as well as Mage-3 mRNA expression. This study proves the principle that DC "vaccines" can frequently expand tumor-specific CTLs and elicit regressions even in advanced cancer and, in addition, provides evidence for an active CD8<sup>+</sup> CTL-tumor cell interaction in situ as well as escape by lack of tumor antigen expression.

Key words: dendritic cells • vaccination • active immunotherapy • melanoma • cytotoxic T lymphocytes

It is now established that the immune system has cells, particularly CD8<sup>+</sup> CTLs, that can recognize tumor antigens and kill tumors (1, 2). Nevertheless, a major problem is that these T cells are either not induced or only weakly induced, i.e., the T cells are not evident in the systemic circulation. One possibility is that there is inadequate tumor antigen presentation by dendritic cells (DCs),<sup>1</sup> "nature's adjuvant" for eliciting T cell immunity (3). Another is that

tumor-reactive T cells are tolerized by the tumors (1, 4). Melanoma provides a compelling setting in which to pursue a current goal of cancer immunotherapy, the generation of stronger tumor-specific T cell immunity, particularly with CTLs (4). The majority of tumor antigens identified so far are expressed by melanomas (2). Limited antimelanoma CTL responses have been detected (5), and infusions of IL-2 expanded killer cells can lead to rejection of melanoma (6).

Conventional adjuvants promote antibody rather than CTL responses. Therefore, several novel strategies are being explored to induce tumor-specific T cell immunity. DC vaccination is one of these (3). Immature DCs capture

<sup>1</sup>Abbreviations used in this paper: CNS, central nervous system; DCs, dendritic cells; DTH, delayed-type hypersensitivity; MCM, monocyte-conditioned medium; RT, reverse transcriptase; TT, tetanus toxoid.

antigens but lack full T cell-stimulatory activity (7). In the presence of appropriate stimuli, such as inflammatory cytokines, the DCs mature. DCs upregulate T cell adhesion and costimulatory molecules as well as select chemokine receptors that guide DC migration into lymphoid organs for priming of antigen-specific T cells. The use of DCs as adjuvants is supported by many animal experiments with primarily mature DCs (3, 8). These studies have shown that the injection of tumor antigen-loaded DCs reliably induces tumor-specific CTL responses, tumor resistance, and in some cases, regression of metastases (3, 8). In the few pilot trials reported so far for humans, immature DCs have been employed (9-11). Scattered tumor responses are reported, but evidence for the induction of tumor-specific CTLs by DC vaccination has not been shown.

We have developed a technique to generate large numbers of homogenous populations of mature and stable DCs from monocytes in the absence of nonhuman proteins (12, 13). We are now exploring the use of these DCs as vaccine adjuvants in humans. Here we provide the proof of the principle by demonstrating that three intracutaneous injections of Mage-3A1 peptide-pulsed mature DCs reliably enhance Mage-3A1-specific CD8<sup>+</sup> and recall CD4<sup>+</sup> T cell immunity in heavily pretreated, progressive stage IV melanoma patients with large tumor loads. Expansions of Mage-3A1-specific CTL responses have not been previously detected after Mage-3A1 peptide vaccination in less advanced melanoma patients (14), underscoring the potent adjuvant properties of DCs. As regressions of metastases also occurred upon DC-mediated immunization and were accompanied by CD8<sup>+</sup> T cell infiltration, we propose that the induced Mage-3A1-specific CTLs are active *in vivo*.

## Materials and Methods

### Patient Eligibility Criteria

Patients were eligible if they suffered from stage IV (i.e., distant metastases) cutaneous malignant melanoma (1988 American Joint Committee on Cancer/Union Internationale Contre Cancer pTNM staging system) that was not curable by resection and was progressive despite chemo(immuno)therapy. Further inclusion criteria were an expected survival  $\geq 4$  mo, Karnofsky index  $\geq 60\%$ , age  $\geq 18$  yr, measurable disease, HLA-A1 positivity, expression of Mage-3 gene shown by reverse transcriptase (RT)-PCR in at least one excised metastasis, and no systemic chemo-, radio-, or immunotherapy within 4 wk (6 wk in the case of nitrosurea drugs) preceding the first DC vaccination. A positive skin test to recall antigens was not required. Important exclusion criteria were active central nervous system (CNS) metastasis, any significant psychiatric abnormality, severely impaired organ function (hematological, renal, liver), active autoimmune disease (except vitiligo), previous splenectomy or radiation therapy to the spleen, organ allografts, evidence for another active malignant neoplasm, pregnancy, lactation, or participation (or intent to participate) in any other clinical trial. Concomitant treatment (chemo- or immunotherapy, corticosteroids, investigational drugs, paramedical substances) was prohibited. Palliative radiation or surgical therapy of selected metastases and certain medications (acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs, opiates) to control symptoms were allowed.

### Clinical Protocol and Study Design

The study was performed at the Departments of Dermatology in Erlangen, Würzburg, and Mainz, Germany according to standards of Good Clinical Practice for Trials on Medicinal Products in the European Community. The protocol was approved by the Protocol Review Committee of the Ludwig Institute for Cancer Research (New York, NY) and performed under supervision of its Office of Clinical Trials Management as study LUD #97-001. The protocol was also approved by the ethics committees of the involved study centers.

The study design is shown in Table II. All patients gave written informed consent before undergoing a screening evaluation to determine their eligibility. Extensive clinical and laboratory assessments were conducted at visits 1, 5, and 8 (Table II) and consisted of a complete physical examination, staging procedures, and standard laboratory values as well as special ones (pregnancy test, free testosterone in males, autoantibody profile, and antibodies to HIV-1/2, human T cell lymphotropic virus type I, hepatitis B virus, and hepatitis C virus). Patients were hospitalized and examined the day before each vaccination and were monitored for 48 h after the DC injections. Adverse events and changes in laboratory values were graded on a scale derived from the Common Toxicity Criteria of the National Cancer Institute, National Institutes of Health, Bethesda, MD.

### Production of the DC Vaccine

During prestudy screening, we tested a small amount of fresh blood to verify that appropriate numbers of mature DCs could be generated from the patient's monocytes (12). Sufficient DC numbers could be successfully generated in all patients, but in some patients the test generation revealed that TNF- $\alpha$  had to be added to assure full maturation. To avoid repetitive blood drawings, we performed a single leukapheresis during visit 2 to generate DCs as described (13). In short, PBMCs from the leukapheresis ( $\geq 10^{10}$  nucleated cells) were isolated on Lymphoprep<sup>TM</sup> (Nycomed Pharma) and divided into three fractions. The first fraction of  $10^9$  PBMCs was cultured on bacteriological petri dishes (Cat. #1005; Falcon Labware) coated with human Ig (100  $\mu$ g/ml; Sandoglobulin<sup>TM</sup>; Sandoz GmbH) in complete RPMI 1640 medium (BioWhittaker) supplemented with 20  $\mu$ g/ml gentamicin (Refobacin 10; Merck), 2 mM glutamine (BioWhittaker), and 1% heat-inactivated human plasma for 24 h to generate monocyte-conditioned medium (MCM) for later use as the DC maturation stimulus. The second fraction of  $3 \times 10^8$  PBMCs was used for the generation of DCs for vaccination 1 and delayed-type hypersensitivity (DTH) test I. Adherent monocytes were cultured in 1,000 U/ml GM-CSF (10  $\times 10^7$  U/mg; Leukomax<sup>TM</sup>; Novartis) and 800 U/ml IL-4 (purity  $>98\%$ ;  $4.1 \times 10^7$  U/mg in a bioassay using proliferation of human IL-4R<sup>+</sup> CTLL; CellGenix; expressed in *Escherichia coli* and produced under good laboratory practice conditions but verified for good manufacturing practice [GMP] safety and purity criteria by us) for 6 d, and then MCM was added to mature the DCs. MCM was supplemented in patients 04, 06, 09, 11, and 12 with 10 ng/ml GMP-rhu TNF- $\alpha$  (purity  $>99\%$ ;  $5 \times 10^7$  U/mg in a bioassay using murine L-M cells; a gift of Dr. G.R. Adolf, Boehringer Ingelheim Austria, Vienna, Austria) to assure full maturation of DCs. Mature DCs were harvested on day 7. The third fraction of PBMCs was frozen in aliquots and stored in the gas phase of liquid nitrogen to generate DCs for later vaccinations and DTH tests.

DCs for vaccinations were pulsed with the Mage-3A1 peptide (15) (EVDPIGHLY, synthesized at GMP quality by Clinalfa) as tumor antigen, and as a recall antigen and positive control, tetanus toxoid (TT) or tuberculin (if at visit 1 the DTH to TT in the

Multitest Merieux was  $>10$  mm; both purchased from the Bacterial Vaccines Department of the Statens Serum Institute, Copenhagen, Denmark). The recall antigen was added at  $10 \mu\text{g/ml}$  for the last 24 h, and the Mage-3A1 peptide was added at  $10 \mu\text{M}$  directly to the cultures for the last 8 h (if immunity to recall antigen was strongly boosted, the dose of recall antigen was reduced to 1.0 or 0.1  $\mu\text{g/ml}$  or was omitted for the intravenous DC injections to avoid a cytokine release syndrome). On day 7, mature DCs were harvested, resuspended in complete medium, washed, and pulsed once more with Mage-3A1 peptide (now at  $30 \mu\text{M}$ ) for 60 min at  $37^\circ\text{C}$ . DCs were finally washed and resuspended in PBS (GMP quality PBS; BioWhittaker) for injection. DCs to be used for Mage-3A1 DTH tests were pulsed with Mage-3A1 (but no recall antigen); DCs that served as negative control in the DTH tests were not pulsed at all. An aliquot of the DCs to be used for vaccinations was analyzed as described (13) to assure that functionally active and mature DCs were generated. The features of the DCs are described in Results. Release criteria were typical morphology ( $>95\%$  nonadherent veiled cells) and phenotype ( $>95\%$  HLA-DR $^{+++}$ CD86 $^{+++}$ CD40 $^{+}$ CD25 $^{+}$ CD14 $^{-}$  and  $>65\%$  homogeneously CD83 $^{++}$ ).

#### Immunization Schedule

A total of five vaccinations (three into the skin followed by two intravenously) with antigen-pulsed DCs were given at 14-d intervals (Table II). This design was chosen to explore the toxicity and efficacy of various routes in this trial. For vaccinations 1–3,  $3 \times 10^6$  DCs were given subcutaneously at two sites ( $1.5 \times 10^6$  DCs in  $500 \mu\text{l}$  PBS per site) and  $3 \times 10^6$  intradermally at 10 sites ( $3 \times 10^5$  DCs in  $100 \mu\text{l}$  PBS per site). The injection sites were the ventromedial regions of the upper arms and the thighs close to the regional lymph nodes and were rotated clockwise. Limbs where draining lymph nodes had been removed and/or irradiated were excluded. For intravenous vaccinations 4 and 5, a total of  $6$  and  $12 \times 10^6$  antigen-pulsed DCs (resuspended in 25 or 50 ml PBS plus 1% autologous plasma) was administered over 5 and 10 min, respectively. Premedication with an antipyretic (500 mg acetaminophen/paracetamol p.o.) and an antihistamine (2.68 mg clemastinhydrogenfumarat i.v.) was given 30 min before intravenous DC $^{+}$  vaccination.

#### Evaluation of Immune Status

**Recall Antigen-specific Proliferation and Cytokine Production.** PBMCs were cultured in triplicate at two dose levels ( $3 \times 10^4$  and  $1 \times 10^5$  PBMCs/well) plus or minus TT or tuberculin (at 0.1, 1, and  $10 \mu\text{g/ml}$ ) and pulsed on day 5 with [ $^3\text{H}$ ]thymidine for 12 h. In all cases, the highest cpm were obtained with the highest doses of PBMCs and antigen and are shown in Fig. 2. IL-4 and IFN- $\gamma$  levels were measured in culture media by ELISA (Endogen, Inc.). In a separate plate, staphylococcal enterotoxin (SEA; Serva) was added at 0.5, 1, and 5 ng/ml, and proliferation was assessed after 3 d to provide a positive control for helper T cell viability and responsiveness.

**Enzyme-linked Immunospot Assay for IFN- $\gamma$  Release from Single Antigen-specific T Cells.** To quantitate antigen-specific, IFN- $\gamma$ -releasing, Mage-3A1-specific effector T cells, an enzyme-linked immunospot (ELISPOT) assay was used as described (16). PBMCs ( $10^5$  and  $5 \times 10^5$ /well) or in some cases CD8 $^{+}$  or CD4 $^{+}$  T cells (isolated by MACS $^{\text{TM}}$  according to the manufacturer, Miltenyi Biotec) were added in triplicate to nitrocellulose-bottomed 96-well plates (MAHA S4510; Millipore Corp.) precoated with the primary anti-IFN- $\gamma$  mAb (1-D1K; Mabtech) in  $50 \mu\text{l}$  ELISPOT

medium (RPMI 1640 and 5% heat-inactivated human serum) per well. For the detection of Mage-3A1-reactive T cells, the APCs were irradiated T2A1 cells (provided by P. van der Bruggen, Ludwig Institute of Cancer Research, Brussels, Belgium) pulsed with MHC class I-restricted peptides (Mage-3A1 peptide and the HIV-1 p17-derived negative control peptide GSEELRSLY) added at  $7.5 \times 10^4$ /well (final volume  $100 \mu\text{l}$ /well). After incubation for 20 h, wells were washed six times, incubated with biotinylated second mAb to IFN- $\gamma$  (7-B6-1; Mabtech) for 2 h, washed, and stained with Vectastain Elite kit (Vector Labs.). For detection of TT-reactive T cells, TT was added at  $10 \mu\text{g/ml}$  directly to the PBMCs ( $1$  or  $5 \times 10^5$  PBMCs/flat-bottomed 96-well plate). Assays were performed on fresh PBMCs. Spots were evaluated and counted using a special computer-assisted video imaging analysis system (Carl Zeiss Vision) as described (16).

**Semiquantitative Assessment of CTL Precursors.** The multiple microculture method developed by Romero et al. (17) was used to obtain a semiquantitative assessment of CTLp (precursors) specific for Mage-3A1 peptide. Aliquots of frozen PBMCs were thawed and assayed together. CD8 $^{+}$  T cells were isolated with magnetic microbeads (MACS $^{\text{TM}}$  separation columns; Miltenyi Biotec) and seeded at  $10^4$ /well in 96-well round-bottomed plates in RPMI 1640 with 10% heat-inactivated human serum. The CD8 $^{-}$  PBMCs were pulsed with peptide Mage-3A1 or the influenza PB1 control peptide VSDGGPNLY ( $10 \mu\text{g/ml}$ ; 30 min at room temperature), irradiated (30 Gy from a cesium source), and added as an APC population at  $10^5$ /well together with IL-2 ( $10 \text{ IU/ml}$  final) and IL-7 ( $10 \text{ ng/ml}$  final) in a total volume of  $200 \mu\text{l}$ /well. On day 7,  $100 \mu\text{l}$  fresh medium was substituted, and peptide Mage-3A1 or PB1 ( $1 \mu\text{g/ml}$  final) and IL-2 ( $10 \text{ U/ml}$ ) was added. On day 12, each microwell was divided into three equal samples to test cytolytic activity in a standard 4-h  $^{51}\text{Cr}$ -release assay on peptide-pulsed ( $10 \mu\text{g/ml}$  for 1 h at  $37^\circ\text{C}$ ) T2A1 cells, nonpulsed T2A1 cells, and K562 target cells, respectively. All of the assays were performed with an 80-fold excess of nonlabeled K562 to block NK activity. Microwells were scored positive if lysis of T2A1 targets with peptide minus lysis without peptide was  $\geq 12\%$  and this specific lysis was greater than or equal to twice the lysis of T2A1 targets without peptide plus six as described (18). We aimed at testing 30 microwells of  $10^4$  CD8 $^{+}$  T cells. Therefore, 1/30 positive wells equals at least one CTLp in  $3 \times 10^5$  (i.e., 30 wells at  $10^4$  CTLp per well) CD8 $^{+}$  T cells (corresponding to  $\sim 3 \times 10^6$  PBMCs).

**DTH.** DTH to Mage-3A1 peptide was assessed by intradermal injection at two sites of each  $3 \times 10^6$  Mage-3A1 peptide-loaded DC in  $0.1 \text{ ml}$  PBS. Negative controls were nonpulsed autologous DCs in  $0.1 \text{ ml}$  PBS and  $0.1 \text{ ml}$  PBS. DTH to seven common recall antigens (Multitest Merieux) including TT and tuberculin was performed on visits 1, 5, and 8 (Table II).

#### Assessment and Analysis of Tumor Tissue

For recruitment into the study, Mage-3 gene expression in at least one metastatic deposit had to be demonstrated by RT-PCR as described (14). Accessible superficial skin metastases were removed whenever possible after the vaccinations and subjected to Mage-3 RT-PCR as well as routine histology and immunohistology (to characterize cellular infiltrates).

#### Statistical Analysis

For analysis of the immune response, pre- and postimmunization values were compared by paired  $t$  test after logarithmic transformation of the data. Significance was set at  $P < 0.05$ .

## Results

### Patient Characteristics

All 13 patients were HLA-A1<sup>+</sup>, had proven Mage-3 mRNA expression in at least one excised metastasis, and suffered from advanced stage IV melanoma, i.e., distant metastases that were progressive despite chemotherapy and, in some cases, chemoimmunotherapy (Table I). We offered DCs to all patients who fulfilled the inclusion and exclusion criteria, i.e., we did not select for subsets of patients. Two patients (numbers 01 and 03) succumbed to melanoma after two and three vaccinations, respectively. 11 patients received all five planned DC vaccinations in 14-d intervals (Table II) and were thus fully evaluable.

### Quality of the Vaccine

All vaccine preparations were highly enriched in mature DCs. More than 95% of the cells were large and veiled in

appearance, expressed a characteristic phenotype by flow cytometry (HLA-DR<sup>+++</sup>CD86<sup>+++</sup>CD40<sup>+</sup>CD25<sup>+</sup>CD14<sup>-</sup>), and acted as strong stimulators of an MLR at DC/T cell ratios of  $\leq 1:300$  (13). Most (mean 80%) expressed the CD83 mature DC marker (19). These features were stable upon removal of cytokines and culture for one to two more days (13). The DCs were pulsed with Mage-3A1 peptide as a tumor antigen and TT or tuberculin as a recall antigen. The latter were internal controls for immunization and possibly provided help for CTL responses (20).

### Toxicity

No major (above grade II) toxicity or severe side effects were observed in any patient, including the two patients who were not fully evaluable. We noticed, however, local reactions (erythema, induration, pruritus) at the intracuta-

Table I. Patients' Characteristics, Status before DC Vaccination, and Response to DC Vaccination

Patient code	Sex-Age	Onset stage IV	Previous therapy	Metastases at study entry <sup>a</sup>							Clinical Response  14 days after the 5 <sup>th</sup> vaccination	Survival
				regional		distant						
				skin	LN	Skin	LN	Lung	Liver	Other		
Patients with objective tumor regression												
04	M48	1/98	PCI							complete regression of all but 1 lung metastasis, overall progression	10 + >9	
06	F61	10/97	CI							complete regression <sup>b</sup> of 1 lung + 4 o.e. <sup>c</sup> metastases, overall progression	8 + >16	
07	F48	8/97	C							complete regression <sup>b</sup> of 1 lung <sup>a</sup> + 2 o.e. <sup>c</sup> metastases, overall progression	13 + 12†	
08	M67	11/97	PC							complete regression <sup>b</sup> of lung + liver + 4 o.e. <sup>c</sup> metastases, overall progression <sup>d</sup>	8 + 3†	
08	F43	5/98	C							Partial regression of 1 lung metastasis, overall progression	4 + >11	
12	M54	9/96	CI							partial regression of axillary LN metastases, overall progression	28 + >8	
Patients without objective tumor regression												
02	F73	5/98	PCI							continuous progression	18 + 5†	
05	F49	10/97	CI							continuous progression	5 + >17	
10	M62	8/98	C							continuous progression	1 + 8†	
11	F72	7/98	C							continuous progression	4 + 9†	
13	M34	12/97	CI							continuous progression	12 + 5†	

Treatment centers: three patients (04, 08, and 12) were treated in Wuerzburg, two in Mainz (patients 10 and 13), and the others in Erlangen. Pretreatment therapy: PCI, polychemoimmunotherapy. Preceding excisions and radiotherapies are not listed.

Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in millimeters). m, multiple (>3 metastases).

Survival: (since onset of stage IV and as of 5 August 1999) is listed as months since onset stage IV until study entry + number of months since study entry. †Patient deceased.

<sup>a</sup>CNS metastases were regressing at study entry after gamma knife treatment.

<sup>b</sup>Developed (in part) after study entry.

<sup>c</sup>Determined by autopsy.

<sup>d</sup>Sudden death from bleeding into CNS metastasis on visit 8.

<sup>e</sup>The regressions of lung metastases in patients 06 and 07 were documented at a staging 3 mo after visit 8.

mediast., mediastinum; pancr., pancreas.



Table II. Study Design

Activities	Screen	Leuka pheresis	Vacc. #1 3 Mio s.c. 3 Mio i.d.	Vacc. #2 3 Mio s.c. 3 Mio i.d.	Vacc. #3 3 Mio s.c. 3 Mio i.d.	Vacc. #4 6 Mio i.v.	Vacc. #5 12 Mio i.v.	Final Evaluation
Clinical visit								
Day	-28/-14	-9	+1	+14	+28	+42	+56	+70
Vaccination			X	X	X	X	X	
Multitest Menouze	X				X			X
DTH to Mage-3A1 peptide-loaded DC			X		X		X	
Recall antigen proliferation		X						X
CTIP analysis		X				X		X
ELISPOT		X	X	X	X	X	X	X
Mage-3A1								
ELISPOT		X	X	X	X	X	X	X
recall antigen								

X, prespecified in the protocol as obligatory; x, optional.

neous vaccination sites that increased with the number of vaccinations. In 9/11 patients, strong DTH reactions (induration >10 mm in diameter) were noted to DCs carrying a recall antigen (Fig. 1). Elevation of body temperature (grade I and II fever) was observed in most (9/11) patients and was also related to pulsing DCs with recall antigen. The most striking example was patient 02, who progressively developed fever (up to 40°C) upon successive vaccinations but did not show a rise in body temperature when TT was omitted for the final (fifth) vaccination. We observed slight lymph node enlargement, clinically in 63% and by sonography in 83% of patients, after the intracutaneous DC injections. Interestingly, these were delayed, being inapparent during the 2 d of monitoring after vaccinations but detected when patients were investigated again the day before the next vaccination (Table II).

#### Immunological Responses

**Boosting of Recall Antigen-specific Immunity.** PBMCs that had been frozen before vaccination and 14 d after vaccination 5 were thawed and assayed together, as specified in the protocol (Table II). In most patients, a significant boost of antigen-specific immunity developed to TT (and tuberculin in patient 10) ( $P < 0.004$ ; Fig. 2). Supernatants from the proliferative assays contained large amounts of IFN- $\gamma$  (mean 1,679 pg/ml, range 846–4,325) but little IL-4 (IFN- $\gamma$ /IL-4, 317:1). In five patients, we studied the kinetics of the immune response to TT by IFN- $\gamma$  ELISPOT analysis. We found an increase after the intracutaneous vaccinations ( $P < 0.02$ ) but a peculiar decrease after the intravenous vaccinations ( $P < 0.008$ ; Fig. 3). Thus, comparing recall immunity before and after all five vaccinations (Fig. 2) as prespecified in the protocol (Table II) obviously underestimated the extent of boosting.




Figure 1. Local reactions to DCs carrying Mage-3A1 peptide and TT at the intradermal and subcutaneous vaccination sites in patient 09 (24 h after vaccination 2; top panel) and 02 (48 h after vaccination 3; bottom panel). Erythema at the 10 intradermal (left) and 2 subcutaneous (right) vaccination sites was followed by induration >10 mm in diameter (with secondary purpura in patient 02). These local reactions represent strong DTH reactions to DCs carrying TT, as such strong reactions did not occur in response to unpulsed DCs or DCs pulsed with Mage-3A1 peptide alone in DTH tests I–III (Table II; reactions not shown).




Figure 2. Recall antigen-specific immunity (tuberculin in patient 10; TT in all others) as assayed by antigen-specific proliferation. The cpm values determined after therapy (14 d after vaccination 5) are shown as multiples of pretherapy cpm values. Absolute cpm (cpm with recall antigen minus cpm without antigen) after therapy was 68,917 in patient 02, 85,225 in patient 04, 16,759 in patient 05, 7,913 in patient 06, 16,367 in patient 07, 107,923 in patient 09, 22,790 in patient 10, 4,507 in patient 12, and 1,831 in patient 13 (SEM for all measurements was <20%). Patients 08 and 11 could not be evaluated due to shortage of cells after therapy.

**Expansion of Mage-3A1-specific CTLp.** Aliquots of PBMCs, frozen before the first and after the third and fifth vaccinations, were thawed at the same time (Table II) and subjected to a semiquantitative recall assay for CTLp (reference 17; Fig. 4). Before vaccination, CTLp frequencies were low or undetectable. In 8/11 patients, we found a significant expansion of Mage-3A1-specific CTLp as indicated by the increase (mean, eightfold;  $P < 0.008$ ) of positive microcultures in the multiple microculture procedure employed for the semiquantitative assessment of CTLp (17). Interestingly, in six patients, the CTLp frequencies were maximal after the three intracutaneous vaccinations ( $P < 0.0013$ ) but then decreased after the two additional intravenous vaccinations in all but one of these patients ( $P < 0.026$ ). Only in 1/11 patients did we observe an increase of CTLp to an irrelevant PB1 influenza peptide that served as a specificity control (not shown).




Figure 3. Kinetic analysis of immunity to recall antigens as assessed by TT-specific IFN- $\gamma$  ELISPOT (SEM for all measurements was <20%). Blood was drawn (see Table II, Study Design) before the first DC vaccination and then every 14 d just before administration of the next DC vaccination (e.g., pre Vacc # 2 means immediately before vaccination 2, i.e., 14 d after vaccination 1), and finally after therapy. Time points at which vaccinations were not performed lack bars. Note the increase after the intracutaneous vaccinations and the decline upon the two vaccinations after intravenous ones. Patient 10, who received tuberculin-pulsed DCs, exhibited no significant change in the TT-specific IFN- $\gamma$  ELISPOT as expected.

**ELISPOT Analysis for IFN- $\gamma$ -releasing, Mage-3A1-specific T Cells.** We also tried to detect Mage-3A1-specific CTL effectors in uncultured fresh, nonfrozen PBMCs by performing ELISPOT analyses at 14-d intervals on all patients. A significant increase of Mage-3A1-reactive IFN- $\gamma$  spot-forming cells was apparent only in patients 07 and 09 after the first and second vaccinations, respectively, but the frequency of Mage-3A1-specific effectors was very high (~5,000 and 10,500/10<sup>7</sup> CD8<sup>+</sup> T cells; not shown).

**DTH Test to Mage-3A1 Peptide-loaded DCs.** Tests of DTH to Mage-3A1 peptide-loaded DCs yielded erythema and/or induration (>5 mm diameter) in 7/11 patients (not shown). The results were, however, equivocal due to the frequently observed background to nonpulsed DCs (up to 10 mm in diameter) and the variability from test site to test site.

### Clinical Responses

At the end of the trial, i.e., ~2 wk after the fifth vaccination (Table II), we observed temporary growth cessation of some individual metastases, but more intriguingly, in 6/11 patients, complete regression of individual metastases in skin, lymph nodes, lung, and liver (Table I and Fig. 5). Resolution of skin metastases was found in three patients (Table I, patients 06, 07, and 08) and in two of them (06 and 07), it was preceded by local pain, itching, and slight erythema. The six regressing skin lesions of patients 06 and 07 (Table I) were also excised and examined by immunohistology. Clusters of CD8<sup>+</sup> T cells were seen around and in the tumor, the latter often necrotic, suggesting an immune attack (Fig. 6).

In patients 06 and 08, the metastases excised at study entry (four and two, respectively) proved to be Mage-3 mRNA<sup>+</sup>. However, all of the samples removed at the end (two and six, respectively) were Mage-3 mRNA<sup>-</sup>, suggesting immunoselection for antigen-negative tumor cells. Remarkably, significant infiltration of CD8<sup>+</sup> T cells was not found in any of these lesions.

### Discussion

In deciding on the source of DCs for this phase I trial, we selected mature, monocyte-derived DCs for the follow-






Figure 4. Mage-3A1 CTLp frequency analysis as assessed by semiquantitative recall assay. The y-axis and the numbers above the bars indicate the percentage of positive wells found before vaccination 1, before vaccination 4 (14 d after vaccination 3), and after therapy (usually 14 d after vaccination 5).

ing reasons. Monocyte-derived DCs currently represent the most homogenous and potent DC populations, with several defining criteria and quality controls (12, 13, 21). The method for generating production of these DCs is very reproducible and allows the cryopreservation of large numbers of cells at an identical stage of development (12, 13). Furthermore, these DCs can be produced in the absence of potentially hazardous FCS (12, 13, 21). FCS exposure also leads to large syngeneic T cell responses in culture, so their clinical use (11) might produce nonspecific immunostimulatory effects. Unlike other investigators (9–11), we chose to use mature rather than immature DCs for our first melanoma trial. The DCs that have been used with efficacy in animal experiments were primarily mature (3, 8). Mature DCs are much more potent in inducing CTL and Th1 responses in vitro (reference 22 and Jonuleit, H., A. Gieseke, A. Kandemir, L. Paragnik, J. Knop, and A.H. Enk, manuscript in preparation), and the DCs are also resistant to the immunosuppressive effects of IL-10 (23) that can be produced by tumors (24–26). Mature DCs also display an extended half-life of antigen-presenting MHC class I (26a) and class II molecules (27). Finally, mature DCs have a high migratory activity (21) and express CCR7 (28), a receptor for chemokines produced constitutively in

lymphoid tissues (28). Mature DCs, as used in this cancer therapy trial, have recently also been shown to rapidly generate broad T cell immunity in healthy subjects (28).

Mature DCs were loaded with only one melanoma peptide, Mage-3A1, to avoid uncertainties regarding loading of DCs with multiple peptides (11) of varying affinity and off rate. Successful loading was verified with a Mage-3A1-specific CTL clone and ELISPOT analysis (not shown). The Mage-3A1 peptide (15) was selected for several reasons. It is essentially tumor specific (2) and expressed in tumors other than melanoma (2), and the Mage-3A1 epitope is likely a rejection antigen (14). Moreover, the Mage-3A1 CTLp frequency is exceedingly low in noncancer patients (reference 18; 0.4–3 per  $10^7$  CD8<sup>+</sup> T cells) as well as in cancer patients, even after peptide vaccination (14). Thus, any induction or boost of Mage-3A1 CD8<sup>+</sup> T cell responses would indicate a significant superiority in the adjuvant capacities of DCs.

DTH assays with peptide-pulsed DCs were carried out as described by Nestle et al. (11) to detect Mage-3A1 immunity (not shown). However, we did not detect unequivocal DTH. This was due to the frequently observed background to nonpulsed DCs (possibly due to cytokine production by DCs) and the noteworthy variability from test site to test site. As Mage-3A1-specific T cells are CD8<sup>+</sup>




Figure 5. Regression (arrows) of a globular (13 mm in diameter) lung metastasis in patient 07 that was then no longer detectable in serial 6-mm-thick computed tomography scans.




Figure 6. Regressing subcutaneous metastases in patient 06 display a CD8<sup>+</sup> lymphocytic infiltrate (alkaline phosphatase/antialkaline phosphatase immunohistochemical staining with anti-CD8 mAb) that surrounds (A) and infiltrates (B) the tumor. Areas of damaged (B, ★) and necrotic (C, ★) melanoma cells are obvious in the vicinity of the CD8<sup>+</sup> T cell infiltrate. The metastasis expressed Mage-3, as demonstrated by RT-PCR (data not shown). Magnifications: A, 100; B, 250; C, 160.

T cells and DTH assays typically detect primed CD4<sup>+</sup> T cells, we suspect that DTH to MHC class I peptide-pulsed DCs may also for this reason prove not to be a sensitive or reliable way to monitor specific CD8<sup>+</sup> T cell-mediated immunity.

In contrast, we found sizable expansions of Mage-3A1-specific CTL precursors in PBMCs from a majority (8/11) of patients ( $P < 0.008$ ; Fig. 4). This is an important proof of the principle of DC-based immunization, and it is also significant from the point of view that tumors can induce tolerance or anergy. It is very promising that CTLp expansions can be induced in far advanced and heavily pretreated stage IV melanoma patients. However, active Mage-3A1-specific effectors were generally not observed in ELISPOT assays, except for in two patients with high frequencies ( $>5,000/10^7$  CD8<sup>+</sup> T cells). Perhaps active CD8<sup>+</sup> effectors were rapidly sequestered in the numerous metastases, as suggested by the biopsy studies illustrated in Fig. 6. An alternative explanation is that looking for effectors in peripheral blood 14 d after a preceding vaccination might simply be too late.

Interestingly, in six patients, CTLp had increased to their highest levels after the three intracutaneous vaccinations ( $P < 0.0013$ ) and then decreased ( $P < 0.026$ ) with subsequent intravenous immunizations (Fig. 4). The decrease in CTLp might be due to emigration of activated Mage-3-reactive CTLs into tissues, tolerance induction, or clonal exhaustion via the intravenous route. We also observed decreased responses to recall antigens in the five patients that we studied before and after intravenous vaccination (Fig. 3). The effect of the intravenous route requires additional study, as it may be counterproductive. In contrast, our results clearly demonstrate that the intracutaneous route is effective, so that the less practical intranodal injection propagated by other investigators (11) does not seem essential. It will, however, be necessary to compare subcutaneous and intradermal routes to find out if one is superior.

We found regression of individual metastases in 6/11 patients when patients were staged 14 d after the fifth vaccination (Table I). This percentage of responses was unexpected in far advanced stage IV melanoma patients who were all progressive despite standard chemotherapy and even chemimmunotherapy. In the study by Nestle et al. (11), chemotherapy was only given to 4/16 melanoma patients, and objective tumor responses were observed in 5/16. Therefore, we attribute the regressions to DC-mediated induction of Mage-3A1-specific CTLs. This interpretation is supported by the heavy infiltration with CD8<sup>+</sup> T cells of regressing but not nonregressing (skin) metastases. The observation that all of the metastases in patients 06 and 08 that were excised at the end of the study were Mage-3 mRNA<sup>-</sup> (whereas those removed at the onset were uniformly positive) suggests immune escape of and selection for Mage-3 antigen-negative tumors. Immune escape might also have been responsible for the lack of tumor response in those nonresponders that had mounted a Mage-3A1-specific CTL response.

After the end of the trial, surviving patients received further vaccinations with DCs and several tumor peptides (Mage-1, tyrosinase, and Mage-3) that were no longer part of the protocol. It is encouraging that 5/11 patients are still alive (Table I) 9–17 mo after study entry, as the expected median survival in patients progressive after chemo(immuno)therapy is only 4 mo (29, 30). One of the initial responders (patient 06) has recently experienced a complete response and has now been disease free for 2 mo. It is interesting that Marchand et al. (14) have also observed that regressions, once they have started, proceed slowly and may take months to complete.

In conclusion, the use of a defined DC vaccine combined with detailed immunomonitoring provides proof that vaccination with mature DCs expands tumor-specific T cells in advanced melanoma patients. In addition, we have found some evidence for the direct interaction between

CD8<sup>+</sup> CTLs and tumor cells as well as for escape of antigen-negative metastases. We are convinced that DC-mediated immunization can be intensified further to reveal the presence of expanded populations of effector cells. Efficacy might be increased at the level of the DC, e.g., by optimizing

variables such as DC maturational state, route, dose, and schedule or by improving the short life span of DCs in vivo (31, 32); at the level of the T cell, e.g., by providing melanoma-specific CD4<sup>+</sup> T cell help (33, 34) or IL-2 (35); and by treating patients earlier in their disease course.

We are grateful to all patients for their confidence and cooperation. We appreciate the support of J. Knop, Head of the Department of Dermatology in Mainz. We thank our colleagues H.B.-R. Balda, H. Hintner, F.S.M. Meurer, and C.R. Neumann for referring patients and T.L. Diepgen for statistical analysis. We are particularly grateful to T. Boon and P. van der Bruggen, who helped us in many ways, and to A. Knuth and T. Wölfel for help in establishing the semiquantitative CTL and ELISPOT assays, respectively. We are obliged to the Protocol Review Committee and Office of Clinical Trials Management of the Ludwig Institute for Cancer Research, in particular H.F. Oettgen and E. Hoffman, for their suggestions on improving the protocol and for supervising the trial.

This work was supported by a grant from the Deutsche Krebshilfe (project #70-2291). B. Thurner was supported by the Training and Mobility of Researchers (TMR) programme of the European Union (EUNIDI).

Address correspondence to Gerold Schuler, Dermatologische Klinik mit Poliklinik, Hartmannstr. 14, D-91052 Erlangen, Germany. Phone: 49-9131-85-0, ext. 33661; Fax: 49-9131-85-6175; E-mail: schuler@derma.med.uni-erlangen.de

Submitted: 1 June 1999 Revised: 21 September 1999 Accepted: 24 September 1999

## References

- Schreiber, H. 1999. Tumor Immunology. In *Fundamental Immunology*. W.E. Paul, editor. Lippincott-Raven Publishers, Philadelphia. 1237-1270.
- Van den Eynde, B.J., and P. van der Bruggen. 1997. T cell defined tumor antigens. *Curr. Opin. Immunol.* 9:684-693.
- Schuler, G., and R.M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. *J. Exp. Med.* 188:1183-1187.
- Pardoll, D.M. 1998. Cancer vaccines. *Nat. Med.* 4(Suppl.): 525-531.
- Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. *J. Exp. Med.* 188:1641-1650.
- Rosenberg, S.A. 1998. New opportunities for the development of cancer immunotherapies. *Cancer J. Sci. Am.* 4(Suppl.):S1-4.
- Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature*. 393:245-252.
- Lotze, M.T., H. Farhood, C.W. Wilson, and W.J. Storkus. 1999. Dendritic cell therapy of cancer and HIV infection. In *Dendritic Cells: Biology and Clinical Applications*. M.T. Lotze and A. Thomson, editors. Academic Press, San Diego, CA. 459-485.
- Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat. Med.* 2:52-58.
- Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. *Prostate*. 29:371-380.
- Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat. Med.* 4:328-332.
- Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kämpgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. *J. Immunol. Methods*. 196:137-151.
- Thurner, B., C. Röder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Keikavoussi, E. Kämpgen, A. Bender, and G. Schuler. 1999. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. *J. Immunol. Methods*. 223:1-15.
- Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int. J. Cancer*. 80:219-230.
- Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J. Exp. Med.* 179:921-930.
- Herr, W., B. Linn, N. Leister, E. Wandel, K.H. Meyer zum Buschenfelde, and T. Wölfel. 1997. The use of computer-assisted video image analysis for the quantification of CD8<sup>+</sup> T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. *J. Immunol. Methods*. 203:141-152.
- Romero, P., J.C. Cerottini, and G.A. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses

- in cancer immunotherapy. *Mol. Med. Today*. 4:305-312.
18. Chaux, P., V. Vantomme, P. Coullie, T. Boon, and P. van der Bruggen. 1998. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. *Int. J. Cancer*. 77:538-542.
  19. Zhou, L.J., and T.F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. *J. Immunol.* 154:3821-3835.
  20. Lanzavecchia, A. 1998. Immunology. Licence to kill. *Nature*. 393:413-414.
  21. Jonuleit, H., U. Kuhn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A.H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. *Eur. J. Immunol.* 27:3135-3142.
  22. Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. Cerundolo, D.F. Nixon, et al. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. *J. Clin. Invest.* 104:173-180.
  23. Steinbrink, K., H. Jonuleit, G. Müller, G. Schuler, J. Knop, and A.H. Enk. 1999. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8<sup>+</sup> T cells resulting in a failure to lyse tumor cells. *Blood*. 93:1634-1642.
  24. Enk, A.H., H. Jonuleit, J. Saloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. *Int. J. Cancer*. 73:309-316.
  25. Sato, T., P. McCue, K. Masuoka, S. Salwen, E.C. Lattime, M.J. Mastrangelo, and D. Berd. 1996. Interleukin 10 production by human melanoma. *Clin. Cancer Res.* 2:1383-1390.
  26. Dummer, W., J.C. Becker, A. Schwaaf, M. Leverkus, T. Möll, E.B. Bröcker. 1995. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. *Melanoma Res.* 5:67-68.
  - 26a. Keikavoussi, P., C. Carstens, C. Scheicher, F. Koch, W. Fries, E.B. Bröcker, N. Koch, and E. Kämpgen. 1999. Full maturation of human monocyte derived dendritic cells results in stable expression of MHC class I molecules. *Arch. Dermatol. Res.* 291:110. (Abstr.)
  27. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. *Nature*. 388:782-787.
  28. Dieu, M.C., B. Vanbervliet, A. Vicari, J.M. Bridon, E. Oldham, S. Alt-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. *J. Exp. Med.* 188:373-386.
  29. Balch, C.M., A.N. Houghton, A.J. Sober, and S. Soong. 1998. Cutaneous Melanoma. 3rd ed. Quality Medical Publishing Corporation, St. Louis, MO. 596.
  30. Kamanabrou, D., C. Straub, M. Heinsch, C. Lee, and A. Lippold. 1999. Sequential biochemotherapy of INF- $\alpha$ /IL-2, cisplatin (CDDP), dacarbazine (DTIC) and carmustine (BCNU). Result of a monocenter phase II study in 109 patients with advanced metastatic malignant melanoma (MMM). *Proc. Am. Soc. Clin. Oncol.* 18:2044a. (Abstr.)
  31. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. *J. Exp. Med.* 180:1263-1272.
  32. Wong, B.R., R. Josien, S.Y. Lee, B. Sauter, H.L. Li, R.M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. *J. Exp. Med.* 186:2075-2080.
  33. Topalian, S.L., M.I. Gonzales, M. Parkhurst, Y.F. Li, S. Southwood, A. Sette, S.A. Rosenberg, and P.F. Robbins. 1996. Melanoma-specific CD4<sup>+</sup> T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. *J. Exp. Med.* 183:1965-1971.
  34. Chaux, P., V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, R. Luiten, A.M. Eggermont, T. Boon, and P. van der Bruggen. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. *J. Exp. Med.* 189:767-778.
  35. Shintzu, K., R.C. Fields, M. Giedlin, and J.J. Mule. 1999. Systemic administration of Interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. *Proc. Natl. Acad. Sci. USA*. 96:2268-2273.